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A. Summary 
The increasing global prevalence of diabetes poses a huge challenge to health 
services.  The diagnosis is accompanied by a reduction in life expectancy, 
primarily due to cardiovascular disease which is inextricably linked to 
microvascular complications such as diabetic nephropathy (DN).  
Microalbuminuria (MA) is generally accepted as the primary clinical hallmark of 
DN, but despite widespread prescribing of agents blocking the renin angiotensin 
aldosterone system (RAAS) in these patients many continue to progress towards 
end-stage renal disease (ESRD).  Clinical trials evaluating early initiation of RAAS 
blocking agents in untargeted, nonalbuminuric diabetic patients have shown 
potential for delaying disease progression but these effects are generally 
counterbalanced by side effects and adverse events associated with these 
therapies.  Discovery of novel biomarkers to identify individuals at highest risk of 
DN who would stand to benefit most from targeted preclinical intervention 
would be a significant step towards implementation of personalised medicine in 
this population. 
One technique which shows promise is proteomics, based on the concept of 
separation and quantification of peptides in a biological sample to produce a 
disease-specific pattern.  A panel of 273 urinary peptides (CKD273) has been 
shown to have potential for identification of nonalbuminuric diabetic patients 
who are at risk of progression to overt DN.  However, many such novel 
biomarkers are described in the literature and to date none have successfully 
made the transition from research studies to routine clinical practice.  In order 
to be considered for clinical implementation novel biomarkers are required to be 
subject to a rigorous evaluation process.  In brief there are several key steps 
beginning with proof-of-concept studies; progressing through validation in 
independent populations to demonstration of incremental value beyond the 
current guideline-endorsed tests; thereafter proof of clinical applicability in 
determining treatment strategies and cost-effectiveness are required.  The work 
contained within this thesis is designed to address each of these aspects with 
regard to use of the CKD273 proteomic panel as a biomarker for early detection 
of DN. 
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The first challenge in biomarker evaluation requires demonstration of an unmet 
clinical need and availability of a suitable treatment option for individuals who 
are identified as “high risk”.  Recent years have seen a resurgence of interest in 
the role of aldosterone in the initiation and progression of cardiorenal diseases. 
In fact, evidence suggests that aldosterone breakthrough can occur in patients 
established on angiotensin converting enzyme inhibitors (ACE-I) or angiotensin 
receptor blockers (ARB), suggesting a potential role for mineralocorticoid 
receptor antagonists in treatment and prevention of chronic kidney disease 
(CKD).  In chapter 3 the results of a meta-analysis of studies evaluating effects 
of addition of MRA to ACE-I or ARB in patients with CKD are presented.  This 
work confirms that this strategy is an effective means to lower blood pressure 
and minimise proteinuria in patients with CKD.  A small reduction in glomerular 
filtration rate (GFR) associated with treatment likely reflects improvement of 
glomerular hyperfiltration and is associated with improved clinical outcomes.  
There is a threefold increase in relative risk of developing hyperkalaemia above 
predefine study limits with mean increase of 0.19mmol/L from baseline, hence 
the risk of hyperkalaemia is quantifiable and appropriate selection of patients 
may render this acceptable in the face of the potential benefits of treatment. 
Chapter 4 illustrates a local pilot study where the CKD273 biomarker is validated 
for diagnosis of DN.  This project included 45 individuals with type 2 diabetes 
(T2DM) fitting into 3 categories according to the traditional definition of DN: 15 
were normoalbuminuric; 15 had microalbuminuria and 15 had overt 
macroalbuminuria.  Urinary proteomic analysis confirmed that CKD273 classifier 
score did indeed increase across the study categories and receiver operating 
curve analysis confirmed that 0.343 was the near optimal threshold for diagnosis 
of DN; a finding that is consistent with other published literature. 
Whilst its utility as an early marker of risk of progressive renal disease is 
debated, there is little doubt that MA serves as a very useful tool for highlighting 
increased cardiovascular risk.  The work described within chapters 4 and 6 was 
designed in order to evaluate the specificity of CKD273 for identification of early 
renal disease rather than generalised subclinical vascular disease, through 
employing a number of clinical vascular phenotyping techniques and biomarker 
analyses.  Results of these cross-sectional analyses showed that there was no 
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association between CKD273 classifier score and vascular phenotypes suggesting 
that CKD273 could indeed be a more specific renal biomarker, although such 
conclusions cannot be inferred from cross-sectional work.   
Chapter 7 aimed to take the classifier from cross-sectional to prospective 
analyses for prediction of hard clinical endpoints.  This study involved urinary 
proteomic analysis of stored baseline urine samples from a cohort of 
microalbuminuric T2DM patients with preserved renal excretory function at 
baseline who were followed up over a 4 year period. This cohort was of 
particular interest as the majority of patients who have MA do not progress to 
ESRD, meaning that biomarkers could be employed in this context to identify 
those at higher or lower risk of progressive disease.  The overall number of 
events were low and survival analysis showed that the CKD273 classifier is not a 
predictor of decline in GFR in this cohort, a fact that is perhaps not surprising 
given that its role appears to be more that of a preclinical disease biomarker 
and these patients had evidence of established renal disease at baseline.   
The ultimate test of a novel biomarker is evaluation in a prospective, biomarker-
guided clinical trial where results of biomarker analysis are used to determine 
therapeutic intervention.  The Proteomic Prediction and Renin Angiotensin 
Aldosterone System Inhibition Prevention of Early Diabetic Nephropathy in Type 
2 Diabetic Patients with Normoalbuminuria (PRIORITY) trial, described in 
chapters 2 and 5 of this thesis aims to specifically address this requirement.  
This pioneering multicentre study is the first clinical trial to prospectively 
evaluate a proteomic biomarker and will serve to determine whether CK273 does 
indeed have the potential to make the leap from bench to bedside.   
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1. Introduction 
1.1 Diabetes - a global healthcare emergency 
The world prevalence of both type 1 (T1DM) and type 2 diabetes (T2DM) is 
increasing, with the rise in type 2 diabetes fuelled by global trends in 
urbanisation and modern lifestyle changes such as dietary choices and sedentary 
behaviour, which in turn lead to obesity.  Figures from the 2015 International 
Diabetes Federation (IDF) Global Diabetes Atlas estimate that at present there 
are 415 million adults living with diabetes worldwide, a sobering 46% of these 
individuals are not yet diagnosed.  By 2040 it is projected that 642 million 
people will be affected by diabetes unless preventative steps are taken, 
prompting the IDF to describe diabetes as “the largest global health emergency 
of the 21st century”. 
In 2015 diabetes caused 5 million deaths across the globe, more than the total 
combined mortality resulting from tuberculosis, HIV/AIDS and malaria [1].  
Extremes of blood glucose account for only a small proportion of these deaths, 
and mortality in diabetes is more commonly attributable to complications of the 
disease including: cardiovascular disease; peripheral vascular disease; and 
kidney disease.  Improvements in diabetes management over the past 50 years 
have led to reduction in complication rates and improved life expectancy for 
patients with diabetes.  However, the increasing prevalence of diabetes is 
driving an increasing burden of morbidity and early mortality.  As a result, 
diabetes and its complications place an enormous strain on healthcare services 
as well as affected individuals and their families.  The sequelae of diabetes can 
in part be tackled by early diagnosis and intensified treatment strategies, a 
point which was highlighted at the 2015 G7 summit where the IDF urged all 
member nations to implement cost-effective policies to deal with the increasing 
burden of diabetes on healthcare services [1]. 
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1.2 Diabetic nephropathy 
Diabetic nephropathy (DN), traditionally defined as urine albumin excretion 
(UAE) > 300mg/24hrs and declining renal function in the absence of urinary tract 
infection or any other renal disease [2], remains the leading cause of end-stage 
renal disease (ESRD) necessitating transplantation or dialysis worldwide [3].  
Despite an overall stabilisation of incidence rates in recent years [4] nearly one 
third of individuals with diabetes show some evidence of renal involvement 
during the course of their disease.  DN accounts for approximately 20% of 
diabetes-related deaths directly, as well as indirect effects which arise as a 
consequence of the significantly increased cardiovascular risk associated with 
the condition [5].  In the Finnish Diabetic Nephropathy (FinnDiane) cohort of 
patients with T1DM, DN was associated with a 3.6-fold increase in mortality in 
comparison to the general population over a 7 year follow-up period [6].  The UK 
Prospective Diabetes Study (UKPDS) demonstrated that risk of death increased 
3.4-fold in T2DM patients with DN, and 14-fold in patients with DN and ESRD over 
10 years of follow-up [7].  The association between DN and mortality is a graded 
relationship, increasing as the disease progresses [6, 7]. 
 
1.2.1 Classical 5-stage natural history of DN 
Mogensen et al [8] first defined what are traditionally thought of as the 5 stages 
of DN in 1983, derived mainly but not exclusively from studies in patients with 
T1DM.  This classification is described below and summarised in Table 1-1.  The 
first 2 stages cannot be detected by conventional blood or urine tests and 
therefore evolve in clinical silence over a number of years. 
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Stage Description Onset/Duration Histology GFR UAE BP 
1 
Glomerular 
hyperfiltration 
Often at diagnosis; may 
persist for many years 
Increased glomerular 
size; nephron 
hyperplasia 
Increased 
Normal; may rise 
transiently with exercise 
Normal 
2 
Mesangial 
expansion 
Detectable by 2 years after 
diagnosis; progresses over 
several years 
Thickened GBM; 
mesangial matrix 
expansion 
Increased Normal Normal 
3 
Microalbuminuria 
(“incipient DN”) 
Present after 10-15 years; 
approximately 80% progress 
to overt DN 
As above Normal/increased 30-300mg/24 hours 
Incipient 
increase 
4 
Macroalbuminuria 
(“overt DN”) 
Onset after 15-20 years; 
progress to ESRD inevitable 
Kimmelstiel-Wilson 
lesions; diffuse 
glomerulosclerosis; 
arteriolar hyalinosis 
Declines by 
10ml/min/1.73m² 
per year 
>300mg/24 hours Elevated 
5 ESRD Outcome after 25-30 years Glomerular closure 
Less than 
15ml/min/1.73m² 
May decline due to 
nephron closure 
Elevated 
 
 
Table 1-1.  The traditional 5-stage classification of diabetic nephropathy. 
GBM, glomerular basement membrane; GFR, glomerular filtration rate; UAE, urine albumin excretion; BP, blood pressure; DN, diabetic nephropathy; 
ESRD, end-stage renal disease. Adapted from Mogensen et al, Diabetes 1983; 32: 64-78. 
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The first stage is characterised by a relative improvement in kidney function, 
termed “glomerular hyperfiltration”.  This is generally accepted as an increase 
in glomerular filtration rate (GFR) of > 2 standard deviations above the mean but 
the threshold for classification has ranged between 125 and 140ml/min/1.73m2 
in different studies [9-11].  Hyperfiltration can be demonstrated at the time of 
clinical diagnosis of diabetes in some individuals, and has been attributed to 
both increased glomerular capillary plasma flow resulting from altered 
resistance in the efferent and afferent arterioles as well as the effect of 
increased resorption of glucose at the proximal tubule [12, 13]; a theory 
supported by the fact that these changes are at least partially reversible by 
insulin therapy [14, 15].  Histologically this process is accompanied by increased 
glomerular size and nephron hyperplasia; as well as a measurable increase in 
overall kidney size [8].  The pathogenic significance of hyperfiltration in relation 
to the evolution of DN remains under scrutiny.  In a meta-analysis of 10 cohort 
studies including 780 patients with T1DM, hyperfiltration was associated with an 
increased risk of progressive disease [16], however these findings are more 
challenging to corroborate in T2DM due to the insidious onset of the disease and 
the co-existence of non-diabetic renal disease in some patients.   
The hallmark of the second stage of DN is the development of significant 
structural changes within the renal parenchyma in the absence of any 
measurable clinical decline in renal function.  The characteristic pathological 
abnormalities include thickening of the glomerular basement membrane (GBM) 
followed by alterations in the composition of the mesangium [8] as a 
consequence of extracellular matrix (ECM) accumulation.  Expansion of the 
mesangium distorts the glomerular capillaries thereby diminishing the filtration 
surface [17].  Hyalinosis of the efferent arteriole is another pathological feature 
which is relatively specific for DN and can be used to differentiate the condition 
from nephropathy of alternative aetiology at biopsy.  This term refers to 
intramural collections of plasma proteins and lipids within the renal capillaries 
and arterioles [17].  Distortion of the GBM and mesangium can be considerably 
advanced by the time clinical signs of DN are detectable, and the presence of 
these histological alterations in T1DM has been shown to be predictive of 
progressive disease in 30-40% of patients [18, 19]. 
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Following the clinically silent haemodynamic and morphological changes that 
precede any measurable decline in renal filtration or excretory function, the 
primary manifestation of stage 3 of Mogensen’s DN classification is development 
of microalbuminuria (MA).  This parameter remains the earliest and most 
commonly used indicator of DN in current clinical practice.  The diagnostic 
thresholds traditionally used to define MA are: UAE of 30-300mg over the course 
of a 24-hour urine collection; or spot albumin: creatinine ratio (ACR) of 2.5-30 
mg/mmol for males, 3.5-30mg/mmol for females in 2 of 3 first morning 
collections.  There is good agreement between these methods [20] but spot 
collections are generally more convenient for patients in day to day clinical 
practice.  Mogensen termed this stage “incipient DN” as although renal function 
remains within normal limits, progression of UAE over several years appears to 
be paralleled by an upward trend in blood pressure, and studies at the time 
suggested that approximately 80% of patients who developed MA were likely to 
progress further in subsequent years [21, 22].  It was also noted at this stage 
that patients experienced transient exercise-induced amplification of UAE, 
returning to baseline levels during recovery.  Progression of the structural and 
microcirculatory changes in the glomeruli described above are very likely to be 
involved in this phenomenon [8].  “Incipient DN” is essentially the interphase 
between preserved renal function and the later decline that is characteristic of 
more advanced disease, highlighting risk of progression and therefore also the 
need for clinical intervention to slow the development of DN.    
Stage 4 of the traditional classification system is the point of transition to overt 
DN, with its key clinical feature being persistent albuminuria (UAE>300mg/24hrs 
or >30mg/mmol in spot ACR).  Histopathologically, advanced DN is characterised 
by nodular glomerulosclerosis, also termed “Kimmelstiel-Wilson lesions”.  These 
are composed of accumulated mesangial matrix, lipid particles and other 
cellular debris and their presence is generally associated with longer duration of 
diabetes as well as other unfavourable clinical features [23].  The changes seen 
in diffuse glomerulosclerosis represent the endpoint of multiple mechanisms 
resulting in excessive accumulation of matrix proteins within the mesangium, 
and in advanced disease are often followed by interstitial fibrosis and tubular 
atrophy [24].  These changes are accompanied clinically not only by albuminuria 
but also often by hypertension.  It is at this time point that GFR begins to fall; in 
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untreated patients the approximate rate of decline is 10ml/min/1.73m2 per year 
[8] and is the final path to ESRD (stage 5). 
 
1.2.2 Proposed pathological classification of DN 
Although pathological staging systems exist for many renal conditions this has 
not traditionally been the case for DN, despite the existence of a number of 
hallmark histological features as described above.  In 2010 a uniform 
classification system to encompass both T1DM and T2DM was proposed by the 
Renal Pathological Society with the aim of categorising prognostic severity [17] 
(Table 1-2).  Appropriate standards suggested for full evaluation of renal tissue 
in order to identify these key features include: light microscopy with staining; 
immunofluorescence; and electron microscopy. 
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a.  Glomerular lesions in DN 
 
Class Description Required Criteria 
I 
Mild, non-specific 
changes and GBM 
thickening 
No evidence of changes 
associated with stages II-IV; 
GBM>395nm in females, 
>430nm in males 
IIa 
Mesangial expansion 
(mild) 
<25% total mesangium 
involved 
IIb 
Mesangial expansion 
(severe) 
>25% total mesangium 
involved 
III 
Nodular 
glomerulosclerosis 
(Kimmelstiel-Wilson 
lesions) 
At least 1 Kimmelstiel-Wilson 
lesion 
IV 
Advanced 
glomerulosclerosis 
Lesions from class I-III may 
be present;  sclerosis in 
>50% of glomeruli 
 
 
Table 1-2.  Proposed pathological classification of diabetic nephropathy. 
DN, diabetic nephropathy; GBM, glomerular basement membrane; IFTA, interstitial fibrosis and tubular atrophy. Adapted from Tervaert et al, JASN 
2010; 21: 556-563. 
 
b.  Interstitial and vascular lesions in DN 
 
Lesion Required Criteria Score 
Interstitial 
lesions (IFTA) 
Absent 
<25% 
26-50% 
>50% 
0 
1 
2 
3 
Inflammatory 
infiltrates 
Absent 
IFTA-associated 
IFTA-independent 
0 
1 
2 
Arteriolar 
hyalinosis 
Absent 
At least 1 area 
More than 1 area 
0 
1 
2 
Arteriosclerosis 
in large vessels 
No intimal abnormality 
<thickness of media 
>thickness of media 
0 
1 
2 
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1.2.2.1 Glomerular lesions 
The 4 classes of glomerular lesions seen in DN are briefly summarised below. 
 Class I: These specimens show either no specific changes or GBM 
thickening defined as >395nm in females and >430nm in males. 
 Class II:  This stage is characterised by mesangial expansion, which can be 
further defined as mild or severe depending on the total volume of 
mesangium involved.  Class IIa refers to “mild” mesangial expansion 
affecting less than 25% of the total mesangium observed at biopsy, while 
class IIb indicates “severe” mesangial expansion which is seen in more 
than 25%. 
 Class III:  A specimen containing at least one Kimmelstiel-Wilson lesion 
with no more than 50% global glomerulosclerosis is designated as class III. 
 Class IV:  A class IV biopsy specimen displays more than 50% global 
glomerulosclerosis with supportive evidence that this is attributable to 
DN, i.e. other lesions described for class I-III or indicative features from 
the clinical history. 
 
1.2.2.2 Vascular lesions 
 As described previously, efferent arteriolar hyalinosis is highly specific for 
DN, whereas hyalinosis of the afferent arteriole occurs in a variety of 
other renal pathologies.  However, most studies do not distinguish 
between these subtypes and refer simply to “arteriolar hyalinosis”.  
Biopsy specimens are allocated a score of between 0 and 2 depending on 
the presence and extent of this feature. 
 Non-specific arteriosclerosis of larger vessels can also be observed in DN 
biopsy specimens.  This can also be associated with other conditions such 
as hypertension.  Samples are again scored in the range 0-2, depending on 
the presence and extent of vascular intimal thickening. 
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1.2.2.3 Tubulointerstitial lesions 
 Inflammatory infiltrates comprising macrophages and lymphocytes are a 
widely recognised feature of DN.  Specimens are scored 0 if this feature is 
not detected; 1 if it is only observed around atrophic tubules; and 2 if 
other areas are also involved. 
 Interstitial fibrosis and tubular atrophy tend to follow initial glomerular 
changes in DN.  These are scored in combination according to the total 
percentage of tubules and interstitium affected.  A score of 0 is awarded 
if this feature is absent; 1 is indicative of less than 25%; 2 if between 26 
and 50%; and 3 if more than 50% of the biopsy is affected.   
This classification system does not discriminate between T1DM and T2DM.  
Recently a number of histopathological differences between nephropathy in 
T1DM and T2DM have been described, including earlier appearance of atubular 
glomeruli and increased glomerular volume in T2DM compared to T1DM [25, 26].  
Furthermore, there are some limitations in terms of clinical application.  First, 
there is little published evidence as yet to corroborate these histopathological 
disease stages with clinical outcomes, therefore no comment on prognostic 
severity can be made in relation to staging at biopsy.  In a retrospective study 
using renal biopsy samples from 396 patients with T2DM and DN the severity of 
glomerular lesions; degree of interstitial inflammation; and tubular atrophy were 
all predictive of renal outcomes independent of other clinical parameters. 
However promising these results, it should be borne in mind that this was 
retrospective work and the effect of different pharmacological strategies was 
not assessed [27].  Second, it is not widespread routine clinical practice to 
perform a renal biopsy in all patients with diabetes and renal dysfunction, far 
less those in the earlier stages of disease with MA in the context of normal GFR.  
Therefore such a system could not be implemented at present for routine 
diagnosis of DN, rather in cases where there is significant diagnostic doubt and 
exclusion of other renal pathologies is required. 
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1.2.3 The evolving natural history of DN 
The classical progressive 5-stage model of DN first described in 1983 was 
developed primarily from studies in patients with T1DM.  Disentangling the 
natural history of T2DM is more challenging due to the insidious onset of the 
disease, the confounding influence of the effects of ageing on the kidney and 
vasculature and the not-infrequent co-existence of multiple comorbid 
conditions, including the presence of non-diabetic renal disease in some 
patients.  In recent years a number of features of the traditional 5-stage 
progression of DN have been challenged. 
 
1.2.3.1 MA is not indicative of inevitable disease progression 
At the time the original 5-stage classification of DN was developed, studies 
suggested that the majority of MA positive patients, i.e. those in disease stage 3, 
were likely to progress to macroalbuminuria over the next 5-15 years [22, 28, 
29].  Prospective work in the subsequent 2 decades has confirmed that 
progression rates are significantly lower than this.  Furthermore regression to 
normoalbuminuria is not infrequent and in many cases outweighs progression to 
macroalbuminuria. 
In a 10-year observational study of 939 patients with T1DM, Rossing and 
colleagues reported that only 28% of those who were MA-positive at baseline 
progressed to overt DN during follow up while 16% regressed to 
normoalbuminuria [30].  The Joslin Study of the Natural History of 
Microalbuminuria reported similar results; 33% of their MA-positive patients 
progressed to overt DN over an 8 year follow up period while 40% regressed to 
normoalbuminuria [31].  In the European Concerted Action on the Epidemiology 
of Diabetes (EURODIAB) study, of 352 patients who were MA positive at baseline 
only 13.9% progressed to macroalbuminuria and 35.5% reverted to 
normoalbuminuria during a 7.5 year follow up period [32]. 
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In the early studies the predictive power of MA was significantly lower in T2DM 
due to the substantial cardiovascular mortality rates among these patients, 
thereby limiting progression to ESRD.  In a 1984 retrospective analysis by 
Mogensen and colleagues the 10 year mortality rate among a cohort of patients 
with T2DM was 77.6%, mainly due to cardiovascular events, while only 22.4% of 
the cohort progressed to macroalbuminuria as a result [21].  More recently in the 
Steno-2 study where 151 subjects were microalbuminuric at baseline, 31.1% 
progressed to macroalbuminuria and 30.5% regressed to normoalbuminuria 
during the 7.8 year follow up period [33].  Similarly a 2005 Japanese study with 
8 years follow-up found that 17% of patients who were microalbuminuric at 
inclusion progressed to macroalbuminuria while 21% reverted to 
normoalbuminuria [34].  The near-universal use of drugs blocking the renin-
angiotensin aldosterone system (RAAS) over the past 2 decades must be 
considered as a factor in the evolution of our understanding of DN.  Some studies 
have certainly described an effect of RAAS blockade [33, 35] whilst others have 
seen changes independent of drug therapy [31, 34]. 
 
1.2.3.2 Early renal function decline 
Although early studies defined MA as a step towards inevitable development of 
advanced kidney disease it is now widely accepted that decline in GFR is not 
conditional on progression through micro- then macroalbuminuria, and several 
authors have described “early renal function decline” in patients with diabetes.  
Of the 480 patients with T1DM followed up in the Pittsburgh Epidemiology of 
Diabetes Complications Study, 9.3% of those who were noted to be MA-positive 
at baseline already had impaired renal function [36].  The 1st Joslin Kidney Study 
on the Natural History of Microalbuminuria in Type 1 Diabetes focused solely on 
prospective follow up of patients who were MA positive and reported that 
although rate of progression to advanced kidney disease was high, almost 50% of 
cases did not develop overt albuminuria in advance of decline in GFR, and in the 
subgroup who did develop albuminuria GFR had already begun to decline before 
UAE reached the diagnostic threshold [37].  Further analysis of GFR decline in 
this cohort using the linear slope of serum cystatin C concentrations 
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demonstrated that the process of renal function deterioration began during the 
MA stage in a third of the cohort [38].  More recently the early GFR slope has 
been shown to be more strongly associated with time to ESRD than traditional 
risk predictors such as glycated haemoglobin (HbA1c), systolic blood pressure or 
UAE [39].   
The prevalence and predictive value of early renal function decline is less well-
studied in T2DM.  This is because time of onset of diabetes is often difficult to 
determine and the disease can go unrecognised for many years, therefore 
complications are often present at diagnosis.  In a longitudinal study of 195 Pima 
Indians with T2DM, 42% of those who were MA-positive at baseline had 
simultaneous evidence of reduced GFR, and the cumulative incidence of ESRD 
after 10 years was almost 3-times greater in the subgroup who showed evidence 
of early renal function decline.  Despite this progression to ESRD remained 
commoner in those patients who developed macroalbuminuria, and although the 
hazard ratio for subsequent development of ESRD was 4.78 time higher in 
patients with early renal function decline after adjustment for traditional 
factors such as age and HbA1c, this association was attenuated after adjustment 
for UAE [40].  This work echoed the observation in T1DM that early renal 
function decline can precede macroalbuminuria in a proportion of patients. 
Taken together these data suggest the emergence of an alternative model of the 
natural history of DN whereby the onset of MA signals a progressive decline in 
renal function in a subgroup of patients that occurs independently of, or in 
parallel to, progression to macroalbuminuria.  Specific correlates of early GFR 
loss include age and HbA1c [37, 41] as well as inflammatory markers such as 
soluble tumour necrosis factor receptors (STNFR) and high-normal serum uric 
acid levels [41], leading some authors to hypothesise that this phenotype is 
associated with inflammation and tubular injury rather than the glomerular 
damage highlighted by elevated UAE [42].   MA and early renal function decline 
could therefore represent two separate phenotypes with distinct underlying 
aetiologies.  Supportive evidence for this model comes from the description of a 
further disease subtype, non-albuminuric DN.  
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1.2.3.3 Non-albuminuric DN 
While studies have shown that early loss of GFR can occur in microalbuminuric 
patients predominantly although not exclusively with T1DM, many reports have 
now described development of renal dysfunction at an even earlier stage when 
UAE is still within normal limits, termed “non-albuminuric DN”.  This pathway 
has been described in studies of T1DM and to a greater extent in T2DM. 
In the multicentre Developing Education on Microalbuminuria for Awareness of 
renal and cardiovascular risk in Diabetes (DEMAND) study of almost 25,000 
patients with T2DM, 40% of those who had estimated GFR (eGFR) below 60 
ml/min/1.73m2 were normoalbuminuric [43].  By the same token of 1,132 
participants in UKPDS who developed renal impairment over the 15 year follow 
up period, 50% remained normoalbuminuric [44]. Similar rates of non-
albuminuric DN were found in the National Evaluation of the Frequency of Renal 
Impairment co-existing with NIDDM (NEFRON) and Renal Insufficiency and 
Cardiovascular Events (RIACE) cohort, where 55% and 56% of participants with 
renal impairment respectively were normoalbuminuric [45, 46].  Lower rates of 
non-albuminuric DN were found in T1DM from the Diabetes Control and 
Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and 
Complications (EDIC) study, in which only 29% of those who developed renal 
impairment during follow  up were normoalbuminuric [47].   
The theory that non-albuminuric DN represents a distinct disease phenotype 
driven by alternative pathogenic mechanisms is reinforced by a number of 
additional points.  First, data primarily generated from studies in T2DM suggests 
that the independent determinants of reduced eGFR and increased UAE are 
different [44, 48] as shown in Figure 1-1. 
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Figure 1-1.  Independent correlates of reduced eGFR and albuminuria 
eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; BMI, body mass 
index; LDL, low density lipoprotein. 
 
Second, the association of this phenotype with the presence of retinopathy is 
weaker than that generally seen in albuminuric DN.  For example in the RIACE 
cohort most patients with non-albuminuric DN did not have diabetic retinopathy, 
in fact 43% of participants with eGFR below 60 ml/min/1.73m2 had neither 
retinopathy nor albuminuria.  Conversely, chronic kidney disease (CKD) was 
present in almost 60% of those with diagnosis of advanced retinopathy [46, 49].  
Thirdly, it has been proposed that early senescence of the diabetic kidney 
encompassing processes such as vascular disease, fibrosis and cholesterol emboli 
may contribute to the development of non-albuminuric DN [50], rather than the 
classical diabetic glomerulosclerosis described previously.  This is evident at a 
histopathological level in renal biopsies from patients with T2DM, renal 
dysfunction and varying degrees of UAE.  In one study only around half of the 
normoalbuminuric patients displayed typical glomerulopathy as described earlier 
and all had evidence of arteriosclerosis; while tissue from patients with micro- 
or macroalbuminuria demonstrated classic histological appearances associated 
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with DN [51].  The weaker association with retinopathy and lack of association 
with HbA1c have also been purported to indicate that that prevailing pathology 
underlying non-albuminuric DN is macrovascular rather than microvascular 
disease [46]. 
The evidence set out above further supports the concept that a rise in UAE and 
decrease in GFR do not necessarily go hand in hand in the natural history of DN. 
In fact they could be viewed as complementary manifestations rather than 
obligatory diagnostic features of the disease as illustrated in Figure 1-2.  It 
should be borne in mind that both are associated with increased risk of acute 
kidney injury, repeated episodes of which can also underlie progression of CKD 
[52].  The modern history of MA has evolved into one of frequent 
remissions/regressions rather than the previously held belief that it represented 
inevitable progression to DN. 
 
 
 
 
Figure 1-2.  Albuminuric and non-albuminuric pathways to DN. 
GFR, glomerular filtration rate; UAE, urine albumin excretion; ESRD, end-stage renal 
disease. 
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1.3 Pathogenesis of DN 
Although hyperglycaemia is a crucial factor in the evolution of DN many 
additional factors have been implicated.  The interaction between these 
pathways is complex and as such the pathogenesis of DN remains incompletely 
understood. 
 
1.3.1 The glomerular filtration barrier 
In order to understand how these mechanisms contribute to the development of 
DN it is important to appreciate the structure and functions of the glomerular 
filtration barrier.  Successful urine production in the kidney by filtration of blood 
requires the presence of an intact glomerular filtration barrier.  This structure 
facilitates selective ultrafiltration of blood as it is freely permeable to water, 
small solutes and low molecular weight proteins but generally precludes the 
passage of large, or negatively charged, plasma proteins.  The glomerular 
filtration barrier is comprised of 3 layers as illustrated in Figure 1-3: the 
fenestrated endothelium; the GBM; and the podocytes [53]. 
Glomerular endothelial cells are characterised by the presence of fenestrations, 
transcellular holes that occupy up to 40% of the cell surface.  This adaptation 
results in efficient filtration function by rendering the glomerular endothelium 
highly permeable to water.  However they are also large enough to allow free 
passage of larger molecules such as albumin which require reabsorption by the 
tubules [54].  The glomerular endothelial cells are covered by glycocalyx, a layer 
of proteoglycans and glycoproteins with specific molecular and charge 
characteristics that regulates endothelial permeability and glomerular filtration 
[55]. 
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Figure 1-3.  Main components of the glomerular filtration barrier. 
Adapted from Mora-Fernandez et al, J Physiol 2014; 592: 3997-4012. 
 
 
The GBM separates the urinary space from the vasculature and is composed of a 
layer of ECM proteins situated between the glomerular endothelium and the 
podocytes.  Its main components are: type IV collagen; laminin; nidogen; and 
heparan sulphate proteoglycan, with type IV collagen being the most abundant.  
The GBM offers structural support to the glomerular capillaries and contributes 
to permselectivity as its components form an anionic charge barrier to diffusion 
[56]. 
Podocytes cover the urinary aspect of the GBM.  These are glomerular visceral 
epithelial cells which have a network of cellular extensions commonly referred 
to as “foot processes”.  The podocyte foot processes interact at intercellular 
junctions termed “slit diaphragms”.  These further enhance the filtration barrier 
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and are involved in several signalling pathways [53].  One of the major 
components of the slit diaphragms is nephrin, a transmembrane glycoprotein 
which bridges adjacent foot processes thereby acting as the “pore” of the slit 
diaphragm.  Any injurious stimulus to the podocytes can result in effacement 
and loss of the slit diaphragm, leading to dysfunction of the glomerular filtration 
barrier and proteinuria [57]. 
 
1.3.2 Cellular effect of hyperglycaemia 
The DCCT and UKPDS established a key role for hyperglycaemia in the 
development of diabetic microvascular complications [58, 59].  The effects of 
hyperglycaemia at a cellular level and the complex inter-related mechanisms 
subsequently modulated by these effects are discussed below.  Notably, it has 
been shown that DN is not attributable to hyperglycaemia alone.  Transplant 
studies in which kidneys from non-diabetic donors were transplanted into 
diabetic patients have shown that nephropathy can develop in the recipient 
irrespective of the level of glycaemic control [60].  It is widely acknowledged 
that hyperglycaemia is a single element in what is a far more complex 
interaction involving a network of pathophysiological mechanisms (Figure 1-4).   
The damaging effects of hyperglycaemia are primarily seen in vascular 
endothelial cells; mesangial cells and capillaries in the glomerulus; and Schwann 
cells of the peripheral nerves.  Glucose-related damage occurs in only a few 
particular cell types despite the fact that all cells of the body are exposed to 
elevated glucose levels in diabetes.  This is because the majority of cells are 
able to rapidly respond to hyperglycaemia by reducing glucose transport into the 
cell, thereby maintaining constant intracellular glucose concentrations.  In 
contrast, the cell types most frequently affected in hyperglycaemic conditions 
do not have the capability to respond to fluctuating extracellular glucose levels 
rapidly or efficiently, resulting in continued transport of glucose into the cells 
[61, 62].  Exposure of these cells to hyperglycaemia and subsequent inability to 
modulate glucose transport triggers a number of processes including: activation 
of protein kinase C (PKC); enhanced flux of polyols; generation of advanced 
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glycation end-products (AGEs) and reactive oxygen species.  The end-result is 
unregulated cellular energy production in the context of excessive glucose 
availability.   
PKC plays a central role in the pathogenesis of DN.  This enzyme is activated by 
diacylglycerol, a product of glucose metabolism by glycolysis, as well as AGEs 
and the polyol pathway [57].  Several PKC isoforms are expressed in the kidney.  
PKC activation affects a number of transcription factors, cytokines, and 
functional enzymes which are central to DN development including: endothelial 
nitric oxide synthase (eNOS); endothelin-1 (ET-1); vascular endothelial growth 
factor (VEGF); matrix-metalloproteinase-2 (MMP-2); transforming growth factor-
β (TGF-β); connective tissue growth factor (CTGF); and nuclear factor-κB (NF-
κB).  The end result is altered microvascular flow and angiogenesis, increased 
capillary permeability and increased ECM protein production [63].   
Excess glucose is also channelled via the polyol pathway.  Under basal 
conditions the enzyme aldose reductase metabolises toxic aldehydes to inactive 
alcohols, but in hyperglycaemic conditions it acts to reduce glucose to sorbitol.  
In a high glucose environment almost a third of circulating glucose is diverted 
down this pathway.  As aldose reductase activity is dependent on nicotinamide 
adenine dinucleotide phosphate (NADPH), increased glucose flux via the polyol 
pathway leads to depletion of NADPH.  As NADPH is an essential cofactor for 
regeneration of reduced glutathione, metabolism of glucose via the polyol 
pathway dysregulates glutathione and glutathione peroxidase activity resulting 
in decreased nitric oxide (NO) availability and oxidative stress [62].   
Nonenzymatic reduction of sugars with free amino groups of proteins, nucleic 
acids and lipids results in the formation of AGEs.  Again, under basal conditions 
AGE production is low but their concentrations are increased in hyperglycaemic 
conditions.  After binding to the AGE receptor (RAGE), intracellular actions of 
AGEs include activation of PKC and transcription factors such as NF-κB which 
modulate expression of growth factors and cytokines, in particular TGF-β, which 
plays a pivotal role in development of glomerulosclerosis and fibrosis [64].  At an 
extracellular level, AGE form covalent crosslinks between proteins, thereby 
altering the composition and function of vessel walls and basement membranes.  
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As a result of modification by AGEs these matrix components are rendered less 
susceptible to enzymatic degradation by matrix metalloproteinases (MMPs) and 
are therefore able to accumulate in an unregulated manner, contributing to GBM 
thickening and mesangial expansion.  Glycation of proteoglycans alters their 
electronegativity and AGEs can thereby modify filtration across the basement 
membrane [57].   
 
 
 
 
 
 
Figure 1-4.  Cellular effects of hyperglycaemia. 
PKC, protein kinase C; AGE, advanced glycation end-products; VEGF, vascular 
endothelial growth factor; TGF-β, transforming growth factor β; ET-1, endothelin-1; 
NADPH, nicotinamide adenine dinucleotide phosphate; NF-ƙB, nuclear factor kappa B; 
eNOS, endothelial nitric oxide synthase; NO,  nitric oxide.  
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1.3.3 Collagen turnover 
The most prominent histological feature of DN is excess accumulation of ECM in 
the mesangium and GBM, resulting from an imbalance between production and 
degradation of its components.  Thickening of the GBM is accompanied by 
glomerular hyperfiltration and alterations in hydrostatic pressure which are 
thought to lead to development of MA.  Changes in the mesangial matrix and 
tubulointerstitium appear to be more closely related to decline in renal function 
as impingement of expanded matrix on glomerular capillaries reduces available 
filtration surface and narrows the vessel lumen [65].  
These histological appearances are accompanied by accumulation of ECM 
components including collagen types I, III and IV, proteoglycans and fibronectin 
resulting from activation of fibroblasts.  A number of stimuli have been shown to 
potentiate fibroblast activity including infiltration of inflammatory mediators 
such as TGF-β, fibroblast growth factor (FGF), leucocytes and macrophages.  The 
RAAS plays a pivotal role in many aspects of the pathogenesis of DN, and ECM 
synthesis by renal fibroblasts can also be triggered through angiotensin II (Ang II) 
mediated activation of the angiotensin type 1 receptor [66].  Environmental 
stimuli such as hyperglycaemia and hypoxia are also thought to play a role [67].  
In fact, hyperglycaemia can also mediate these pro-fibrotic effects through its 
action on other renal cell types.  For example, exposure to high glucose levels 
upregulates TFG-β expression in glomerular epithelial cells [68]. 
Since ECM also undergoes metabolic turnover through enzymatic degradation by 
MMPs it follows that any inhibitory effects on this process may also promote ECM 
accumulation.  MMP production by mesangial cells accounts for the majority of 
ECM turnover in the kidney [69].  Their activity is regulated by tissue inhibitors 
of metalloproteinases (TIMPs) and both have been implicated in the pathogenesis 
of DN.  Studies have also suggested a role for pro-inflammatory cytokines such as 
interleukin-1 (IL-1), tumour necrosis factor-α (TNF-α) and TGF-β as well as AGEs 
in regulation of MMP activity [70, 71].  Similarly, in addition to their role in ECM 
turnover, MMPs have also been shown to stimulate the release of cytokines and 
growth factors associated with renal fibrosis; further evidence that many of the 
mechanisms underlying DN are intertwined.   
22 
 
 
In rodent models of T2DM, expression of MMP-9 is increased in the kidneys of 
animals that develop DN [72].  Increased urinary MMP-9 concentration has been 
demonstrated in humans with T2DM and nephropathy, and levels increase with 
degree of UAE [73].  Notably, plasma MMP-9 concentration has been shown to 
correlate with degree of urinary podocyte excretion in patients with DN, 
suggesting that dysregulation of ECM turnover may have adverse effects on 
podocyte integrity [74].  Evidence surrounding the role of MMP-2 in DN is 
conflicting.  It has been shown that MMP-2 induces activation of renal tubular 
myofibroblasts, a key step in the development of renal disease [75].  In addition, 
expression and activity of MMP-2 appear reduced in advanced human DN.  
However, in rodent models of streptozotocin-induced DN renal expression and 
activity of MMP-2 are increased in the early stages of disease, and MMP-2 
knockout mice progress to advanced DN more rapidly [76] suggesting a potential 
protective role.   
In addition to their role in MMP activity, high glucose concentrations and AGEs 
have also been shown to alter the availability of TIMPs through enhancing CTGF 
expression which subsequently triggers increase in TIMP-1 availability from 
human mesangial cells [77].  Data focussing on the role of TIMPs in DN are 
inconsistent.  For example, circulating TIMP-1 concentrations have been shown 
to be reduced in humans with T2DM and nephropathy in comparison to non-
diabetic renal disease, and levels are correlated with worsening degrees of 
glomerular lesions [78].  However in patients with T1DM from the EURODIAB 
study, higher plasma TIMP-1 levels were associated with higher degrees of 
albuminuria [79].  TIMP-1 has also been shown to have pro-inflammatory effects 
through up-regulation of intercellular adhesion molecule-1 (ICAM-1) [80] as well 
as modulating cell proliferation, apoptosis and angiogenesis [81]; additional 
functions which could contribute to the development of renal fibrosis and 
further evidence of the complex interrelationships between multiple pathogenic 
pathways in the development of DN. 
Although the evidence surrounding availability of MMPs and TIMPs in DN is 
conflicting, it highlights complex alterations in matrix turnover as a key pathway 
to disease development.  Of course altered collagen turnover is also key to the 
evolution of cardiovascular disease, where biomarkers such as the telopeptide of 
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collagen type 1 (CITP) as an indicator of collagen breakdown, and procollagen 
type 1 carboxyterminal propeptide (PICP) as an indicator of collagen production 
have been shown to be differentially regulated in myocardial disease [82].  The 
conflicting evidence described above may be a reflection of the fact that 
collagen turnover is differentially regulated in the vasculature and renal 
parenchyma during the development of DN. 
 
1.3.4 Endothelial dysfunction and inflammation 
The endothelium is a unicellular layer of squamous cells lining the internal wall 
of the vasculature. Once considered to act simply as a semi-permeable 
membrane between the interstitium and the vascular wall; it is now recognised 
that the endothelium is a tissue capable of a wide range of biological functions 
including: adhesion and migration of inflammatory cells; fibrinolysis; and 
angiogenesis [83].  To carry out these functions the endothelium produces ECM 
components; NO, ET-1; Ang II; tissue plasminogen activator (t-PA); plasminogen 
activator inhibitor-1 (PAI-1); von-Willebrand factor (vWF); as well as various 
cytokines and adhesion molecules [84].  The endothelium thereby serves as a key 
locus for maintenance of vascular function by balancing the counter-regulatory 
pathways controlling vasoconstriction; inflammation; oxidative stress; cell 
proliferation; and thrombosis – mechanisms which have been implicated in the 
pathogenesis of many diabetes complications including DN.  Any injurious 
stimulus to the endothelium can result in endothelial dysfunction, thereby 
upsetting the delicate balance between these processes. 
Endothelial dysfunction is first evident when stressed tissues release chemokines 
such as monocyte chemoattractant protein-1 (MCP-1).  These factors trigger 
increased expression of adhesion molecules such as ICAM-1 and E-selectin as well 
as attracting inflammatory cells to the stressed site.  Factors such as reactive 
oxygen species, Ang II, AGEs and reduced bioavailability of NO can induce 
inflammatory cell proliferation and activation of genes within these cells leading 
to production of cytokines including TNF-α and interleukin (IL)-1 as well as IL-6 - 
an important regulator of one of the most clinically relevant markers of 
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inflammation, C-reactive protein (CRP).  The injured endothelial cells increase 
their expression of PAI-1 and release pro-coagulant factors, thereby contributing 
to the evolution of impaired vasoreactivity and a pro-coagulant state [85]. 
Accumulating evidence points towards the enzyme eNOS as a key mediator of 
many of the mechanisms described above.  NO generation has an inhibitory 
effect on platelet aggregation and adhesion of inflammatory cells to the vascular 
endothelium [86] and regulation of vascular smooth muscle tone and endothelial 
permeability is in part controlled by the eNOS-NO system [87].  Similarly there 
has been considerable interest in the role of ET-1, a peptide produced primarily 
by the endothelium that potentiates vascular injury through stimulation of 
growth factors and cytokines, in the progression of diabetes complications and 
renal disease in particular.  The kidneys are exquisitely sensitive to ET-1 as 
components of the ET system are present in glomerular cells, microvasculature 
and the tubules [88] and ET-1 is therefore capable of promoting intrarenal 
inflammation, fibrosis and ultimately glomerulosclerosis.   
 
1.3.4.1 Clinical assessment of endothelial function 
The heterogeneous functions of the vascular endothelium render clinical 
assessment of endothelial function particularly challenging, as no single test can 
provide a comprehensive physiological overview of the entire vascular tree.  
Although a number of the factors mentioned above can be measured in serum or 
plasma and have therefore been proposed as clinical markers of endothelial 
dysfunction [89], the preferred clinical method for assessment of endothelial 
function in humans is endothelium-dependent vasorelaxation [90].  The majority 
of techniques to assess endothelium-dependent vasorelaxation focus primarily on 
regulation of vascular tone as a surrogate measure of the NO-mediated 
vasodilator response and the effect of shear stress.  Originally developed in 
coronary vessels many are now conducted in the forearm and digital circulation 
in order to permit more practical, non-invasive, repeatable studies.  In 
particular brachial artery flow-mediated dilatation (FMD) is currently accepted 
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as the gold standard for non-invasive assessment of peripheral vasoreactivity 
[90]. 
 
1.3.4.2 Endothelial dysfunction in diabetes 
High glucose conditions have been shown to blunt the NO response in human 
endothelial cells [91], an effect which may account for the many cellular effects 
of hyperglycaemia as well as triggering disequilibrium at a microvascular level.  
AGEs, which are generated as a result of cellular exposure to hyperglycaemia, 
have also been shown to have an NO-scavenging effect and thereby may also 
contribute to compromised endothelial function in diabetes [92].  It has also 
been demonstrated that ET-1 synthesis is enhanced by hyperglycaemia [93].  
Endothelial progenitor cells (EPCs) gather at sites of injury and contribute to re-
endothelialisation of damaged vessels.  Circulating EPC levels have also been 
shown to be reduced in both number and function in patients with diabetes [94].  
In view of the above it is perhaps not surprising that impaired endothelial 
function, as indicated by abnormal endothelium-dependent vasodilation and 
increased plasma levels of biomarkers (such as vWF and adhesion molecules), 
have been demonstrated in patients with both T1DM and T2DM [95, 96].  It is 
important to note that as with the general complications of diabetes, 
hyperglycaemia is only one factor in the development of endothelial dysfunction 
and others such as genetic determinants and environmental influences may also 
play a key role in determining which patients progress to more aggressive 
angiopathy.   
 
1.3.4.3 Endothelial dysfunction in diabetic nephropathy 
In 1989 Deckert and colleagues published the “Steno Hypothesis”.  They 
proposed that albuminuria is in fact indicative of a state of global systemic 
microvascular dysfunction and therefore a possible unifying link between the 
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increased UAE observed in DN and the burden of vascular disease commonly 
associated with the condition [97]. 
There is considerable evidence implicating pro-inflammatory and adhesion 
molecules in DN development.  In cross sectional studies in T1DM and T2DM 
levels of biomarkers such as CRP and adhesion molecules are increased in 
patients with DN [98, 99].  In addition brachial artery FMD is significantly lower 
in DN and correlates with degree of proteinuria [100].  Prospective studies have 
also shown that composite scores of endothelial dysfunction biomarkers predict 
progression of renal disease in patients with DN independently of major risk 
factors such as hypertension and poor glycaemic control [101, 102]. 
At an earlier stage in the traditionally accepted disease process, markers of 
inflammation and endothelial dysfunction are strongly associated not only with 
progression of UAE but also with risk of death in patients with diabetes and MA 
[103].  Clinical assessment of endothelium-dependent vasodilation has also 
confirmed impaired brachial FMD in patients with MA compared to 
normoalbuminuric controls [104].  This finding was extended to the general 
population in the Hoorn Study, where FMD was shown to be impaired in patients 
with MA irrespective of whether they had a history of diabetes [105], further 
supportive evidence for the Steno Hypothesis that MA is indicative of generalised 
endothelial dysfunction.  It is important to note, however, that not all 
microalbuminuric patients have evidence of endothelial dysfunction.  It has been 
hypothesised that those MA positive patients who do display some imbalance at 
endothelial level are more likely to develop aggressive complications [106]. 
Endothelial dysfunction appears to be present in some patients with diabetes at 
an even earlier stage in the disease process, before development of clinically 
evident complications.  For example, circulating markers of endothelial 
dysfunction such as CRP and E-selectin are elevated while EPC counts are 
reduced in some young people with T1DM without clinical evidence of 
microvascular disease or MA.  Brachial FMD is also impaired in this patient group 
in comparison to non-diabetic controls [107].  Similarly, endothelial dysfunction 
indicated by elevated plasma concentrations of biomarkers and impaired 
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endothelium dependent vasodilation has been demonstrated in early and 
otherwise uncomplicated T2DM [96, 103]. 
As endothelial dysfunction appears to precede MA in some patients with diabetes 
it is tempting to postulate that MA and hence DN are direct consequences of 
underlying disequilibrium at an endothelial level.  In the DCCT baseline E-
selectin levels were predictive of later development of DN [108].  It has been 
proposed that endothelial dysfunction could trigger MA through direct effects on 
glomerular pressure and permeability.  In addition the paracrine functions of the 
endothelium could indirectly influence mesangial cells and podocytes, however 
the molecular pathways underlying this relationship remain to be fully dissected 
[109].  Similarly, few have evaluated the role of endothelial dysfunction in the 
evolution of non-albuminuric DN.   
 
1.3.5 The renin angiotensin aldosterone system 
The RAAS is another critical element underlying the development of CKD.  The 
classical RAAS cascade begins with secretion of prorenin from juxtaglomerular 
cells in response to a reduction in blood volume.  This is then converted to renin 
which activates production of angiotensin I from angiotensinogen.  Ang II is one 
of the key effector hormones of the RAAS, and is produced as a result of the 
action of angiotensin converting enzyme (ACE) on angiotensin I.  The immediate 
effects of Ang II to support the circulation in the event of intravascular volume 
depletion include: vasoconstriction; potentiation of aldosterone secretion and 
subsequent salt retention; as well as increased myocardial contractility and 
therefore cardiac output.  Despite its physiological role, Ang II has a number of 
deleterious effects on the vasculature in the longer term, effecting a slow 
structural remodelling of the cardiovascular system through processes such as 
hyperplasia of vascular smooth muscle, sensitisation of the vessels to low 
concentrations of vasoconstrictors and excessive deposition of ECM components 
[110].  These effects are mainly mediated via the Ang II type 1 (AT1) receptor 
and explain the amelioration of cardiovascular diseases seen independently of 
reduction in blood pressure in treatment with RAAS blocking agents.  Conversely 
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stimulation of the Ang II type 2 (AT2) receptor generally opposes these actions, 
promoting vasodilation through production of NO in the microcirculation [111]. 
Aldosterone is secreted by the zona glomerulosa of the adrenal cortex in 
response to Ang II and potassium, and acts at the mineralocorticoid receptor 
(MR) located in the collecting duct of the kidney to increase sodium absorption 
and potassium loss, thereby mediating volume status and blood pressure.  
Recently there has been a resurgence of interest in the non-genomic actions of 
aldosterone.  In addition to the renal collecting duct, the MR is also expressed 
on vascular smooth muscle cells, fibroblasts and cardiac myocytes.  Binding of 
aldosterone to the MR in these sites results in pro-fibrotic and pro-inflammatory 
effects, stimulation of cytokine release and cell proliferation thereby triggering 
development of vasoconstriction and cardiovascular disease [112, 113]. 
 
1.3.5.1 The RAAS in DN 
The RAAS has long been implicated in the pathophysiology of DN, in particular 
since the first studies showing significant benefits of ACE-inhibitors (ACE-I) on 
progression of renal disease.  The circulating RAAS appears to be suppressed in 
patients with diabetes, where plasma renin activity and Ang II are generally 
normal or reduced.  Notably RAAS components are also located in the kidney and 
studies have demonstrated intrarenal generation of Ang II, leading to the 
suggestion that paracrine actions of the intrarenal RAAS or enhanced renal 
sensitivity to Ang II are important in DN [114, 115].   
In rat mesangial cells exposure to hyperglycaemia has been shown to trigger 
release of Ang II and TGF-β [116].  Similarly, in animal models of diabetes renin 
mRNA and protein expression are increased in the juxtaglomerular and tubular 
cells in association with increased Ang II production [117], while down-regulation 
of the protective AT2 receptor is consistently reported [118].  Furthermore, 
renal concentrations of Ang II have been shown to progressively increase in these 
animals in conjunction with reduction in availability of NO metabolites, effects 
which are ameliorated by treatment with an AT1 receptor blocker [119].  Ang II 
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produced by mesangial cells mediates ECM deposition via TGF-β, another 
mechanism which appears to be inhibited by AT1 receptor blockade in both 
human and animal studies [116, 120].  The above evidence supports a model of 
downregulation of AT2 receptors through which the AT1 receptor is left 
unopposed with rising Ang II levels leading to hypertension, mesangial cell 
contraction, enhanced deposition of ECM and release of growth factors such as 
TGF-β. 
As detailed above, aldosterone has emerged as a key mediator of accelerated 
vascular and renal damage in recent years.  Broadly speaking its effects can be 
considered in two distinct categories.  First, the classical picture of increased 
sodium reabsorption results in functional alterations in renal haemodynamics.  
For example, in animal models of mineralocorticoid-induced hypertension 
increased glomerular flow is evident in association with vasodilation of the 
afferent and efferent arterioles [121].  In human subjects with primary 
hyperaldosteronism pressure-natriuresis curves shift to the right, indicating that 
higher blood pressure is required in order to maintain sodium excretion in the 
face of the increased tubular reabsorption triggered by aldosterone excess [122].  
Taken together, the classical effects of aldosterone act to drive increased 
perfusion pressures through an intrarenal vasodilatory response, which in turn 
causes glomerular hyperfiltration to counteract the effects of aldosterone on 
sodium reabsorption at the distal tubule. 
Second, the non-genomic effects of aldosterone can effect histological damage 
and structural changes in renal vessels, although to an extent some of these 
changes can also be attributed to functional changes in blood flow within the 
vessels.  It is now widely accepted that aldosterone stimulates collagen 
production and modulates fibroblast differentiation and activity, as well as 
promoting myocardial and vascular hypertrophy and intrarenal vascular 
remodelling [123].  In animal models, aldosterone has been shown to induce 
vascular damage independently of effects on volume status and blood pressure.  
This is thought to result from multiple mechanisms; these include endothelial 
dysfunction, upregulation of AT1 receptors, increased production of TGF-β and 
reactive oxygen species and alterations in the properties of vascular smooth 
muscle cells, the end result being altered ECM and vessel wall composition 
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within the kidney [123].  For example, action of aldosterone on fibroblasts leads 
to increased expression of type I collagen mRNA and stimulates type IV collagen 
deposition in rodent mesangial cells [124].  In addition, aldosterone-dependent 
podocyte apoptosis has been demonstrated in rat models of diabetes [125].  
Aldosterone has also been shown to enhance PAI-1 expression in smooth muscle 
cells which in turn results in excess circulating TGF-β thereby promoting fibrosis 
[126] as well as mediating NF-κB dependent inflammation [127].  Through 
promotion of vascular smooth muscle cell hyperplasia, upregulation of AT1 
receptors and inhibition of norepinephrine reuptake aldosterone advances 
vasoconstriction [128].  In terms of clinical data fewer studies are available.  In 
patients with primary hyperaldosteronism there is a clear association between 
aldosterone and UAE [129], and baseline GFR has been noted to be higher in 
these patients in comparison to matched controls with essential hypertension, 
reflecting hyperfiltration due to elevated intraglomerular hydrostatic pressure 
[130]. 
The majority of clinical evidence for the role of aldosterone in progression of DN 
comes from clinical studies of RAAS blockade with ACE-I or angiotensin receptor 
blockers (ARBs) where the phenomenon of “aldosterone breakthrough” has been 
described.  This term essentially refers to incomplete suppression of plasma 
aldosterone in patients treated with ACE-I or ARB.  Studies have shown that in a 
proportion of patients commenced on these therapies plasma aldosterone level 
returns to pre-treatment level or even higher [131].  Reported incidence of 
aldosterone breakthrough varies between 20 and 50% of patients in published 
studies [132].  It appears that those patients who do demonstrate aldosterone 
breakthrough have worse clinical outcomes.  For example, in hypertensive T2DM 
patients treated with ARB those who showed aldosterone breakthrough 
experienced a progressive increase in UAE after 6 months of therapy compared 
to the group whose aldosterone levels remained controlled.  The effect was 
attenuated following addition of MR antagonist (MRA) [132].  Similarly, in T1DM 
patients with hypertension and DN those who exhibited aldosterone 
breakthrough experienced enhanced decline in GFR [133].  Few have 
investigated the determinants of this phenomenon but in one post-hoc analysis 
factors independently associated with aldosterone breakthrough at one year 
were greater magnitude of short-term reductions in systolic blood pressure, 
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eGFR and sodium intake, suggesting that intensive blood pressure lowering with 
sodium restriction may be a triggering factor [134].  Although data are relatively 
limited and the longer term implications are unknown, given what is known 
about the deleterious non-genomic effects of aldosterone [135] the 
breakthrough phenomenon could have important clinical consequences, and may 
provide at least partial explanation for the relentless progression of DN in some 
patients despite treatment with ACE-I or ARB. 
 
1.3.6 Haemodynamic changes 
Systemic hypertension is an important factor in progression of renal disease in 
diabetes.  Of equal importance however are the intrarenal haemodynamic 
changes resulting from the processes of inflammation, matrix accumulation and 
vascular remodelling described above which ultimately contribute to albumin 
leakage from the glomerular capillaries and decreased resistance in the 
glomerular arterioles.  This allows transmission of systemic pressure to the 
glomerular capillaries and development of hyperfiltration; the earliest stage of 
DN [136].  Animal studies confirm the presence of increased intraglomerular 
pressure as a result of preferential vasodilation of the afferent arteriole [137].  
The resultant increased mechanical strain to which these vessels are subjected 
induces overexpression of glucose transporter-1 (GLUT-1) thereby triggering a 
self-perpetuating cycle of increased glucose uptake, further activation of the 
polyol pathway, PKC and generation of AGEs [138]. 
As previously described, ischaemic atherosclerotic changes can also be present 
in the renal microvasculature in DN.  Renal resistive index (RRI) as measured by 
duplex ultrasonography is an integrated measure of vascular compliance and 
downstream impedance.  RRI is a useful method for quantification of alterations 
in the renal parenchymal circulation and is closely related to renal 
arteriosclerosis [139].  Clinical studies have shown increased RRI in patients with 
DN compared to control subjects [140].  Notably, higher RRI has been shown to 
predict progression of renal disease in diabetic patients with MA [141] and in 
fact normoalbuminuric patients with diabetes have higher RRI than control 
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subjects, reflecting the fact that these haemodynamic alterations occur early in 
the disease process [142]. 
 
1.3.7 A final common pathway? 
The pathogenesis of DN is complex and remains only partially understood.  The 
mechanistic pathways described above do not function in isolation, but rather 
loss of glomerular autoregulation and the metabolic effects of hyperglycaemia 
interact as shown in Figure 1-5.  Hyperglycaemia, often in association with 
systemic hypertension leads to glomerular hypertension via a number of 
mechanisms.  Glomerular hypertension results in injury to the microvasculature 
and thereby triggers a sequence of reactions at the level of the endothelium and 
mesangium.  Vascular stress results in over-expression of GLUT-1 which 
potentiates further glucose entry into cells and in turn leads to PKC activation, 
increased production of TGF-β and AGEs, reduced NO bioavailability as well as 
collagen deposition.  The reduced bioavailability of NO increases Ang II activity 
at the AT1 receptor, further potentiating the cycle of glomerular hypertension, 
expression of TGF-β, ECM deposition and damage to the renal microvasculature 
and parenchyma [143].   
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Figure 1-5.  Interaction of metabolic and haemodynamic pathways in DN. 
AGEs, advanced glycation end-products; PKC, protein kinase C; RAAS, renin angiotensin 
aldosterone system; TGF-β, transforming growth factor β; ECM, extracellular matrix; GFR, 
glomerular filtration rate.  Adapted from Cooper, Lancet 1998; 352: 213-19.   
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1.4 Biomarkers for prediction of DN 
The Kidney Disease Improving Global Outcomes (KDIGO) clinical practice 
guidelines highlight the importance of prompt identification and intervention in 
CKD, irrespective of aetiology [144].  Development of ESRD requiring dialysis or 
transplantation is among the most feared consequences of CKD, however 
symptoms experienced by patients tend to result from the more advanced stages 
of disease and are therefore a late indicator.  The earlier stages of CKD are 
often clinically silent and identified incidentally during assessment of other 
conditions.  Failure to recognise any downward trend in renal function in a 
timely manner leads to relentless progression towards ESRD as well as 
development of complications of CKD including cardiovascular morbidity and 
mortality; acute kidney injury; hypertension; anaemia and disorders of bone 
metabolism.  In contrast, early detection of CKD allows introduction of 
interventions and risk factor management to minimise these risks where 
possible; a strategy that is beneficial to patients, clinical services and 
healthcare budgets.  In current clinical practice diagnosis and prognosis of CKD is 
based on two key biomarkers: eGFR and albuminuria.  Although the gold 
standard tool for confirmation of DN is renal biopsy the majority of diagnoses are 
made on clinical grounds according to the traditional definition of DN which 
requires the presence of albuminuria and/or reduced GFR.  Current guidelines 
recommend monitoring of both these parameters on a regular basis, as both 
have been shown to be independently associated with progressive renal and 
cardiovascular disease [145]. 
 
1.4.1 Glomerular filtration rate 
GFR is the preferred index of renal function for diagnosis and classification of 
CKD (Table 1-3).  The normal GFR in healthy adults is approximately 125 
ml/min/1.73m2 although this declines with age [144].  The gold standard method 
for determination of GFR is measured clearance of exogenous filtration markers 
such as inulin, iothalamate and 51Cr-EDTA [146].  These techniques are time-
consuming and require experienced personnel, therefore their clinical use is 
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often limited to tertiary referral centres and situations where a precise measure 
of GFR is required, such as assessment of potential kidney donors [144].  The 
routine assessment of GFR in clinical practice relies on formulae that generate 
estimates based on serum creatinine. Until recently the Modification of Diet in 
Renal Disease (MDRD) formula was most commonly used for estimation of GFR in 
clinical laboratories.  However, this tool was developed in patients with pre-
existing CKD, meaning that results can be imprecise at general population level 
and GFR at higher levels (i.e. >60ml/min/1.73m2) is underestimated [147].  The 
MDRD formula has since been superseded in many institutions by the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) tool, which offers 
increased accuracy at higher levels of eGFR [148] and thereby reduces the rate 
of false-positive diagnosis of stage 3 CKD [149].  Irrespective of the formula 
used, in clinical practice eGFR levels of less than 60ml/min/1.73m2 are reported 
numerically to the requesting clinician, but results higher than this threshold are 
not generally formally quantified.  This is based on the rationale that GFR of less 
than 60ml/min/1.73m2 has been shown to confer a greater risk of progression to 
ESRD [150]. 
 
 
CKD category Description eGFR (ml/min/1.73m2) 
G1 Normal or increased GFR >90 
G2 Mildly decreased 60-89 
G3a Mild-moderately decreased 45-59 
G3b 
Moderately-severely 
decreased 
30-44 
G4 Severely decreased 15-29 
G5 Renal failure <15 
 
 
Table 1-3.  CKD classification based on estimated glomerular filtration rate (eGFR 
categories). 
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.  GFR, glomerular 
filtration rate.  Adapted from KDIGO 2012 Clinical Practice Guideline for the Evaluation 
and Management of Chronic Kidney Disease, Kidney International Supplements, 2013; 
volume 3. 
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The traditional definition of DN relies in-part on detection of reduced GFR, 
however this method is less than ideal for identification of the early stages of 
disease for a number of reasons. 
 Although clinically useful in day-to-day practice, the P30 (an estimated 
performance measure, expressed as the percentage likelihood that the 
eGFR is within 30% of the measured value) for most formulae used for 
estimating GFR is between 80 and 90%, meaning that eGFR has at most a 
90% chance of being within 30% of the actual measured GFR [151].   
 The existing equations for estimation of GFR are thought to be less 
precise at higher levels, a fact that is of some concern in DN as the 
earliest stages of disease are characterised by a relative increase in GFR 
as previously described.  The link between hyperfiltration, progressive 
renal function decline and albuminuria remains to be fully elucidated, 
however this potentially critical stage in the evolution of DN remains 
undetected by routine clinical parameters. 
 Both the MDRD and CKD-EPI formulae have been shown to be less accurate 
in patients with diabetes in comparison to healthy control populations 
[152].   
 As creatinine is derived from muscle, reliance on creatinine-based 
methods for determination of eGFR will be subject to significant 
variability, particularly in individuals who are significantly over- or 
underweight [153]. 
 
1.4.2 Albuminuria 
Diagnosis and classification of CKD now relies on combined quantification of both 
GFR and level of UAE, as the presence of both these factors identifies individuals 
at particularly high risk of progression to ESRD [144, 150].  Although often 
transient in nature, the presence of persistent albuminuria has marked clinical 
significance as an early indicator of underlying renal pathology. Levels of 
albumin excretion are quantified as normal; moderately increased or severely 
increased (Table 1-4), and levels above 30mg/g (or 3mg/mmol) have been shown 
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to be associated with subsequent risk of mortality and CKD progression across 
both general and high-risk populations [154, 155].  One such high-risk group 
includes patients with diabetes. 
 
 
Albuminuria 
category 
Description UACR 
A1 Normal - mildly increased 
<30mg/g 
<3mg/mmol 
A2 Moderately increased 
30-300mg/g 
3-30mg/mmol 
A3 Severely increased 
>300mg/g 
>30mg/mmol 
 
 
Table 1-4.  CKD classification based on albuminuria categories. 
UACR, urine albumin: creatinine ratio.  Adapted from KDIGO 2012 Clinical Practice 
Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney 
International Supplements, 2013; volume 3. 
 
 
 
 
The development of assays for detection of MA in the 1960s revolutionised 
diabetes management, and almost 60 years later this marker continues to be 
monitored in routine practice as the earliest index of DN.  Traditionally UAE has 
been graded using the following categories in patients with diabetes: 
“normoalbuminuria” (UACR <30mg/g or <3mg/mmol); “microalbuminuria” (UACR 
30-300mg/g or 3-30mg/mmol); and “macroalbuminuria” (UACR >300mg/g or 
>30mg/mmol).  If a positive result is obtained repeat confirmatory testing should 
be performed, with two out of three positive subsequent measurements 
considered to imply persistence. 
Long term follow up studies published in the 1980s, prior to the introduction of 
RAAS blocking agents and therefore not influenced by their effect on UAE, 
demonstrated that MA was highly predictive of progression to overt DN in both 
type 1 and type 2 diabetes [21, 22, 28].  In a recent meta-analysis, drug-induced 
reduction in albuminuria of 30% translated into a 25% reduction in risk of 
progressive ESRD irrespective of choice of agent [156].  In addition MA has been 
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demonstrated to provide important prognostic information on cardiovascular 
morbidity and mortality in diabetic patients with and without nephropathy [145, 
157-159] as well as at general population level [160].  Moreover, the presence of 
MA has been shown to indicate increased risk of all-cause mortality in both 
patients with T1DM and T2DM in comparison to those who remain 
normoalbuminuric [161, 162].  Consequently, UAE has evolved into both a key 
prognostic marker and therapeutic target in the management of patients with 
diabetes.   
Although undoubtedly an essential tool for stratification of risk and monitoring 
of treatment effects in current clinical practice, there are a number of 
limitations associated with use of UAE as an early biomarker of DN. 
 Our understanding of the natural history of DN has evolved as described 
earlier in this chapter.  We now know that significantly fewer patients 
with detectable MA progress to overt DN than previously thought [30-32] 
and it is widely accepted that decline in GFR in patients with diabetes is 
not conditional on progression through the traditionally defined grades of 
UAE, as evidenced by the description of disease subtypes such as early 
GFR decline [36, 37, 40] and non-albuminuric DN [43, 44].  Similarly, the 
presence of MA is no longer viewed as a definitive and irreversible stage 
of DN.  Studies have shown that remission of MA to normoalbuminuria 
occurs frequently in patients with diabetes [31, 33, 35, 163]. 
 Although traditionally accepted as the earliest clinical indicator of DN, by 
the time MA reaches the diagnostic threshold of 30mg/g or 3mg/mmol 
significant histological changes have already developed within the GBM 
and mesangial matrix in relative clinical silence [38, 164].   These are 
often preceded by alterations in glomerular perfusion pressure and its 
associated injurious effects on the renal microvasculature.  Rather than 
being an early indicator of disease, clinical MA is effectively identifying 
individuals who may have already advanced through the initial stages of 
DN development. 
 It is clear from recent literature that the relationship between UAE, renal 
and cardiovascular outcomes is a continuum starting from levels well 
within the limits of what is currently considered to be the “normal” range 
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[145, 154, 165, 166].  In this regard the thresholds defined in clinical 
guidelines are somewhat arbitrary and there has been a trend towards 
reporting UAE as a continuous variable alongside CKD stage to define risk 
[151]. 
 Measurement of UAE is not standardised and results are variably reported 
as 24-hour excretion rates or spot collections corrected for urinary 
creatinine.  In addition day-to-day variability within individuals is 
significant and UAE can be influenced by a number of patient-specific 
factors such as blood pressure; dietary protein intake; exercise; fever; 
and presence of urinary tract infection [151]. 
 Independent prediction of cardiovascular morbidity and mortality as well 
as progression to ESRD by MA renders it an important clinical tool.  
However, at present there is no clear means by which to differentiate MA 
linked to cardiovascular disease from MA relating to renal disease; 
moreover albumin excretion is influenced by the multitude of patient-
specific factors listed above.  It could therefore be argued that any 
fluctuation in UAE may reflect modification of a different disease process 
and is not specific to the evolution of renal disease.   
The pathogenesis and clinical presentation of DN are far more varied than 
previously defined in the traditional 5-stage classification and as a result there is 
currently no precise formula for diagnosis of the condition.  The increasing 
prevalence of diabetes and the invasive nature of the procedure means that it is 
impractical to perform a renal biopsy on all patients with elevated UAE or 
reduced eGFR and clinicians therefore rely on laboratory measures interpreted 
in the context of patient characteristics to reach a diagnosis. 
While eGFR and UAE undoubtedly provide important information on prognosis 
their utility as tools for early identification of DN is limited and there is an 
unmet clinical need for specific novel biomarkers to identify patients in the 
earlier stages of DN as well as to categorise individuals in whom there is 
diagnostic uncertainty.  In recent years there has been a surge of publications 
describing novel biomarkers for DN.  A number of individual molecules have been 
described as illustrated in Figure 1-6, most of them proteins and polypeptides, 
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each of which typically captures a specific mechanistic process underlying DN 
development. 
 
1.4.3 Cystatin C 
Cystatin C is a low molecular weight plasma protein that is freely filtered at 
glomerular level and subsequently catabolised and reabsorbed in the tubules to 
such an extent that under normal physiological conditions it does not return to 
the blood in its intact form [167].  Serum levels are closely correlated with 
measured GFR and unlike creatinine are not affected by gender, age or body 
mass [168].  Cystatin C has been shown to be an accurate marker of renal 
function, even at the low levels found when GFR remains within the currently 
accepted “normal” range [169] and increases in serum concentration have been 
shown to predict decline in GFR independently of UAE [170].  In patients with 
diabetes, serum cystatin C increases progressively with declining GFR, and 
elevated levels can be detected even when GFR is within the supra-normal range 
while anti-hypertensive medications may render MA undetectable as can be seen 
in the early stages of DN [171].  Whilst it shows promise as a tool for early 
identification of GFR decline and formulae for estimation of GFR based on 
Cystatin C are more accurate at higher levels of GFR, they have not yet been 
shown to improve precision of monitoring early GFR decline in patients with 
diabetes [169]. 
 
1.4.4 Markers of glomerular dysfunction 
As described above, renal damage in diabetes is in part characterised by 
alterations in GBM structure and permeability.  A number of urinary biomarkers 
have been described for identification of glomerular damage in patients with 
diabetes. 
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1.4.4.1 Transferrin 
Transferrin is a plasma protein with slightly greater molecular weight than 
albumin.  As it is less ionic and therefore less easily repelled by GBM, it is more 
readily filtered at the glomerulus [172] and thereby excreted earlier and in 
greater quantities than albumin.  Early clinical studies in DN used transferrin 
rather than albumin to assess progression of DN [173, 174] and transferrinuria 
has been shown to rise in parallel with UAE [175].  The presence of 
transferrinuria has been demonstrated in patients with diabetes and glomerular 
lesions, even in the normoalbuminuric stage, and the degree of excretion 
correlates with the degree of underlying interstitial fibrosis and tubular atrophy 
at a histological level [176].  Furthermore, increased baseline urinary transferrin 
has been shown to independently predict development of MA over 2-5 years 
follow up [172, 175].  Although these findings suggest that measurement of 
urinary transferrin could be a useful tool for early detection of DN it is not a 
specific indicator and is also elevated in a number of other renal diseases [177]. 
 
1.4.4.2 Type IV collagen 
Type IV collagen is a major constituent of the mesangial matrix as well as 
glomerular and tubular basement membranes.  Its high molecular weight means 
that under normal conditions it cannot be filtered at glomerular level and 
excretion is therefore thought to be indicative of the rate of matrix turnover in 
kidney disease [175].  Studies have shown an association between urinary type IV 
collagen excretion and risk of progressive decline in renal function in patients 
with type 2 diabetes and proteinuria [178] as well as in normoalbuminuric 
patients [179].  No clear association has been demonstrated with progressive 
UAE.  The ratio of type IV collagen to albumin appears to be increased to a 
greater degree in DN as opposed to other glomerular diseases, indicating a 
potential role differentiating DN from non-diabetic renal disease [180]. 
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1.4.4.3 Caeruloplasmin 
Caeruloplasmin is an acute phase protein which plays a key role in copper 
metabolism.  Urinary caeruloplasmin: creatinine ratio is elevated in patients 
with DN and excretion appears to rise in parallel with UAE [181].  In a small 
prospective study higher urinary caeruloplasmin levels predicted progression to 
clinical MA in normoalbuminuric patients with type 2 diabetes and excretion has 
been shown to regress following intervention to improve glycaemic control or 
addition of ARB treatment [175]. 
 
1.4.4.4 Podocytes and related proteins 
Recent years have seen a heightened interest in urinary excretion of podocytes 
or podocyte-specific proteins as early markers of glomerular pathology.  It has 
been reported that morphologically the number of podocytes present per 
glomerulus is a strong predictor of progressive renal disease in Pima Indians with 
MA [182].  Urinary podocyte excretion has been shown in diabetic patients with 
both MA and overt albuminuria and is thought to result in disruption of the 
glomerular filtration barrier.  Reduced podocyte numbers have not been seen in 
normoalbuminuric patients [74].  Few authors have focussed on podocyte 
alterations in Caucasian patients to date, but small studies have confirmed 
increased podocyte loss in T2DM patients with DN in correlation with foot 
process widening and increasing proteinuria [183, 184].  
Nephrin is a transmembrane protein expressed in podocytes and its urinary level 
is regarded as an indicator of podocyte damage.  Urinary nephrin excretion has 
been shown to correlate with degree of UAE and decline in GFR [185].  Several 
studies have shown elevated urinary nephrin levels in normoalbuminuric patients 
with diabetes [186-188] although to date none have confirmed that this finding 
is predictive of trends in UAE or GFR. 
Podocalyxin is another podocyte-associated protein which can be quantified in 
urine.  Urinary podocalyxin has been shown to be elevated in patients with 
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diabetes, increasing progressively from normo- to micro- and macroalbuminuria, 
and in addition excretion appears to be correlated with clinical risk factors such 
as HbA1c [189].  As with nephrin, no prospective studies have confirmed the 
clinical predictive potential of podocalyxin.   
 
1.4.5 Markers of tubular dysfunction 
Low molecular weight plasma proteins can be excreted in the urine in increased 
quantities either as a result of abnormal tubular reabsorption or secretion by 
tubular epithelial cells.  Similarly detection of a variety of enzymes in the urine 
is another sensitive indicator of tubular dysfunction.  These cannot be filtered at 
the glomerulus, thus their presence in the urine is indicative of release from 
damaged tubular epithelial cells. 
 
1.4.5.1 Neutrophil gelatinase-associated lipocalin (NGAL) 
This molecule belongs to the lipocalin family; a group of proteins which regulate 
the binding and transporting of small hydrophobic molecules as well as immune 
regulation and apoptosis.  Stored primarily in the neutrophil granules it is also 
expressed in the kidney where it acts as a mediator of tubular cell proliferation 
and undergoes near complete tubular reabsorption in healthy conditions.  NGAL 
is considered a sensitive marker of acute kidney injury [190] but recent studies 
have also explored its role in DN.   
Associations between urinary NGAL excretion and features of diabetes and the 
metabolic syndrome such as obesity, hyperglycaemia and insulin resistance have 
been reported [191].  In addition, urinary NGAL excretion has been shown to 
increase from normo- to micro- and macroalbuminuria in patients with type 1 or 
type 2 diabetes and to parallel eGFR in diabetic patients with glomerular 
hyperfiltration, suggesting utility as a diagnostic marker in early DN  [192, 193].  
Higher urinary NGAL was a predictor of subsequent decline in eGFR in a cohort 
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of T2DM patients with overt proteinuria [194] but to date there is no evidence 
that it can perform adequately as a prospective indicator of DN risk in 
normoalbuminuric patients. 
 
1.4.5.2 Kidney injury molecule-1 (KIM-1) 
KIM-1 is a membrane protein expressed on proximal tubular cells that is involved 
in phagocytosis of damaged cells.  Undetectable in the urine in healthy 
conditions, it appears to be a sensitive and specific biomarker of proximal 
tubular injury as well as for early detection of acute kidney injury [195].  To 
date the evidence for its use as a biomarker of DN is conflicting.  A small 
prospective study demonstrated association between baseline urinary KIM-1 and 
subsequent GFR decline in a cohort of patients with DN; however this lost 
significance following adjustment for traditional risk markers [195] and similar 
results have been reported in T2DM [196].  In one study, however, low baseline 
urinary levels of KIM-1 were associated with regression of MA in T1DM [197] and 
more recently KIM-1 was included in a panel of 14 serum biomarkers significantly 
associated with rapid GFR decline over a 3 year follow up period in a small 
cohort of T2DM patients with CKD 3 [198].  Most recently in a large study of 1500 
patients with T1DM baseline KIM-1 was not found to add any incremental 
prognostic benefit to measurement of UAE for DN prediction over 6 years of 
follow-up [199]. 
 
1.4.5.3 N-acetyl-β-D-glucosaminidase (NAG) 
NAG is a high-molecular weight lysosomal enzyme secreted by the proximal 
tubule in response to kidney injury, and urinary excretion is increased in a 
variety of renal diseases.  Elevated urinary NAG excretion has been 
demonstrated in patients with diabetes compared to healthy controls, even in 
normoalbuminuric groups [194].  Higher baseline NAG excretion as well as 
upward trends over time independently predicted onset of MA in samples from 
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the DCCT [200] and similarly lower levels at baseline were associated with 
regression of MA in another study [197].  Significant increases in urinary NAG 
excretion have also been reported with other microvascular diabetes 
complications, leading some authors to attribute NAG similar diagnostic utility to 
MA [201]. 
 
1.4.5.4 α1-microglobulin (A1M) 
A1M is a low molecular weight glycoprotein with the result that it is freely 
filtered at the glomerulus and reabsorbed in the proximal tubule.  Damage to 
tubular cells therefore results in increased urinary excretion of A1M.  Elevated 
urinary A1M excretion has been demonstrated in patients with diabetes 
compared to control subjects and correlate with HbA1c and diabetes duration 
[202].  In cross sectional studies urinary A1M has been shown to increase with 
degree of UAE and increased excretion has also been detected in 
normoalbuminuric patients, leading to speculation that it may provide 
information in addition to UAE for early DN detection [203].  Prospective work 
exploring the potential of A1M as an early predictor of DN is lacking.   
 
1.4.5.5 β2-microglobulin (β2M) 
β2M is another low molecular weight protein which can be detected in increased 
quantities in the urine of patients with tubular injury [204].  Elevated urinary 
excretion has been associated with macrovascular complications and 
hypertension in patients with diabetes [205] but results focussing on β2M as a 
biomarker of DN are conflicting.  Small studies have suggested an association 
with other validated biomarkers such as cystatin C [206] but the relative 
instability of urinary β2M in response to variations in temperature or pH limit its 
clinical applicability and no direct comparisons with UAE have been published. 
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1.4.5.6 Retinol-binding protein (RBP) 
RBP is primarily synthesised in hepatocytes but is also expressed in other insulin 
sensitive tissues such as adipose tissue and muscle.  As with A1M its low 
molecular weight mean that following glomerular filtration it is almost 
completely reabsorbed at the tubule and thus its excretion in urine is indicative 
of tubular dysfunction.  Increased urinary RBP has been reported in diabetic 
patients with MA compared to normoalbuminuric subjects [202].  Associations 
between urinary RBP and both micro- and macrovascular diabetes related 
complications have been reported [205].  In one recent cross-sectional study 
serum RBP levels progressively increased from normo- to micro and 
macroalbuminuria and were found to be more specific for DN than NGAL or UAE 
[207].  Again, no larger scale prospective work has confirmed the proposed 
predictive potential of RBP.   
 
1.4.5.7 γ-Glutamyltransferase (GGT) 
GGT is predominantly considered to be a marker of hepatobiliary function but is 
also present in the proximal tubules and urinary excretion has been investigated 
as an indicator of tubular dysfunction.  Detection of increased urinary GGT has 
been reported in patients with T2DM and levels correlated with traditional 
markers of renal function as well as glycaemic control [208].  More recently 
elevated urinary GGT excretion was demonstrated in patients with T2DM and 
glomerular hyperfiltration [209]. 
 
1.4.5.8 Liver-type fatty acid binding protein (L-FABP) 
L-FABP is mainly expressed in the liver and proximal tubules.  Acting as an 
intracellular carrier protein, L-FABP is produced in response to tubular injury 
and its presence in the urine is thought to be indicative of the same [210].  A 
cross-sectional study in patients with T1DM showed significantly higher urinary L-
FABP excretion in diabetic patients compared to control subjects.  Furthermore, 
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levels increased with degree of UAE and regressed upon treatment with ACE-I 
[211].  In T2DM, L-FABP was not found to be predictive of GFR decline over 2 
years of follow-up [212]. 
 
1.4.5.9 Uromodulin (UMOD) 
Also known as Tamm-Horsfall protein, UMOD is a glycoprotein produced in the 
ascending limb of the proximal tubule and the distal convoluted tubule.  Its 
physiological functions remain incompletely understood but research has 
highlighted a potential role in the pathogenesis of CKD [213].  There is ongoing 
debate as to whether UMOD acts primarily in the initiation and progression of 
DN, or plays a more protective role.  Certainly in the later stages of fulminant 
nephropathy urinary excretion of UMOD appears to be reduced [214-216].  
However, the picture is complicated by the fact that in the earlier stages of 
disease excretion is increased.  Studies have shown elevated baseline UMOD 
excretion in normoalbuminuric patients with T1DM who later progressed to 
develop MA, and in subjects with diabetes and normal GFR [217, 218].  However, 
no consistent correlation between UMOD excretion and UAE has been 
demonstrated to date. 
 
1.4.6  Markers of inflammation 
Accumulating evidence points towards a mechanistic role for inflammation in the 
pathogenesis of DN [97, 98, 101, 103].  Studies have shown increased subclinical 
inflammation and endothelial dysfunction in diabetic patients who progress to 
overt DN years before the development of disease that is detectable by 
traditional clinical means [108].  As such, a number of mediators of these 
processes have attracted attention as potential early biomarkers of DN.  
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1.4.6.1 TNF-α 
TNF-α is an inflammatory cytokine which plays a key role in mediating tissue 
damage.  As well as production by infiltrating inflammatory cells in kidney 
disease, TNF-α can also be produced locally within renal endothelial, tubular 
and glomerular epithelial cells.  Through promotion of inflammation, 
extracellular matrix accumulation, production of reactive oxygen species and 
glomerular barrier damage TNF-α exerts a focal role in the pathogenesis of 
kidney injury and progression of albuminuria [219, 220].  Serum and urinary 
levels of TNF-α are increased in patients with diabetes compared to healthy 
controls [221] and urinary excretion appears to increase progressively with 
nephropathy severity in patients with T2DM and micro- or macroalbuminuria as 
opposed to normoalbuminuric subjects [222]. 
The effects of TNF-α are mediated by TNF receptors 1 and 2 which although 
membrane-bound can also be detected in serum in soluble form (STNFR 1 and 2).  
Serum levels of STNFR correlate with GFR in patients with diabetes [223] and 
accumulating evidence highlights the potential importance of these receptors as 
early biomarkers of DN.  For example, patients with higher baseline STNFR levels 
have been shown to be significantly more likely to progress to CKD stage 3 and 
later ESRD over 12 years of follow-up, both in T1 and T2DM [224, 225].  This 
association appears to be stronger in patients without proteinuria, raising the 
possibility that the STNFRs could indeed have to potential to provide prognostic 
information above UAE status in the normoalbuminuric population.  Until 
recently, little was known about the underlying histological lesions developing in 
human kidneys when these markers are elevated.  This relationship was recently 
examined in a cohort of Pima Indians with T2DM where an inverse correlation 
was seen between STNFR levels and glomerular filtration surface, and STNFR 
correlated positively with GBM width and percentage of glomerular sclerosis 
[226].  These results corroborate the roles of inflammation and TNF signalling in 
the pathogenesis of DN.  However, it is unclear whether the measurement of 
serum SNTFR abundance is indicative of renal or rather systemic receptor 
activation. 
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1.4.6.2 IL-6 
Inflammatory cytokines such as IL-6 have been shown to be powerful 
independent predictors of cardiovascular morbidity and mortality [227].  
Inflammation has also been shown to predict future development of CKD.  In a 
large population based cohort study IL-6 was among a number of inflammatory 
markers that was not only associated with prevalent CKD at baseline, but also 
with development of CKD over a 15 year follow up period [228].  Serum IL-6 is 
elevated in patients with diabetes in comparison to healthy control subjects, 
and has been shown to be directly correlated with GBM thickening in a cohort of 
patients with T2DM [229].  Peripheral blood mononuclear cells (PBMCs) from 
patients with diabetes appear to display a more inflammatory phenotype with 
increased mRNA expression of IL-6 in individuals with micro- or 
macroalbuminuria, and in one study UAE was an independent predictor of PBMC 
IL-6 mRNA expression [221].  In a cohort of patients with T2DM and MA, a 
collection of inflammatory biomarkers (CRP, IL-6 and fibrinogen) and in 
particular baseline IL-6, independently predicted progression to onset of clinical 
DN [102].  To date there is no prospective evidence confirming any benefit 
above UAE in terms of early identification of DN risk in nonalbuminuric patients. 
 
1.4.6.3 MCP-1 
MCP-1 is a proinflammatory chemokine which has been shown to induce cytokine 
production as well as monocyte recruitment.  In the kidney MCP-1 is synthesised 
in tubular epithelial cells and mesangial cells through a NF-ƙB dependent 
mechanism.  The resultant recruitment of inflammatory cells into the 
interstitium culminates in the fibrosis, inflammation and tubular atrophy that is 
characteristic of DN [230].  Elevated urinary MCP-1 levels have been described in 
patients with DN [231].  Furthermore, excretion appears to parallel progression 
through the clinical stages of disease and correlate with UAE [232, 233].  These 
results support a role of MCP-1 in evolution of DN, however prognostic utility 
beyond MA is yet to be proven.   
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1.4.6.4 α-1-acid glycoprotein (AGA) 
AGA is produced mainly in the liver and released in response to stimulation by 
inflammatory cytokines including TNF-α and IL-6.  Increased levels are 
associated with a number of cardiovascular conditions including diabetes [234].  
Urinary AGA excretion correlates with UAE in patients with diabetes and the two 
appear to increase in parallel with each other [235, 236].  More recently in a 
urinary proteomic study, AGA was shown to predict progression to MA over 6 
years of follow up in a cohort of T1DM patients without any evidence of 
nephropathy at baseline [217]. 
 
1.4.7 Markers of oxidative stress 
As described earlier in this chapter, oxidative stress is thought to be a key factor 
underlying development of diabetes complications and a number of products of 
oxidative damage can be measured in blood and urine.  Several of these show 
some promise as biomarkers of DN. 
 
1.4.7.1 8-oxo-7,8-dihydroguanosine (8-OHdG) 
8-OHdG is a by-product of oxidative DNA damage.  It is renally excreted without 
further degradation and therefore has been proposed as a useful urinary marker 
of oxidative stress [237].  Increased urinary excretion of 8-OHdG has been 
described in patients with diabetes compared to healthy control subjects, and 
appears to parallel increases in UAE [238, 239].  Treatment with ARBs has also 
been shown to reduce urinary 8-OHdG excretion in patients with DN and 
hypertension [240].  Furthermore, in a study of 500 T2DM with normo- or 
microalbuminuria those with higher urinary 8-OHdG at baseline were more likely 
to progress to DN,  and 8-OHdG predicted disease progression more strongly than 
other traditional risk factors including blood pressure and HbA1c [239], hinting 
at potential as an early biomarker of risk of progressive disease.  However, it 
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remains to be seen whether 8-OHdG offers any additional prognostic information 
beyond markers currently used in clinical practice. 
 
1.4.7.2 Pentosidine 
AGEs are the result of cellular exposure to hyperglycaemia and have been 
implicated in the pathogenesis of DN as described previously.  Pentosidine is a 
structural component of AGEs which is filtered at the glomerulus and 
subsequently catabolised at the proximal tubule.  While serum levels reflect 
oxidative stress, urinary pentosidine is thought to signify a degree of tubular 
dysfunction in addition.  Increased urinary excretion has been demonstrated in 
patients with diabetes compared to healthy controls, while higher urinary and 
plasma levels are seen in overt DN [241-243] as well as in patients with MA [244].  
At a histological level pentosidine has been shown to accumulate in mesangial 
and nodular lesions in DN [245].  Moreover, in a nested case-control study from 
the DCCT urinary pentosidine excretion was found to be predictive of subsequent 
progression to macroalbuminuria on univariate analysis, although significance 
was reduced in multivariate modelling [200]. 
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Figure 1-6.  Biomarkers evaluated in DN. 
DN, diabetic nephropathy; NGAL, neutrophil gelatinase associated lipocalin; KIM-1, 
kidney injury molecule 1; NAG, N-acetyl-b-d-glucosaminidase; L-FABP, liver-type fatty 
acid binding protein; RBP, retinol binding protein; GGT, gamma glutamyl transferase; 
UMOD, uromodulin; 8-OHdG, 8-oxo-7, 8-dihydro-2’-deoxyguanosine; AGA, alpha-1-acid 
glycoprotein; STNFR 1 / 2,  soluble TNF-α receptors 1 and 2; IL-6, interleukin-6; MCP-1, 
monocyte chemoattractant protein-1. Adapted from Currie, World Journal of Diabetes 
2014; 5: 763-776. Image courtesy of Medical Illustration Department, Glasgow Royal 
Infirmary, Glasgow. 
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1.4.8 Genetic markers 
Strong familial clustering of DN has previously been shown [246, 247], leading to 
attempts to identify associated genetic variants.  This brings a number of 
challenges and results to date have largely been disappointing as the complex 
underlying pathophysiology is likely to be determined by numerous variants, 
potentially acting additively or synergistically.  In addition it is difficult to 
account for the significant influence of environmental factors. 
Family Investigation of Nephropathy and Diabetes (FIND) and Genetics of Kidneys 
in Diabetes (GoKinD) are examples of groups using genome wide association 
scans to study DN susceptibility.  The multicentre FIND consortium used family 
based linkage analyses in diverse ethnic groups to identify genetic loci that are 
associated with nephropathy in patients with T2DM [248].  A preliminary genome 
scan found links between multiple loci (e.g. 7q21.3; 10p15; 14q23.1) and DN 
status as well as GFR phenotype in African-American and European-American 
populations [249].  The GoKinD group focus on genetic association studies of DN 
in T1DM [250] and have linked candidate loci near the FERM domain containing 3 
(FRMD3) gene, which is involved in cytoskeletal integrity, to DN [251].  In 
addition this work identified sorbin and SH3 domain containing 1 (SORBS1) gene 
polymorphisms which were significantly associated with DN, although these were 
not confirmed in a further analysis using additional cohorts [252].  A meta-
analysis of genetic association studies in DN published in 2011 found 21 different 
variants associated with DN.  Two of these were in the FRMD3 gene, others 
included cysteinyl-tRNA synthetase (CARS), VEGF and ACE [253].  Further studies 
are required to confirm these associations and to explain the pathways through 
which they influence development of DN. 
 
1.4.9 Summary 
Translation of a biomarker into clinical practice requires extensive validation in 
large studies to confirm accuracy, reproducibility, sensitivity and specificity.  
These stages are discussed in more detail in section 4.1.  Despite extensive 
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research into biomarkers with potential for early prediction of DN, no single 
candidate has emerged that unequivocally outperforms UAE in these regards.  
Although some show promise, in particular the STNFRs, none have yet been 
confirmed to provide additional benefit beyond the traditional parameters used 
in day to day clinical practice.  As described earlier in this chapter, there are 
multiple pathophysiological processes contributing to development of DN.  
Furthermore, the interaction between these mechanisms remains incompletely 
understood meaning it may be impossible for a single biomarker to accurately 
predict progression of such a complex condition.  The next logical step in the 
search for early identifiers of at-risk individuals may be use of panels of multiple 
biomarkers, thereby simultaneously capturing several pathophysiological 
mechanisms to improve disease prediction.  High-throughput tools such as 
proteomic and metabolomic profiling are emerging as key strategies for 
biomarker discovery and these methods will be discussed below. 
 
1.5 Metabolomics 
The human metabolome is the product of interactions between the genome, 
transcriptome and proteome.  Metabolomics has recently emerged as a 
technique with potential for biomarker discovery and essentially involves 
measurement of intermediates and end-products of cellular metabolism in a 
biological sample, thereby characterising physiological and pathological changes 
that result from different disease processes.  Metabolomic analysis can be 
performed on any biological material including serum; plasma; tissue or urine; 
and in recent years a number of studies have explored the application of 
untargeted metabolomic profiling in chronic kidney disease [254] although to 
date relatively few focussed on DN in particular.   
In a small cross-sectional study of plasma samples from non-diabetic subjects 
with CKD stage 2-4 major differences in arginine metabolism, carboxylate anion 
transport and coagulation pathways were identified with CKD progression [255].  
Small cross-sectional studies using serum samples from patients with T2DM have 
identified a number of differentially-regulated metabolites including products of 
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amino acid and lipid metabolism as well as indicators of altered protein 
methylation such as symmetric dimethylarginine, to distinguish patients with 
overt DN from normoalbuminuric subjects [256, 257].  Application of 
metabolomic analysis to stored baseline samples from the Prevention of Renal 
and Vascular Endstage Disease (PREVEND) trial highlighted differences in urine 
hexose and glutamine between individuals who transitioned in albuminuria 
status over a median 2.9 years follow up period.  Addition of these metabolites 
to a predictive model including traditional risk markers such as UAE and eGFR 
appeared to improve accuracy of risk estimation for CKD progression [258].  
Whilst these results are interesting, metabolomic research is still in its infancy 
and prospective projects assessing the predictive power of these tools to identify 
individuals at risk of DN are lacking.  The complexity of the metabolome is 
probably the key factor limiting clinical applicability of these techniques at 
present.   
 
1.6 Proteomics 
Proteomics is defined as “the knowledge of the structure, function and 
expression of all proteins in the biochemical or biological context of organisms” 
[259] and involves large-scale evaluation of the protein and peptide content of a 
biological sample.  Whilst genomics describes the potential to develop disease 
and may play a key role in risk prediction, each gene in the human genome can 
be subject to differential translation and post-translational modifications to 
encode numerous different proteins.  Proteomics therefore indicates the actual 
state of the organism at a given time point that results from interplay between 
genetic and environmental factors, thereby acting to identify the point at which 
an individual’s genetic risk progresses to clinical disease.  Proteomic analysis of 
biological samples can highlight differentially expressed proteins to distinguish 
particular disease processes; offer potential for early disease detection prior to 
onset of characteristic symptoms or standard biochemical abnormalities; and 
offer “hypothesis-generating” capabilities by providing deeper mechanistic 
insights into the pathogenesis of complex conditions.  As a result, the number of 
published papers describing the proteomic signature of specific conditions has 
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grown exponentially in recent years and a draft map of the human proteome 
encompassing more than 80% of protein-coding genes was published in 2014 
[260] with ongoing initiatives such as the Human Proteome Organisation now 
comprehensively exploring this on a much larger scale [261]. 
 
1.6.1 Sample selection and preparation 
Proteomic analysis can be conducted on any biological sample or tissue: cultured 
cells; bodily fluids i.e. blood, urine or cerebrospinal fluid.  Large scale work is 
generally limited to blood or urine as obtaining tissue samples often requires 
invasive procedures.  
Plasma and serum are often the biofluids of choice as blood is in direct contact 
with organs.  However, these sample types are prone to proteolytic degradation 
which can make accurate analysis challenging; for example increased proteolytic 
activity is observed in serum or plasma samples immediately following 
phlebotomy and clotting [262].  In addition, the plasma proteome is highly 
complex due to albumin-binding of a number of proteins as well as the variable 
concentrations of plasma proteins in a sample, ranging from picomolar to 
millimolar. 
For these reasons urine is an attractive sample type for proteomic research.  
Urine contains proteins originating from numerous biochemical processes within 
the body; it can be collected non-invasively; is generally available in large 
quantities; and undergoes the majority of its proteolytic degradation during 
passage through the urinary tract prior to voiding, making it more stable for 
accurate analysis of peptide composition and meaning that less pre-analytical 
preparation is required.  In addition, the urinary proteome remains stable for 
several hours when stored at room temperature and even after freezing at -20°C 
for several years [263, 264].  
Ideally pre-analytical handling of samples for proteomic processing should be 
minimised to avoid interference or artefact.  However, a number of abundant 
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molecules such as albumin, salt and lipids can affect the reproducibility and 
comparability of results, hence most protocols require a degree of sample 
preparation to remove these.  Pre-analytical fractionation reduces the 
complexity of samples allowing efficient and reproducible analysis.  The steps 
taken to minimise variability in sample processing for the purpose of this specific 
research project will be discussed in more detail in chapter 2. 
 
1.6.2 Proteomic platforms 
In general terms proteomics first requires separation of proteins and peptides 
from other sample components as well as from each other; followed by 
subsequent identification and analysis of their individual abundance using mass 
spectrometry.  Many different techniques are available for proteomic analysis.  
The advantages and disadvantages of each have been extensively reviewed [263, 
264] and choice of platform is generally dependent on the sample type to be 
analysed; the number of samples to be processed; available equipment and 
expertise.  A detailed description of each of these platforms is beyond the scope 
of this thesis but they will be summarised briefly in the following paragraphs.    
 
1.6.2.1 2-dimensional gel electrophoresis (2-DE) 
This protocol separates the proteins contained in a sample based on their 
isoelectric point and molecular weight.  Following treatment with in-gel 
proteolytic digestion the gel spots are extracted and mass spectrometry (MS) is 
employed to identify and quantify peptide fragments.  Although 2-DE enables 
high resolution protein separation the lack of automaticity means that large 
scale simultaneous analysis of high numbers of proteins is not feasible.  
Furthermore its utility for high resolution separation of the low-molecular 
weight proteome is limited [265]. 
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1.6.2.2 Surface-enhanced laser desorption/ionisation (SELDI) – mass 
spectrometry 
SELDI-based proteomic techniques are based on selecting a small well-defined 
fraction of the sample proteome characterised by factors such as pH and salt 
content.  The process uses hydrophilic surfaces which selectively adsorb proteins 
allowing unbound molecules to be removed.  Subsequent addition of a matrix to 
the surface results in crystallisation and separation of proteins by binding to the 
matrix, reducing sample complexity.  The reproducibility of these peptide 
binding techniques is variable and much of the sample proteome is removed 
prior to MS analysis, making comparisons of different datasets unreliable and 
resulting in loss of a significant quantity of proteome information [266]. 
 
1.6.2.3 Liquid chromatography (LC) – mass spectrometry 
LC is a powerful tool for peptide separation.  Peptides are separated using a 
chromatographic column, based on their elution through a liquid phase from a 
solid or stationary phase as a result of different characteristics such as charge or 
hydrophobicity.  The eluting peptides are ionised before being separated and 
quantified using MS.  The main limitations with this technique are the moderate 
reproducibility of what can be a complex separation process as well as the 
length of time taken to run a single sample [264]. 
 
1.6.2.4 Capillary electrophoresis (CE) – mass spectrometry 
Capillary electrophoresis separates peptides in a sample in a single step by 
passage through a buffer-filled capillary.  From the end of the capillary the 
separated peptides are delivered into a mass-spectrometer in a nano-ion spray.  
The advantages of CE-MS include the robust and repeatable single-step 
separation of peptides, which is particularly beneficial when analysing a large 
number of samples that may contain interfering compounds, and the fact that 
CE capillaries are relatively inexpensive in comparison to LC columns.  The 
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limited loading capacity in comparison to LC-MS is a disadvantage, and as with 
LC-MS this technique is reliable only for evaluation of the low molecular weight 
urinary proteome, proteins with molecular weight greater than 20kDa must be 
removed from the sample by ultrafiltration prior to analysis [267]. 
In order to allow direct comparison between disease cases and controls, specific 
software tools are required.  A commonly used classification of samples is based 
on support vector machine modelling by generation of high dimensional 
polypeptide models reliant on peptides which display significant differences 
between cases and controls.  Each peptide then allegorises one dimension in an 
n-dimensional space [268].  The end result of this processing is a single 
numerical score or “classification factor” for the purposes of diagnosis of 
disease. 
The proteomic data described in this thesis were generated using CE-MS 
technology which will be described in detail in chapter 2.   
 
1.6.3 The clinical perspective 
Application of proteomic technologies in clinical research is attractive for a 
number of reasons. 
 Non-targeted techniques offer a means to disentangle the complex 
cellular processes contributing to disease development in an unbiased 
manner. 
 Deeper understanding of the integrated cellular perturbations which 
precede the development of clinically detectable disease brings potential 
to identify novel therapeutic targets. 
 Proteomic techniques essentially offer a “multi-marker” approach to 
disease detection, capturing alterations in multiple pathophysiological 
mechanisms simultaneously.  This could offer improved and more accurate 
disease detection at a much earlier stage. 
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 Tools to identify individuals in the very early stages of disease may inform 
earlier intervention for “at risk” individuals, or targeting of therapies 
towards those who stand to gain most benefit rather than broadly 
exposing a large, unselected population to the risks associated with many 
pharmacological agents. 
Despite the potential advantages that translation of these approaches into 
routine clinical practice could bring, proteomic research remains largely in the 
preclinical stages.  The following paragraphs will illustrate the current state of 
clinical proteomic research in cardiovascular and renal disease. 
 
1.6.3.1 Atherosclerosis 
Despite being an almost ubiquitous precursor to numerous cardiovascular and 
renal conditions there are relatively few published data from human studies 
applying proteomics in atherosclerotic disease.  A number of studies have used 
cultured cells to build insights into the mechanisms underlying early 
development of atherosclerosis.  However, one key limitation of this approach is 
that the culture process itself can alter the cellular proteome meaning that 
probing the precise proteome of these cells within the vessel lumen is not 
possible.  A more reliable approach may be focussing on plaque proteomics.  
Reduced secretion of heat shock protein 27 from ruptured plaques has been 
described, as well as a correlation with reduced plasma levels in patients with 
atherosclerotic disease [269].  Osteopontin is also among the more extensively 
investigated biomarkers highlighted by proteomic studies in atherosclerotic 
plaques [270], however this work remains in its early stages and proteomic tools 
for prediction of atherosclerotic disease are lacking.    
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1.6.3.2 Hypertension 
Hypertension remains one of the most important challenges to health services.  
With the exception of rarer cases of secondary hypertension, the multitude of 
interrelated processes underpinning essential hypertension remain poorly 
understood and use of untargeted proteomic approaches seems an attractive 
means to identify as yet unknown mechanisms.  Despite this, clinical studies in 
human subjects are lacking with the majority of work to date focussing on tissue 
from animal models such as Dahl salt-sensitive rats and rodents exposed to 
aortic constriction to induce pressure overload.  Studies have shown differential 
expression of proteins associated with oxidative stress, glycolysis and collagen 
turnover in ventricular homogenates from these animals [271, 272].  
Furthermore, these peptide patterns are altered following treatment suggesting 
potential utility of proteomic biomarkers for gauging response to treatment 
[273].  Processes such as hypertension and atherosclerosis are often the 
clinically silent precursors to overt cardiovascular diseases such as heart failure 
and coronary artery disease, both of which have been the focus of proteomic 
research in recent years. 
 
1.6.3.3 Stroke 
Prompt and accurate diagnosis of stroke is important to guide therapeutic 
intervention, particularly in view of the limited time frame for administration of 
thrombolytic therapy.  Use of proteomic biomarkers to accurately confirm 
presence of cerebral ischaemia in cases of diagnostic doubt is an attractive 
prospect which remains minimally investigated in human subjects.  One recent 
study used CE-MS analysis of urine samples obtained from patients within 24 
hours of diagnosis of acute stroke for development of a diagnostic proteomic 
signature.  A panel of 35 differentially expressed urinary peptides including 
uromodulin and various collagen fragments was able to distinguish stroke cases 
from controls with high specificity [274]. 
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1.6.3.4 Heart Failure 
Using 2D-E coupled to MS for analysis of myocardial tissue from heart failure 
patients a number of altered protein patterns have been described.  Heat shock 
protein 70 (HSP70), belonging to the stress protein family, is among the most 
altered and has been found to be increased 1.64-fold in failing myocardium 
across different aetiologies in one study [275].  This highlights again the 
potential of discovery-based proteomic strategies in identifying novel 
mechanisms and biomarkers although tissue work should be interpreted with 
caution given the potential effects of pre-analytical processing on the proteome. 
A number of studies have described alterations in the human plasma proteome 
for detection of left ventricular remodelling post-myocardial infarction; a 
clinically silent process which is strongly predictive of subsequent heart failure.  
In plasma samples from patients with sequential echo data available post-
translational variants of α1-chain of haptoglobin were elevated in those who 
displayed higher degrees of remodelling.  Importantly, this marker is not readily 
detectable by Western blot or enzyme-linked immunosorbent assay (ELISA) and 
traditional biomarkers such as creatine kinase did not differentiate between 
patients with high versus low remodelling [276].  Analysis of the “deep” plasma 
proteome has also highlighted down-regulation of the N-terminal human albumin 
fragment in patients with excessive remodelling as a potential tool for 
identification of these patients at an earlier stage [277].  Urinary proteomic 
studies using CE-MS processing have compiled a panel of 85 peptides for 
identification of patients with asymptomatic diastolic dysfunction, the majority 
of which were differentially regulated collagen fragments [278]. 
 
1.6.3.5 Coronary Artery Disease 
Coronary artery disease remains one of the leading causes of mortality 
worldwide, with traditional parameters of limited use in determining risk on an 
individual patient basis.  Identification of novel biomarkers highlighting those 
with early stage or asymptomatic disease may allow clinicians to direct 
63 
 
 
aggressive therapies towards those who are at highest risk and a number of 
studies focussing on proteomics for detection of coronary artery disease have 
been published. 
Proteins shown to be up-regulated from plasma studies in coronary artery 
disease patients include complement components, proteolytic enzymes such as 
cathepsin S, and coagulation cascade components such as fibrinogen [279, 280].  
Alterations in the plasma proteome continue to develop months after an acute 
ischaemic event raising the question of the influence of pharmacotherapy and 
potential utility of proteomic techniques for monitoring response to treatment 
[281]. 
Although the majority of clinical proteomic studies published to date have been 
cross-sectional, a panel of urinary peptides has recently been described for 
diagnosis of coronary artery disease which has also shown potential for 
prediction of later coronary events.  The CAD238 panel was developed using CE-
MS analysis of spot urine samples from individuals with angiography-proven 
coronary artery disease compared to healthy control subjects, identifying 
coronary artery disease in a blinded test cohort with a high degree of sensitivity 
and specificity [282].  Application of this biomarker panel to stored baseline 
urine samples collected from Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT) participants showed it to be predictive of later cardiac events over five 
years in patients without known coronary disease at baseline [283].  CAD238 has 
recently been shown to correlate with measures of coronary artery disease 
severity [284] but it remains to be seen whether CAD238 can outperform other 
cardiovascular biomarkers or inform therapeutic decision-making. 
 
1.6.3.6 Chronic kidney disease 
As discussed in section 1.4, CKD is a strong independent predictor of 
cardiovascular morbidity and mortality [285, 286] and risk is increased even in 
the earliest, pre-clinical stages of disease which are not detectable by 
traditional clinical parameters [287].  Consequently, there is an unmet clinical 
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need for novel disease biomarkers to allow early, targeted intervention to be 
guided towards the patients who stand to benefit most from treatment.  A 
multitude of biomarkers have been evaluated in this context, but none have 
transitioned into clinical practice. 
Proteomics is an attractive tool in CKD, as a panel of multiple biomarkers has 
the potential to capture early changes in the multiple interrelated mechanisms 
implicated in CKD development and provide an integrated overview of an 
individual’s disease status.  For example, untargeted plasma proteome analysis 
using LC-MS in samples from patients with CKD recently highlighted differential 
regulation of peptides associated with a number of molecular mechanisms 
implicated in CKD development such as coagulation, inflammation and 
endothelial dysfunction.  In addition increased expression of lysosome C and 
leucine-rich-alpha-2 glycoprotein, mediators thought to be involved in vascular 
and cardiac disease, was noted; highlighting the close interrelationship between 
renal and cardiovascular disease [288]. 
Urine has proved to be a particularly useful sample type for proteomic studies in 
CKD.  In 2010, Good et al performed CE-MS analysis of urine samples from 230 
patients with CKD of mixed aetiology and 379 healthy control subjects.  This 
work resulted in identification of a panel of 273 differentially expressed urinary 
peptides that differentiated CKD from controls with high sensitivity and 
specificity in a blinded test cohort [268].  This classifier was termed CKD273, 
and to date remains the proteomic classifier that has been most rigorously 
evaluated in independent studies, with a classifier score above 0.343 defined as 
the threshold for CKD [268].   Component peptides include mainly fragments of 
collagen types I and III (approx. 70%), albumin fragments (3%), as well as 
uromodulin (4%), α-1 antitrypsin (6%), fibrinogen-α chain (2%), with others such 
as β2M, clusterin, osteopontin, cystatin B and antithrombin III making up the 
remaining 15% [268].  There is some overlap with other cardiovascular disease 
panels such as CAD238, potentially reflecting multiple common mechanistic 
pathways linking CKD and cardiovascular disease.   
In addition to potential diagnostic utility, the predictive power of CKD273 has 
been evaluated in a number of studies.  In 76 patients attending renal outpatient 
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services with CKD of any aetiology, baseline CKD273 score was predictive of 
death or requirement for dialysis over mean 3.6 years follow-up [289].  Data 
from a recent cross-sectional study using urine samples from 522 patients with 
CKD showed that baseline CKD273 score identified those who displayed rapid 
GFR decline (>5% per year) over 4 years of follow up with higher sensitivity and 
specificity than UAE.  Addition of CKD273 to a model including traditional 
parameters such as eGFR and UAE significantly improved prediction of adverse 
outcomes [290]. 
Findings in patients with pre-existing CKD cannot be readily extrapolated to the 
general population.  However, a recent study of 621 samples from patients 
participating in the population-based Flemish Study on Environment, Genes and 
Health Outcomes (FLEMENGHO) study, CKD273 predicted subsequent increase in 
serum creatinine and decline in eGFR over 4.8 years follow up [291].  Similarly, 
it has been shown that the classifier performs best as a predictor of progressive 
CKD in patients with early stage disease where eGFR remains above 
70ml/min/1.73m2 [292].  In the studies described above, CKD273 correlated with 
UAE and eGFR, leading some to suggest that it has value as a composite single 
marker of renal excretory function and glomerular filtration.   
 
1.6.3.7 CKD273 in diabetic nephropathy 
As the complex interrelationships between the multiple mechanistic pathways 
underlying DN development remains incompletely understood, a proteomic 
approach is an appropriate strategy both for delineating these mechanisms 
further and for identifying early disease-specific biomarkers.  Multi-marker 
proteomic approaches are advancing from the realms of discovery and validation 
into prospective clinical studies in DN.  The availability of stored sequential 
urine samples from large diabetes cohorts with long follow-up periods has 
allowed researchers to investigate the urinary proteome not only of patients 
with a clinical diagnosis of DN, but also to delve into earlier changes in 
normoalbuminuric patients, many years before the development of overt DN.  
CE-MS analysis has been primarily employed for DN biomarker discovery and 
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several disease-specific proteomic panels have been described [293-295].  
Although initially developed in samples from patients with CKD of multiple 
diverse aetiologies, the CKD273 panel has shown particular promise in DN. 
When applied to urine samples from a longitudinal cohort of patients with both 
T1 and T2DM who were normoalbuminuric at baseline, the CKD273 classifier 
identified individuals who later progressed to macroalbuminuria up to 5 years 
before its development, and was shown to perform better than MA in this regard 
(receiver operating characteristic plot analysis gave area under the receiver 
operating curve (AUC) for CKD273 0.93; 0.67 for MA), with patients reaching the 
diagnostic CKD273 threshold on average 1.5 years prior to development of MA.  
This relationship remained statistically significant following adjustment for 
traditional parameters such as age, eGFR at baseline, blood pressure and HbA1c 
[295].  Further to this, CE-MS analysis of urine samples from participants in the 
PREVEND study showed that baseline CKD273 score accurately identified 
individuals who “transitioned” in UAE status over 3 years follow up; either from 
normo-to microalbuminuria, or from micro-to macroalbuminuria [296].  
Recently, urinary proteomic analysis of stored baseline urine samples from 
participants in the Diabetic Retinopathy Candesartan Trials (DIRECT) showed 
that CKD273 independently predicted development of MA over a 4 year follow up 
period [297].  It appears therefore that changes in the urinary proteome have 
the potential to distinguish normoalbuminuric patients at risk of progressive 
renal disease, even in the absence of any other clinical indicator of renal 
dysfunction.   
In addition to its potential predictive power, the CKD273 classifier has been 
shown to be stable despite long term storage over up to 35 months [295] and to 
accurately identify DN with high consistency in a validation study undertaken 
across multiple centres, irrespective of confounding factors such as age and 
gender [298].  Application of the classifier to samples from hypertensive T2DM 
patients with MA randomised to receive the ARB Irbesartan or placebo over 2 
years showed that the peptide pattern evolved towards a “healthier” profile 
after ARB treatment while no change was observed in those treated with 
placebo [299].  This indicates that urinary proteomics could theoretically be 
employed to determine the impact of therapeutic interventions in DN.  While 
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the results to date are interesting, it should be borne in mind that they have 
been generated through retrospective analyses of small heterogeneous cohorts, 
often with limited follow-up and comparative studies with alternative DN 
biomarkers are lacking.  Furthermore, the technology required for CE-MS 
analysis is expensive and not widely available.  There preliminary data require 
substantiation by way of prospective testing in large studies with adequate 
follow up recording clinically meaningful endpoints, along with a full assessment 
of cost-effectiveness in clinical practice. 
 
1.7  Treatment of diabetic nephropathy 
Mortality rates have consistently been shown to be elevated in patients with 
diabetes complicated by nephropathy in comparison to those with 
uncomplicated disease.  The goals of treatment for these patients are to prevent 
progression of UAE and decline in GFR leading to ESRD.  Much of the excess 
mortality results from cardiovascular disease, and both UAE and eGFR are known 
to be independent and additive predictors of cardiovascular morbidity and 
mortality as well as all-cause mortality [300].  Current guidelines recommend 
that clinicians should consider the presence of diabetes, CKD or both in 
combination as a coronary risk equivalent, thus employing the same 
multifactorial preventative strategies to manage cardiovascular risk is critical 
both in patients with MA and overt DN [151, 301-303].  Treatment strategies in 
patients with DN will be discussed below.  While each of these will be discussed 
individually, studies have shown that intensive risk factor control addressing 
blood pressure, glycaemic control, cardiovascular risk, diet and lifestyle is key to 
risk reduction. 
 
1.7.1 Control of blood pressure and albuminuria 
The prevalence of hypertension is increased in patients with DN and control of 
blood pressure is a key factor in DN management.  Optimal blood pressure 
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targets in the general diabetic population have been debated over recent years.  
The majority of randomised trials support a beneficial impact of blood pressure 
control on cardiovascular complications of diabetes, and these are summarised 
in Table 1-5.  While target blood pressures varied considerably between these 
trials a reduction in renal endpoints as well as cardiovascular events were 
generally seen in association with improved control.  The exception was the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, in which 
particularly tight control (target systolic pressure of below 120mmHg) was 
associated with increased rates of adverse events such as electrolyte 
disturbance and symptomatic hypotension and no significant benefit on 
cardiovascular outcomes [304].  Combination of these data in a recent meta-
analysis showed that a 10mmHg reduction in systolic blood pressure nevertheless 
conferred 13% reduction in all-cause mortality and 11% reduction in 
cardiovascular events including myocardial infarction, stroke, heart failure and 
revascularisation in T2DM [305]. 
It should be borne in mind, however, that while retrospective studies have 
explored tight blood pressure control in CKD, there have been few specific 
prospective studies evaluating the impact of different blood pressure goals on 
progression of DN.  In fact, much of the evidence supporting tight blood pressure 
goals in DN is extrapolated from post-hoc analyses of studies where comparison 
between different blood pressure targets was not a prespecified endpoint.  As 
such the evidence is inconsistent [306].  Post-hoc analyses of early randomised 
controlled trials of ARB treatment in DN have suggested that systolic pressures of 
above 140mmHg were associated with higher risk of progression to the primary 
renal endpoint [307, 308].  In view of the lack of prospective studies there is 
little consensus across guidelines; with some suggesting that clinicians should 
aim for a blood pressure of less than 140/90mmHg to slow progression of DN, 
whereas others advocate a target of 130/80mmHg in certain circumstances [144, 
302, 309-311]. 
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Trial Name 
BP in 
conventional 
arm (mmHg) 
BP in 
intensive 
arm 
(mmHg) 
Impact on 
cardiovascular 
endpoints 
Impact on 
microvascular 
endpoints 
UKPDS 154/87 144/82 
32% reduction in 
diabetes-related 
deaths 
37% reduction in 
microvascular 
endpoints, particularly 
progression of 
retinopathy. 
Trend towards 
reduction in 
progression of DN 
STENO-2 146/78 131/73 
29% reduction in 
risk of 
cardiovascular 
events 
Reduced incidence of 
DN and progressive 
retinopathy 
ADVANCE 140/75 136/74 
14% reduction in 
all-cause mortality 
18% reduction in 
cardiovascular 
death 
9% reduction in major 
microvascular or 
macrovascular events 
(separate reductions 
not independently 
significant) 
ACCORD 134/71 119/64 No improvement  
No reduction in 
advanced 
microvascular 
complications, but 
delayed onset of 
macroalbuminuria and 
21% reduction in 
development of MA 
 
 
Table 1-5.  Summary of achieved BP in trials of intensive multifactorial therapy in 
diabetes. 
Of note, BP control was a component of multifactorial intervention in all trials. UKPDS, UK 
Prospective Diabetes Study; ACCORD, Action to Control Cardiovascular Risk in Diabetes; 
ADVANCE, Action in Diabetes and Vascular disease: preterAx and diamicroN-MR 
Controlled Evaluation; BP, blood pressure; DN, diabetic nephropathy; MA, 
microalbuminuria. 
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1.7.1.1 ACE-inhibitors and angiotensin receptor blockers 
As described earlier in this chapter, activity of the RAAS is a critical pathway in 
DN development.  It is clear from a multitude of landmark clinical trials that 
ACE-I and ARBs have renoprotective qualities independent of their effect on 
blood pressure in DN [312-316] and these agents should therefore be considered 
as first-line treatment in patients with diabetes and hypertension, MA or 
advanced DN [144, 302, 309]. 
Beyond their antihypertensive effects these agents also have beneficial effects 
on UAE.  Although evidence confirming a link between reduction of UAE and 
corresponding impact on cardiovascular endpoints is lacking, minimising UAE is 
associated with slowed progression of DN.  This was first evidenced by the 
Captopril Trial [312] and later confirmed in the Reduction of Endpoints in Non-
insulin dependent diabetes with the Angiotensin Antagonist Losartan (RENAAL) 
trial, where 35% reduction in proteinuria led to a 16% reduction in renal 
endpoint rates [315].  Similar results were shown in the Irbesartan Diabetic 
Nephropathy Trial (IDNT) [314].  A recent meta-analysis evaluating the impact of 
minimising UAE on renal endpoints found that reducing albuminuria by 30% 
conferred a 25% reduction in risk of progression to ESRD [156].  This effect was 
independent of drug class and highlights the potential long term benefits of this 
strategy in patients with DN. 
The use of ACE-I and ARB has significantly improved the outlook for patients with 
DN, but many still progress to ESRD and there remains an unmet need for 
therapeutic strategies to delay DN progression or prevent its development 
altogether.  A multitude of studies have evaluated alternative or enhanced 
RAAS-blocking strategies, some of which will be summarised below. 
 
1.7.1.2 Dual RAAS blockade 
In general, the term dual RAAS blockade is used to refer to studies of combined 
ACE-I and ARB therapy rather than other RAAS blocking agents such as direct 
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renin inhibitors or MRAs.  In view of the impressive results from trials of ACE-I or 
ARB monotherapy in DN it was assumed that combination of these agents may 
serve to intensify the anti-albuminuric effect. 
The Ongoing Telmisartan Alone and in combination with Ramipril Global 
Endpoint Trial (ONTARGET) evaluated the effect of telmisartan, ramipril or both 
in combination on renal endpoints in a large cohort of 25000 patients with 
atherosclerotic disease or diabetes (37% of participants) and evidence of end-
organ damage over a period of 56 months.  The combined primary endpoint of 
death, dialysis or doubling of creatinine was similar in the ramipril and 
telmisartan groups, but incidence increased significantly in the dual therapy 
arm.  The same effect was seen in the higher renal risk cohort including patients 
with DN; diabetes and hypertension and eGFR below 60ml/min/1.73m2.  Despite 
the higher number of renal events with combination therapy, this intervention 
was associated with beneficial effects on risk of developing MA or overt 
albuminuria [317].  A post-hoc analysis investigating whether individuals with 
lower baseline eGFR or higher UAE would gain more benefit from this treatment 
did not yield any more positive results with more renal events, hyperkalaemia 
and symptomatic hypotension associated with dual RAAS blockade [318]. 
The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic 
Nephropathy (ORIENT) trial investigated the effects of dual RAAS blockade on a 
cohort of 577 patients with T2DM and DN.  While additional olmesartan 
treatment did reduce blood pressure and albuminuria, there was no difference 
in the primary renal outcome between arms of the study and discontinuation of 
therapy due to hyperkalaemia was more common in patients on dual therapy.  
These effects were overshadowed by a significantly higher number of 
cardiovascular deaths in the intervention arm [319]. 
Most recently the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) 
randomised 1400 patients with T2DM, reduced eGFR and albuminuria to 
combined therapy with lisinopril and losartan in comparison to losartan 
monotherapy.  While combination therapy was associated with slower decline in 
eGFR and reduced ESRD events at 6-12 months, this effect was not sustained 
over longer follow up.  Again, this trial was terminated prematurely in view of 
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safety concerns resulting from increased numbers of patients reaching the 
primary endpoint (death, decline in eGFR or dialysis) in the group treated with 
dual therapy.  In addition, combination therapy was associated with higher rates 
of hyperkalaemia and acute kidney injury [320].  In response to these results 
dual RAAS blockade is not endorsed by clinical guidelines as a therapeutic 
strategy in DN.   
 
1.7.1.3 Renin inhibitors 
In recent years the addition of direct renin inhibitors to ACE-I or ARB in patients 
with DN has been evaluated.  The open-label Aliskiren in the Evaluation of 
Proteinuria in Diabetes (AVOID) trial randomised 600 T2DM patients with 
hypertension and albuminuria to receive either the direct renin inhibitor 
aliskiren or placebo in addition to ARB therapy for 6 months and found that 
aliskiren treatment reduced UAE by 20% in comparison to placebo, with very 
minimal differences in blood pressure or decline in GFR between the groups 
[321].  Following this promising result the Aliskiren Trial in Type 2 Diabetes Using 
Cardiovascular and Renal Disease Endpoints (ALTITUDE) trial was designed.  This 
study randomised over 8000 patients with T2DM and renal or cardiovascular 
disease to receive aliskiren or placebo in addition to ACE-I or ARB.  The trial was 
stopped after a mean follow up of 33 months due to increased cardiovascular 
events in the intervention group.  There was no significant difference in renal 
endpoints between aliskiren or placebo treated patients [322].  As a result 
combination therapy with aliskiren and other RAAS blocking agents is not 
recommended in T2DM following an announcement from the European Medical 
Association in February 2012.      
 
1.7.1.4 Mineralocorticoid receptor antagonists 
Despite the widespread use of ACE-I and ARB many patients continue to progress 
to overt DN and ESRD.  There has been a resurgence of interest in the non-
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genomic effects of aldosterone beyond its effects on blood pressure and 
electrolyte balance [112, 135].  In addition, as described earlier in this chapter, 
evidence suggests that a subgroup of patients treated with ACE-I or ARB display 
“aldosterone breakthrough” and in retrospective analyses this cohort tend to 
have more rapidly progressive disease [132-134].  As a result the incorporation of 
MRA with ACE-I or ARB remains an area of interest in DN. 
This combination has been explored in a number of studies which in general 
show beneficial effects on blood pressure and albuminuria in patients with DN 
[323-330] as well as CKD of alternative aetiology [331-341]. Trials to date have 
been relatively short, and the majority are small and underpowered to detect 
significant differences in meaningful clinical renal or cardiovascular endpoints.  
In addition, use of MRA in patients with CKD raises safety concerns due to 
increased risk of hyperkalaemia and acute kidney injury and this strategy is not 
currently recommended in clinical guidelines.  The introduction of novel 
potassium binding agents and nonsteroidal MRAs may however herald a paradigm 
shift in this debate.  A comprehensive meta-analysis of trials evaluating use of 
MRA in addition to conventional RAAS blocking agents in CKD will be presented in 
chapter 3. 
 
1.7.2 Glycaemic control 
Landmark trials such as UKPDS and DCCT demonstrated that improved glycaemic 
control significantly reduced incidence and progression of microvascular 
complications of diabetes, including DN.  In fact, the DCCT showed a decline in 
microvascular complications with HbA1c reduction as values approached the 
non-diabetic range [58, 59].  Based on these promising results, two larger studies 
were developed to test the hypothesis that near-normalisation of glucose in 
patients with T2DM would lead to even more significant reductions in 
microvascular and macrovascular complications; ACCORD and ADVANCE (Action 
in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled 
Evaluation)  [316, 342].  Both trials demonstrated beneficial effects of intensive 
glucose lowering on UAE but not on the later stages of DN, and neither showed a 
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significant benefit in terms of cardiovascular outcomes.  In fact, the more 
stringent glycaemic target in ACCORD (HbA1c<6.5%, or 48mmol/mol) was 
proposed as a factor underlying increased mortality rates in the intensive 
treatment group.  These findings are summarised in Table 1-6.  It is important to 
note that the evidence of benefit from improved glycaemic control in DN is 
almost exclusively based on impact on UAE, there is little evidence of benefit on 
other renal outcomes such as doubling of serum creatinine or decline in GFR. 
 
 
Trial 
Name 
HbA1c in 
conventional 
arm 
HbA1c in 
intensive 
arm 
Impact on CVD Impact on UAE 
DCCT 
8.5% 
(75mmol/mol) 
7.1% 
(53mmol/mol) 
Trend towards 
reduction in risk 
of all 
macrovascular 
events 
Trend towards 
reduction in risk 
of cardiac 
events 
60% reduction in 
risk of developing 
sustained MA 
54% reduction in 
risk of developing 
clinical DN 
UKPDS 
7.9% 
(63mmol/mol) 
7.0% 
(53mmol/mol) 
Trend towards 
reduction in MI 
33% reduction in 
development of 
sustained MA 
ADVANCE 
7.3%  
(56mmol/mol) 
6.5%  
(48mmol/mol) 
No significant 
reduction in 
macrovascular 
outcomes 
90% reduction in 
new onset MA 
30% reduction in 
progression to 
macroalbuminuria 
ACCORD 
7.6% 
(60mmol/mol) 
6.3% 
(45mmol/mol) 
Trend towards 
reduction in MI, 
stroke and 
cardiovascular 
death 
21% reduction in 
new onset MA 
32% reduction in 
progression to 
macroalbuminuria 
VADT 
8.4% 
(68mmol/mol) 
6.9% 
(52mmol/mol) 
No significant 
reduction in 
macrovascular 
outcomes 
32% reduction in 
new onset MA 
37% reduction on 
progression to 
macroalbuminuria 
 
 
Table 1-6.  Summary of HbA1c and resultant outcomes in trials of intensive therapy 
in diabetes. 
Of note, glycaemic control was a component of multifactorial intervention in the majority of 
trials. UKPDS, UK Prospective Diabetes Study; ACCORD, Action to Control 
Cardiovascular Risk in Diabetes; ADVANCE, Action in Diabetes and Vascular disease: 
preterAx and diamicroN-MR Controlled Evaluation; VADT, Vetarans Affairs Diabetes Trial; 
HbA1c, glycated haemoblogin; CVD, cardiovascular disease; UAE, urine albumin 
excretion; DN, diabetic nephropathy; MI, myocardial infarction; MA, microalbuminuria. 
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Although none of these studies focussed specifically on patients with DN, most 
guidelines advocate an HbA1c target of <7% (53mmol/mol) to minimise 
progression of microvascular complications [144, 309].  These are subject to 
interpretation based on patient characteristics, for example in older individuals 
with significant comorbidities and limited life expectancy or patients at risk of 
hypoglycaemia a target of >7% (53mmol/mol) may be more appropriate, while 
young patients without pre-existing cardiovascular disease may be more able to 
achieve a lower target with minimal adverse effects.   
 
1.7.2.1 Renal endpoints in recent outcome studies of glucose-lowering 
medications 
Several eagerly anticipated outcome studies have evaluated the impact of novel 
pharmacological approaches to T2DM treatment on macro- and microvascular 
outcomes.  Two key recently published studies have shown particularly 
encouraging results.   
The (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes 
Mellitus Patients (EMPA-REG) study demonstrated that the sodium-glucose 
cotransporter-2 (SGLT2) inhibitor empagliflozin produces significant reductions 
in cardiovascular mortality in patients with T2DM [343].  At a mechanistic level 
this agent has been shown to reduce intraglomerular pressure and thereby 
minimise hyperfiltration in patients with T1DM [344, 345].  A secondary aim of 
the EMPA-REG trial was to determine the impact of therapy on microvascular 
outcomes, particularly the progression of CKD.  Results showed that treatment 
with empagliflozin reduced the relative risk of doubling of serum creatinine, 
requirement of RRT and progression to macroalbuminuria in this patient group 
[346].  The nonglycaemic effects of SGLT2 inhibitors include natriuresis, 
modulation of glomerular haemodynamics and uric acid lowering [347], all of 
which could contribute to the renal outcomes seen in EMPA-REG.  The trial 
population included patients with T2DM at high cardiovascular risk and a 
proportion had established kidney disease (eGFR 30-59ml/min/1.73m2 or 
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albuminuria) at baseline, therefore these promising results cannot be 
immediately generalised to all T2DM patients.   
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results (LEADER) trial evaluated the impact of the glucagon-like 
peptide-1 (GLP-1) receptor agonist   Liraglutide on cardiovascular endpoints in 
patients with T2DM.  Experimental studies have shown that GLP-1 receptor 
agonists may protect the vascular endothelium by ameliorating oxidative stress 
and inflammation, thereby potentially acting to minimise glomerulosclerosis and 
albuminuria [348].  As well as showing significant benefit in terms of 
cardiovascular outcomes, liraglutide treatment was associated with a reduction 
in new onset of macroalbuminuria over a 3.5 to 5 year period [349].  Beyond the 
beneficial impact on glycaemic control, blood pressure and bodyweight, effects 
on proximal tubular sodium reabsorption leading to natriuresis have also been 
highlighted as potential mechanisms underlying the renal outcomes reported in 
LEADER [350]. 
 
1.7.3 Lipid-lowering 
DN is accompanied by changes in lipid metabolism as CKD progresses.  Clinical 
trials in patients with CKD who are not dialysis dependent suggest that statins 
alone, or in combination with ezetimibe, reduce incidence of cardiovascular 
morbidity and mortality compared to placebo.  In fact, the absolute benefit 
from statin treatment tends to be higher in patients with diabetes compared to 
the general population, most likely due to the inherent increased cardiovascular 
risk associated with the condition.  The clinical benefit of treatment in patients 
receiving dialysis is less certain [351].  In view of the significant cardiovascular 
burden associated with DN, statins are recommended in all diabetic patients 
with nephropathy [352] and there are meta-analysis data supporting their safety 
in this population [351].  While guidance suggests that statin therapy should not 
be initiated in patients who are receiving dialysis, these medications should not 
necessarily be discontinued [353].  
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1.7.4 Dietary modifications 
Guidelines recommend reducing sodium intake to less than 2g per day.  The 
rationale behind this is based on proposed effects on blood pressure and 
cardiovascular disease.  Whether this is true in patients with diabetes remains 
unclear [353, 354].  However, low sodium intake has been shown to enhance the 
effects of ACE-I and ARB on blood pressure and UAE [355]. 
The relationship between dietary protein intake and DN has long been debated.  
Certainly kidney disease confers metabolic abnormalities that can complicate 
identification of optimal protein intake, such as loss of muscle mass and 
susceptibility to malnutrition.  Small studies in patients with T1DM and DN 
suggested that low protein diet (0.6-0.89g/kg/day) leads to slower rate of GFR 
decline and reduction in relative risk of ESRD [356], however other studies and 
meta-analyses have failed to show a significant benefit on renal function in 
diabetes [357].  At present guidelines recommend an intake of 0.8g 
protein/kg/day for patients with overt DN who are not on dialysis [144, 309]. 
 
1.7.5 Novel treatment strategies 
There have been no notable advances in the management of DN since the 
publication of studies such as RENAAL and IDNT [314, 315].  In fact, the majority 
of recent attempts to develop new therapies have failed to translate into 
clinical practice due to lack of efficacy, unacceptable side effects or 
unacceptable cardiovascular effects.  Some key studies evaluating alternative 
pharmacological interventions in DN will be summarised below. 
 
1.7.5.1 Endothelin antagonists 
ET-1 has been highlighted as a mediator of progressive renal disease through its 
effects on the endothelin type A receptor.  Short-term proof of concept studies 
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evaluating the addition of endothelin antagonists to ACE-I or ARB in DN showed 
that these agents significantly reduced proteinuria and blood pressure [358], 
however subsequent clinical trials have been less convincing.  In 2010 A 
Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Assess 
the Effect of the Endothelin Receptor Antagonist Avosentan on Time to Doubling 
of Serum Creatinine, End Stage Renal Disease or Death in Patients With Type 2 
Diabetes Mellitus and Diabetic Nephropathy (ASCEND) was published.  Patients 
with T2DM and overt nephropathy were randomised to receive the ET antagonist 
avosentan or placebo in addition to RAAS blockade for 6 months.  Although the 
significant antiproteinuric effect of treatment was confirmed, the study was 
terminated prematurely due to serious safety concerns after increased rates of 
death, congestive cardiac failure and pulmonary oedema were observed with 
avosentan treatment [359].  Subsequent to this the safety of lower doses of a 
more selective ET-antagonist, atrasentan, was evaluated in a similar patient 
cohort and shown once again to significantly reduce proteinuria.  Although there 
was more weight gain in the intervention group, rates of cardiac failure and 
oedema were not different [360].  A definitive conclusion to the endothelin story 
may come from the multicentre Study of Diabetic Nephropathy with Atrasentan 
(SONAR) trial, which is due to complete in 2018. 
 
1.7.5.2 Nuclear 1 factor (erythroid-derived 2)–related factor 2  
Oxidative stress is another key mediator of CKD progression.  Animal studies 
have shown that this mechanism is associated with impaired nuclear 1 factor 
(erythroid-derived 2)–related factor 2 (Nrf2) receptor activity.  Bardoxolone is a 
potent activator of the Nrf2 pathway, and its clinical utility in treatment of DN 
was evaluated in the Bardoxolone Methyl Evaluation in Patients with Chronic 
Kidney Disease and Type 2 Diabetes Mellitus: the Occurrence of Renal Events 
(BEACON) trial.  This study was also terminated prematurely after an increased 
number of heart failure related deaths or hospitalisations were noted in the 
intervention group [361]. 
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1.7.5.3 Neutral endopeptidase inhibition 
Inhibitors of neutral endopeptidase (NEP) have been shown to augment the 
natriuretic and blood pressure–lowering effects of natriuretic peptides.  Daglutril 
is a combined endothelin converting enzyme and NEP inhibitor which was 
recently evaluated in combination with losartan in a small cohort of patients 
with T2DM and albuminuria.  Over a short treatment period daglutril did lead to 
reductions in blood pressure, but did not significantly affect UAE in comparison 
to placebo [362].  The combined NEP and angiotensin inhibitor 
sacubitril/valsartan has recently entered routine clinical practice in 
management of patients with heart failure.  Studies focusing on renoprotective 
utility of this agent have been conflicting and the overall effect of NEP inhibition 
on renal haemodynamics is unclear.  Its short term effects on eGFR, blood 
pressure and UAE in patients with CKD is currently being assessed in a 
multicentre study of 400 participants, at least 20% of whom have DN, and results 
are anticipated in 2017 [363]. 
 
1.7.5.4 Pentoxifylline 
As described earlier, inflammation appears to be another key mechanism in the 
initiation and progression of DN, and inflammatory biomarkers such as the 
STNFRs have shown promise as tools for early disease detection.  Pentoxifylline 
is a nonspecific phosphodiesterase inhibitor which is often used clinically in the 
treatment of peripheral vascular disease.  The anti-inflammatory and anti-
proliferative actions of the drug have led to beneficial effects in animal models 
of progressive renal disease and beneficial effects on protein excretion in 
diabetic nephropathy have been noted [364].  In a small, open-label randomised 
trial, administration of pentoxifylline in addition to RAAS blocking agents led to 
significant reductions in UAE and reduced decline in GFR in patients with T2DM 
and DN over 2 years of treatment [365].  More definitive results from larger 
scale, multicentre studies are required to confirm this promising finding.   
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1.7.5.5 Uric acid lowering 
Longitudinal studies have shown that baseline serum uric acid levels are 
associated with later development of albuminuria or GFR decline in patients 
with diabetes [366] [367], lending support to the hypothesis that uric acid 
lowering could potentially be a useful strategy in delaying the progression of DN.  
In small prospective studies including patients with CKD both with and without 
hyperuricaemia at baseline, allopurinol treatment has been shown to slow 
disease progression and reduce the incidence of cardiovascular events over a 1 
to 2 year follow up period [368, 369].  This strategy will be evaluated for 
prevention of DN in patients with T1DM in a prospective multi-centre double 
blind placebo-controlled trial designed by the Preventing Early Renal Function 
Loss in Diabetes (PERL) consortium [370]. 
 
1.8 Prevention of diabetic nephropathy 
MA is predictive of development of progression to overt DN and ESRD, and 
highlights risk of cardiovascular morbidity and mortality.  This linear association 
is evident at levels of UAE well within what is traditionally accepted as “normal” 
range.  Not only are RAAS blocking medications key tools for blood pressure 
reduction, they have also been shown to have effects on UAE independent of 
blood pressure lowering.  Use of these agents in established DN is almost 
universal practice, however whether the benefits of treatment extend into the 
earlier, pre-clinical stages of disease in patients with lower cardiovascular or 
renal risk burden remains unclear.  A number of studies have tested the 
hypothesis that early initiation of RAAS blockade is a potential approach for 
prevention of MA, and thereby indirectly for prevention of the excess associated 
renal and cardiovascular risk. 
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1.8.1 ACE-Inhibitors 
The European Controlled Trial of Lisinopril in Insulin-Dependent Diabetes 
(EUCLID) first demonstrated a large reduction in risk of development of MA with 
ACE-I in normoalbuminuric patients with T1DM, although this did not reach 
statistical significance [371].  Subsequently the Heart Outcomes Prevention 
Evaluation (HOPE) study assessed the impact of ACE-I on later cardiovascular 
events in patients at cardiovascular risk and included a subgroup of more than 
3000 patients with diabetes, resulting in a large sub-study focussing on MA and 
cardio-renal outcomes in this population.  While treatment with ACE-I 
significantly reduced the risk of cardiovascular and renal outcomes a 9% 
reduction in relative risk of developing MA was also noted in patients who were 
normoalbuminuric at study inclusion, although the study was underpowered to 
evaluate differences in particular subgroups [372].  The Bergamo Nephrologic 
Diabetic Complications Trial (BENEDICT) was later designed to determine 
whether ACE-I and calcium channel blocker (CCB) could prevent onset of MA.  
The investigators randomly assigned 1200 normoalbuminuric T2DM patients with 
hypertension to receive either ACE-I; CCB; both in combination; or placebo over 
a 3 year treatment period.  Results showed that intervention with combined 
ACE-I and CCB, as well as ACE-I alone, led to a 44% reduction in the incidence of 
MA [373].  The lack of any enhancing effect of additional CCB suggested that this 
relationship was indeed independent of degree of blood pressure reduction 
achieved, although patients with higher baseline blood pressure seemed to 
benefit more from treatment [374].  More recently, the ADVANCE investigators 
observed a 21% reduction in incidence of MA in a cohort of patients with T2DM 
and additional cardiovascular risk factors treated with ACE-I in conjunction with 
tight glycaemic targets [316].  Once again it should be noted that baseline blood 
pressure in the ADVANCE trial was above optimal levels.  It appears, therefore, 
that ACE-I can blunt or prevent early increases in UAE in patients whose blood 
pressure is suboptimal. 
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1.8.2 Angiotensin receptor blockers 
Primarily designed to evaluate the use of the ARB candesartan for prevention of 
retinopathy events in normoalbuminuric, normotensive patients with diabetes, 
DIRECT study included incidence of MA as a prespecified endpoint.  In the renal 
outcomes analysis, treatment with ARB did not affect the incidence of MA over a 
follow up period of 4.7 years.  It was postulated that these findings could be 
explained by the relatively young age and low vascular disease burden of the 
study cohort, meaning that a significantly longer duration of follow-up would be 
required to establish if early initiation of treatment would be clinically 
beneficial [375].  The Randomised Olmesartan and Diabetes Microalbuminuria 
Prevention (ROADMAP) trial evaluated the impact of early initiation of the ARB 
olmesartan in a large cohort of normoalbuminuric T2DM patients, treated to a 
tighter blood pressure target of less than 130/80mmHg.  Over a mean follow up 
period of 3.2 years treatment with olmesartan was associated with 23% increase 
in time to onset of MA in comparison to placebo, an effect which retained 
significance following adjustment for blood pressure.  As seen in the BENEDICT 
and ADVANCE cohorts, those with higher baseline blood pressure tended to have 
a greater benefit, possibly a reflection of greater RAAS activity translating into 
increased treatment effect [376].  However, the apparently beneficial renal 
effects seen in ROADMAP were overshadowed by a 5-fold (statistically 
significant) increase in incidence of fatal cardiovascular events in patients on 
active treatment.   
 
1.8.3 Summary 
The majority of the trials described above were included in a 2012 meta-analysis 
on the effects of ACE-I or ARB therapy on renal outcomes in diabetes, with 
studies comparing ACE-I or ARB monotherapy to other active antihypertensive 
drugs or placebo included in the final analysis.  Results showed that while these 
agents were efficacious in reducing the risk of established clinical endpoints 
such as doubling of serum creatinine; progression to macroalbuminuria; and 
reducing risk of ESRD in the context of no significant difference in blood pressure 
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reduction against comparator drugs, there was no clear beneficial effect on 
development of MA itself [377].  Included studies were certainly heterogeneous 
at baseline with differences in eGFR; UAE; and baseline blood pressure which 
may go some way towards accounting for this finding.  The data are conflicting 
however, as a recent systematic review  found a 16% reduction in relative risk of 
developing MA with preventative ACE-I or ARB therapy [378].  Nonetheless, 
current clinical guidelines do not support the use of early “preventative” 
therapy in normoalbuminuric, normotensive patients with diabetes.  A number of 
issues remain to be addressed however. 
 The first point to consider is that these studies of “early intervention” 
were carried out in unselected populations.  This is important as it is now 
widely accepted that rates of progression to overt DN are far lower than 
described in the early literature.  It would seem therefore that universal 
prescribing of these agents has the potential to create a significant 
burden of adverse effects in many patients who do not derive any clear 
clinical benefit.  Use of predictive biomarkers to identify those who are at 
highest risk of progressive disease to target individualised preventative 
therapy may lead to significant improvements in outcomes. 
 Second, although RAAS blockade with ACE-I and ARB has revolutionised 
management of diabetes and its complications and these agents are 
almost universally prescribed to patients with hypertension or MA, many 
patients continue to progress to ESRD.  In view of progress in 
understanding of the complex pathogenesis of DN, it is feasible that 
alternative therapeutic strategies could also be of use in this regard and 
time will tell whether the novel therapies currently under evaluation will 
be the next “game changer” in DN prevention. 
 Finally in order to translate findings into clinical practice the focus is 
almost universally on established clinical endpoints such as progression to 
ESRD; doubling of creatinine; or death.  These events may occur with 
some regularity in trials involving patients with CKD, but in order to build 
similar meaningful data in lower risk patients who are at an early stage in 
the DN pathway very large sample sizes with far longer follow periods 
would be needed.  There is therefore an argument for the use of 
surrogate markers in such “low risk” groups.  UAE is one such surrogate, 
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although its utility is debated.  It could be argued that the strong 
association with renal and cardiovascular outcomes as well as the 
proposed clinical impact of reduction in UAE make this an ideal surrogate 
endpoint for clinical trials.  On the other hand, UAE is highly variable and 
is not specific to DN; moreover not all treatments that lower UAE reduce 
the risk of ESRD. Perhaps alternative biomarkers are needed not only for 
accurate risk stratification of patients, but also to inform recruitment into 
clinical trials, meaning that smaller study populations and shorter term 
trials could be used to determine efficacy of treatments.  Whether this 
strategy would provide adequate information regarding patient safety is 
unclear. 
 
1.9 The PRIORITY trial 
Although an innumerable number of biomarkers have been described in the 
literature for early diagnosis of DN, as detailed earlier in this chapter, none have 
yet been shown to outperform MA.  In order to make the transition from 
research tool into clinical practice such novel markers must be rigorously 
evaluated using a number of key steps [379] including: 
 validation in prospective studies; 
 proof of incremental predictive value beyond the currently established 
standard biomarkers; 
 utility in informing clinical decision-making; 
 demonstration of potential for improving clinical outcomes through 
evaluation in a randomised clinical trial. 
To date, the CKD273 biomarker has been proven to identify DN with a high 
degree of sensitivity and specificity, as well as to predict renal endpoints 
including progression to ESRD.  The next logical step is to assess whether it can 
outperform MA as a predictor of DN and consequently inform therapeutic 
decision-making, for example targeting of early intensified RAAS blockade 
towards higher risk normoalbuminuric patients with diabetes.  The Proteomic 
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Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention of 
Early Diabetic Nephropathy in Type 2 Diabetic Patients with Normoalbuminuria 
(PRIORITY) trial was specifically designed to address these key questions [380]. 
PRIORITY is a multicentre study funded by a European Union Seventh Framework 
Programme Grant.  Part-observational study and part-biomarker directed 
randomised controlled trial, PRIORITY aims to determine whether the CKD273 
urinary proteomic classifier can accurately predict development of MA in 
normoalbuminuric diabetic individuals as well as to evaluate whether early 
enhanced RAAS blockade with addition of MRA can reduce risk of progression to 
MA in “high risk” individuals.  Much of the work contained within this thesis was 
generated in parallel to the conduct of the PRIORITY trial, which will be 
described in greater detail in chapter 2. 
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1.10 Aims of this thesis 
This thesis will focus primarily on the CKD273 urinary proteomic biomarker and 
its utility as an early indicator of DN.  The complementary studies described will 
take the biomarker from validation to prospective evaluation in a clinical trial 
and are based on the following hypotheses: 
 CKD273 has potential as a tool for early, preclinical detection of DN in 
normoalbuminuric patients with type 2 diabetes. 
 CKD273 is a specific biomarker of early renal disease and not simply 
related to underlying vascular disease. 
 CKD273 may be useful to identify patients with elevated UAE who are at 
risk of progressive GFR decline. 
 Spironolactone is a safe and effective treatment option for slowing 
progression of CKD. 
Specific aims of this thesis are therefore: 
 To validate the CKD273 urinary proteomic panel for diagnosis of DN in a 
local test-cohort; 
 To explore clinical utility beyond the current guideline-endorsed standard 
tools for DN diagnosis, in particular to demonstrate the specificity of 
CKD273 as a renal biomarker;  
 To determine whether CKD273 is a useful indicator of risk of progressive 
disease in patients with evidence of early-stage established kidney 
disease; 
 To evaluate the safety and effectiveness of MRAs as a therapeutic strategy 
in patients with established CKD, thereby demonstrating the availability 
of a potentially suitable treatment option for early stage “high risk” 
patients; 
 The above concepts will then be used to inform the development of a 
biomarker-guided prospective clinical trial as the ultimate test of the 
clinical potential of a novel biomarker. 
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2. Methods 
2.1 Summary 
The work contained within this thesis was conducted in parallel with the 
multicentre PRIORITY trial.  Several complementary projects designed and 
implemented alongside the main clinical trial are summarised below. 
 To determine the safety and effectiveness of enhanced RAAS blockade 
with MRAs in patients with CKD, a meta-analysis of randomised controlled 
trials of addition of MRA to ACE-I or ARB was performed focussing on 
effects on blood pressure; GFR; proteinuria and potassium (chapter 3). 
 In advance of the commencement of the main trial a pilot study was 
carried out in order to refine study procedures and inform the setup of 
both the PRIORITY trial and additional sub-studies locally (chapter 4). 
 In order to explore the relationship between the CKD273 classifier and 
subclinical vascular and renal disease in more detail a number of 
additional vascular phenotyping and biomarker sub-studies were 
implemented (chapter 6) in the local PRIORITY study cohort (chapter 5). 
 To assess the utility of the CKD273 proteomic panel for prediction of renal 
and cardiovascular endpoints in patients with more advanced kidney 
disease, proteomic analysis was performed using stored baseline urine 
samples from a cohort of microalbuminuric T2DM patients with 6 years of 
follow up data available (chapter 7). 
This chapter will focus primarily on the design and methodology of the PRIORITY 
trial.  Specific clinical and laboratory techniques employed in the 
complementary projects summarised above will be described in more detail in 
the relevant results chapters. 
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2.2 The PRIORITY trial 
This multicentre randomised controlled trial and observational study was 
designed to address two key objectives: 
1) To confirm that urinary proteomics can predict development of MA (as a 
surrogate marker for the development of overt DN) in a cohort of 2000 
normoalbuminuric T2DM patients. 
2) To investigate whether early initiation of preventive therapy with 
spironolactone 25mg once daily reduces risk of transition to MA in those 
patients deemed by urinary proteomic analysis to be at high risk of 
progression to DN. 
The chief investigator of the PRIORITY trial is Professor Peter Rossing, lead 
clinician at the Steno Diabetes Research Centre in Gentofte, Denmark.  The 
protocol was developed in discussion with all study partners as well as an 
external advisory board and safety aspects are monitored by an independent 
data monitoring committee.   
 
2.2.1 Funding and ethical approval 
The PRIORITY trial was funded by a European Commission Research and 
Innovation 7th Framework Programme Grant (PRIORITY; 279277) and was 
registered with the European Union Drug Regulating Authorities Clinical Trials 
(EudraCT) database (ref 2012-000452-34).  The study was approved by the 
Medicines and Healthcare Regulatory Authority (ref 42739/0001/001-0001) on 8th 
October 2013.  Local approval was obtained from the West of Scotland Research 
Ethics Committee 1 (ref 13/WS/0284) on 13th December 2013, and from NHS 
Greater Glasgow and Clyde Research and Development (R&D) (ref GN12DI096) on 
28th February 2014. Invitation letters, participant information sheet, consent 
form, alert card and information letter to the GP can be found in Appendices 1 
to 5.  
89 
 
 
2.2.2 Study population and selection of participants 
Investigators at 17 European centres aim to recruit a total of 2000 T2DM patients 
between February 2014 and October 2016, with Glasgow proposing to contribute 
500 participants.  Individuals with T2DM aged between 18 and 75 years with 
eGFR ≥ 45ml/min/1.73m2 and normoalbuminuria defined as UACR < 30mg/g in 
two of three consecutive morning urine samples were deemed eligible for 
inclusion dependent on the criteria shown in Tables 2-1 and 2-2. 
 
 
 
1. Written informed consent 
2. Age ≥18 years and <75 years 
3. Diagnosed with T2DM according to WHO criteria 
4. Normoalbuminuria (UACR <30 mg/g in at least 2 of 3 samples from ‘run in’ period) 
5. eGFR >45 mL/min/1.73 m2 at screening visit 
6. Willing and able to comply with the protocol for the duration of the study 
7. Female without childbearing potential at the screening visit. Defined as one or more 
of following: 
7.1 Female patients ≥50 years of age on the day of inclusion, who have been 
postmenopausal for at least 1 year; 
7.2 Female patients <50 years of age at the day of inclusion, who have been 
postmenopausal for at least 1 year and serum FSH levels >40 mIU/mL as well 
as serum oestrogen levels <30 pg/mL or a negative oestrogen test; 
7.3 minimum 6 weeks post-surgical sterilisation OR a negative urine pregnancy 
test at the screening visit AND one or more of following: 
7.3.1 Correct use of reliable contraception methods 
7.3.2 General sexual abstinence from the time of screening/during the 
study until a minimum of 30 days after the last administration of study 
medication if this is already established as the patient’s preferred and 
usual lifestyle 
7.3.3 Having only female sexual partners 
7.3.4 Sexual relationship with sterile male partners only 
 
 
Table 2-1.  PRIORITY study inclusion criteria. 
eGFR, estimated glomerular filtration rate; FSH, follicle stimulating hormone; HbA1c, 
glycated haemoglobin; T2DM, type 2 diabetes mellitus; UACR, urine albumin to creatinine 
ratio; WHO, world health organisation. 
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1. Systolic BP <110 or >160 mmHg at baseline 
2. Diastolic BP >100 mmHg at baseline 
3. T1DM according to WHO criteria 
4. HbA1c <6.5% (48 mmol/mol) AND T2DM of > 5 years duration AND never treated 
with an antidiabetic drug of any kind  
5. Treatment with more than one RAAS blocking agent (ACE-I, ARB or direct renin 
inhibitor) 
6. Lithium treatment 
7. Known or suspected hypersensitivity to spironolactone or to any of its excipients 
8. Use of potassium sparing diuretics, such as: spironolactone, eplerenone or amiloride 
9. Serum potassium level >5.4mmol/L at screening visit 
10. Hyponatraemia determine by the investigator 
11. Current cancer treatment or within 5 years from baseline (except basal cell skin 
cancer or 
squamous cell skin cancer) 
12. Any clinically significant disorder, except for conditions associated with T2DM which 
in the investigators opinion could interfere with the results of the trial 
13. Cardiac disease defined as: heart failure (NYHA class III–IV) and/or diagnosis of 
unstable angina pectoris and/or MI, stroke, PTCA or CABG within the last 3 months 
14. Non-diabetic CKD  
15. Liver cirrhosis and abnormal liver function tests within the last 3 years 
16. Addison’s disease 
17. Breastfeeding 
18. Intend to become pregnant or not use adequate birth control within the study period 
19. Known or suspected abuse of alcohol or narcotics 
20. Inability to understand the informed consent form 
21. Participation in any other intervention trial within 30 days of inclusion in PRIORITY 
 
 
Table 2-2.  PRIORITY study exclusion criteria. 
ACE-I, ACE-inhibitors; ARB, angiotensin II receptor blockers; BP, blood pressure; CABG, 
coronary artery bypass grafting; CKD, chronic kidney disease;; eGFR, estimated 
glomerular filtration rate; HbA1c, glycated haemoglobin; NYHA, New York Heart 
Association; PRIORITY, proteomic prediction and renin angiotensin aldosterone system 
inhibition prevention of early DN in type 2 diabetic patients with normoalbuminuria; PTCA, 
percutaneous transluminal coronary angioplasty; RAAS, renin-angiotensin-aldosterone 
system; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus; UACR, urine 
albumin to creatinine ratio; WHO, world health organisation. 
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Patients attending for screening who did not meet the pre-specified inclusion 
and exclusion criteria did not progress further in the trial.  Urinary proteomic 
testing was not performed for these patients.  In cases for whom it was deemed 
appropriate (i.e. blood pressure marginally out with target for inclusion or 
potassium level considered to be spurious), re-screening of participants at least 
one week after the initial screening assessment was permitted.   
 
2.2.3 Local recruitment strategies 
A variety of strategies were developed in order to identify potential Glasgow 
participants.  These are briefly summarised below. 
 
2.2.3.1 Secondary care clinics 
With the approval of the West of Scotland Research Ethics Committee and local 
consultants in diabetes and endocrinology, members of the study team screened 
T2DM clinic lists within the Greater Glasgow area using the TrakCare and Clinical 
Portal systems.  This was done 4 weeks in advance of the clinic date.  Any 
patient deemed potentially suitable to participate was posted an information 
letter including study team contact details and an individual reply slip to allow 
them to express an interest in participating (Appendix 1).  Following receipt of 
reply slips or contact by other means, members of the study team made 
telephone contact with interested patients to discuss the study in more detail.  
Participant information sheets (PIS; Appendix 2) were then dispatched either by 
post or email and appointments were made for preliminary screening visits. 
 
2.2.3.2 Scottish diabetes research network (SDRN) 
The SDRN was commissioned by the Chief Scientist Office (CSO) in 2006 as a 
means to facilitate generation of high quality diabetes research in Scotland.  The 
92 
 
 
network aims to enhance patient participation in research and has developed a 
national register of individuals who have given prior consent to being contacted 
for research studies. 
With ethical approval in place an application was submitted to the SDRN to 
facilitate a registry search for individuals within the Glasgow area whose clinical 
characteristics met basic study inclusion and exclusion criteria.  The resultant 
list included patient name; preferred contact method; address; date of birth; 
eGFR; diabetes medication; and cardiovascular disease status.  The registry does 
not hold UACR information and the list was therefore re-screened by the author 
using the local Clinical Portal system to determine whether or not patients were 
normoalbuminuric. After this process, individuals who were deemed suitable for 
inclusion were sent an invitation letter and if interested in participating were 
able to contact the study team directly by telephone or email, or by return of an 
included reply slip (Appendix 1).  Subsequent to this initial contact a PIS was 
dispatched and appointment made for screening visit (Appendix 2). 
 
2.2.3.3 Retinal screening service 
The Greater Glasgow and Clyde retinal screening service provides annual retinal 
photography for all individuals with diabetes aged 12 and over in the area.  
Patients can attend a number of fixed screening sites within Glasgow and a 
mobile service is also available to cover outlying areas.  With the approval of the 
service manager invitation letters (Appendix 1) were displayed at retinal 
screening centres within Glasgow.  These documents contained study team 
contact details as well as a reply slip, allowing interested individuals to contact 
the study team for further information.  Following this initial contact and if 
deemed suitable for inclusion a PIS was dispatched and appointment made for 
screening (Appendix 2). 
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2.2.3.4 Advertising in local media 
In order to reach T2DM patients not routinely attending review clinics or retinal 
screening services, ethical approval was granted to place information notices in 
news publications.  On two separate occasions during the course of the study a 
1/8 page advertisement was placed in the West of Scotland edition of the Daily 
Record newspaper.  This conveyed some basic information about the study, as 
well as contact details and a study specific email address allowing interested 
individuals to contact the study team directly for further information. Following 
initial contact, a PIS was sent by post or email and screening appointment 
arranged. 
 
2.2.3.5 Recruitment from primary care 
This strategy began with recruitment of patients from GP practices affiliated 
with the NHS Greater Glasgow and Clyde Clinical Research Facility.  This scheme 
is a formal arrangement between a selection of GP practices within the area and 
NHS R&D through which a number of mechanisms are approved for identification 
of potential recruits into clinical studies.  With the agreement of practice 
management or the principal GP study nurses were able to search practice 
databases for individuals who met the study inclusion and exclusion criteria.  A 
list of individuals who could be approached was then created and reviewed by 
practice medical staff to ensure that no inappropriate invitations were made.  
Invitation letters were then produced, signed by the principal GP and sent to 
individuals eligible to participate.  As with other strategies, these letters 
included contact details for the study team and a tear-off reply slip allowing 
interested individuals to make direct contact (Appendix 1).  Those wishing to 
participate were then sent a study PIS and appointments made for screening 
(Appendix 2). 
Around 100 local practices are formally affiliated with the University of Glasgow.  
However, a number of the highest recruiting centres were already engaged in 
identifying participants for another large diabetes study with very similar 
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inclusion and exclusion criteria.  This left a more limited pool of affiliated 
practices to approach.  For this reason ethical approval was sought to extend 
invitations to GP practices on a city-wide basis, irrespective of existing 
affiliation with the University.  The mechanisms for screening of practice lists 
and invitation of potential participants was as detailed above. 
 
2.2.3.6 Pilot study participants 
As detailed in section 2.1, a local pilot study was developed and conducted in 
advance of the main trial and this will be described in more detail in chapter 4.  
Any individuals who had taken part in the pilot project and were eligible for the 
PRIORITY trial were sent an invitation letter by the study team, containing 
contact details and a reply slip to indicate willingness to participate (Appendix 
1).  Those who expressed an interest were sent a PIS and an appointment was 
confirmed for screening (Appendix 2). 
 
2.2.4 Study design 
The key aspects of the design of the PRIORITY trial are illustrated in Figure 2-1.  
In summary, this multicentre project is being conducted at 17 institutions 
throughout Europe.  Part-observational study and part-randomised controlled 
trial, the objective is to risk stratify 2000 normoalbuminuric T2DM patients for 
later development of DN using the CKD273 urinary proteomic classifier.  Those 
identified as “high-risk” are randomised in a double-blind manner to receive 
either spironolactone 25mg or placebo, while “low-risk” individuals enter an 
observational study.  The visit schedule is summarised in Figure 2-2 and 
described below.  Recruitment opened in February 2014 and closed in September 
2016, and the follow up period will end in September 2018. 
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Figure 2-1.  PRIORITY study design. 
T2DM, type 2 diabetes; MA, microalbuminuria; eGFR, estimated glomerular filtration rate. 
 
 
2.2.4.1 Screening visit 
The first study visit for all participants was the screening visit.  At this stage the 
PIS was discussed, any questions about the trial were answered and an informed 
consent form was signed (Appendix 3).  Concurrent medications were reviewed 
briefly, primarily to determine whether the patient was already being treated 
with an ACE-I or ARB.  Height, weight, blood pressure (average of 3 
measurements taken after 10 minutes rest in sitting position) and heart rate 
were documented.  A spot sample of urine was obtained, dipstick analysis 
performed (and urine pregnancy testing in female participants with childbearing 
potential) and stored at -80°C for later proteomic analysis.  Stability testing has 
confirmed that classifier score is not significantly affected by timing of sample 
collection, handling or storage methods, nor by subject activity level [381], 
therefore no specific advice regarding activity levels, dietary or medication 
changes was given prior to study visits.  In addition blood samples were taken for 
N=2000 
normoalbuminuric 
T2DM
CKD
273
High risk Low risk
Spironolactone 
25mg
Placebo
Follow-up until September 2018 for: development of MA; retinopathy 
events; decline in eGFR; cardiovascular events.
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measurement of electrolytes and HbA1c.  Patients were not given any specific 
advice about avoiding heavy exercise before the study visit. 
Participants were subsequently provided with the materials necessary to obtain 
3 consecutive first morning urine samples at home and post these back to the 
study team for measurement of UACR, as well as with PIS specific to the local 
sub-studies which will be discussed in more detail later. 
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Figure 2-2.  PRIORITY study visit schedule. 
BP, blood pressure; UE, urea and electrolytes; HbA1c, glycated haemoglobin; UACR, 
urine albumin: creatinine ratio. *Participants in high-risk group only. 
 
 
2.2.4.2 Run-in period 
In the 8-12 week interval between screening and baseline visits, study 
participants collected 3 consecutive first morning void samples for measurement 
of UACR and returned these to the study team using pre-paid postage materials 
provided at screening.  Received samples were stored at -80°C and shipped to 
the Steno Diabetes Research Centre in Gentofte, Denmark on a 3-weekly basis 
for measurement of UACR.  From there, samples from participants who were 
confirmed to be normoalbuminuric were shipped to Mosaiques Diagnostics in 
Hanover, Germany for urinary proteomic analysis.  Results were received by the 
study team in advance of participants’ baseline visits.  Individuals entering the 
high-risk group based on urinary proteomics were contacted by the study team 
at least 1 week prior to the baseline visit in order to inform them of the result. 
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2.2.4.3 Baseline visit 
The baseline visit was scheduled for 8-12 weeks from screening date.  On arrival, 
results of screening investigations were discussed with participants and study 
personnel confirmed that they are happy to continue in the trial.  The PIS for the 
local sub-studies was reviewed and informed consent obtained if participants 
were interested in this aspect of the study (appendices 10 and 11).  Medical 
history, tobacco and alcohol use and a full list of concomitant medications 
including drug; dose; frequency; start and stop dates; and indication for 
treatment was then documented.  Blood pressure was measured and a full 
physical examination performed by the study doctor.  Investigation of any 
abnormalities not previously documented was arranged by the study team at the 
discretion of the principal investigator. Blood and urine samples were taken for 
local measurement of electrolytes, eGFR, HbA1c and lipid profile, as well as for 
local biomarker sub-studies which will be described later, and for storage in the 
PRIORITY study biobank at the Steno Diabetes Research Centre.  Participants in 
the high-risk group were randomised and provided with study medication as well 
as a participant alert card (Appendix 4) and arrangements made for a 2-week 
safety visit.  Following these key study procedures, patients who consented to 
participate in the local sub-studies then underwent an assessment of vascular 
function which will be described in more detail later.  After the baseline visit an 
information letter was dispatched to the GP of each participant detailing which 
arm of the study they had been allocated to (Appendix 5). 
 
2.2.4.4 High risk group – safety visit 
Two weeks from randomisation, high-risk participants were asked to return for a 
brief safety visit.  Study personnel enquired about any adverse events since the 
baseline visit, blood pressure was re-checked and a blood sample was taken for 
measurement of electrolytes and eGFR.   
  
99 
 
 
2.2.4.5 High risk group – quarterly study visits 
Participants in the high-risk group returned for 3-monthly review by the study 
team from inclusion until the end of the study.  During these visits medical 
history was reviewed with particular reference to any changes in medication or 
adverse events in the preceding 3 months.  Blood pressure was recorded and a 
symptom-directed physical examination performed.  Blood samples were taken 
for local measurement of electrolytes, eGFR and HbA1c, (lipid profile is checked 
on an annual basis) and participants were asked to return 3 consecutive first 
morning void urine samples for measurement of UACR.  Study medication was 
returned, compliance determined (defined as taking 80-110% of allocated 
treatment within a 3 month period) and a new supply issued.   
 
2.2.4.6 Low-risk group – annual visits 
Participants in the low-risk group were invited to return for review on an annual 
basis until the end of the trial.  Medical history was recorded with particular 
reference to cardiovascular events and retinopathy status, and concomitant 
medications reviewed.  Blood pressure was recorded and a symptom-directed 
physical examination was performed.  Blood samples were taken for local 
measurement of electrolytes, eGFR, HbA1c and lipid profile and participants 
were asked to return 3 consecutive first morning void urine samples for 
measurement of UACR.   
 
2.2.4.7 End of study 
At the final visit, study procedures will be performed as described in the annual 
visits section above.  In addition blood samples will be taken for storage in the 
PRIORITY study biobank at the Steno Diabetes Research Centre.  After the end of 
the trial, participants will continue to receive standard diabetes care in either a 
primary or secondary care clinic according to local guidelines.  
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2.2.4.8 Endpoints 
Development of confirmed MA (UACR>30mg/g) in at least 2 out of 3 consecutive 
first morning void samples with at least a 30% increase from study inclusion, or 
UACR more than 40mg/g is the primary endpoint in the PRIORITY trial.  
Additional secondary endpoints that will be evaluated both in the whole study 
population and in the intervention group are listed below. 
 Comparison of a composite of fatal and non-fatal cardiovascular events 
(myocardial infarction, coronary artery bypass graft, percutaneous 
coronary intervention, stroke, hospitalisation for heart failure) and all-
cause mortality. 
 Comparison of incidence of retinopathy and laser-treatment. 
 Changes in geometric mean UACR throughout the study, assessed both as 
slope of UACR and absolute change from study inclusion. 
 Development of macroalbuminuria (UACR >300mg/g) in at least 2 out of 3 
consecutive first morning void urine samples. 
 Development of eGFR < 60ml/min/1.73m2 in participants whose eGFR was 
>60ml/min/1.73m2 at inclusion. 
 Changes in eGFR throughout the study period, assessed both as slope of 
eGFR and absolute change from study inclusion. 
 
2.2.5 Statistical considerations 
Statistical considerations relevant to the main PRIORITY trial are discussed 
below.  Statistical methods used in the complementary projects are detailed in 
chapters 3, 4, 5, 6 and 7. 
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2.2.5.1 Sample size 
The expected proportions of T2DM patients developing MA within the study 
period were: 24% of patients in the high-risk group receiving active study 
medication; 40% in the high-risk group receiving placebo; and 8.5% in the low-
risk group. Using the sample size formula for two proportions test (α= 0.05 
β=0.80) randomized 1:1, 129 participants were required in each arm of the 
intervention group. To account for a 10% expected drop-out rate, it was planned 
to randomise 300 high-risk patients.  High-risk patients were expected to 
comprise 15% of included patients.  In order to identify 300 high-risk patients, 
2000 patients were be included in total.  To account for an estimated screening 
failure rate of 25% a total of 2700 individuals were screened.   
 
2.2.5.2 Proteomic classification 
The study population are risk-stratified based on CKD273 classifier score at 
inclusion.  The threshold for classification of high-risk individuals was 
determined to be 0.154.  This figure was determined from previously published 
data [268, 295]. 
 
2.2.6 Randomisation and unblinding 
2.2.6.1 Randomisation  
The interactive web response system (IWRS) for randomisation and allocation of 
study medication was developed by the Robertson Centre for Biostatistics, 
University of Glasgow.  All participants with a high-risk urinary proteomic score 
at screening who were eligible to continue in the trial were computer-
randomised in a 1:1 manner to either the intervention or placebo arms of the 
trial using a block randomisation process.  Randomisation was stratified 
according to whether the participant was already prescribed ACE-I or ARB in 
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order to ensure that the number of patients on these agents was balanced 
between the active treatment and placebo groups. 
 
2.2.6.2 Blinding and unblinding procedure 
Investigators and study participants are blinded to the type of intervention 
allocated.  Placebo and active drug are indistinguishable from each other in 
terms of appearance, pack labelling and instructions for use.  All study 
medication packs are labelled with a unique pack identification number.  At the 
time of randomisation each high risk participant was allocated a pack number by 
the IWRS.  Allocation of subsequent pack numbers is triggered by an electronic 
request from study personnel in advance of quarterly study visits. 
In the event of a serious medical occurrence that could be linked to study 
medication when it is essential to confirm whether the affected patient is 
treated with spironolactone, emergency unblinding can be performed.  This is 
carried out via a telephone response system and the contact number is printed 
on participant alert cards. After emergency unblinding an email alert is 
generated to the study sponsor, study management and the Robertson Centre for 
Biostatistics.  No more than 3 unblinding requests are permitted within 24 hours 
to avoid malicious use of the system.  Planned unblinding will be performed by 
staff at the Robertson Centre for Biostatistics at the end of the trial after the 
final analysis plan is determined and a date agreed by the scientific steering 
committee. 
 
2.2.7 Adverse events 
The study protocol defines adverse events (AEs) as “any untoward medical 
occurrence in a trial participant after baseline”.  It is not necessary to 
demonstrate a causal relationship to study medication.  These are considered 
serious adverse events (SAEs) in the event that they result in death; are life-
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threatening; require hospitalisation; result in persistent incapacity; or are 
congenital defects. 
AE information is collected at study visits, with particular reference to the 
following: 
 type of event 
 start and end dates of event 
 grading according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE) [382] 
 causality of study drug 
 treatment measures taken 
 outcome 
These incidences are documented in the individual patient record as well as on 
the study electronic case report form (eCRF).  The same evaluation process is 
required for SAEs with the caveat that these must also be documented on paper 
SAE reporting forms and faxed or emailed to the study sponsor within 24 hours of 
study staff becoming aware of the event.  For the PRIORITY trial, SAE monitoring 
is performed by the Institute of Clinical Pharmacology at Hanover medical school 
with authorisation of the sponsor.     
 
2.2.7.1 Hyperkalaemia 
Hyperkalaemia is often a concern in trials evaluating intensified RAAS blockade.  
Participants have potassium levels checked at every study visit, and inclusion in 
the trial is not permitted if screening serum potassium is greater than 
5.4mmol/L.  A study-specific management protocol is followed in the event that 
a participant is found to be hyperkalaemic.  
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2.2.8 Sample processing 
Processing of blood and urine samples required in the context of the PRIORITY 
trial is described below.  Additional biomarker analysis performed as part of the 
local sub-studies will be described within the relevant results chapters. 
 
2.2.8.1 Albuminuria measurement 
As detailed above, study participants are asked to collect 3 consecutive first 
morning void samples for measurement of UACR during the run-in period then at 
each routine study visit thereafter throughout their inclusion in the trial.  These 
are collected at home and then returned to the study team using pre-paid 
postage kits provided at screening.  Upon receipt a dipstick test is performed on 
the most recent sample.  If there is evidence of urinary tract infection the 
samples are discarded and a repeat collection is arranged following appropriate 
treatment.  Samples are then stored at -80°C and shipped on dry ice to the 
Steno Diabetes Centre for analysis on a 3-weekly basis. 
Following receipt at the central laboratory samples are thawed and centrifuged 
at 1680g for 10 minutes before measurement of urine albumin and creatinine 
(Vitros 5600 immunoanalyser, Ortho Clinical Diagnostics, France).  The 
geometric mean UACR from all 3 samples as well as each individual UACR result 
is then entered onto the eCRF to be accessed by the local study team with any 
screening failures highlighted. 
 
2.2.8.2 Urinary proteomic sample preparation 
As detailed above, participants are asked to provide a spot urine sample at the 
screening visit.  A dipstick test is performed and if there is evidence of infection 
the sample is discarded and a repeat obtained following appropriate treatment.  
Samples are then stored at -80°C and shipped on dry ice to the central 
laboratory on a 3-weekly basis.  Once normoalbuminuria is confirmed on the 
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corresponding run-in specimens samples for proteomic processing are shipped to 
Mosaiques Diagnostics in Hanover, Germany for analysis.   
0.7µL of urine is required for CE-MS processing.  Shortly before analysis the 
samples are thawed and diluted with 0.7ml of 2mol/L urea and 10mmol/L NH4OH 
containing 0.02% sodium dodecyl sulphate.  In order to remove proteins with 
molecular weight greater than 20kDa samples are spun at 3000g using a 
Centrisart ultracentrifugation device (Sartorius, Göttingen, Germany) until 1.1ml 
of filtrate has been collected.  The filtrate is then desalinised using a PD-10 
column (GE Healthcare Biosciences, Stockholm, Sweden) which is pre-
equilibrated using 0.01% NH4OH in high-performance liquid chromatography-
grade water (Figure 2-3).  Samples are then lipophilised using a freeze-drier 
(Speed-Vac RVC 2-18/Alpha 1-2, Christ, Osterode a.H., Germany), suspended in 
high-performance liquid chromatography-grade water and stored at 4°C until CE-
MS analysis. 
 
 
 
 
Figure 2-3.  Desalinisation using PD-10 column. 
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2.2.8.3 CE-MS sample processing 
CE-MS analysis is performed using a P/ACE MDQ capillary electrophoresis system 
(Beckman Coulter, USA) coupled to a micro-time of flight (micro-TOF) -mass 
spectrometer (Bruker Daltonic, Germany) as shown in Figure 2-4.  The initial 
step involves passage of the sample through a buffer filled capillary, with 
resultant separation of peptides based on migration time.  To do this silica 
capillaries are first rinsed with running buffer containing 30% methanol and 0.5% 
formic acid for 3 minutes.  Approximately 700nl of sample is then injected into 
the capillary and a charge of +30kV applied at the inlet for separation of 
peptides.  The length of the capillary is maintained at a temperature of 35°C 
during processing.  Prior to introduction of the next sample the capillary is 
rinsed with 0.1M NaOH, followed by water and finally running buffer. 
 
 
 
 
 
 
 
Figure 2-4.  Capillary electrophoresis – mass spectrometry. 
Capillary electrophoresis (left) coupled to micro-TOF mass spectrometer (centre) 
illustrating electrospray interface (right). 
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The capillary electrophoresis system is coupled to a micro-TOF-mass 
spectrometer (Bruker Daltronic, Germany.)  The sample is introduced into the 
MS system as a nano-ion spray; the electro-ionisation interface shown in Figure 
2-4 (Agilent technologies, Palo-Alto, Ca, USA) is grounded with potential fixed to 
-4kV.  Mass spectra are accumulated every 3 seconds over a range of 
mass:charge ratios (350-3000) followed by calculation of the mean.  Data 
acquisition is automatic via the capillary electrophoresis program.  A vast 
amount of information is generated in a single CE-MS run as often more than 
1000 spectra are produced for each sample.  As a result a number of analytical 
steps are required in order to process this information correctly.  The 
repeatability and stability of this technique has been confirmed between 
individuals in the same laboratory, as well as between laboratories [381]. 
 
2.2.8.4 CE-MS data processing 
Data analysis is performed using a bespoke Mosaiques-Visu software tool.  The 
software detects each CE-MS peak and calculates the charge based on isotopic 
distributions and conjugated masses.  The Mosaiques-Visu software then 
deconvolutes the data, allowing multiple mass spectral peaks generated for each 
peptide at differentially charged states to be recorded as a single mass using a 
probabilistic clustering algorithm.  Only signals observed in a minimum of 3 
consecutive spectra with a signal-to-noise ratio of at least 4 were considered for 
inclusion.  As multiple analytical and patient-specific confounding factors can 
affect the reliability of these analyses, data are normalised based on the 
abundance of 29 “housekeeping” peptides which are not affected by patient 
age, gender or disease states as an internal standard [383].  The result of this 
processing is a list of mass-spectral peaks characterising each peptide by its 
molecular mass, signal intensity and CE migration time.  Peptides in different 
samples are considered to be identical if mass deviation is minimal. 
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2.2.8.5 Urinary peptidome database 
All detected features in the urine samples that pass quality control criteria are 
then deposited in a Microsoft Structured Query Language database to allow 
further exploration of and comparison with other samples.    Features in 
different samples are considered identical if mass deviation is lower than 
±50ppm at 800Da, increasing to ±75ppm for 15kDa features.  Features detected 
in specific clusters are assigned to the respective protein IDs.  Those that cannot 
be related to a specific cluster are attributed a value of 0.  A number of features 
appear sporadically in only a handful of samples, these entities are of 
questionable significance only those detected in more than 20% of urine samples 
are further investigated as a “noise-filtering” process. 
 
2.2.8.6 Generation of CKD273 classification factor 
In order to allow direct comparison between individuals or patient groups the 
data generated in a CE-MS run is transformed into a single numerical score, 
termed a “classification factor”.  This is calculated in high dimensional 
parameter using MosaCluster software which employs support vector machine 
(SVM) based mathematical modelling.  The software operates by generating 
polypeptide models combining peptides which are differentially expressed 
between affected patients and healthy controls.  Each of these peptides 
represents one dimension in the n-dimensional parameter.  Statistical variability 
of the SVM classification process has been consistently shown to be less than 
10%, both under the same operating conditions over a short period of time and 
when determined by different operators with different devices over a longer 
time period [268]. 
 
2.2.8.7 Routine clinical biochemistry 
Clinical biochemical parameters including urea and electrolytes; HbA1c and lipid 
profile are measured locally within NHS Greater Glasgow and Clyde clinical 
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laboratories.  Following entry of these data, the study eCRF generates each 
participant’s eGFR using the CKD-EPI formula [149]. 
 
2.2.9 Data storage 
Details of each study visit were stored locally in hard copy case report forms, 
identifiable only by patient’s unique study numbers.  These documents were 
held within a locked filing cabinet and accessed only by members of the 
immediate study team.  In addition, consent forms were scanned onto the local 
Clinical Portal database, thereby making local clinicians involved in treating 
these patients aware that they are participants in a clinical trial.  Details of 
study visit were also entered onto the Clinical Portal system by study personnel 
to ensure that this information is available to participants’ GPs online. 
As well as being stored locally, information pertaining to each study visit is also 
manually input into the study-specific eCRF by study personnel who have been 
trained in operation of the system and have authorised access by use of a unique 
password and ID.  Verification and management of data within the eCRF is 
overseen by staff at Hannover Clinical Trials Centre, and in addition any entries 
which appear to be erroneous are highlighted and “queried” electronically by 
the system.  This data is stored in pseudonymised form.  The link document 
through which study numbers can be linked with personal information including 
participant name and date of birth is stored in paper copy in the local study-
specific site file.  This file is held in a separate room from the paper CRFs.  
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3. The safety and effectiveness of mineralocorticoid 
antagonists in combination with ACE-inhibitors 
and/or angiotensin receptor blockers in patients 
with chronic kidney disease: A systematic review 
and meta-analysis 
3.1 Introduction 
The global prevalence of CKD is estimated at between 8 and 16% and continues 
to rise [384].  Irrespective of aetiology CKD is associated with significantly 
increased risk of cardiovascular death, cardiovascular events and hospitalisation 
[285, 385].  Although the magnitude of risk is higher in dialysis dependent 
patients [385] many individuals with earlier stage CKD die from cardiovascular 
disease before progressing to renal replacement therapy.  In fact, the risk of 
cardiovascular events is increased by 43% even in patients with CKD stages 3a 
and b [285]. As a result, CKD places a huge burden on healthcare services as well 
as patients and their families. 
To date the most effective treatment strategies to slow disease progression and 
thereby reduce the incidence of end-stage renal disease are control of blood 
pressure and proteinuria [144] both of which are predictive of mortality in adults 
with CKD [315] [386].  The beneficial effects of RAAS blockade with ACE-
inhibitors or angiotensin receptor blockers in CKD patients are well established 
[315, 387-389] and these agents are standard of care for control of blood 
pressure and proteinuria in both diabetic and non-diabetic CKD [144].  Although 
these routinely-prescribed first-line medications effectively reduce 
cardiovascular and renal events as well as blood pressure and urine protein or 
albumin excretion, many patients still progress to ESRD or die from 
cardiovascular events.  A number of studies have therefore investigated the 
effectiveness of dual RAAS blockade [320, 322, 390]  on progression of renal and 
cardiovascular disease, and meta-analyses have shown that combined RAAS 
blockade is more effective than monotherapy in terms of reduction of blood 
pressure and proteinuria [391-393].  However, in general any positive effects on 
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blood pressure or albuminuria have been offset by risks of hyperkalaemia, acute 
kidney injury and symptomatic hypotension and as such this strategy is not 
recommended in routine clinical practice [144].   
Recent years have seen a renewed appreciation of the role of aldosterone as a 
mediator of cardiovascular and renal disease beyond its effects on fluid and 
electrolyte homeostasis and thereby blood pressure control.  These “non-
classical” effects include induction of vascular and glomerular sclerosis; 
inflammation; and vasoconstriction [113, 394, 395].  RAAS blockade with long-
term ACE-I or ARB monotherapy can potentially result in incomplete suppression 
of circulating aldosterone levels, a phenomenon termed “aldosterone 
breakthrough”.  Small studies have shown that “aldosterone breakthrough” is 
associated with more rapid decline in GFR, progression of albuminuria and 
worsening symptomatology in chronic cardiac and renal disease [133, 396, 397] 
perhaps because any residual aldosterone attenuates the cardio- or reno-
protective effects of these agents.  These insights have stimulated interest in 
the use of MRAs in combination with ACE-I or ARB in patients with CKD to control 
proteinuria and delay disease progression. 
A number of trials examining the effects of addition of MRA to ACE-I or ARB 
therapy in patients with CKD of any aetiology have been published within the 
past decade [323, 325-341, 398-402].  These studies are small and generally of 
insufficient duration to report impact of treatment on hard clinical endpoints, 
however the results were first meaningfully combined in a 2009 meta-analysis by 
the Cochrane Collaboration [392] which was later updated in 2014 [393].  The 
overall conclusion of these projects was that although addition of MRA 
significantly reduced proteinuria and blood pressure these beneficial effects 
were outweighed by increased risk of hyperkalaemia, a factor known to limit 
prescribing of these agents in patients with CKD [403, 404].  Although the 
methodology behind these analyses is undoubtedly sound, a number of additional 
trials have been published since the latest update [338, 340, 341] and several 
confounding issues are evident.  Firstly, a proportion of included studies 
permitted addition of other antihypertensive agents to MRA in the treatment 
arm during the course of the trial, thus rendering it impossible to dissociate the 
effect of MRA from those of alternative agents added.  Secondly, these analyses 
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focussed mainly on published proteinuria data only, consolidating a number of 
disparate measures.  As a result, meaningful meta-analysis of these effects was 
not feasible.  Given that a variety of measures of spot or 24 hour urinary protein 
or albumin excretion are reported in CKD studies it is possible that not all 
available data on protein/albumin leak was analysed and a more robust 
determination of these effects is required.  Thirdly, the risk of hyperkalaemia 
reported is a reflection of the number of participants developing a serum or 
plasma potassium level above the pre-defined limits in individual trial protocols 
rather than the true incidence of clinically significant hyperkalaemia requiring 
treatment, which is potentially of greater interest to the clinicians responsible 
for the care of patients with CKD.   
In view of these factors an updated meta-analysis of trials combining MRA with 
ACE-I and/or ARB therapy in patients with CKD was performed using unpublished 
summary data from original authors where possible including from three studies 
not considered in the most recent Cochrane review [393].  Outcomes of 
particular interest were impact of MRA on: blood pressure; urinary protein and 
albumin excretion; renal excretory function; potassium (including incidence of 
clinically significant hyperkalaemia necessitating medical treatment); as well as 
the hard clinical endpoints all-cause death; cardiovascular morbidity and 
mortality; and requirement of renal replacement therapy where these data were 
available.  By excluding studies where MRA was combined with additional 
antihypertensive agents in the intervention arm, this meta-analysis aim to report 
as purely as possible the effect of MRA without the confounding impact of 
additional therapies.  This work was carried out by the author together with Dr 
Alison Taylor, clinical research fellow in nephrology. 
 
3.2 Methods 
A literature search was performed by two authors (the author and Dr Alison 
Taylor) independently using PubMed (1966-1st Dec 2014), EMBASE (1947-1st Dec 
2014) and the Cochrane Clinical Trials Database.  The full search strategy is 
shown in (Appendix 6).    
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3.2.1 Trial Type 
Randomised controlled trials in human subjects of both selective and non-
selective MRAs compared to placebo, or open label trials using MRA as additional 
therapy compared to standard care in the control arm, in participants with CKD 
stage 1-5 for delay or prevention of disease progression were analysed.  The 
initial period of randomised crossover studies was also considered for inclusion. 
Trials were considered eligible if MRA was used alone, or in combination with 
ACE-I, ARB, or both, i.e. additional MRA as dual or triple RAAS blockade.  Studies 
where additional antihypertensive therapy was added to MRA in the intervention 
arm were excluded, as were studies directly comparing MRA to non-RAAS 
blocking antihypertensive agents.   
 
3.2.2 Participants 
Studies including participants with CKD stage 1-5 with albuminuria or proteinuria 
were considered eligible for the analysis.  Studies in patients requiring renal 
replacement therapy were not included in the formal analysis but the terms 
haemodialysis; peritoneal dialysis; and renal transplantation were used in the 
search strategy to ensure all appropriate trials were identified.  These studies 
were later used in a separate sub-analysis of mortality outcomes. 
 
3.2.3 Interventions 
Trials of both selective and non-selective MRAs compared to placebo; ACE-I; 
ARB; or both were included in the analysis.  Four weeks was considered to be the 
minimum acceptable duration of intervention and studies of less than 4 weeks 
duration were excluded. 
  
115 
 
 
3.2.4 Outcome Measures 
The primary outcome measures included the effect of addition of MRA on the 
following: 
a) End of treatment systolic and diastolic blood pressure (mmHg) 
b) End of treatment urinary albumin or protein excretion, measured as 
either 24 hour collection or spot albumin: or protein: creatinine ratio 
c) End of treatment renal excretory function including: serum creatinine 
(µmol/L); isotopic glomerular filtration rate (GFR, mL/min); estimated 
GFR (eGFR, ml/min/1.73m²); creatinine clearance (ml/min).  In cases 
where several measures of renal function were reported, these data were 
meta-analysed using the following hierarchy:  
i. isotopic GFR;  
ii. creatinine clearance from 24 hour collection;  
iii. eGFR using the MDRD or CKD-EPI formulae;  
iv. estimated creatinine clearance using Cockcroft-Gault formula. 
d) End of treatment serum or plasma potassium, incidence of potassium 
level above pre-defined study upper limit, and incidence of clinically 
significant hyperkalaemia necessitating intervention with potassium-
lowering therapies. 
e) Death, requirement of renal replacement therapy and cardiovascular 
events. 
 
3.2.5 Data Collection 
A list of titles and abstracts was produced using the search strategy shown in 
(Appendix 6).  These were assessed independently by two reviewers (the author 
and Dr Alison Taylor) who discarded those not meeting the pre-defined inclusion 
criteria.  Full texts of the remaining trials were then independently assessed and 
considered for inclusion.  Any discrepancies between reviewers were settled by a 
third author (Dr Paddy Mark, reader in nephrology).  Data were then retrieved 
from the full texts of published papers using specific extraction forms as shown 
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in (Appendix 7).  If required data were not given in the published manuscript 
study authors were contacted to request further information.   
 
3.2.6 Assessment of Bias 
Trial quality was assessed independently by two reviewers (the author and Dr 
Alison Taylor) using the Cochrane Collaboration risk of bias assessment tool 
[405].  Factors considered were:  
a) adequate sequence generation; 
b) allocation concealment; 
c) blinding of participants; trial personnel and outcome assessors; 
d) reporting of incomplete outcome data; 
e) suggestion of selective outcome reporting; 
f) intention-to-treat analysis. 
 
3.2.7 Statistical Analysis 
Statistical analysis was performed by the author and Dr Alison Taylor with the 
support of Dr David Preiss (senior clinical research fellow, Nuffield Department 
of Public Health, University of Oxford).  Random effects meta-analysis was 
performed for continuous and categorical outcomes in order to manage 
between-trial heterogeneity introduced by analysing varied trial populations.  
For continuous outcomes weighted mean differences were calculated using one 
of two different approaches depending on the data available for analysis: 
a) final visit results for the outcome of interest were compared between 
intervention and control arms after using meta-analysis to verify that 
baseline data were not different between the trial arms; 
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b) where sufficient data were available, change in weighted mean difference 
in the outcome of interest from baseline to end-of-trial was calculated by 
meta-analysis. 
For categorical outcomes risk ratios (RRs) were calculated from available data as 
the ratio of cumulative incidence and 95% confidence intervals for trial 
participants at baseline and for those who developed the outcome of interest.   
Authors variously reported urinary protein or albumin excretion using either 24 
hour collection values, spot albumin or protein: creatinine ratios.  Due to the 
distribution of data, standard deviations were not routinely available for these 
measures in many of the included trials, making meaningful analysis challenging.  
Where data were available, percentage change from baseline in any measure of 
urinary protein or albumin excretion was analysed using weighted means and 
weighted standard deviations in exploratory analyses.   
Heterogeneity between trials was quantified using the I2 statistic to provide a 
measure of the proportion of overall variation attributable to inter-trial 
heterogeneity, with p<0.10 considered significant.  Publication bias was 
determined for the most commonly reported outcomes using funnel plots and 
Egger tests.  All statistical analyses were conducted using Stata version 13 
(StataCorp, College Station, Texas). 
 
3.3 Results 
3.3.1 Literature Search and Trial Characteristics 
3.3.1.1 Search Results 
The combined search of PubMed, EMBASE and the Cochrane database resulted in 
identification of 299 citations.  After removal of duplicate citations 143 titles 
and abstracts remained for screening.  A further 87 citations were excluded at 
this stage due to: combined intervention with MRA and additional 
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antihypertensive agents (8 studies); description of outcome measures not pre-
specified for this analysis (5 studies); cohort of participants requiring renal 
replacement therapy (11 studies); description of additional outcomes in a 
duplicate cohort (4 studies); non-randomisation (4 studies); intervention of less 
than 4 weeks duration (2 studies); trial results later retracted (1 study).  Two 
review articles were also removed at this stage.  After full text assessment of 
the remaining 56 articles, 19 trials including a total of 1646 participants [323, 
325-341, 398] were selected for inclusion.  The summary study flow chart is 
shown in Figure 3-1.   
 
 
 
 
 
 
 
Figure 3-1.  Study flow chart. 
Reproduced from Currie et al, BMC Nephrology 2016;17: 237 
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3.3.1.2 Supplemental Information 
Where required data were not reported in the published manuscript original 
authors were contacted by email with data extraction form attached (Appendix 
7) and relevant fields highlighted.  As a result, additional unpublished summary 
data was supplied by 8 authors of 10 (53%) trials [325-327, 329, 330, 335, 338-
340, 398] for inclusion in the final analysis.    
 
3.3.1.3 Trial Characteristics 
a) Study Design 
Of the 19 studies selected for inclusion 5 were randomised placebo-controlled 
trials; 7 trials had randomised controlled design comparing intervention with 
addition of MRA to standard care as control group; and 7 were randomised 
crossover studies.  Participant groups were varied: 6 trials included participants 
with non-diabetic CKD of mixed aetiology; 8 trials recruited participants with 
diabetic nephropathy; 2 studies focussed on participants with CKD and 
hypertension; and 3 included participants with both diabetic and non-diabetic 
CKD.  Trial duration ranged from 8 to 52 weeks, the smallest trial recruited 18 
participants and the largest 359. 
 
b) Intervention 
Fourteen trials used Spironolactone 25-50mg as intervention and 5 trials used 
Eplerenone at doses ranging from 25-100mg per day.  Eighteen trials added 
Spironolactone or Eplerenone to ACE-I or ARB, compared to ACE-I or ARB alone 
(i.e. dual RAAS blockade compared to monotherapy) while one study added 
Spironolactone to ACE-I and ARB (i.e. triple compared to dual RAAS blockade). 
  
120 
 
 
c) Endpoints 
The majority of trials reported at least one of 4 different urinary protein or 
albumin excretion measures as the primary endpoint.  Authors reported either 
24 hour urinary protein or albumin excretion; urine albumin: creatinine ratio; or 
urine protein: creatinine ratio.  In 3 trials protein or albumin excretion was a 
secondary outcome measure where blood pressure, pulse wave velocity (PWV) 
and left ventricular mass index (LVMI) respectively were the primary outcomes 
of interest [335, 336, 340]. 
Varied methods of reporting renal excretory function were also used.  Where 
eGFR was calculated methods included the MDRD and CKD-EPI tools, while the 
Cockcroft-Gault method was used to measure creatinine clearance.  Three trials 
measured isotopic GFR using 51Cr-EDTA [325, 329, 398].  Characteristics of 
participants and interventions in included trials are shown in Table 3-1. 
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1
 
Study Kidney 
disease 
No. of 
patients 
included 
Intervention 
Group 
Control 
group 
Co-
intervention 
Study 
duration 
Baseline eGFR 
(ml/min/1.73m2) 
Endpoints 
Abolghasmi 2011 CKD with resistant 
hypertension 
41 Spironolactone 
25-50mg 
Placebo multi-drug regime 
including ACE-
I+/-ARB 
12 weeks Not available BP, 
potassium, creatinine, 
urinary sodium 
Ando 2014 CKD with 
hypertension 
314 Eplerenone 50 
mg 
Placebo ACE-I+/-ARB of 
at least 8 weeks 
duration 
1 year Treatment 67.7±14.3 
Control 
68.6±13.6 
UACR, creatinine, eGFR, 
urinary L-FABP, 24hr 
urinary sodium, 
incidence of 
cerebrovascular and 
cardiovascular events 
Bianchi 2006 Non-diabetic CKD 
(idiopathic GN) 
165 Spironolactone 
25mg 
ACE-I+/-ARB ACE-I+/-ARB 1 year Treatment 62.4±21.9 
Control  62.2±19.0 
24 hr urinary protein, BP, 
creatinine, eGFR 
potassium 
Boesby 2011 
(XO) 
Non-diabetic CKD 40 Eplerenone 25-
50mg 
multi-drug 
regime including 
ACE-I+/-ARB 
multi-drug regime 
including ACE-
I+/-ARB 
8 weeks 59±26 
 
24 hr urinary albumin, BP, 
potassium, creatinine 
clearance 
Boesby 2013 Diabetic and non-
diabetic CKD 
26 Eplerenone 25-
50mg 
ACE-I+/-ARB ACE-I+/-ARB 24 weeks 36±10 
 
cfPWV, AIx, AASI, 
24hr urinary albumin 
Chrysostomou 
2006* 
Diabetic and non-
diabetic CKD 
41 Spironolactone 
25mg 
Placebo as 
ARB; 
Placebo as 
Spironolactone 
ACE-I alone; 
ACE-I+ARB 
3 months Not available 24hr urinary protein, BP, 
creatinine, creatinine 
clearance, potassium 
Edwards 2009 Non-diabetic 
CKD with no 
renovascular 
diagnosis 
112 Spironolactone 
25mg 
Placebo ACE-I/ARB 36 weeks Treatment    49±12 
Control 
53±11 
LVMI, cfPWV, aortic 
distensibility, AIx, BP 
 
 
Table 3-1.  Summary of included studies. 
Continues on following pages.  Reproduced from Currie et al, BMC Nephrology 2016;17: 237 
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Study Kidney 
disease 
No. of 
patients 
included 
Intervention 
Group 
Control 
group 
Co-
intervention 
Study 
duration 
Baseline eGFR 
(ml/min/1.73m2) 
Endpoints 
Epstein 2006+ Diabetic 
nephropathy 
359 Eplerenone 
50mg or 
100mg 
Placebo ACE-I 12 weeks ACE±EPL 50 
73(62.1-83.6) 
ACE±EPL 100 
75 (62.8-85.9) 
Control 
74 (60.5-82.2) 
UACR, potassium, BP, 
eGFR 
 
Guney 2009 
 
 
Non-diabetic 
CKD 
24 Spironolactone 
25mg 
ACE-I+/-ARB ACE-I+/-ARB 6 months Treatment 
63.0±22.71 
Control 
56.3±35.6 
UPCR, urinary TGF-β1, 
eGFR, creatinine, 
potassium, BP, 
aldosterone 
Mehdi 2009 Diabetic 
nephropathy 
81 Spironolactone 
25mg 
Placebo or 
ARB 
ACE-I 48 weeks Not available 
 
UACR, BP, creatinine 
clearance, potassium 
Nielsen 2012 
(XO) 
Diabetes with 
microalbuminuria 
21 Spironolactone 
25mg 
Placebo ACE-I/ARB 60 days Not available 
 
24hr urinary albumin, 
BP, GFR, urinary L-
FABP, urinary NGAL, 
urinary KIM-1 
Rossing 2005 
(XO) 
Diabetic 
nephropathy 
20 Spironolactone 
25mg 
Placebo ACE-I+/-ARB 8 weeks Not available 
 
24 hr urinary albumin, 
BP, GFR 
Saklayen 2008 
(XO) 
Diabetic 
nephropathy 
24 Spironolactone 
25-50mg 
Placebo ACE-I/ARB 3 months Treatment 
61.9±23.4 
Control 
54.4±20.1 
BP, creatinine, 
potassium, UPCR 
Schjoedt 2005 
(XO) 
Diabetic 
nephropathy 
20 Spironolactone 
25mg 
Placebo ACE-I+/-ARB 2 months Not available 24hr urinary albumin, 
BP, GFR 
  
 
 
 
1
2
3
 
Study Kidney 
disease 
No. of 
patients 
included 
Intervention 
Group 
Control 
group 
Co-
intervention 
Study 
duration 
Baseline eGFR 
(ml/min/1.73m2) 
Endpoints 
Tylicki 2008 
(XO) 
Non-diabetic 
CKD 
18 Spironolactone 
25mg 
ACE-I+ARB ACE-I+ARB 8 weeks 107.8 (93-140.9) 
 
24hr urinary protein, 
BP, creatinine, 
potassium, PRA, 
urinary NAG, urinary 
PIIINP 
Tylicki 2012 
(XO) 
Non-diabetic 
CKD 
18 Eplerenone 
50mg 
ARB+Aliskiren ARB 8 weeks Not available UACR, BP, creatinine 
clearance, potassium 
van den 
Meiracker 2006 
 
 
Diabetic 
nephropathy 
53 Spironolactone 
25-50mg 
Placebo ACE-I/ARB 1 year Treatment 93.1±45 
Control 
66.3±35.1 
24hr urinary protein, 
BP, creatinine, eGFR, 
potassium 
Wang 2013 Diabetic and non-
diabetic CKD 
208 Spironolactone 
20mg 
multi-drug 
regime 
including ACE-
I+/-ARB 
multi-drug 
regime 
including ACE-
I+/-ARB 
16 weeks Treatment 
65.8±22.2 
Control 66.5±24.3 
24hr urinary protein, 
creatinine, potassium, 
eGFR, BP, aldosterone 
Ziaee 2013 Diabetes with 
microalbuminuria 
60 Spironolactone 
25mg 
ACE-I ACE-I 12 weeks Treatment 
79.8±18 
Control 
82.5±19.1 
UACR, BP, potassium, 
eGFR 
 
 
Data are mean±SD or median (IQR). UACR, urine albumin:creatinine ratio; UPCR, urine protein:creatinine ratio; ACE-I, angiotensin converting enzyme 
inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; NG, glomerulonephritis; L-FABP, liver-type fatty acid binding protein; XO, 
crossover study design; cfPWV, carotid-femoral pulse wave velocity; AIx, augmentation index; AASI, ambulatory arterial stiffness index; LVMI, left 
ventricular mass index; TGF-β1, transforming growth factor-β1; NGAL, neutrophil gelatinase associated lipocalin; KIM-1, kidney injury molecule-1; PRA, 
plasma renin activity; NAG, n-acetyl-β-D-glucosaminidase; PIIINP, amino-terminal propeptide of type III procollagen; *this study had 4 arms; +this study 
had 3 arms 
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3.3.1.4 Trial Quality 
Trial quality was variable as assessed using the Cochrane Collaboration tool [405] 
as shown in Table 3-2. Sequence generation was adequately described in 9 (47%) 
trials and allocation concealment was adequate in 8 (42%).  Both participants 
and investigators were blinded in 12 (63%) trials and intention-to-treat analysis 
was performed in 4 (21%) studies.  Dropouts were adequately accounted for in 16 
(84%) trials and there were no differences in dropout rates between intervention 
and control arms.   
 
 
 
 
 
1
2
5
 
 
Trial Random 
sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Blinding of 
participants 
(performance 
bias) 
Blinding of 
personnel 
(performance 
bias) 
Blinding of 
outcome 
assessment   
(detection 
bias) 
Incomplete 
outcome 
data 
(attrition 
bias) 
Selective 
reporting 
(reporting 
bias) 
Intention to treat 
analysis 
Abolghasmi  
2011 
Unclear risk 
(don’t state how 
participants were 
randomised) 
Unclear risk Low risk 
(double-blind) 
Low risk  
(double blind) 
Low risk  
(not stated in 
paper but 
unlikely that 
biochemical 
outcomes would 
be influenced) 
Unclear risk  
(don’t report 
whether all 
patients 
completed 
study) 
Low risk  
(protocol not 
available but 
all prespecified 
outcome 
measures 
reported) 
Not performed 
Ando  
2014 
Low risk 
(computer 
generated list) 
Low risk 
(list created by 
central 
statistician, 
block size 
concealed to all 
investigators) 
Low risk 
(double blind) 
Low risk 
(double blind) 
Low risk  
(data collection 
and 
management 
personnel and 
statisticians all 
blinded for 
duration) 
Low risk  
(losses to 
follow up 
disclosed – 18, 
should not 
affect results as 
predicted drop-
out rate in 
sample size 
calculation was 
10%) 
Low risk 
(All 
prespecified 
outcomes 
were reported) 
Yes 
 
 
Table 3-2.  Risk of bias assessment. 
Continues on following pages.  XO, crossover study design. Reproduced from Currie et al, BMC Nephrology 2016;17: 237 
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Trial Random 
sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Blinding of 
participants 
(performance 
bias) 
Blinding of 
personnel 
(performance 
bias) 
Blinding of 
outcome 
assessment   
(detection 
bias) 
Incomplete 
outcome 
data 
(attrition 
bias) 
Selective 
reporting 
(reporting 
bias) 
Intention to treat 
analysis 
Bianchi  
2006 
Low risk 
(computer 
generated list) 
Unclear risk 
(further 
description of 
allocation not 
included) 
High risk  
(open label) 
High risk  
(open label) 
High risk  
(open label) 
Low risk  
(drop-outs 
disclosed) 
Low risk  
(all 
prespecified 
outcomes 
reported, most 
drop outs from 
high risk group 
were as a 
results of K+ 
but this was 
disclosed in 
paper) 
Not performed 
Boesby  
2011 
Unclear risk 
(“investigator 
drew sealed 
opaque 
envelopes” but 
no detail on how 
randomisation 
list created) 
Low risk 
(sealed, opaque 
envelopes) 
High risk  
(open label XO) 
High risk 
 (open label XO) 
High risk  
(open label XO) 
Low risk  
(drop-outs 
disclosed) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Modified 
(drop outs after 
randomisation still 
included in final 
analysis) 
Boesby  
2013 
Unclear risk 
(“randomisation 
done by GCP-
unit” but no 
detail on how) 
Unclear risk  
(not 
documented) 
High risk  
(open label) 
High risk 
 (open label) 
High risk  
(open label) 
Low risk  
(drop-outs 
disclosed, 
groups still 
equal) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Not performed 
  
 
 
 
1
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Trial Random 
sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Blinding of 
participants 
(performance 
bias) 
Blinding of 
personnel 
(performance 
bias) 
Blinding of 
outcome 
assessment   
(detection 
bias) 
Incomplete 
outcome 
data 
(attrition 
bias) 
Selective 
reporting 
(reporting 
bias) 
Intention to treat 
analysis 
Chrystosostomou 
2006 
Unclear risk  
(“randomisation 
done by clinical 
trial pharmacists 
not involved in 
study”) 
Low risk 
(simple 
randomisation) 
Low risk  
(double blind) 
Low risk  
(double blind) 
Low risk  
(unblinded after 
3 months but 
unlikely to have 
influenced 
outcome 
measures) 
Low risk  
drop outs 
disclosed but 
only  1 so 
unlikely to 
affect outcome) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Yes 
Edwards  
2009 
Unclear risk 
(no detail on 
how sequence 
generated) 
Unclear risk  
(no detail on 
how allocation 
performed) 
Low risk  
(double blind) 
Low risk  
(double blind) 
Low risk  
(not stated in 
paper but 
unlikely that 
biochemical 
outcomes would 
be influenced) 
Low risk  
(drop outs 
disclosed) 
Low risk 
(all 
prespecified 
outcomes 
reported) 
Not performed 
Epstein  
2006 
Unclear risk  
(no detail on 
how 
randomisation 
performed) 
Unclear risk  
(no detail given) 
Low risk 
 (double blind) 
Low risk 
 (double blind) 
Low risk  
(not stated in 
paper but 
unlikely that 
biochemical 
outcomes would 
be influenced) 
Low risk 
(drop outs fully 
disclosed) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Not performed 
Guney  
2009 
Unclear risk 
(no detail on 
how 
randomisation 
performed) 
Unclear risk  
(no detail given) 
High risk  
(not blinded) 
High risk 
(not blinded) 
High risk 
(not blinded) 
Low risk  
(drop outs fully 
disclosed) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Not performed 
  
  
1
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Trial Random 
sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Blinding of 
participants 
(performance 
bias) 
Blinding of 
personnel 
(performance 
bias) 
Blinding of 
outcome 
assessment   
(detection 
bias) 
Incomplete 
outcome 
data 
(attrition 
bias) 
Selective 
reporting 
(reporting 
bias) 
Intention to treat 
analysis 
Mehdi  
2009 
Low risk 
(computer 
randomisation, 
by diabetes 
type) 
Low risk  
(performed by 
staff at 
investigational 
study drug unit) 
Low risk  
(double blind) 
Low risk  
(double blind) 
Low risk  
(not stated in 
paper but 
unlikely that 
biochemical 
outcomes would 
be influenced) 
Low risk 
 (drop outs 
disclosed but 
only  1 so 
unlikely to 
affect outcome) 
Low risk 
(all 
prespecified 
outcomes 
reported) 
Yes 
Nielsen  
2012 
Low risk 
(computer 
generated 
randomisation) 
Low risk  
(unknown block 
size and 
frequency) 
Low risk  
(double blind) 
Low risk  
(double blind) 
Low risk  
(not stated in 
paper but 
unlikely that 
biochemical 
outcomes would 
be influenced) 
Unclear risk 
 (don’t report 
whether all 
patients 
completed 
study) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Unable to 
comment - 
?assume all 
participants 
completed study 
Rossing  
2005 
Low risk 
(computer 
generated 
randomisation) 
Low risk  
(sealed 
envelopes) 
Low risk  
(double blind) 
Low risk  
(double blind) 
Low risk 
 (“code not 
broken until all 
data entered 
into a database 
which was 
locked for 
editing”) 
Low risk  
(drop outs 
disclosed but 
only  1 so 
unlikely to 
affect outcome) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Not performed 
Saklayen  
2008 
Unclear risk 
(“sequence 
generated 
randomly by a 
clinical trials 
pharmacist”) 
Unclear risk  
(no detail given) 
Low risk  
(double blind) 
Low risk 
 (double blind) 
Low risk  
(“investigators 
blinded until 
code was 
broken at end of 
study”) 
Low risk  
(drop outs fully 
disclosed) 
Unclear risk 
 (intended 
outcome 
measures not 
stated in 
methods 
section) 
Not performed 
  
 
 
 
1
2
9
 
Trial Random 
sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Blinding of 
participants 
(performance 
bias) 
Blinding of 
personnel 
(performance 
bias) 
Blinding of 
outcome 
assessment   
(detection 
bias) 
Incomplete 
outcome 
data 
(attrition 
bias) 
Selective 
reporting 
(reporting 
bias) 
Intention to treat 
analysis 
Schojedt  
2005 
Low risk  
(computer 
generated) 
Low risk  
(concealed with 
computer 
generated 
envelopes) 
Low risk  
(double blind) 
Low risk  
(double blind) 
Low risk 
(“code not 
broken until all 
data entered 
into a database 
which was 
locked for 
editing”) 
Low risk 
 (drop outs fully 
disclosed) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Not performed 
Tylicki 
2008 
Low risk 
(computer 
generated) 
Low risk  
(“independent of 
study 
personnel”) 
High risk 
(not blinded) 
High risk  
(not blinded) 
High risk  
(not blinded) 
Low risk  
(no drop outs) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Not 
performed/required 
Tylicki  
2012 
Low risk  
(computer 
generated) 
Unclear risk  
(no detail given) 
Low risk  
(double blind) 
Low risk  
(double blind) 
Low risk  
(not stated in 
paper but 
unlikely that 
biochemical 
outcomes would 
be influenced) 
Low risk  
(no drop outs) 
Low risk  
(all 
prespecified 
outcomes 
reported) 
Not 
performed/required 
Van der 
Meiracker  
2006 
Low risk 
(computer 
generated) 
 
Unclear risk  
(no detail given) 
Low risk  
(double blind) 
Low risk  
(double blind) 
Low risk  
(not stated in 
paper but 
unlikely that 
biochemical 
outcomes would 
be influenced) 
Low risk 
 (drop outs fully 
disclosed) 
Unclear risk  
(intended 
outcome 
measures not 
stated in 
methods 
section) 
Not performed 
  
  
1
3
0
 
Trial Random 
sequence 
generation 
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Selective 
reporting 
(reporting 
bias) 
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methods 
section) 
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3.3.1.5 Heterogeneity 
Heterogeneity was considerable for meta-analysis of the majority of outcomes 
(final visit systolic and diastolic blood pressure; final visit serum creatinine, 
albumin: creatinine ratio, protein: creatinine ratio, 24 hour urinary protein and 
albumin excretion; final visit potassium).  Limited heterogeneity was seen for 
other outcomes (change from baseline systolic and diastolic blood pressure; final 
visit creatinine clearance, eGFR, GFR hierarchy; change from baseline potassium 
and risk of hyperkalaemia).  The I2 values for these variables are given in Tables 
3-4 and 3-5 and Figures 3-5 to 3-10.  
 
3.3.1.6 Publication Bias 
There was a suggestion of publication bias for systolic blood pressure as 
determined by funnel plot (Figure 3-2) and Egger test (p=0.08), but not for end 
of study GFR (Figure 3-3, Egger test p=0.89) or hyperkalaemia risk (Figure 3-4, 
Egger test p=0.81). 
 
 
 
 
Figure 3-2.  Funnel plot for systolic blood pressure. 
SBP, systolic blood pressure; WMD, weighted mean difference. Reproduced from Currie 
et al, BMC Nephrology 2016;17: 237.  
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Figure 3-3.  Funnel plot for end of study glomerular filtration rate (GFR). 
eGFR, estimated glomerular filtration rate; WMD, weighted mean difference.  Reproduced 
from Currie et al, BMC Nephrology 2016;17: 237. 
 
 
 
 
 
 
 
 
Figure 3-4.  Funnel plot for risk ratio for hyperkalaemia. 
WMD, weighted mean difference. Reproduced from Currie et al, BMC Nephrology 
2016;17: 237.  
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3.3.2 Clinical Outcomes 
Meta-analysis of baseline data for all outcomes of interest showed that these 
were balanced across studies (Table 3-3), confirming that use of end-of-trial 
meta-analysis was an appropriate analysis strategy to employ. 
 
3.3.2.1 Effect of MRA treatment on blood pressure 
Addition of MRA led to significant reductions in both systolic and diastolic blood 
pressure in comparison to ACE-I and/or ARB alone.  Based on final visit blood 
pressure results, MRA led to a 5.7mmHg reduction (95% CI -9.04, -2.34) in 
systolic blood pressure.  In the 9 trials where change from baseline was 
available, addition of MRA again resulted in a 3.3mmHg (95% CI -5.56, -1.04) 
reduction in systolic blood pressure compared to ACE-I and/or ARB alone (Figure 
3-5).  Enhanced RAAS blockade with MRA also produced a 1.7mmHg reduction 
(95% CI -3.37, -0.10) in final visit diastolic blood pressure, and in trials where 
change from baseline was available for analysis a 2.8mmHg reduction (95% CI -
3.35, -2.33) was seen with the addition of MRA to standard RAAS blockade (Table 
3-4).   
 
 
 
 
1
3
4
 
 
Variable Units 
No. of 
trials 
No. patients in 
treatment 
No. patients in 
placebo/control 
Effect size (95% CI) I2 (p value) 
Systolic BP mmHg 17 693 686 0.46 (-0.75, 1.66) 0.0% (0.981) 
Diastolic BP mmHg 17 693 686 0.63 (-0.18, 1.43) 0.0% (0.739) 
Serum Potassium mmol/L 17 708 702 -0.01 (-0.05, 0.04) 0.0% (0.992) 
Creatinine µmol/L 18 646 640 -0.20 (-4.50, 4.10) 25.1% (0.160) 
Estimated GFR ml/min/1.73m2 9 459 454 -0.10 (-3.13, 2.94) 35.1% (0.137) 
Creatinine Clearance ml/min 6 132 130 -3.30 (-9.64, 3.04) 16.5% (0.307) 
Urinary protein creatinine ratio mg/mmol 4 146 150 0.06 (-0.68, 0.20) 19.6% (0.292) 
Urinary albumin creatinine ratio g/g creatinine 7 364 360 3.44 (-8.82, 15.71) 64.8% (0.009) 
24 hr urinary protein excretion g/24 hours 4 145 140 0.04 (-0.14, 0.22) 0.0% (0.815) 
24 hr urinary albumin excretion mg/24 hours 6 151 155 -3.26 (-42.14, 35.62) 0.0% (0.716) 
 
 
Table 3-3.  Comparison of baseline data in meta-analyses 
BP, blood pressure; GFR, glomerular filtration rate.  Reproduced from Currie et al, BMC Nephrology 2016;17: 237 
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Variable Measurement 
No. of study 
groups 
No. patients in 
intervention 
No. patients in 
placebo/control 
Effect size 
(95% CI) 
I2 (p value) 
Systolic BP 
(mmHg) 
Change from baseline 9 260 266 -3.30 (-5.56, -1.04) 40.0% (0.101) 
Final visit 16 666 659 -5.69 (-9.04, -2.34) 81.8% (0.000) 
Diastolic BP 
(mmHg) 
Change from baseline 9 260 266 -2.84 (-3.35, -2.33) 0.0% (0.799) 
Final visit 16 666 659 -1.73 (-3.37, -0.10) 68.3% (0.000) 
 
 
 
Table 3-4.  Effect of MRA with ACE-I and/or ARB compared with ACE-I/ARB monotherapy on end of treatment blood pressure. 
BP, blood pressure.  Reproduced from Currie et al, BMC Nephrology 2016;17: 237 
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Figure 3-5.  Effect of addition of MRA to ACE-I and/or ARB on blood pressure. 
Based on change from baseline blood pressure.  SBP, systolic blood pressure; MRA, 
mineralocorticoid receptor antagonist; WMD, weighted mean difference.  Reproduced 
from Currie et al, BMC Nephrology 2016;17: 237 
 
 
3.3.2.2 Effect of MRA treatment on renal excretory function 
Based on end-of-trial results, addition of MRA to ACE-I and/or ARB led to a non-
significant increase in serum creatinine of 3.8µmol/L (95% CI -2.14, 9.79).  In 
studies where creatinine clearance was reported meta-analysis revealed a non-
significant reduction of 2.5 ml/min (95% CI -7.05, 2.04) using final visit values.  
However, when the hierarchy of GFR results were analysed as previously 
detailed above, a small but statistically significant reduction was seen with 
addition of MRA using final visit values (-3.15 ml/min/1.73m2; 95% CI -5.36, -
0.95) as shown in Figure 3-6.   
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Figure 3-6.  Effect of addition of MRA to ACE-I and/or ARB on end-of treatment renal 
excretory function. 
Analysis based on end-of-treatment renal excretory function.  In cases where multiple 
measures were reported analysis was based on the following hierarchy: isotopic GFR; 
creatinine clearance from 24 hour collection; eGFR using MDRD or CKD-EPI formulae; 
estimated creatinine clearance using Cockroft-Gault formula. GFR, glomerular filtration 
rate; MRA, mineralocorticoid receptor antagonist; WMD, weighted mean difference.  
Reproduced from Currie et al, BMC Nephrology 2016;17: 237 
 
 
 
 
3.3.2.3 Effect of MRA treatment on urinary albumin/protein excretion 
A variety of measures of urinary protein or albumin excretion were reported in 
included studies which are summarised in Table 3-5.  In trials where UACR was 
reported addition of MRA led to a non-significant reduction of 10.91mg/mmol 
(95% CI -26.15, 4.32) using end-of-trial results.  No authors reported change from 
baseline ACR.  In studies reporting 24 hour UAE, MRA led to a significant 
reduction of -332.91 mg/24hrs (95% CI -624.08, -41.02).  Three study groups 
reported change in 24 hour albumin excretion from baseline and meta-analysis 
again confirmed a significant reduction of 292.23 mg/24hrs (95% CI -422.19, -
162.27). 
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Variable Measurement 
No. of 
study 
groups 
No. patients in 
intervention 
No. patients in 
placebo/control 
Effect size (95% CI) I2 (p value) 
Creatinine (µmol/L) Final visit 16 601 595 3.83 (-2.14, 9.79) 50.4% (0.011) 
Creatinine 
Clearance (ml/min) 
Final visit 6 132 130 -2.51 (-7.05, 2.04) 0.0% (0.599) 
eGFR 
(ml/min/1.73m2) 
Final visit 13 626 617 -2.71 (-4.85, -0.57) 0.0% (0.727) 
GFR hierarchy* Final visit 17 692 682 -3.15 (-5.36, -0.95) 0.0% (0.790) 
Urinary ACR 
(mg/mmol) 
Final visit 7 355 351 -10.91 (-26.15, 4.32) 83.4% (0.000) 
Urinary PCR  
(g/g creatinine) 
Final visit 4 146 150 -0.91 (-1.35, -0.46) 58.4% (0.065) 
24 hour urinary 
albumin excretion  
(mg/24 hours) 
Final visit 6 151 155 
-332.91 (-624.80, -
41.02) 
66.5% (0.011) 
Change from 
baseline 
3 90 94 
-292.23 (-422.19, -
162.27) 
0.0% (0.606) 
24 hour urinary 
protein excretion 
(g/24 hours) 
Final visit 2 124 121 -0.41 (-0.90, 0.09) 77.1% (0.037) 
 
 
Table 3-5.  Effect of MRA with ACE-I and/or ARB compared with ACE/ARB monotherapy on end of treatment renal excretory function and 
urinary protein/albumin excretion. 
eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; ACR, albumin: creatinine ratio; PCR, protein: creatinine ratio.  Reproduced 
from Currie et al, BMC Nephrology 2016;17: 237. 
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In trials where urine protein: creatinine ratio was used, MRA added to ACE-I 
and/or ARB led to a significant change in end-of-trial values (-0.91g/g 
creatinine; 95% CI -1.35, -0.46).  No trials reported change from baseline 
protein: creatinine ratio.  In studies where 24 hour urinary protein excretion was 
recorded, addition of MRA resulted in a non-significant reduction (-0.41 g/24hrs; 
95% CI -0.90, 0.09) in end-of-trial values. 
Analysis of absolute values in the case of urinary protein or albumin measures 
may be misleading as these data are non-parametric; in order to combine the 
data in a more appropriate manner relative change from baseline in any measure 
of protein/albumin excretion was assessed where these results were available.  
Using a difference in means analysis in order to allow inclusion of data from all 
19 trials, addition of MRA resulted in a 38.7% (weighted SD 21.5%) reduction in 
any measure of urinary protein or albumin excretion.  Focussing only on data 
from the 5 trials where percentage change in urinary protein/albumin excretion 
was available enhanced RAAS blockade with the addition of MRA led to a 
weighted mean difference of -31.03% (95% CI -35.34, -26.72) as shown in Figure 
3-7.   
 
3.3.2.4 Effect of MRA treatment on potassium 
Weighted means analysis confirmed that additional MRA treatment did lead to 
increased potassium levels based on end-of-trial values (0.21mmol/L; 95% CI 
0.08, 0.33) although there was significant heterogeneity between included 
studies (I2=82.7%, p=<0.001).   When analysed as change from baseline where 
these data were available using random effects meta-analysis a similar increase 
was seen with addition of MRA (0.19mmol/L; 95% CI 0.12, 0.270).   
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Figure 3-7.  Effect of addition of MRA to ACE-I and/or ARB on urinary protein or 
albumin excretion. 
Analysis based on change from baseline UPCR; 24 hour urine protein; UACR or 24 hour 
urine albumin in the 5 studied where this was reported.  MRA, mineralocorticoid receptor 
antagonist; WMD, weighted mean difference.  Reproduced from Currie et al, BMC 
Nephrology 2016;17: 237 
 
 
 
 
Risk of developing hyperkalaemia above the pre-defined trial upper limit was 
increased threefold with the addition of MRA to ACE-I and/or ARB as shown in 
Figure 3-8 (RR 3.02; 95% CI 1.75, 5.18).  Number needed to harm for one year of 
MRA treatment calculated from trials where at least one case of hyperkalaemia 
was reported was 10 (95% CI 5, 27).  Neither baseline serum creatinine (p=0.21) 
nor diabetes status (p=0.38) conferred an increased risk of hyperkalaemia based 
on included studies (Figure 3-9). Relative risk of being withdrawn from the 
intervention arm of the trial due to hyperkalaemia was increased to a similar 
extent (RR 3.21; 95% CI 1.19, 8.71).  Number needed to harm over one year of 
treatment in trials where therapy was discontinued in at least one participant 
was 23 (95% CI 7, 267).   
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Figure 3-8.  Relative risk of developing hyperkalaemia above the threshold pre-
defined by investigators in each study with addition of MRA to ACE-I and/or ARB. 
K, potassium; MRA, mineralocorticoid receptor antagonist; RR, relative risk.  Reproduced 
from Currie et al, BMC Nephrology 2016;17: 237 
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Figure 3-9.  Relative risk of developing hyperkalaemia above study thresholds 
according to diabetes status. 
Mixed refers to studies including both diabetic and non-diabetic patients; non-DM refers to 
studies where patients with diabetic nephropathy were not included; DM refers to studies 
including only patients with diabetic nephropathy.  DM, diabetes mellitus; RR, relative risk.  
Reproduced from Currie et al, BMC Nephrology 2016;17: 237 
 
 
 
 
 
Focusing on clinically significant hyperkalaemia which necessitated medical 
intervention, only 1 trial reports hospitalisation of a study participant due to 
hyperkalaemia (plasma potassium 7.1mmol/L after 2 weeks of therapy 
necessitating infusion of IV insulin and dextrose and cardiac monitoring) [398]. 
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3.3.2.5 Vascular parameters 
Two trials reported the effects of addition of MRA to ACE-I and/or ARB on 
surrogate cardiac and vascular markers including: LVMI [335], ejection fraction 
(EF) [335]; augmentation index corrected for heart rate of 75 beats/minute 
(AIx@75) [335, 340] and carotid-femoral pulse wave velocity (cfPWV) [335, 340]. 
In one study in 112 participants with non-diabetic CKD stage 3A, addition of MRA 
resulted in significant improvement in LVMI compared to placebo (-14±13g vs 
+3±11g respectively, p=<0.01).  There was no effect on EF with MRA over the 36 
week treatment period [335].  Two groups reported the effect of MRA on cfPWV.  
In the trial described above, addition of MRA significantly improved cfPWV over 
a 36 week treatment period in comparison to placebo (-0.8 ± 1.0 vs -0.1 ± 0.9 
m/s respectively, p=<0.01).  Significant improvement in AIx@75 was also seen (-
5.2 ± 6.1% vs -1.4 ± 5.9%, p=<0.05) [335].  In another study of effects of 24 
weeks MRA treatment in patients with both diabetic and non-diabetic CKD stage 
3-4, addition of MRA resulted in a statistically significant 4.4% reduction in 
AIx@75 (p=0.04) and of 0.1m/s in cfPWV, although this was not statistically 
significant (p=0.8) [340]. 
 
3.3.2.6 Morbidity and mortality 
Included studies were small and study duration was no longer than 1 year, 
therefore trials were not powered to determine the effects of addition of MRA 
therapy on hard clinical outcomes.  There were no reported of participants 
commencing dialysis or requiring renal transplantation during the course of the 
included studies.  Morbidity and mortality data from included studies are 
summarised in Table 3-6.  One study reported a participant death in the 
intervention arm, the cause of which was unknown [338], but no deaths were 
reported among the 18 remaining included trials.  Two trials reported 
cardiovascular morbidity [328, 338].  In one of these trials, the duration of which 
was one year, a single study participant allocated to the intervention arm 
developed atrial fibrillation while another participant in the control group 
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suffered a stroke [338].  Another study, lasting 48 weeks, reported 6 
cardiovascular events in the intervention group (2 strokes, 2 hospitalisations for 
heart failure, 1 myocardial infarction and 1 coronary artery bypass graft) whilst 
one participant in the control arm suffered a stroke [328]. 
 
 
 
 
 
 
Table 3-6.  Morbidity and mortality reported in included studies. 
MRA, mineralocorticoid receptor antagonist; CVA, cerebrovascular accident; MI, 
myocardial infarction; CABG, coronary artery bypass graft.  Reproduced from Currie et al, 
BMC Nephrology 2016;17: 237 
 
  
Trial 
Number of 
participants 
(control) 
Number of 
participants  
(MRA) 
Event 
Events in 
control arm 
Events in 
MRA arm 
Ando 
2014 
152 162 Death 0 1 (0.6%) 
   
Atrial 
fibrillation 
0 1 (0.6%) 
   CVA 1 (0.7%) 0 
      
Medhi 
2009 
27 27 Heart failure 2 (7.4%) 0 
   CVA 2 (7.4%) 1 (3.7%) 
   MI 1 (3.7%) 0 
   CABG 1 (3.7%) 0 
145 
 
 
3.3.2.7 Mortality in Renal Replacement Therapy Trials 
Studies in patients requiring renal replacement therapy were excluded from the 
main analysis, however all-cause mortality data was available from 6 trials [399-
402, 406, 407].  The populations and interventions evaluated in these trials are 
summarised in Table 3-7.  There was no heterogeneity between trials included in 
this analysis (I2=0.0%, p=0.543).  Random effects meta-analysis demonstrated a 
significant reduction in all-cause mortality in patients randomised to MRA 
treatment in comparison to controls (RR 0.40; 95% CI 0.23, 0.69) as shown in 
Figure 3-10. 
 
 
 
 
 
 
Figure 3-10.  Effect of addition of MRA to ACE-I and/or ARB on all-cause mortality in 
patients requiring dialysis. 
MRA, mineralocorticoid receptor antagonist; RR, relative risk.  Reproduced from Currie et 
al, BMC Nephrology 2016;17: 237 
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Trial Intervention Duration Population 
Number of 
Participants 
(control) 
Number of 
participants 
(MRA) 
Deaths (control 
arm) 
Deaths (MRA 
arm) 
Ito, 
2014 
Spironolactone 
25mg 
2 years 
Peritoneal 
dialysis 
80 78 5 (6.3%) 2 (2.5%) 
Matsumoto, 
2014 
Spironolactone 
25mg 
3 years Haemodialysis 152 157 30 (19.7%) 10 (6.4%) 
Taheri, 
2009 
Spironolactone 
25mg 
6 months 
Haemodialysis 
with EF < 45% 
8 8 2 (25%) 3 (37.5%) 
Taheri, 
2012 
Spironolactone 
25mg 
6 months 
Peritoneal 
dialysis 
9 9 3 (33.3%) 0 
Vukusich, 
2010 
Spironolactone 
50mg 
2 years Haemodialysis 23 30 1 (4.3%) 0 
Walsh, 
2015 
Eplerenone 
50mg 
13 weeks Haemodialysis 77 77 2 (2.5%) 1 (1.3%) 
 
 
Table 3-7.  Mortality reported in excluded RRT studies 
RRT, renal replacement therapy; MRA, mineralocorticoid receptor antagonist; EF, ejection fraction.  Reproduced from Currie et al, BMC Nephrology 
2016;17: 237 
   
147 
 
 
3.4 Discussion 
The world prevalence of CKD is increasing, attributable at least in part to the 
alarming global epidemics of hypertension, obesity and diabetes [408].  Current 
guidelines suggest RAAS blockade with ACE-I or ARB to slow disease progression 
in patients with CKD irrespective of aetiology [144].  Despite the routine 
prescribing of these agents in clinical practice many patients continue to 
progress to end stage renal disease, or die from cardiovascular complications of 
their disease [285].  Studies focusing on enhanced RAAS blockade with combined 
ACE-I and ARB therapy have raised concerns due to adverse effects and this 
strategy is not currently recommended [144].  Accumulating evidence points 
towards the pivotal role of aldosterone in the development and progression of 
CKD, and clinical studies included in this review have shown the beneficial 
effects of addition of MRAs to ACE-I and/or ARB including reduction of urinary 
protein or albumin excretion and blood pressure.  Concerns remain that this 
combination has the potential to cause hyperkalaemia and further deterioration 
in renal function in patients with pre-existing CKD.  Furthermore, the effects of 
addition of MRA on hard clinical endpoints such as all-cause mortality or 
cardiovascular outcomes remains unclear. 
This meta-analysis confirmed that enhanced RAAS blockade through addition of 
MRA to ACE-I and/or ARB therapy is associated with significant reductions in 
blood pressure and urinary protein or albumin excretion at the cost of a small 
reduction in GFR and a quantifiable risk of hyperkalaemia.  Data on hard clinical 
endpoints including morbidity and mortality are limited meaning that meta-
analysis of impact of MRA on these outcomes was not possible.  These findings 
are in keeping with the previously published meta-analyses [392, 393].  These 
publications, however, have analysed mainly published protein or albumin 
excretion data; and due to the disparate measures of proteinuria and 
albuminuria used in these studies and inability to obtain additional data from 
authors in many cases, meta-analysis of the effects of MRA on proteinuria or 
albuminuria was not possible.  In this meta-analysis additional unpublished 
summarised data were obtained from a number of authors, resulting in more 
comprehensive assessment of the impact of MRA on urinary protein or albumin 
excretion.  By excluding studies where MRA was combined with additional 
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antihypertensive agents in the intervention arm, this meta-analysis reports 
purely the effect of MRA without the confounding impact of additional 
therapies.   
The association between albuminuria and progression to ESRD is well-
documented, resulting in its evolution into a surrogate outcome measure in 
many clinical trials.  Although clinical studies confirming the beneficial impact 
of reducing albumin or protein excretion on morbidity and mortality are lacking, 
a recent meta-analysis including data from over 78,000 patients reported that a 
30% reduction in albuminuria confers 23.7% reduction in risk of progression to 
ESRD, irrespective of the drug class used [156].  This study demonstrates that 
addition of MRA to RAAS blockade with ACE-I and/or ARB in patients with CKD 
has the potential to reduce urinary protein or albumin excretion by more than 
30%, which could theoretically translate into even greater benefits in terms of 
risk of progression of renal, and potentially cardiovascular disease [409, 410]. 
It is possible that reductions in proteinuria and albuminuria seen with MRA are 
not entirely blood pressure independent, however disentangling this relationship 
is impossible in the presence of substantial blood pressure lowering associated 
with addition of MRA across all included trials.  Plotting the percentage 
reduction in proteinuria/albuminuria (any measure) against systolic blood 
pressure at final visit across all included studies is suggestive of an association 
between the two.  However, it should be borne in mind that intensive blood 
pressure lowering beyond 120mHg systolic does not seem to confer additional 
reno-protective benefits, and in some cases has been shown to be associated 
with accelerated progression of renal disease [411, 412]. 
Hyperkalaemia is an inherent risk associated with prescription of RAAS blocking 
agents, particularly when considering dual or in some trials triple therapy.  A 
population-based time series analysis indeed suggested that an increase in 
prescribing of spironolactone in patients with heart failure was associated with 
higher rates of hyperkalaemia [413], and studies of dual RAAS blockade in 
patients with diabetic and non-diabetic CKD have been associated with increased 
rates of hyperkalaemia in the intervention arm [320, 322].  Certainly this meta-
analysis confirms a mean increase from baseline of 0.19mmol/L with addition of 
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MRA to ACE-I and/or ARB, and a 3-fold increased relative risk of developing 
hyperkalaemia.  But how do we define hyperkalaemia?  In the context of this 
analysis the relative risk of hyperkalaemia must be carefully interpreted as the 
risk of serum or plasma potassium rising above the upper limit pre-defined by 
the trial investigators, rather than clinically significant hyperkalaemia 
necessitating medical treatment.  In fact, from all 19 trials included in this 
analysis, only 1 reported a single incidence of a study participant being admitted 
to hospital for administration of IV insulin and dextrose to treat a plasma 
potassium of 7.1 mmol/L [398].  Hyperkalaemia as defined in included studies 
ranged from potassium of 5.5-6 mmol/L, values which in clinical practice many 
nephrologists would not routinely treat.  It should also be considered that the 
toxic effects of a given potassium level are to an extent depended on baseline 
potassium and the rate of increase, rather than simply its numerical occurrence, 
factors which in general are not considered within the context of clinical trials.  
Furthermore, it has been demonstrated that although potassium values do rise 
with regular dosing of RAAS blocking agents, the pattern appears to be that of an 
early initial increase thereafter followed by a steady-state rather than continued 
rise [414].  Taking into consideration the potential to achieve substantial 
reductions in urinary protein excretion, a quantifiable risk of developing 
hyperkalaemia should not necessarily dissuade clinicians from prescribing these 
agents, particularly if close biochemical monitoring is employed  and 
participants with high-normal baseline potassium values are excluded from 
treatment.  Recent data suggest that the nonsteroidal MRA Finerenone 
effectively reduced albuminuria in patients with DN with less incidence of 
hyperkalaemia (1.8% of treatment group) and no cases of serum potassium 
>6mmol/L [415]  making it a promising agent for future study.  In this study 
patients with serum potassium of >4.8mmol/L were excluded, again highlighting 
the potential importance of selectively targeting therapy towards those at lower 
risk of complications.  Moreover, a recent phase 2 study in patients with DN and 
hyperkalaemia on RAAS inhibitors confirmed that the potassium-binding polymer 
Patiromer resulted in significant reduction in potassium over a 4 week treatment 
period [416] although the majority of patients had CKD stage 2-3 and effects of 
this agent in more advanced disease are yet to be determined.   
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Worsening of renal excretory function is another concern frequently associated 
with use of MRAs or enhanced RAAS blockade.  In this meta-analysis the addition 
of MRA in patients with CKD who are already established on ACE-I and/or ARB 
was associated with an approximate reduction of 3.15ml/min/1.72m2 in any 
measure of GFR, a value which although statistically significant would be 
unlikely to cause concern in a clinical setting in the majority of cases.  In fact it 
is has been shown that an initial decline in GFR is associated with a more 
favourable course of renal function, and it has been shown that those individuals 
who experience greater decline in GFR in the short term stand to benefit most 
[417].  Applicability of these results to the general CKD population remains 
limited by the short duration of trials included and the effects of this strategy on 
longer term renal outcomes is unclear.  In addition, no data is available on 
change in GFR upon withdrawal of treatment to determine whether these trends 
are reversible. 
The trials included in this analysis were short (maximum duration 1 year) and 
underpowered to determine the impact of addition of MRA to ACE-I and/or ARB 
on longer term renal outcomes, morbidity or mortality.  The present analysis 
cannot therefore draw conclusions regarding long-term safety and efficacy of 
combination treatment with MRA and ACE-I and/or ARB, despite postulated 
benefits in terms of reduction in protein or albumin excretion [156, 409, 418].  
Moreover, mean baseline GFR was >35 ml/min/1.73m2 in all included studies, 
meaning effects of treatment in more advanced disease remain to be 
determined.  The ongoing Benefits of Aldosterone Receptor Antagonism in 
Chronic Kidney Disease (BARACK-D) study aims to follow more than 2000 
participants with stage 3b CKD over the course of a 36 month randomised 
controlled trial of spironolactone versus placebo, and will address some of these 
unanswered questions [419]. 
Strengths of this analysis include independent systematic literature-searching, 
assessment of study quality and data extraction by two independent reviewers 
following a pre-specified strategy.  In addition, 8 authors (10 trials) provided 
supplemental unpublished information resulting in a more complete dataset and 
the ability to perform more comprehensive analysis of the effects of addition of 
MRA on urinary protein or albumin excretion.  Furthermore, supplemental data 
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was obtained from 3 trials not included in the previous meta-analysis [338, 340, 
341] resulting in accumulation of data from a higher number of participants 
(1646 compared to 1549), making this the largest analysis to date.   
A significant limitation of this analysis is that included studies are relatively 
small and powered to detect differences in surrogate endpoints.  Duration of 
these trials was also short and long-term follow up data on clinical endpoints 
such as mortality and progression of CKD are lacking.  Seven (37%) of the 
included trials had a crossover rather than randomised controlled trial design 
and reporting of methodology was variable such that adequate assessment of 
trial quality was not feasible in all cases.  The marked heterogeneity in measures 
of urinary protein or albumin excretion reported made this analysis particularly 
challenging and likely means this outcome is still not as comprehensively 
assessed as it could be.  Whilst these results demonstrate a significant reduction 
in any measure of urinary protein or albumin excretion and studies have shown 
that there is high agreement between albumin: creatinine ratio and 24 hour 
excretion values [20] standardisation of reporting of proteinuria or albuminuria 
across clinical trials would enable far more consistent and reliable analysis in the 
future, particularly if investigators continue to use these measures as surrogates 
for progression of renal disease [420]. 
In conclusion, addition of MRA represents a promising therapeutic strategy for 
reduction of blood pressure and proteinuria or albuminuria in patients with CKD 
already established on standard RAAS blockade.  The risk of hyperkalaemia 
associated with this treatment combination is quantifiable and could be 
minimised by selecting appropriate patients for treatment and close monitoring 
of biochemistry, while use of nonsteroidal MRAs may further minimise this risk in 
the future.  Well-designed, larger and longer-term studies are needed to 
determine the safety and efficacy of enhanced RAAS blockade on hard clinical 
endpoints such as progression to ESRD, all-cause mortality and cardiovascular 
outcomes. 
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4. Pilot Study 
4.1 Introduction 
This chapter will focus on local validation of the CKD273 biomarker for diagnosis 
of DN, as well as preliminary exploration of its relationship to subclinical organ 
damage. 
 
4.1.1 Biomarkers 
Biomarkers are defined as characteristics which are "objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention" [421].  The current 
guideline-endorsed biomarkers for diagnosis and monitoring of DN are 
albuminuria and eGFR [144] but for reasons already discussed in section 1.4 
neither provide sufficient diagnostic sensitivity or specificity for early disease 
detection.  This is particularly relevant as we enter the era of personalised 
medicine, driving to direct early targeted intervention towards the individuals at 
highest risk of progressive disease [373, 376, 380].  Although innumerable 
studies have described biomarkers with potential for preclinical prediction of DN 
no single candidate has yet made the leap from bench to bedside, as translation 
into clinical practice requires a number of key biomarker evaluation steps as 
shown in Figure 4-1 [379].    
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Figure 4-1.  Stages of biomarker development. 
Adapted from Currie G and Delles C. Current Diabetes Reports, 2016; 16: 104. 
 
 
 
4.1.2 Studies evaluating the CKD273 biomarker 
Use of proteomics to identify novel biomarkers for DN is an attractive concept, 
as multi-parametric classifiers have the potential to simultaneously capture 
numerous underlying mechanistic aspects of a heterogeneous disease process.  
As well as offering diagnostic advantages, use of proteomics also has potential 
for exploration of the pathogenesis of complex conditions.  Studies evaluating 
the diagnostic and predictive performance of the CKD273 classifier in CKD 
patients and more specifically DN have already been described in section 1.6.  
To date, CKD273 is the urinary proteomic classifier that has been most rigorously 
Proof of concept studies
(in animal models or small scale pilot human work)
Validation
(proof that biomarker predicts disease in a prospective cohort or 
nested case-control study)
Incremental value
(does biomarker add predictive information beyond the current 
gold-standard?)
Clinical utility/outcomes
(demonstration of improved outcomes in the context of 
biomarker-guided clinical trials to show influence on treatment 
decisions)
Cost-effectiveness
(demonstration of sufficient improvement of outcomes to justify 
cost of implementation)
155 
 
 
evaluated in a number of independent studies of both case-control and 
longitudinal design [422] and this progress is summarised graphically in Figure 4-
2.  It should be emphasised, however, that proof of clinical utility and health 
economic analysis have not yet been achieved. 
 
 
 
 
 
 
 
 
Figure 4-2.  Progress in evaluation of CKD273 biomarker. 
Illustration of published studies evaluating the CKD273 biomarker and progress through 
stages of biomarker evaluation. 
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4.1.3 Microalbuminuria as a cardiovascular biomarker 
The evidence for use of MA as an indicator of renal disease is robust and it 
remains the gold standard clinical index of DN in routine practice.  In addition, 
there is little doubt that MA also identifies individuals who are at high 
cardiovascular risk as shown by Mogensen (seminal paper published in 1984) [21].  
In T2DM the presence of MA is associated with a 2.4-fold increased risk of 
cardiovascular death [423], and similar relationships are seen in the healthy and 
hypertensive populations [160, 424-426].  This risk is not determined by the 
categorical presence of MA per-se, but should rather be considered as a 
continuum which extends both beyond MA into the macroalbuminuric range 
[427]; as well as to even lower levels which are well within the 
normoalbuminuric range [145, 166]. 
The mechanisms which link MA with cardiovascular disease remain incompletely 
understood, and can be only partially explained by other cardiovascular risk 
factors such as smoking, hypertension and unfavourable lipid profile.  As 
described in chapter 1, “The Steno Hypothesis” proposes that MA reflects 
generalised vascular dysfunction, simultaneously affecting the microvasculature 
supplying the retina and kidneys, as well as the intima of larger vessels.  They 
reasoned that higher degrees of UAE were associated with transcapillary escape 
of albumin as an indicator of vascular permeability, and albuminuric patients 
were shown to have higher circulating levels of endothelial dysfunction markers 
compared to normoalbuminuric individuals matched for disease duration.  These 
findings were independent of traditional risk factors such as blood pressure; 
diabetes duration and HbA1c and led the authors to postulate that difference in 
ECM composition and therefore increased permeability may offer a potential 
explanation [97].  Numerous publications have since described links between MA 
and both circulating and clinical endothelial function measures in patients with 
and without diabetes [105, 109, 428, 429].  Similarly, circulating markers of 
inflammation are associated with the presence and extent of MA [96, 103, 430]. 
Endothelial dysfunction and inflammation are important early events in the 
initiation and progression of atherosclerotic disease, and therefore offer a 
plausible link between MA and cardiovascular risk.  As a potential early 
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biomarker of DN in normoalbuminuric patients, could CKD273 therefore simply 
be an indicator of generalised vascular dysfunction and early atherosclerotic 
disease rather than a specific renal biomarker?  In a low-risk cohort of 
normoalbuminuric T2DM patients such as those participating in the PRIORITY 
trial, hard clinical outcomes will take many years to develop.  As a first step, 
exploration of intermediate vascular phenotypes and circulating biomarkers may 
provide some useful information. 
 
4.1.4 Assessment of subclinical organ damage 
A number of clinical tools for measurement of early functional or morphological 
alterations in the vasculature in advance of diagnosis of overt cardiovascular 
disease have been developed, and some are now endorsed for stratification of 
intermediate-risk patients in clinical guidelines [431].  These are summarised in 
Figure 4-3.  For the purposes of this study two of the less operator-dependent 
measurements were selected: central haemodynamics and carotid intima-media 
thickness (cIMT).   
 
4.1.4.1 Central haemodynamic indices 
During systole pressure waves are generated and propagate towards the 
peripheral vasculature.  Eventually these waves are reflected backwards as a 
result of reduced vascular diameter; bifurcations or vascular stiffness gradients.  
Merging of these reflected waves with the antegrade wave lead to its 
amplification, with the result that peripheral pressures are often higher than 
central aortic pressure [432].  It is this central, rather than peripheral pressure 
that is exerted on the heart, brain and kidneys.  As vessels stiffen the reflected 
wave arrives earlier, whereas with vasoconstriction its amplitude is altered.  
These processes result in increased central pressure and traumatic degeneration 
of the elastic component of the arterial wall [433].  
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Figure 4-3.  Markers of subclinical cardiovascular organ damage. 
ABPI, ankle brachial pressure index; CAC, coronary calcium score; cIMT, carotid intima 
media thickness; PAT, peripheral arterial tonometry; FMD, flow mediated dilatation; CRP, 
C-reactive protein; TnT, high sensitivity cardiac troponin T; BNP, brain natriuretic peptide. 
 
 
 
Central haemodynamics can be assessed by indices of central blood pressure as 
well as measures of wave reflection.  These can be measured invasively, but in 
the context of clinical studies non-invasive methods are often preferable.  Pulse 
wave analysis records pressure waves from carotid, radial or brachial arteries 
and uses a transfer function to extrapolate central pressure indices, 
augmentation pressure and augmentation index (AIx): the ratio of augmentation 
pressure to pulse pressure [434].  Many of these measurements can be made 
with validated automated devices; some have been shown to independently 
predict all-cause mortality and cardiovascular events; and antihypertensive 
therapies have shown that improvement in some of these parameters can 
translate into risk reduction [435, 436].   
Genetic risk Subclinical disease Cardiovascular events
Clinical tools
Pulse wave analysis
Pulse wave velocity
ABPI
CAC
cIMT
PAT
FMD
Circulating biomarkers
CRP
TnT
BNP
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4.1.4.2 Carotid intima media thickness 
Early in the development of atherosclerotic disease the vessel subintimal layer is 
infiltrated by lipids and inflammatory cells, a precursor to atheroma and 
vascular fibrosis.  Imaging can be used to detect these early structural changes 
and a thickened intima-media complex serves as an indicator of atherosclerosis 
[437].  Measurement of cIMT and presence of plaque can be determined using B-
mode transcutaneous ultrasound by measuring the distance from intima to 
adventitia, typically visible as a double-line on imaging of the arterial wall [438].  
The European Society of Cardiology guidance specifies a measurement of 0.9mm 
as the cut-off for increased cIMT [439] however this marker is heavily influenced 
by age and therefore a single cut-off may lead to misclassification of some age-
groups [437].  Many studies have demonstrated higher cIMT in individuals at 
cardiovascular risk [438], and its predictive power for future cardiovascular 
events is well established, with every 0.1mm increase in cIMT corresponding to 
16% increased cardiovascular risk in one meta-analysis [440].  Changes in cIMT, 
however, do not appear to have a prognostic implication [440] and cIMT 
measurement has modest utility for reclassification of individuals at 
intermediate cardiovascular risk [441].   
 
4.2 Aims 
This study aimed to: 
 validate the CKD273 urinary proteomic classifier for diagnosis of DN; 
 explore the relationship between CKD273 and subclinical organ damage. 
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4.3 Methods 
This section provides a general description of recruitment, protocols and 
techniques used in the conduct of this pilot study (Figure 4-4).  A full description 
of the design of the PRIORITY trial can be found in chapter 2. 
 
 
 
 
Figure 4-4. Pilot study outline. 
T2DM, type 2 diabetes; NA, normoalbuminuria; MA, microalbuminuria; DN, diabetic 
nephropathy; PIS, participant information sheet; HbA1c, glycated haemoglobin; eGFR, 
estimated glomerular filtration rate; UACR, urine albumin: creatinine ratio; PWA, pulse 
wave analysis; cIMT, carotid intima-media thickness. 
 
 
4.3.1 Ethical approval 
The PRIORITY pilot study was approved by the West of Scotland Research Ethics 
Committee 4 (reference 13/WS/0154) and NHS Greater Glasgow and Clyde 
Research and Development (reference GN13CA187) in June 2013.  The PIS can be 
found in (Appendix 8).  
Study Visit
Consent
Medical history
Anthropometric measures
Blood samples (HbA1c, eGFR, lipids, 
biomarkers)
Urine samples (UACR, proteomics)
PWA
cIMT
Telephone contact
Appointment made 
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Urinary proteomics
(University of 
Glasgow)
Cardiovascular and 
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(University of 
Navarra)
Biomarker 
analysis (end of 
recruitment)
15 NA
15 MA
15 DN
Screening-T2DM 
outpatient clinic
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discussed with patient)
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4.3.2 Participant selection and recruitment 
Individuals with T2DM were identified from secondary care clinics at Stobhill 
Hospital in Glasgow in discussion with consultants and specialist nurses 
responsible for these clinics.  For this pilot project a convenient sample size of 
45 patients across the spectrum of DN was decided upon: 15 nonalbuminuric 
patients; 15 with MA and 15 with overt DN confirmed by consultant diabetologist 
and/or nephrologist.  Of note, diagnosis of DN was primarily made on the basis 
of detection of albuminuria and/or reduced eGFR rather than by renal biopsy.  
Patients attending the clinic were approached by a member of the study team 
and provided with both verbal and written information about the project.  Those 
who expressed an interest in participating were given an invitation letter as well 
as PIS, and an appointment was made for the study visit after a follow up 
telephone call within 1 week of the clinic appointment.   Individuals with T2DM, 
aged between 18 and 75 years who were able to provide written informed 
consent and willing and able to attend a single study visit were deemed eligible 
to participate.  Individuals with type 1 diabetes; any condition that would affect 
interpretation of clinical vascular studies (e.g. atrial fibrillation; ventricular 
bigeminy; cardiac pacemaker); uncontrolled blood pressure (>180mmHg systolic 
and/or >100mmHg diastolic); patients with anuric ESRD and those with non-
diabetic CKD were excluded from the study.   
 
4.3.3 Study visits 
All study visits were held at the British Heart Foundation Glasgow Cardiovascular 
Research Centre in a quiet room, temperature controlled to 22-24°C.  
Participants were advised to abstain from caffeinated beverages for at least 6 
hours prior to their scheduled appointment.  Upon arrival, the PIS was discussed 
and any questions about the study were answered prior to obtaining informed 
consent (Appendix 9).  Study procedures were then performed as described 
below. 
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4.3.3.1 Basic clinical parameters 
A brief medical history and list of concurrent medications was obtained.  Height 
and weight were recorded and body mass index (BMI) calculated.  After being 
seated for 10 minutes resting heart rate and blood pressure were measured.  
Blood pressure was recorded using the Omron MX2 automated device, which was 
regularly calibrated by the medical physics department.  The average of 3 
consecutive readings was documented.  If blood pressure was found to be above 
140/90mmHg the patient was advised to see their GP for a repeat measurement 
within the next 2 weeks.  Peripheral blood samples were then taken and 
participants were asked to provide a spot urine sample. 
 
4.3.3.2 Pulse wave analysis 
Pulse wave analysis was performed using the SphygmoCor system (Atcor Medical, 
Australia) with participant lying supine and the dominant wrist resting on a 
pillow in a slightly dorsiflexed position.  Blood pressure was re-checked and this 
value input into the SphygmoCor software for reference.  The radial pulse was 
palpated digitally, then the applanation tonometer (Millar Instruments, Houston, 
USA) was applied over the radial artery at the site of maximal pulsation.  The 
tonometer was connected to a dedicated laptop computer for data collection 
and analysis.  Once a satisfactory waveform was obtained sequential readings 
were recorded over a 9 second period before the proprietary software 
determined an average arterial waveform as shown in Figure 4-5. The software 
then calculated central blood pressure and AIx.  As AIx is highly dependent on 
heart rate this value was also automatically corrected to heart rate of 75 beats 
per minute (AIx@75).  The mean of 3 readings meeting the quality checks 
described below was recorded for analysis. 
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Figure 4-5.  Pulse wave analysis. 
Representative example of pulse wave analysis output generated using the SphygmoCor 
device (Atcor Medical, Australia). 
 
 
 
The SphygmoCor software utilises an internal quality control measure termed 
the “operator index”, where a score of 100% is the highest achievable.  
Measurements where operator index was ≥ 80% were deemed acceptable for the 
purposes of this study.  In addition any low amplitude waveforms were 
discarded.  All measurements were performed by the author and prior to 
commencing the study 20 test measurements were reviewed by an independent 
observer to ensure they met acceptable standards.  
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4.3.3.3 Carotid intima media thickness 
Carotid ultrasonography was performed in a dedicated, temperature controlled 
room using the Acuson Sequoia 512 scanner and L7 5-12 MHz linear array probe 
(Siemens, Erlangen, Germany).  Participants were asked to remove clothing from 
their upper body and given a gown to wear in order to optimise exposure, they 
were then asked to lie in the supine position.  Longitudinal brightness-mode (B-
mode) still images and video clips were then recorded from the distal 1cm of the 
common carotid artery; carotid bulb; and internal carotid artery bilaterally; 
taking care to ensure the image was horizontal and to maximise the length over 
which the double-line pattern representing thickness of the tunica intima and 
media was visible.  After the vascular images were obtained, Doppler flow 
velocity in the internal carotid artery was measured as a safety check to exclude 
significant stenosis.  Following discussion with the local stroke unit lead 
sonographer it was decided that any participant where flow velocity was 
>1.25m/s (which could correspond to a > 50% stenosis) would be referred on for 
a confirmatory scan and then to the stroke service for further investigation and 
optimisation of cardiovascular risk where necessary.  Each scan was saved in 
Digital Imaging and Communications in Medicine (DICOM) format for later offline 
measurement using the Syngo Arterial Health Package (Siemens Healthcare 
Limited, Surrey UK).   All scans were performed by the author, trained in 
vascular ultrasound techniques at the Department of Vascular Medicine, 
Academic Medical Centre, Amsterdam.  All images were read in batches by the 
author, blinded to participant identity.  The mean cIMT was calculated for 
common carotid; bulb and internal carotid; and the overall mean of these results 
was also calculated for later data analysis. Figure 4-6 shows a sample cIMT 
measurement at the common carotid artery. 
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Figure 4-6.  Carotid IMT scanning. 
Upper frame shows longitudinal B-mode ultrasound view of the common carotid artery 
with classical “double line” representing the intima and adventitia.  Lower frame shows 
automated measurement of same image using Syngo AHP software. 
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4.3.4 Urine samples 
Each participant was asked to provide a spot urine sample in a sterile foil bowl.  
This was then split between a universal container and 3 x 1ml aliquots.  The 
universal container was labelled with participant name, date of birth and 
community health index (CHI) number and sent to the local NHS Greater Glasgow 
and Clyde biochemistry lab at the Western Infirmary for measurement of UACR.  
The 3 x 1ml aliquots were then frozen at -80°C and stored for later analysis.  
Once the study was complete, 1ml of stored urine from each participant was 
used for CE-MS analysis as described in chapter 2.  This was performed locally at 
the University of Glasgow by Dr Bill Mullen and colleagues. 
 
4.3.5 Blood samples 
Peripheral blood samples were taken from the antecubital fossa using a standard 
tourniquet and vacutainer system.  Samples were collected as follows: 
 2 x 7ml serum tube 
 2 x 7ml EDTA tube 
 7ml Lithium heparin tube 
One serum and one EDTA tube were each labelled with participant name, date 
of birth and CHI number before being sent to the NHS Greater Glasgow and Clyde 
Biochemistry laboratory at the Western Infirmary for measurement of 
electrolytes, eGFR and HbA1c.  As the local laboratory only numerically reports 
those eGFR values that are <60ml/min/1.73m2, eGFR was formally calculated 
using the MDRD formula.  The remaining samples were prepared for storage as 
detailed below. 
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Upon arrival in the laboratory samples were centrifuged at 2700rpm at 4°C for 
10 minutes.  They were then aliquoted as follows: 
 Serum tube - 3 x 500µL serum 
 EDTA tube - 3 x 500µL plasma 
 Lithium heparin tube - 2 x 500µL plasma 
Samples were then labelled with participants unique study identifier only, and 
frozen at -80°C for later analysis. 
 
4.3.5.1 Biomarker studies 
STNFR 1 was selected as a novel predictor of DN, as described in chapter 1.  
Plasma levels were measured using enzyme-linked immunoassay (ELISA) (Life 
Technologies, Paisley, UK) by Jim McCulloch, chief laboratory technician. 
A vast array of potential candidates relating to varied aspects of vascular 
pathophysiology have been proposed as biomarkers for refining cardiovascular 
risk prediction.  High-sensitivity cardiac troponin T (TnT) and N-terminal pro 
brain natriuretic peptide (NT-proBNP) (both measured by ELISA, Roche 
Diagnostics, Basel, Switzerland) were selected as markers of cardiovascular risk 
for the purposes of this study.  In addition, CITP (enzyme immunoassay; Orion 
Diagnostica, Espoo, Finland), PICP (ELISA, Quidel Corporation, San Diego, USA) 
and TIMP-1 (ELISA, GE Healthcare, Little Chalfont, UK) were measured as 
indicators of collagen turnover. 
 NT-proBNP is the precursor of biologically active BNP, which is secreted 
by cardiac tissue in response to stretch or damage.  It is recognised not 
only as a marker of heart failure, but more recently also as a predictor of 
cardiovascular events in the general population as well as in individuals 
with pre-existing cardiovascular disease [442, 443]. 
 TnT is a sensitive and specific indicator of ischaemic myocardial damage 
and is widely accepted as a predictor of future cardiovascular outcomes 
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[444].  More recently the high sensitivity micronecrosis marker has also 
been demonstrated as a powerful predictor of mortality in a variety of 
patient groups [445, 446]. 
Cystatin C was also selected as a robust biomarker of renal disease, as described 
in chapter 1.  Analysis was performed using ELISA (Biovendor, Brno, Czech 
Republic).  Measurement of Cystatin C; hs-cTNT; PICP; CITP; and TIMP-1 was 
carried out at the University of Navarra, Pamplona, Spain by Dr Susana Ravassa.   
 
4.3.6 Statistical analysis 
Statistical analyses were performed using SPSS (SPSS, IMB Analytics, New York, 
USA) and Minitab16 (Pennsylvania, USA) software packages.  Data distribution 
was assessed by manual inspection of histograms and the Kolmogorov-Smirnov 
test.  Data that followed a normal distribution were expressed as mean ± 
standard deviation (SD), otherwise they were summarised using median and 
interquartile range.  For continuous data differences between the 3 study 
categories were determined by one-way analysis of variance (ANOVA) if the data 
were normally distributed, or by Kruskall-Wallis test if not normally distributed.  
Tukey’s family error rate was used to account for multiple comparisons.  Two-
sample t-tests and Mann Whitney U-tests were used for sub-group analysis on 
appropriately distributed data.  Pearson’s correlation coefficient was used to 
examine the univariate relationship between CKD273 classifier score and 
individual vascular parameters (using raw or transformed data as appropriate 
depending on distribution).  P-values <0.05 were considered statistically 
significant. 
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4.4 Results 
Forty five patients with T2DM consented to participate in this study between 
September 2013 and March 2014.   
 
4.4.1 Clinical Characteristics 
Table 4-1 shows the clinical characteristics of study participants.  Patients with 
overt DN had a longer duration of diabetes; higher UACR and creatinine.  Age; 
BMI; blood pressure; HbA1c; and eGFR were not significantly different across the 
3 study categories.  Number of current smokers was higher in the MA subgroup. 
 
 
Variable 
NA 
(n=15) 
MA 
(n=15) 
DN 
(n=15) 
p-value 
Age (years) 61±8 64±6 59±7 0.130 
Gender (number males) 7 13 10 0.677 
Current smokers 1 5 1 *0.024 
Diabetes duration (years) 8 (1-25) 11 (3-39) 20 (5-44) *0.005 
BMI (kg/m²) 34.4±6.20 35.1±8.13 34.4±6.69 0.955 
SBP (mmHg) 144±15 149±20 148±16 0.765 
DBP (mmHg) 83±7 83±10 82±12 0.910 
HbA1c (mmol/mol) 69 (41-108) 64 (47-120) 76 (43-120) 0.144 
UACR (mg/mmol) 1.1 (0-3.3) 7.7 (2.6-22.5) 124.5 (0.8-412.6) *<0.001 
Creatinine (µmol/L) 74 (55-106) 73 (4-129) 155 (81-777) *<0.001 
eGFR (ml/min/1.73m2) 75.7±24.3 67.5±20.3 56.8±37.3 0.196 
 
 
Table 4-1.  Clinical characteristics of study participants according to DN status. 
NA, normoalbuminuria; MA, microalbuminuric; DN, diabetic nephropathy; BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated 
haemoglobin; UACR, urine albumin:creatinine ratio; eGFR, estimated glomerular filtration 
rate.  Data are mean±SD or median (range) depending on distribution.  p-values are by 
one-way ANOVA or Kruskall-Wallis test depending on distribution of data for continuous 
variables, or by Fisher’s exact test for categorical variables.      * denotes statistical 
significance.  
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4.4.2 Validation of CKD273 for diagnosis of DN 
There was an increase in CKD273 classifier score across study subgroups 
(normoalbuminuric, -0.169±0.373; microalbuminuric, 0.421±0.467; and overt DN 
0.765±0.434; p=<0.01 by one-way ANOVA).  As shown in Figure 4-7, following 
correction for multiple comparisons CKD273 score was significantly different 
between normo- and microalbuminuric (-0.169±0.373 vs 0.421±0.467, p=0.011) 
and overt DN patients (-0.169±0.373 vs 0.765±0.434, p=<0.001).  However the 
difference in classifier score between microalbuminuric patients and those with 
overt DN was not statistically significant (0.421±0.467 vs 0.765±0.434, p=0.121). 
 
 
 
 
 
 
Figure 4-7.  CKD273 classifier score across subgroups following correction for 
multiple comparisons. 
NA, Normoalbuminuria; MA, microalbuminuria; DN, diabetic nephropathy.  Comparison by 
one-way ANOVA with Tukey’s correction for multiple comparisons.  Solid lines indicate 
statistical significance, dotted line indicates non-significant difference. 
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There was a significant association between CKD273 and UACR as shown in 
Figure 4-8.  The association with eGFR, however, was not statistically 
significant.  Plasma STNFR1 and Cystatin C levels were measured as novel 
biomarkers of DN, as shown in Table 4-2.  There was a significant association 
between CKD273 and both of these parameters as shown in Figure 4-9.  Among 
traditional clinical parameters, CKD273 did not correlate with age (r=0.009, 
p=0.953); diabetes duration (r=0.264, p=0.08); BMI (r=0.088, p=0.564); systolic 
blood pressure (r=0.099, p=0.518); diastolic blood pressure (r=-0.064, p=0.674); 
or HbA1c (r=-0.122, p=0.426). 
 
 
 
Variable 
NA  
(n=15) 
MA 
(n=15) 
DN 
(n=15) 
p-value 
Cystatin C (ng/ml) 
1019 
(745-1386) 
1146 
(695-2014) 
1746 
(1003-5336) 
*<0.001 
STNFR1 (ng/ml) 2.63 (1-49-3.57) 2.49 (1.52-5.29) 6.29 (4.2-29.5) *<0.001 
NT-proBNP (ng/l) 68.6 (20.9-297) 151 (28-1432) 208 (50-2151) *0.03 
TnT (µg/l) 
0.01  
(0.005-0.025) 
0.015  
(0.008-0.035) 
0.025 
 (0.009-0.066) 
*0.001 
Central pulse 
pressure (mmHg) 
46±14 53±19 52±18 0.565 
AIX@75 (%) 22 (7-38) 25 (9-32) 25 (4-35) 0.788 
cIMT (mm) 0.77±0.20 0.80±0.12 0.74±0.13 0.594 
CITP (ng/ml) 5.1 (2.9-12.9) 6.4 (2.3-14.5) 8.9 (0-44.8) *0.018 
PICP (ng/ml) 
66.2 (40.9-
154.3) 
79 (36.9-163.6) 
127.5 (52.1-
387.6) 
*0.011 
TIMP-1 (ng/ml) 
874.9 
(92-1218) 
1003.1 
(507.4-1170) 
1298 
 (889-2609) 
*<0.001 
 
 
 
Table 4-2.  Clinical characteristics of study participants according to DN status. 
NA, normoalbuminuria; MA, microalbuminuric; DN, diabetic nephropathy; STNFR1, 
soluble tumour necrosis factor 1; NT-proBNP, n-terminal pro-brain natriuretic peptide; 
TnT, high sensitivity cardiac troponin T; AIX@75, augmentation index corrected for heart 
rate 75 beats per minute; cIMT, carotid intima media thickness; CITP, telopeptide of 
collagen type 1; PICP, procollagen type 1 carboxyterminal propeptide; TIMP-1, tissue 
inhibitor of metalloproteinase 1. Data are mean±SD or median (range) depending on 
distribution.  P-values are by one-way ANOVA or Kruskall-Wallis test depending on 
distribution of data for continuous variables.  * denotes statistical significance.   
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Figure 4-8.  Association between CKD273 classifier and clinical indices of DN. 
Correlations by Pearson’s method using raw data for eGFR and transformed data for 
ACR.  ACR, albumin: creatinine ratio; eGFR, estimated glomerular filtration rate.  * 
denotes statistical significance.   
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Figure 4-9.  Association between CKD273 classifier and novel renal biomarkers. 
Correlation by Pearson’s method on transformed data.  * denotes statistical significance.  
STNFR1, soluble tumour necrosis factor receptor 1. 
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Plotting a receiver operating curve, as shown in Figure 4-10, confirmed that 
0.343 was the near-optimal threshold for diagnosis of DN in this test cohort, with 
sensitivity of 80% and specificity of 77%. 
 
 
 
 
Figure 4-10.  Sensitivity and specificity of CKD273 for diagnosis of DN determined 
by receiver operating curve. 
AUC, area under the receiver operating curve. 
 
 
 
 
4.4.3 CKD273 and vascular parameters 
In order to explore the relationship between CKD273 classifier and subclinical 
vascular damage a number of clinical vascular phenotypes and circulating 
biomarkers were measured.  Clinical markers of subclinical organ damage were 
not significantly different between study subgroups, as shown in Table 4-2.  Nor 
were these correlated with CKD273 classifier score (r=0.109, p=0.478 for central 
pulse pressure; r=-0.199, p=0.196 for AIX@75; r=0.006, p=0.998 for cIMT).  
Circulating cardiovascular biomarkers, NT=proBNP and TnT, were significantly 
different across study categories as shown in Table 4-2.  Significant associations 
were seen between these biomarkers and CKD273, as demonstrated in Figure 4-
11.  
AUC 0.777
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Figure 4-11.  Association between CKD273 classifier and circulating cardiovascular 
biomarkers. 
Correlation by Pearson’s method on transformed data.  * denotes statistical significance. 
NT-proBNP, N-terminal pro-brain natriuretic peptide; TnT, high sensitivity cardiac troponin 
T. 
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To offer potential mechanistic insights into these findings a selection of 
circulating markers of collagen turnover were measured.  Results shown in Table 
4-2 demonstrate that these markers were also significantly increased across 
study subgroups.  Moreover, there were significant associations between these 
markers and CKD273 classifier score as shown in Figure 4-12. 
 
 
 
 
 
 
 
Figure 4-12.  Association between CKD273 classifier and markers of collagen 
turnover. 
Correlation by Pearson’s method on transformed data.  * denotes statistical significance.  
TIMP-1, tissue inhibitor of metalloproteinase 1; PICP, procollagen type 1 carboxyterminal 
propeptide; CITP, telopeptide of collagen type 1. 
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4.5 Discussion 
The findings detailed above confirm that the CKD273 classifier is able to reliably 
distinguish T2DM patients with DN from those with normoalbuminuria.  As 
expected, classifier score increased across the study subgroups which reflected 
the spectrum of disease.  The difference between the MA and DN groups, 
however, did not reach statistical significance: this could be explained by small 
sample size; or alternatively may reflect the fact that CKD273 is being evaluated 
as an early marker of disease, thereby its utility in distinguishing two groups of 
patients who already have some evidence of established disease may be limited. 
Previously published work established a CKD273 classifier cut-off of 0.343 for 
diagnosis of DN [268].  This has since been confirmed in several additional 
studies [295, 298] and based on receiver operating curve analysis the results 
described above are in keeping with this.  Siwy et al recently demonstrated in 
165 samples across multiple centres that this threshold accurately distinguished 
DN from control samples, with only 18 of 165 samples being misclassified.  
Receiver operating curve analysis in this study showed area under the receiver 
operating curve (AUC) of 0.95 for CKD273 [298].  From local analysis AUC for 
CKD273 was 0.77, again this may reflect limited sample size as other larger 
studies have confirmed higher AUC [268, 295].  Two out of the 15 (13.3%) 
normoalbuminuric patients had CKD273 scores above the threshold for detection 
of DN.  Previous studies have shown that around 20% of normoalbuminuric 
patients can be expected to fall into the “high risk” category [268, 295, 298]; 
however it is impossible to speculate on the predictive power of the classifier in 
these patients based on a small cross-sectional study. 
Collagen fragments are abundantly represented within the CKD273 classifier 
[268].  As described in chapter 1, altered collagen turnover is seen early in the 
pathogenesis of DN, and this pathway could offer one mechanistic explanation 
for the utility of CKD273 in early DN detection.  As expected, markers of 
collagen turnover increased progressively across study subgroups and significant 
associations were demonstrated between CITP, PICP, TIMP-1 and the CKD273 
classifier.  It is tempting to speculate, therefore, that the classifier is detecting 
early collagen turnover within the GBM and mesangium however this may be an 
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oversimplification as it is well established that altered collagen turnover also 
plays a key role in the initiation and progression of other conditions, in 
particular cardiovascular disease [447, 448].  Moreover fragments of types 1 and 
3 collagen are key components of the CKD273 classifier and these are typically 
associated with vascular rather than renal disease.  Further exploration on the 
relationships between the CKD273 classifier and vascular and renal phenotypes is 
therefore warranted. 
As expected, there was a significant association between CKD273 and UACR.  
Certainly albumin fragments are a component of the classifier [268], and by and 
large the clinical diagnosis of DN was based on albuminuria in this cohort.  For 
this reason it is perhaps not surprising that no direct association with eGFR was 
found, as participants in the DN group had relatively preserved renal excretory 
function.  Previous studies have confirmed a negative linear relationship 
between CKD273 score and eGFR [289, 290].  In view of the albuminuria-based 
discrimination between study subgroups it is not possible from this small sample 
to determine whether the CKD273 classifier captures multiple aspects of DN 
pathogenesis, or is mainly driven by albuminuria.  For this reason exploration of 
its relationship to additional renal markers was a logical step.   Cystatin C and 
STNFR1 were selected as two novel early biomarkers for CKD which have 
arguably the most robust evidence behind them to date [170, 171, 224, 225] and 
associations were demonstrated between these biomarkers and CKD273.  It is 
generally expected that a proposed novel renal biomarker would correlate with 
other renal indices in a cohort of patients representing the spectrum of disease; 
the CKD273 classifier therefore is providing information that is already to some 
degree captured by traditional and novel clinical indices of renal disease.  
However, the correlation coefficients seen in this study are modest, suggesting 
that a significant proportion of the variability in CKD273 score cannot be 
explained by these existing biomarkers and the associated pathophysiological 
mechanisms alone. 
No association was seen between CKD273 classifier and clinical measures of 
vascular structure and function nor did these measures differ between study 
categories.  The lack of a significant difference in clinical markers of vascular 
damage between study subgroups is of uncertain significance.  Again, this may 
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simply be an issue of sample size.  In addition, measurement such as cIMT and 
AIx are generally recommended for restratification of “intermediate risk” 
individuals [431, 437].  The diagnosis of diabetes and presence of either MA or 
clinical albuminuria in the majority would certainly place them in a “high risk” 
category, rendering these vascular measures less useful.  In addition, we cannot 
discount the effect of preventative therapies such as statins or RAAS blocking 
agents which were widely prescribed among the MA and DN subgroups. 
It is possible that a degree of selection bias was also introduced by recruiting 
these participants exclusively from secondary care clinics.  In general, T2DM 
patients are managed in primary care, with only those requiring more intensive 
risk factor control or developing complications being referred to hospital 
outpatient clinics, meaning that recruitment of higher risk normoalbuminuric 
patients into this subgroup is a possibility.  Despite the lack of association with 
clinical measures of vascular structure and function, CKD273 classifier score was 
correlated with circulating cardiovascular biomarkers.  Of course it should be 
borne in mind that these biomarkers are renally excreted, and so some degree of 
correlation with renal indices is to be expected.  However, TnT and NT-proBNP 
predict cardiovascular outcomes independent of GFR [449] and it remains 
unclear therefore, whether CKD273 is identifying a degree of generalised 
microvascular disease affecting not only the kidney but other vascular beds such 
as the coronary microcirculation for example. 
This study was limited by several factors.  The small sample of 45 patients was 
decided upon for convenience as a pilot project, but is undoubtedly 
underpowered to draw clinically meaningful conclusions.  In addition pooling 
results from three selected groups of patients to determine Pearson correlations 
may limit meaningful interpretation of these data, although this is perhaps less 
relevant given that no associations with vascular phenotypes were seen.  The 
cross-sectional nature of the project means that it is impossible to determine 
the predictive power of CKD273 or its usefulness in informing therapeutic 
decision-making and this will be formally evaluated in the PRIORITY trial [380].  
The albuminuria-based classification of patients is a confounding factor in 
interpretation of the clinical vascular data, and as the next progressive step 
evaluation of the relationship of these markers to CKD273 in a clean, 
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homogeneous cohort without the influence of albuminuria would be more useful.  
Furthermore, PWV rather than AIx is generally accepted as the “gold standard” 
non-invasive method for determination of arterial stiffness in the general 
population as well as different disease states [450] and this measurement may 
offer more clinically meaningful results.   
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5. Baseline characteristics of PRIORITY study cohort 
5.1 Introduction 
Recent years have seen a surge of interest in multimarker “omics” technologies 
for early detection of a variety of clinical conditions; fuelled in part by the 
concept that these panels have the potential to simultaneously capture changes 
in many disease-specific pathways simultaneously as well as the drive towards 
“precision medicine” - offering targeted treatments towards individuals at 
highest risk of disease.  Although a multitude of proteomic panels have been 
described, the leap from bench to bedside is a long way off while reliable 
validation and health economic analyses are lacking.  The CKD273 urinary 
proteomic biomarker is arguably the most rigorously evaluated proteomic 
biomarker to date and has been shown in small, retrospective analyses to have 
the potential to predict clinical DN in advance of any detectable changes in UAE 
or eGFR [268, 295, 296].  This could be of particular benefit as many patients 
continue to progress towards ESRD despite intervention with evidence-based 
therapies; and while prescribing of these agents for disease prevention in a 
healthy, unselected population is associated with delay in the onset of MA, this 
comes at the cost of an increased burden of side effects and adverse events 
[376]. 
The stages of biomarker evaluation have been described in chapter 4.  In brief, 
association alone is insufficient to justify translation into the clinic.  The 
ultimate proof of predictive potential in clinical practice is prospective 
validation in a large cohort; where therapy is guided by the biomarker in 
question.  The PRIORITY trial is a unique proteomic biomarker-guided 
observational study and randomised controlled trial designed to determine the 
utility of CKD273 for early diagnosis and informing preventative interventions in 
DN [380].  The study is based on the rationale that it is difficult to identify the 
individuals who are at highest risk of progression to DN based on the current 
“gold standard” clinical markers, UAE and eGFR, which have been evaluated in 
detail in chapter 1.  If the assumption that CKD273 does indeed have the 
potential to identify patients at the highest risk of progression to DN proves 
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correct, then detailed phenotyping of these individuals is of interest.  They are 
normoalbuminuric with preserved eGFR and would be considered “low risk” from 
a clinical standpoint; yet their urinary proteome reflects alterations in clinically 
silent processes driving the development of CKD.  Characterising these patients 
would serve several key purposes.  First; this may improve our understanding of 
the pathogenesis of the condition, many aspects of which remain elusive.  
Second; a significant proportion of these proteomic panels are comprised of 
collagen fragments which can be altered in a multitude of disease processes and 
it is difficult therefore to determine the specificity of these classifiers for the 
disease process in question.  Finally; proteomic technologies are expensive and 
not widely available, therefore if there is some other characteristic which sets 
these “high risk” individuals apart and can be measured more easily at a lower 
cost this too would be valuable information.   
Much of the work described in this thesis was performed in parallel to the 
PRIORITY trial with these precise aims in mind.  In the small cohort of patients 
with and without DN described in chapter 4, cross sectional exploration of 
determinants of the CKD273 classifier did not reveal any strong associations with 
traditional clinical parameters other than UACR.  However, this work was on a 
small scale and confounded to an extent by the presence of varying degrees of 
CKD and UAE.  A more detailed exploration of the relationship between CKD273 
classifier score and markers of subclinical organ damage in a larger homogeneous 
cohort can be found in chapter 6.  Participants in the studies described in 
chapter 6 were part of the PRIORITY cohort, however without comparing them 
to the trial cohort as a whole the local findings within Glasgow cannot be 
generalised.  At the time of writing recruitment into the trial was ongoing, 
therefore a full description of the entire cohort at baseline is not feasible.  This 
chapter will instead describe the composition of the entire PRIORITY study 
population in comparison to the local cohort at the end of the author’s active 
PhD studies.  
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5.2 Aims 
This study aimed to: 
 describe baseline characteristics of the PRIORITY trial population at end 
of January 2016 and compare these to the Glasgow trial cohort at the 
same time point in order to identify and potentially significant 
differences; 
 explore traditional clinical parameters as determinants of CKD273 
classifier score at baseline in the Glasgow trial cohort only, as doing so 
across the whole study population at this stage has the potential to 
introduce recruitment bias and compromise the integrity of the project. 
 
5.3 Methods 
The design and conduct of the PRIORITY trial has been extensively described in 
chapter 2.  This section will therefore focus on methodology specific to 
collection, assimilation and analysis of the baseline data at end of January 2016. 
 
5.3.1 PRIORITY study data access 
All clinical data collected for participants of the PRIORITY trial were entered 
into a bespoke electronic case report form by local study team members.  The 
system was designed by the team at Hannover Clinical Trials Centre (HCTC), a 
contract research organisation responsible for data management throughout the 
trial period.  As a member of the study steering committee, the author 
approached the trial chief investigator and other committee members in January 
2016 to request access to stored baseline data for all sites in order to conduct 
the analysis described in this chapter.  The issue was discussed among steering 
committee members and it was agreed on the same date that a limited 
descriptive analysis could be performed.  An arbitrary cut-off date of 31st 
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January 2016 was agreed upon to coincide with the end of the author’s clinical 
PhD studies.  Trial recruitment was ongoing at the time of writing. 
 
5.3.2 Data extraction 
After the required data were agreed upon by the consortium, data managers at 
HCTC extracted these from the central study database.  Each required field was 
extracted as an individual password-protected Statistical Analysis System (SAS) 
file containing individual patient data for each participant in the trial, identified 
only by unique study ID which allowed identification of Glasgow participant 
data.  These were then imported into SPSS (SPSS, IBM Analytics, New York, USA) 
individually for descriptive analysis. 
 
5.3.3 Challenges encountered with data handling 
Every effort was made to focus on data obtained at the study baseline visit to 
avoid including data from participants who subsequently failed screening or 
withdrew consent in advance of formal inclusion into the trial.  This was not 
possible for all variables however due to both the structure of the database and 
the fact that some measures (such as height, weight and BMI) were only taken at 
screening.  In view of the fact that the database was composed of a number of 
individual data files it was not possible to include only baseline data for each 
observation without merging each individual file into a “master” database.  This 
was decided against for several reasons: 
 This would have offered the author analysis options beyond the 
descriptive work agreed upon by the study steering committee and 
therefore it was decided not to manipulate the data further in that 
respect. 
 As recruitment was ongoing at the time of writing, no full data clean-up 
had yet been performed.  As a result a number of issues with the data 
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were identified during this exercise including: a variety of units being 
used for certain measurements (e.g. mmol/mol vs % for HbA1c) across 
different centres; varied reference values across centres; different 
sample types (e.g. serum versus plasma) and occasional errors with 
implausible values for some clinical observations.  Given that the data 
were not finalised construction of a master database would have been 
inappropriate. 
 This work was not intended to be a formal interim analysis on a clean, 
finalised dataset. 
For the reasons described above it was therefore not possible to limit this 
descriptive analysis to a full cohort of patients with all data points available.  In 
addition, the completeness of the data is dependent upon local data entry at 
study sites and the author or the team at HCTC had no influence over this 
process.  As a result, the numbers of participants included in each sub-analysis 
for individual data points varies for different parameters.  To make this clear 
the number of participants included in each sub-analysis is given in Table 5-1. 
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 Whole cohort 
Whole cohort  
(excl. Glasgow) 
Glasgow 
only 
P-value 
Age 
(yrs) 
63 (24-74) 
n=1153 
63 (27-74) 
n=945 
62 (24-74) 
n=208 
0.517 
Gender 
(males/females) 
725/428 
n=1153 
581/364 
n=945 
144/64 
n=208 
*0.036 
Diabetes duration 
(yrs) 
11.0 (0.3-52.4) 
n=1152 
11.1 (0.3-52.4) 
n=944 
9.8 (0.6-33.1) 
n=208 
*0.001 
RAAS blockade 
(Y/N) 
903/557 (61.8%) 
n=1460 
738/453 (62%) 
n=1191 
165/104 (61.3%) 
n=269 
0.848 
Current smokers 
(%) 
191/932 (17%) 
n=1123 
165/802 (17.1%) 
n=967 
26/130 (16.7%) 
n=156 
0.903 
Retinopathy 
status 
(none/simplex/ 
proliferative) 
914(83%)/152(14%) 
/40 (4%) 
n=1106 
776(85%)/102(11%) 
/37 (4%) 
n=915 
138(72%)/50(26%
) 
/3 (2%) 
n=191 
*<0.001 
Height  
(cm) 
172 (139-205) 
n=1136 
172 (139-205) 
n=939 
170 (146-192) 
n=197 
*<0.001 
Weight  
(kg) 
88 (47-164) 
n=1136 
88 (47-164) 
n=939 
88 (54-146) 
n=197 
0.555 
BMI  
(kg/m²) 
29.7 (17.9-57.1) 
n=1136 
29.4 (17.9-57.1) 
n=939 
30.9 (21-48.9) 
n=197 
*<0.001 
SBP  
(mmHg) 
134 (94-183) 
n=1124 
133 (97-177) 
n=931 
136 (95-183) 
n=193 
*<0.001 
DBP 
(mmHg) 
79 (49-109) 
n=1124 
83 (49-101) 
n=931 
79 (51-109) 
n=193 
0.790 
Heart rate 
(bpm) 
75 (47-116) 
n=1124 
74 (47-111) 
n=931 
78 (51-116) 
n=193 
*<0.001 
HbA1c (mmol/mol) 
56 (31-115) 
n=1107 
55 (31-115) 
n=917 
61 (36-106) 
n=190 
*<0.001 
Cholesterol 
(mmol/l) 
4.22 (1.3-8.6) 
n=1100 
4.2 (1.3-8.6) 
n=910 
4.3 (2.3-7.6) 
n=190 
0.563 
LDL  
(mmol/l) 
2.2 (0.2-5.7) 
n=957 
2.2 (0.2-5.7) 
n=784 
2.1 (0.8-4.8) 
n=173 
0.064 
HDL 
(mmol/l) 
1.2 (0.3-2.6) 
n=1085 
1.2 (0.3-2.6) 
n=909 
1.1 (0.6-2.4) 
n=176 
0.492 
Triglycerides 
(mmol/l) 
1.6 (0.1-14.4) 
n=1107 
1.6 (0.1-14.4) 
n=917 
1.9 (0.7-4.6) 
n=190 
*<0.001 
eGFR 
(ml/min/1.73m2) 
90.6 (44.9-168.3) 
n=1111 
90.7 (44.9-168.3) 
n=921 
90.4 (46.2-123.4) 
n=190 
0.175 
ACR 
(mg/g) 
5.3 (1.14-46.84) 
n=1189 
5.3 (1.14-46.84) 
n=977 
5.2 (1.33-34.51) 
n=212 
0.868 
CKD273 score 
-0.334 (-1.50-0.94) 
n=1194 
-0.358 (-1.50-0.94) 
n=982 
-0.228 (-1.21-
0.71) 
n=212 
*<0.001 
High/low risk 
(% high risk) 
149/1045 (12.5%) 
n=1194 
120/862 (12.2%) 
n=982 
29/183 (13.7%) 
n=212 
0.560 
 
 
Table 5-1.  Comparison of baseline characteristics between Glasgow participants 
and whole PRIORITY study cohort as of 31st January 2016. 
Data are median (range).  Comparisons between Glasgow cohort and remaining 
participants are by Mann Whitney U test.  Categorical variables compared by chi-squared 
test.  n=number of participants for which data available in each sub-analysis. P-value 
refers to comparison between Glasgow population and whole study cohort where * 
denotes statistical significance.  eGFR calculated using  CKD-EPI formula.  CKD273 
threshold for diagnosis of DN 0.343; for classification into PRIORITY study “high risk” 
group 0.154.  RAAS, renin angiotensin aldosterone system; BMI, body mass index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; 
LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular 
filtration rate; ACR, albumin: creatinine ratio. 
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5.3.4 Determinants of CKD273 classifier 
In order to avoid performing a formal interim analysis, and for the reasons 
described above pertaining to challenges encountered during data assimilation, 
it was decided that exploration of the determinants of CKD273 score would be 
limited to data from those participants in Glasgow who had been included in the 
trial between April 2014 and May 2016.  Throughout this period the author had 
been responsible for overseeing participant recruitment into the study and these 
data were readily available in clean format locally as they had been collected in 
the implementation and analysis of the sub-studies conducted in parallel with 
the main trial, described in chapter 6.   
 
5.3.5 Statistical Analysis 
 Comparison of Glasgow subset to whole PRIORITY study cohort as of 
January 2016.  Statistical analysis was performed using SPSS (SPSS, IBM 
Analytics, New York, USA).  Distribution of data was determined by the 
Kolmogorov-Smirnov test as well as manual inspection of histograms and 
Q-Q plots.  None of the data were normally distributed, therefore they 
were expressed as median (range).  Comparisons between the whole 
PRIORITY study cohort and the Glasgow subset were made using the Mann-
Whitney U test.  Data from other centres were analysed only as part of 
the full study cohort as recruitment was ongoing and introduction of 
recruitment bias would therefore be a possibility; some centres had very 
small participant numbers and therefore individual centre comparisons 
would not be meaningful.  P-values <0.05 were considered statistically 
significant. 
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 Exploration of determinants of CKD273 classifier in the Glasgow sub-
population described above.  Distribution was determined as already 
detailed.  Data are given as median (range) or mean ± SD as appropriate.  
Correlations were performed using Pearson’s method on raw data where 
distribution was normal, or on transformed data where this was not the 
case.  General regression modelling was used to adjust analyses for 
confounding variables where necessary.  P-values of <0.05 were deemed 
significant as above. 
 
5.4 Results 
The data described below are from the dataset extracted from the study 
database based on the predetermined cut-off of 31st January 2016.  The 
completeness of the dataset is very dependent on timely and accurate data 
entry at each specific study site.  As expected, there are a number of missing 
data points which may either result from delayed data entry, or the fact that 
study baseline visits have yet to be arranged for some participants.  As agreed at 
the consortium meeting in January 2016, the author was granted access to these 
data for the purposes of a descriptive analysis only and therefore the dataset 
was not manipulated or merged in any way following extraction in Hannover. 
 
5.4.1 Screened patients and screening failures 
By 31st January 2016 there were data pertaining to 1475 study screening visits 
available on the study database.  Table 5-2 shows the number of screened 
patients per study centre.  At the time of writing Glasgow was the second 
highest recruiting centre in the consortium, as shown in Figure 5-1.  Of these 
1475 patients, 1327 had results of run-in sampling for UACR available on the 
central database on 31st January 2016.  Ninety-eight (7%) were MA positive and 
1189 were normoalbuminuric.  UACR data had not yet been input for 40 
participants.  Of those who screen-failed as a result of microalbuminuria at run-
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in, the median UACR was 48.5 (20.4-617) mg/g.  Of note, MA was defined as 
UACR greater than 30mg/g in 2 of 3 consecutive run-in samples, therefore a 
participant could have geometric mean UACR from all 3 samples combined which 
fell below the 30mg/g threshold but still be excluded from the study.  The total 
number of screening failures for any reason at 31st January 2016 was 305 (21%).  
This explains the discrepancy between the number of patients screened (1475) 
and the number of data points shown for each individual descriptive analysis, of 
which the majority are considerably lower.  In addition, as detailed earlier a 
number of measures are only taken at screening, and therefore a higher number 
of data points were available for these parameters.   
 
 
 
Centre 
Patients 
screened 
Steno Diabetes Centre, Gentofte 378 
University Medical Centre, Groningen 167 
University of Glasgow 269 
Istituto de Ricerche Farmacologiche Mario Negri, Bergamo 157 
Universita Karlova v Praze, Prague 74 
Geniko Nosokomeio Athinas Ippokrateio, Hospital Diabetes 
Centre, Athens 
75 
Institut Klinické a Experimentální Mediciny, Prague 54 
Instituto de Investigación Sanitaria de la Fundación Jiménez 
Díaz, Madrid 
8 
Klinikum st. Georg Gmbh, Leipzig 41 
Cyril and Methodius University, Skopje 170 
Diabetes Vascular Research Foundation, Hoogeveen 25 
Universitair Ziekenhuis, Gent 20 
University Medical Centre, Hoorn 37 
Total 1475 
 
 
 
Table 5-2.  Number of screened patients per study site on January 31st 2016. 
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Figure 5-1.  Illustration of recruitment progress per site taken from PRIORITY 
newsletter, January 2016. 
This figure is taken from the consortium newsletter in February 2016.  The number of 
participants included is generally updated several days before distribution, hence patients 
numbers may not precisely match table 5-2. 
 
 
5.4.2 The PRIORITY study cohort in January 2016 
Characteristics of the PRIORITY study cohort at the time of data extraction on 
31st January 2016 are shown in the left hand column of Table 5-1.  Median age of 
participants was 63 years and 63% of the cohort were male.  Diagnosis of 
diabetes was made a median of 11 years prior to inclusion in the trial and the 
majority of participants (61.8%) were already prescribed a RAAS blocking agent 
(either ACE-I or ARB, current treatment with MRAs was not permitted at study 
entry).  Current smokers comprised 17% of the cohort and 18% had either 
simplex or proliferative diabetic retinopathy.  Median BMI fell at the upper end 
of the “overweight” category at 29.7kg/m2 and blood pressure was within target 
range for T2DM patients with no nephropathy.  Median HbA1c of 56 mmol/mol 
indicated good glycaemic control and lipid profile was acceptable (median 
cholesterol 4.2mmol/l; LDL 2.2 mmol/l; HDL 1.2 mmol/l; and triglycerides 1.6 
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mmol/l).  Renal parameters were well within the currently accepted “normal 
range”, with median eGFR of 90.6 ml/min/1.73m2 and UACR of 5.3mg/g.  From 
a clinical perspective one could conclude that this is a relatively low risk group 
of T2DM patients, yet according to proteomic risk scoring 12.5% were 
categorised as “high risk” for later development of DN.    
 
5.4.3 How the Glasgow subgroup compares to the whole study 
population 
The descriptive data specific to the Glasgow sub-population are determined 
from the same dataset extracted on 31st January 2016.  In view of the difficulties 
described above the number of individual data points available for analysis 
ranged from 212 to 156 depending on the parameter in question.  The Glasgow 
cohort did not differ from the whole study population in terms of age; use of 
RAAS blocking agents or smoking status.  However some differences in risk factor 
profiles did emerge.  The Glasgow cohort was more predominantly male in 
comparison to the whole study population (69.2% compared to 61.2%) and had a 
shorter median duration of diabetes (9.8 compared to 11.1 years).  BMI and 
systolic blood pressure were also higher among Glasgow participants (30.9kg/m2 
compared to 29.4kg/m2 for BMI; 136mmHg compared to 133mmHg for systolic 
blood pressure).  Blood glucose was less well-controlled in the Glasgow 
participants (HbA1c 61mmol/mol compared to 55mmol/mol) and triglyceride 
levels were higher (1.9mmol/l compared to 1.6mmol/l), in keeping with the 
difference in BMI.  Although these differences reached statistical significance, 
numerically they are modest and in a clinical setting would be unlikely to result 
in alterations in patient management.  The prevalence of retinopathy was 
significantly higher in Glasgow compared to the rest of the study population (28% 
compared to 15.1%).  The accuracy of these data are again dependent on entry 
at local sites and the means by which these data are collected.  It is therefore 
not possible to draw further conclusions from a descriptive analysis such as this.  
The focus of PRIORITY is of course on prediction of DN. From a renal standpoint 
it is clear that the Glasgow subgroup were comparable to the general study 
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population with no significant difference in eGFR (90.4ml/min/1.73m2 compared 
to 90.7ml/min/1.73m2) or UACR (5.2mg/g compared to 5.3 mg/g).  Despite 
these results, median CKD273 classifier score was higher in Glasgow (-0.228 
compared to -0.358).  Overall 13.7% of Glasgow participants were "high risk", 
compared to 12.2% elsewhere, however this difference did not reach statistical 
significance.  Whether this difference is the result of the variation in risk factor 
control described above cannot be inferred from a descriptive analysis based on 
an as yet incomplete dataset. 
 
5.4.4 Determinants of CKD273 classifier in PRIORITY study 
participants 
As described earlier, this analysis was based on data collected from baseline 
visits of PRIORITY participants in Glasgow between April 2014 and May 2016.  In 
total 204 participants had attended a study baseline visit during the specified 
time period.  Recruitment strategies were described in chapter 2 and Figure 5-2 
illustrates the composition of the cohort based on these streams.  The majority 
of the cohort were recruited from GP practices (55%); followed by secondary 
care clinics (20%), the SDRN (12%), news advertising (9%), retinal screening 
services (2%) and the initial pilot study described in chapter 4 (2%).  The clinical 
characteristics of this group of patients, shown in Table 5-3, are numerically 
similar to the whole study cohort at baseline (Table 5-1) with the exception of 
higher CKD273 classifier score in Glasgow participants (although percentage of 
high risk participants similar to whole study cohort), higher prevalence of 
retinopathy and BMI in the obese rather than overweight range.  Again, risk 
factors are within acceptable guideline-endorsed parameters and renal measures 
are comfortably within the clinically accepted “normal” range.  Despite this 
12.7% of this sub-population were deemed to be at high risk for later 
development of DN according to proteomic risk stratification.   
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Figure 5-2.  Composition of the Glasgow PRIORITY cohort in May 2016. 
Figures are percentage of cohort from each recruitment strategy.  SDRN, Scottish 
Diabetes Research Network; OP, outpatient. 
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Age (yrs) 62 (24-74) 
Gender (males/females) 142/62 (70% male) 
Diabetes duration (yrs) 9 (0.5-33) 
RAAS blockade (Y/N) 119/85 (58% on treatment) 
Current smokers (Y/N) 30/174 (15% smokers) 
Retinopathy status (Y/N) 55/149 (27% retinopathy) 
Height (cm) 170 (101-194) 
Weight (kg) 88 (56-146) 
BMI (kg/m2) 31.2 (20.5-48.9) 
SBP (mmHg) 136.5 (110-160) 
DBP (mmHg) 79±9.1 
HbA1c (mmol/mol) 61 (36-106) 
Cholesterol (mmol/l) 4.2 (2.3-7.6) 
LDL (mmol/l) 2.1 (0.8-4.8) 
HDL (mmol/l) 1.1 (0.6-2.4) 
Triglycerides (mmol/l) 1.9 (0.6-5.1) 
eGFR (ml/min/1.73m2) 88.5±15.2 
ACR (mg/g) 4.9 (1.3-34.5) 
CKD273 score -0.249±0.381 
Risk category (high/low) 26/178 (12.7% high risk) 
 
 
 
Table 5-3.  Clinical characteristics of Glasgow PRIORITY participants attending 
baseline visits between April 2014 and May 2016. 
Data are mean±SD or median (range) as appropriate.  eGFR calculated using  CKD-EPI 
formula.  CKD273 threshold for diagnosis of DN 0.343; for classification into high risk 
group for later development of DN 0.154.  RAAS, renin angiotensin aldosterone system; 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HbA1c, glycated haemoglobin; LDL, low density lipoprotein; HDL, high density lipoprotein; 
eGFR, estimated glomerular filtration rate; ACR, albumin: creatinine ratio. 
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One of the key limiting factors in identification of patients in the early stages of 
DN is the fact that traditional clinical parameters do not perform well as 
predictors of the condition.  Whether any of these parameters contribute 
significantly to the CKD273 classifier score is not yet known and this issue will be 
addressed in the whole PRIORITY study cohort upon completion of recruitment.  
From this local sub-population, CKD273 score was only associated with age 
(r=0.202, p=0.004) and UACR (r=0.209, p=0.003) on univariate analysis as shown 
in Figure 5-3.  There was no association with blood pressure (r=0.054, p=0.446 
for systolic; r=0.040, p=0.570 for diastolic); disease duration (r=-0.194, p=0.107); 
BMI (r=0.117, p=0.095); HbA1c (r=-0.035, p=0.616); cholesterol (r=-0.108, 
p=0.126) or eGFR (r=-0.069, p=0.326).  Results of multivariate regression 
modelling are shown in Tables 5-4 and 5-5.  Model 1 included all parameters 
associated with classifier score on univariate analysis.  While these factors all 
retained significance on multivariate analysis, they explained only 9.06% of the 
variability in CKD273 score.  Model 2 included additional parameters which could 
contribute to DN risk, although not significantly associated with CKD273 score.  
Again, only age, BMI and ACR were statistically significant in this model which 
explained only 7.72% variability.   
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Figure 5-3.  Relationship between CKD273, age and ACR on univariate analysis. 
Correlations by Pearson’s method on raw data for CKD273, ACR and age were 
transformed prior to analysis. * denotes statistical significance.  ACR, albumin: creatinine 
ratio. 
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Variable Coefficient SE Coefficient P-value 
Constant -0.249 0.025 *<0.001 
Age (years) 0.075 0.024 *0.002 
ACR (mg/g) 0.080 0.025 *0.002 
BMI (kg/m2) 0.054 0.024 *0.025 
 
 
Table 5-4.  Regression model 1 including all parameters associated with CKD273 on 
univariate analysis. 
Adjusted R² 9%.  SE, standard error; ACR, albumin: creatinine ratio; BMI, body mass 
index. 
 
 
 
 
 
Variable Coefficient SE Coefficient P-value 
Constant -0.274 0.178 0.125 
Age (years) 0.075 0.029 *0.009 
ACR (mg/g) 0.080 0.026 *0.027 
BMI (kg/m2) 0.054 0.024 *0.025 
SBP (mmHg) 0.002 0.027 0.933 
HbA1c (mmol/mol) -0.006 0.025 0.806 
eGFR (ml/min/1.73m2) 0.002 0.001 0.887 
 
 
Table 5-5.  Regression model 2 including all parameters associated with CKD273 on 
univariate analysis as well as factors which could potentially contribute to DN risk. 
Adjusted R² 7.72%.  SE, standard error; ACR, albumin: creatinine ratio; BMI, body mass 
index; SBP, systolic blood pressure; HbA1c, glycated haemoglobin; eGFR, estimated 
glomerular filtration rate. 
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5.5 Discussion 
At the time of data extraction from the central database 1475 participants had 
been included in the study, although proteomic and UACR processing was 
ongoing for a number of these individuals.  The prevalence of MA among these 
subjects was 7%, which is similar to that seen in the general population [451].  
This low prevalence probably reflects the fact that this was not a random sample 
of the T2DM population but primarily focused screening in order to identify 
normoalbuminuric patients. The PRIORITY trial cohort at end-of-January 2016 
reflect a relatively low-risk group of T2DM patients.  With the exception of being 
overweight this group have well-controlled blood pressure; HbA1c; and 
cholesterol; the majority are non-smokers and two thirds are established on 
RAAS blocking agents.  From a renal standpoint, UACR is well within the 
guideline-defined “normal” range and median eGFR of 90.3ml/min/1.73m2 
reflects normal kidney function according to the current definitions [144] making 
this population ideal for the purposes of evaluating the prospective performance 
of a novel early diagnostic biomarker.   
The Glasgow sub-population comprised 18% of the PRIORITY cohort at the time 
of data extraction.  Study participants in Glasgow were similar to the complete 
PRIORITY population in terms of age; use of RAAS blocking medications; smoking 
status; diastolic blood pressure; cholesterol; UACR and eGFR.  Differences in 
gender; diabetes duration; BMI; systolic blood pressure; and HbA1c did reach 
statistical significance but were numerically modest and are unlikely to be of 
real clinical relevance in terms of therapeutic decision making or to introduce 
any major bias.  Prevalence of retinopathy was significantly higher in Glasgow 
when compared to the rest of the study population (28% vs 15.1%).  At baseline 
36% of UKPDS participants had diabetic retinopathy [59]  and findings locally are 
certainly more in keeping with this.  While local retinopathy data was sourced 
from annual retinal photography within the Scottish National Retinal Screening 
Programme, it is not clear how this was collected across other centres and if 
self-reporting were employed by some this would doubtless result in lower 
prevalence.      
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One notable factor for consideration in the Glasgow sub-population is of course 
the higher median CKD273 classifier score; a difference which did reach 
statistical significance.  The clinical and prognostic significance of this finding is 
unclear and cannot be inferred from this descriptive analysis of baseline 
characteristics.  If considered alongside the apparently increased prevalence of 
retinopathy in Glasgow, it could be speculated that this may imply an 
association between CKD273 and microvascular disease in other vascular beds, 
but as described above the means used to determine retinopathy status in 
different centres is unknown and this finding should not be over-interpreted.  
The Glasgow cohort are phenotypically similar to the whole study population 
with regard to routinely measured clinical parameters and the minor numerical 
differences shown in Table 5-1 seem unlikely to confer significantly increased 
risk of DN.  Certainly data shown in chapter 4 do not suggest a direct association 
between these measurements and CKD273 score, albeit in a smaller study 
population. Furthermore, despite higher median CKD273 score the actual 
proportion of high risk participants was similar across study sub-populations.  It 
should also be borne in mind that this is not yet a complete baseline dataset, 
and therefore clinical phenotypes may well change as recruitment progresses.  
The uncertain implications of this finding along with the minor, yet statistically 
significant numerical differences in some clinical parameters do indicate that 
results of analyses performed in the local study population should be interpreted 
with caution, and cannot be readily generalised to the whole study population at 
this stage. 
Despite being “low risk” according to traditionally accepted clinical parameters, 
12.5% of the PRIORITY study cohort (13.7% Glasgow participants) have been 
categorised as “high risk” for development of DN based on urinary proteomic risk 
stratification and the trial will determine in due course whether this assumption 
is correct.  What characterises these “high risk” individuals remains unclear.  
From the clinical data collected at baseline traditional risk factors are relatively 
well-controlled and renal function well within normal limits.  In order to 
determine the contribution of clinical parameters to CKD273 classifier score 
cross-sectional analysis was performed using data collected from Glasgow study 
participants baseline visits between April 2014 and May 2016.  Using this cohort 
allowed access to a clean and up-to-date dataset, avoiding any manipulation or 
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formal interim analysis of extracted data for the entire PRIORITY cohort which 
could potentially introduce bias while the recruitment period was ongoing.   On 
univariate analysis only age and UACR were associated with CKD273 classifier 
score and these parameters, along with BMI, remained significant on 
multivariate modelling.  However, these factors explained only 9% of the 
variability in CKD273 score, suggesting that other as yet unmeasured and/or 
unknown variables may play a role in risk of progressive renal disease in T2DM.  
This in itself adds weight to the argument for novel biomarkers to identify “at 
risk” individuals.  If significant associations were seen between CKD273 and the 
clinical parameters used to estimate risk, most of which are inexpensive and 
easy to measure, novel early disease biomarkers would be superfluous.   
The particular factors which define “high risk” patients at this early stage in the 
disease process remain elusive.  The results described in chapter 4 could imply a 
role for altered collagen turnover and matrix-metalloproteinase activity, 
however whether the differentially regulated collagens contributing to the 
CKD273 classifier originate from the vasculature or the glomerulus and 
mesangium is unclear.  From the work described in the previous chapter no 
immediate associations were seen between CKD273 and markers of vascular 
stiffness and subclinical atherosclerosis, potentially suggesting that the classifier 
is a more specific marker of early renal disease rather than generalised vascular 
dysfunction.  However, this was cross sectional work in a small cohort across the 
spectrum of DN and these relationships merit further clarification in a larger, 
more homogeneous without the confounding influence of pre-existing CKD.  This 
will be further explored in chapter 6. 
The work described in this chapter has several limitations.  Firstly, this analysis 
is based on data extracted from the central study database at a pre-specified 
time point.  As recruitment will continue until September 2016 it is possible that 
the characteristics of the cohort will change.  In addition, the agreement with 
study steering committee required that this should be a descriptive analysis 
only, focusing on the whole cohort and any differences in the Glasgow subset.  
For this reason further manipulation of the data provided was avoided and as a 
result a complete, clean database was not compiled.  Similarly, the 
completeness of the data relies heavily on timely and accurate data entry at 
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specific study sites, a factor which is outwith the control of the author.  Working 
within the confines of a preliminary incomplete dataset means that these results 
should be interpreted with caution.  There were a number of numerically small 
yet statistically significant differences between the Glasgow cohort and the 
whole study population.  Although these minor differences may not have any 
true clinical significance the associations seen between clinical parameters and 
CKD273 score are not readily generalisable to the complete PRIORITY study 
cohort. 
In summary, the PRIORITY cohort represents a truly low-risk population of T2DM 
patients with normal renal function; an ideal group to study novel biomarkers for 
prediction of DN.  Factors which characterise high risk individuals remain 
elusive, and a clean homogeneous cohort of patients with preserved renal 
function and normoalbuminuria also offers the opportunity to examine the 
relationship between CKD273 biomarker, vascular and renal phenotypes more 
closely without these confounding influences.    
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6. Urinary proteomics for assessment of subclinical 
vascular and renal disease in diabetic patients 
with normal renal function 
6.1 Introduction 
Our understanding of the natural history of DN is evolving and it is generally 
accepted that the traditional 5-stage progression is not uniformly seen in all 
patients, with alternative phenotypes such as early GFR decline and 
nonalbuminuric disease emerging in recent years.  Similarly, it is becoming 
evident that use of an arbitrary diagnostic threshold for MA does not adequately 
define either cardiovascular or renal risk.  There are a wealth of published data 
which prove that the link between UAE and both cardiovascular and renal 
outcomes is a continuum rather than a categorical classification, and that even 
minor elevation of UAE well within the currently accepted “normal range” 
confers a significant increase in risk.  A number of studies have illustrated the 
potential of the CKD273 urinary proteomic classifier for early diagnosis of DN in 
advance of any clinically detectable change in eGFR or UAE [268, 295] and the 
outcome of the PRIORITY trial [380] will determine whether these assumptions 
are correct.  
The Steno Hypothesis has already been described in chapter 4 [97].  In brief, this 
theory proposes that MA is in fact a marker of generalised inflammation and 
vascular disease rather than a specific renal biomarker.  It seems intuitive, 
therefore, that the same could be true of the CKD273 classifier: it captures 
multiple aspects of disease pathogenesis simultaneously; is composed largely of 
differentially regulated collagen fragments [268] which are key mediators of a 
number of disease processes including renal and cardiovascular disease; and 
other proteomic panels which comprise many similar peptide fragments have 
been described in the literature for prediction of cardiovascular events in 
different patient populations [283].  The relationship between CKD273 and 
vascular structure and function in a cohort of patients across the spectrum of DN 
was examined in chapter 4, and although no association was found between 
classifier score and clinical vascular phenotypes the confounding effects of 
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albuminuria and CKD made these data difficult to interpret.  The PRIORITY study 
includes a more homogeneous cohort of patients free from these confounding 
influences.  This is therefore an ideal group of patients in which to evaluate 
whether the CKD273 classifier is providing information on generalised subclinical 
vascular damage and inflammation, or rather providing specific information 
about the kidney.   
 
6.2 Aims 
This study aimed to determine the relationship between CKD273 and: 
 markers of subclinical vascular damage and inflammation; 
 markers of renal function and morphology; 
in a cohort of normoalbuminuric patients with type 2 diabetes and preserved 
renal function. 
 
6.3 Methods 
This study was carried out in parallel to the PRIORITY trial.  A full description of 
the PRIORITY study protocol can be found in chapter 2.  In addition a number of 
the clinical and biochemical analyses performed in this study have been detailed 
in chapter 4.  This section will focus primarily on the techniques which have not 
previously been documented, and will refer to the relevant chapters where 
necessary to avoid repetition. 
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6.3.1 Ethical approval 
This work was approved by the PRIORITY study steering committee as a sub-
study to the main trial following the consortium meeting in January 2014.  It was 
subsequently reviewed and approved by the West of Scotland Research Ethics 
Committee 1 (ref 13/WS/0284) and NHS Greater Glasgow and Clyde R&D (ref 
GN12DI096) in May 2014.   
 
6.3.2 Participant selection and recruitment 
Recruitment streams into the PRIORITY trial have been extensively described in 
chapter 2.  Inclusion into this aspect of the study was primarily based on 
willingness to participate - all patients included in the Glasgow arm of the trial 
were deemed eligible (Figure 6-1). 
At the study screening visit a sub-study specific PIS (Appendix 10) was provided, 
and these investigations were performed at the baseline visit for patients who 
wished to be involved.  This avoided any confounding effect of initiation of study 
medication on results, and minimised inconvenience to study participants that 
may have been caused by additional visits.  Patients with any condition that 
would affect interpretation of the vascular studies (any condition that would 
affect interpretation of clinical vascular studies (e.g. atrial fibrillation; 
ventricular bigeminy; cardiac pacemaker) were excluded. 
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Figure 6-1. PRIORITY study visit schedule illustrating vascular sub-studies. 
BP, blood pressure; UE, urea and electrolytes; HbA1c, glycated haemoglobin; UACR, 
urine albumin: creatinine ratio; cf-PWV, carotid-femoral pulse wave velocity; cIMT, carotid 
intima-media thickness.*Participants in high-risk group only. 
 
 
 
 
6.3.3 Study visits 
Additional investigations were performed at the PRIORITY study baseline visit.  
Routine study procedures performed at this stage are fully described in chapter 
2.  All study visits were held at the British Heart Foundation Glasgow 
Cardiovascular Research Centre and latterly at the Clinical Research Facility on 
the Queen Elizabeth University Hospital campus in a quiet room, temperature 
controlled to 22-24°C.  Participants were advised to abstain from caffeinated 
beverages for at least 6 hours prior to their scheduled appointment.  Following 
routine baseline requirements, the procedures described below were undertaken 
in participants who gave informed consent (Appendix 11).   
Screening
Consent
Height, weight,  BP
Urine-proteomics
UE, HbA1c
Run-in
3 x UACR samples
Baseline
Medical history
Drug history
BP and physical
UE, HbA1c, Lipids
Biobank samples
RANDOMISATION*
High-risk (quarterly)
Medical history
Drug history
BP and physical
UE, HbA1c, Lipids
Study drug issued
3 X UACR samples
Low-risk (annual)
Medical history
Drug history
BP and physical
UE, HbA1c, Lipids
3 X UACR samples
UE check at 
2 weeks
UACR and 
CKD273 
analysis
Additional blood / urine samples
cf-PWV
cIMT
Renal ultrasound
Opt-in to sub-studies?
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6.3.3.1 Pulse wave velocity 
Arterial stiffening is the result of arteriosclerosis which affects the vessel media, 
rather than atherosclerosis, as measured by cIMT for example, which primarily 
affects the intimal layer.  Loss of vascular compliance results in a faster pulse 
wave transit time.  Among the many methods used to evaluate arterial stiffness 
(cf-PWV; defined as the velocity of the pulse as it travels from heart to carotid 
and femoral vessels) is considered the “gold standard” [450].  This is most 
commonly measured by automated devices which record pulse waves from the 
common carotid and femoral vessels using tonometry probes, subsequently 
transit time and distance travelled (which is assimilated to the skin distance 
between the two recording sites) are used to calculate cf-PWV [450].  Arterial 
stiffness robustly predicts all-cause mortality and cardiovascular outcomes even 
after adjustment for traditional cardiovascular risk factors [435, 452].  cf-PWV is 
endorsed by clinical guidelines for reclassification of “intermediate risk” 
patients [431] and its utility has even been demonstrated in patients with pre-
existing CKD [453].  The procedure has the advantage of being non-invasive, 
automated, reproducible and easily performed [437].  For the purposes of this 
study the procedure was performed as described below. 
Pulse wave velocity was measured with the patient lying in supine position with 
neck slightly extended using the automated SphygmoCor XCEL system (Atcor 
Medical, Australia).  Peripheral blood pressure was recorded as described in 
chapter 4, and the result manually input into the SphygmoCor software tool.  A 
blood pressure cuff, connected to the automated software, was placed around 
the upper thigh.  Transit distance was then measured manually.  This involves 
measurement of the distance from carotid pulsation to sternal notch, then from 
sternal notch to the top of the thigh cuff.  These distances were input into the 
SphygmoCor software tool which used an automated algorithm to determine 
transit distance where the former is subtracted from the latter.  The carotid 
pulse was palpated digitally, then the applanation tonometer (Millar 
Instruments, Houston, USA) was applied over the site of maximal pulsation and 
held in position throughout the procedure.  The tonometer was connected to a 
dedicated laptop computer for data collection and analysis.  After a satisfactory 
series of pulse waves were obtained, the thigh cuff inflated automatically for 
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detection of femoral pulsation and recording of femoral pulse waves.  The 
software then calculated cf-PWV after a satisfactory series of simultaneous 
carotid and femoral pulse waves were obtained.  The mean of 2 readings 
meeting quality control checks was recorded (Figure 6-2). 
 
 
 
 
 
Figure 6-2. Assessment of carotid-femoral pulse wave velocity. 
Representative example of carotid-femoral pulse wave velocity output generated using the 
SphygmoCor XCEL device (Atcor Medical, Australia). 
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All procedures were performed by the author or by a single trained research 
nurse for consistency, and the SphygmoCor utilised an internal quality control 
measure where any readings varying by more than 10% from the previous 
recording were highlighted to the operator.   
 
6.3.3.2 Carotid intima media thickness 
This procedure was described in detail in chapter 4 and the same method was 
used for the purpose of this study.  Scanning was performed by the author or a 
trained research nurse.  Intraobserver coefficient of variation was less than 10% 
for both individuals.  Intraclass correlation between observers was 0.956 (95% CI 
0.819-0.990).   
 
6.3.3.3 Renal ultrasound 
Early studies by Mogensen and colleagues showed that the first stages of DN 
were characterised by glomerular hyperfiltration which can be accompanied by 
kidney hypertrophy [8, 454].  It was therefore decided to perform renal 
ultrasound in order to determine whether there was any association between 
CKD273, a proposed marker of early DN, and basic renal morphological 
parameters: kidney length and cortical thickness. 
Renal ultrasonography was performed in a dedicated, temperature controlled 
room using the Acuson Sequoia 512 scanner and L7 5-12 MHz curved array probe 
(Siemens, Erlangen, Germany).  Participants were asked to remove clothing from 
their upper body, loosen any waistbands and given a gown to wear in order to 
optimise exposure, they were then asked to lie in the supine position with the 
ipsilateral arm behind their head to optimise visualisation.  The right kidney was 
visualised longitudinally, and pole to pole length measured.  Transverse images 
were then obtained to measure cortical thickness, and the mean of 3 
measurements from upper, middle and lower poles obtained.  The same 
procedure was then performed for visualisation of the left kidney.  All scans 
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were performed by the author following training by a consultant radiologist at 
the Western Infirmary in Glasgow. 
 
6.3.3.4 Biomarker studies 
STNFR 1 and cystatin C were selected as novel predictors of DN, as described in 
chapters 1 and 4.  Plasma levels were measured by enzyme-linked immunoassay 
(ELISA) (EKF Diagnostics, Walton on Thames, UK) at the University of Glasgow by 
Dr Ruth Mackenzie and Elaine Butler. 
High-sensitivity CRP was selected as an indicator of systemic inflammation and 
vascular disease.  As opposed to TnT and NT-proBNP which reflect ischaemia and 
cardiomyocyte damage, CRP is thought to relate more closely to vascular wall 
biology.  It is well documented that CRP is present in atherosclerotic plaques 
and secreted from injured vascular walls [455] and levels correlate with other 
cardiovascular risk factors and inflammatory markers [437].  There is robust 
evidence linking CRP to future cardiovascular risk [456].  In addition, TnT and 
NT-proBNP were selected as described in chapter 4.  These markers were 
measured by ELISA (Roche, West Sussex, UK) by Elaine Butler and Sarah-Jane 
Duffus at the University of Glasgow, using the Elecsys C411 for NT-proBNP and 
TnT and the Cobas C311 for CRP and Cystatin C.   
 
6.3.4 Statistical analysis 
Statistical analyses were performed using SPSS (SPSS, IBM Analytics, New York, 
USA) and Minitab16 (Pennsylvania, USA) software packages.  Normality of data 
distribution was assessed by manual inspection of histograms and the 
Kolmogorov-Smirnov test.  Normally distributed data were expressed as mean ± 
standard deviation (SD), while data that were not normally distributed were 
expressed as median and interquartile range.  2-sample t-tests were used for 
comparison between “high” and “low” risk groups on raw or transformed data 
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where appropriately distributed.  Pearson’s correlation coefficients were used to 
evaluate determinants of CKD273 classifier score using raw data or transformed 
data where appropriate depending on distribution.  P-values <0.05 were 
considered statistically significant. 
 
6.4 Results 
Between May 2014 and January 2016 144 PRORITY trial participants consented to 
take part in this study.   
 
6.4.1 Clinical characteristics 
The clinical characteristics of the cohort are shown in Table 6-1.  Two thirds 
were male and 62% were currently treated with ACE-I or ARB.  Current or 
previously treated retinopathy was present in 31%.  Median BMI was in the obese 
range and blood pressure was well-controlled although glycaemic control was 
suboptimal.  UACR and eGFR, the guideline-endorsed parameters for diagnosis 
and monitoring of DN, were well within the currently accepted “normal” range.  
Despite this, 16 (11%) of participants fell into the “high risk” category for later 
development of DN according to urinary proteomic classification and the 
PRIORITY trial will later determine whether this assumption is correct.   
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Parameter Mean±SD/Median (range) 
Age (years) 61 (24-73) 
Gender (M/F) 97/47 
Diabetes duration (years) 9.9±6.2 
RAAS blockade? (Y/N) 90/54 
Retinopathy? (Y/N) 45/99 
BMI (kg/m2) 30.8 (21-49) 
SBP (mmHg) 135.2±12.6 
DBP (mmHg) 77.9±12 
HbA1c (mmol/mol) 62.5 (36-106) 
Cholesterol (mmol/l) 4.2 (2.3-7.6) 
Triglycerides (mmol/l) 1.8 (0.7-4.8) 
ACR (mg/g) 5.2 (1.3-39.1) 
eGFR (ml/min/1.73m2) 88.5±14.5 
CKD273 score -0.256±0.371 
Risk category (H/L) 16/128 
 
 
 
Table 6-1.  Clinical characteristics of cohort end January 2016. 
Data are mean±SD or median (range) depending on distribution.  eGFR calculated by 
CKD-EPI formula.  ‘Retinopathy’ encompasses presence of retinal changes on digital 
retinal photography and participants who have undergone laser therapy.  RAAS, renin 
angiotensin aldosterone system; BMI, body mass index; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; ACR, albumin: creatinine 
ratio; eGFR, estimated glomerular filtration rate. 
 
 
 
Table 6-2 compares the clinical characteristics of “high risk” versus “low risk” 
participants.  There were no differences in clinical parameters between the two 
groups with the exception of BMI, systolic blood pressure and treatment with 
RAAS blockade.  However, as only 11% of study participants fell into the “high 
risk” group according to proteomic risk classification these comparisons are 
difficult to interpret.  As an alternative, the cohort were also split by mean 
CKD273 score for analysis which gave two subgroups of 72 participants each.  
Based on this analysis again there was no significant difference in clinical 
parameters between the groups with the exception of age, treatment with RAAS 
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blockade and UACR.  eGFR was numerically lower in participants with CKD273 
score above the mean, however this did not reach statistical significance.  These 
data are also shown in Table 6-2. 
Exploring clinical determinants of CKD273 score, this was associated with age 
(r=0.171, p=0.040) and BMI (r=0.179, p=0.032); but not with disease duration 
(r=0.079, p=0.346); blood pressure (r=-0.049, p=0.094 for systolic; r=-0.017, 
p=0.835 for diastolic); HbA1c (r=0.007; p=0.938) or cholesterol (r=-0.109, 
p=0.192).   
 
6.4.2 CKD273 and renal parameters 
As shown in Table 6-2, there was no significant difference in eGFR or ACR 
between the “high” and “low” risk groups.  When the cohort was divided by 
mean CKD273 score to account for the uneven distribution of participants 
between risk groups, UACR was higher among those with CKD273 score above the 
mean, while remaining well within the low-normal range.  In this analysis the 
difference in eGFR between categories was not statistically significant.  In 
keeping with findings of the pilot study there was no association between 
CKD273 score and eGFR (r=-0.067, p=0.425).  On univariate analysis a weak 
association with UACR was seen (r=0.176, p=0.034); but this was lost following 
adjustment for clinical determinants of CKD273 score.  These plots are 
illustrated in Figure 6-3. 
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Low risk  
(n=128) 
High risk  
(n=16) 
P-value 
CKD273<mean 
(n=72) 
CKD273>mean 
(n=72) 
P-value 
Age (years) 61 (24-73) 61 (44-69) 0.656 61 (24-72) 63 (41-73) *0.008 
Gender (M/F) 87/41 10/6 0.663 52/20 45/27 0.213 
Diabetes duration (years) 10.1±6.4 8.6±4.4 0.375 9.3±6.4 10.6±6 0.215 
RAAS blockade (Y/N) 76/52 14/2 *0.018 37/35 53/19 *0.006 
Retinopathy (Y/N) 40/88 5/11 1.000 22/50 23/49 0.857 
BMI (kg/m2) 30.4 (21-48.9) 35.7 (22.8-47) *0.042 30.3 (21-43) 31.2 (23-49) 0.176 
SBP (mmHg) 134±12 142±13 *0.017 134±12.1 136±13.2 0.324 
DBP (mmHg) 77±9 82±9 0.086 78.38.7 77.4±9.2 0.541 
HbA1c (mmol/mol) 62 (36-106) 67 (45-81) 0.743 64 (36-100) 61.5 (43-106) 0.620 
Cholesterol (mmol/l) 4.1 (2.3-7.6) 4.3 (2.7-6) 0.584 4.2 (2.3-7) 4.2 (2.4-7.6) 0.459 
Triglycerides (mmol/l) 1.8 (0.7-4.8) 1.8 (1-3.1) 0.833 1.7 (0.7-4.6) 1.9 (0.7-4.8) 0.525 
ACR (mg/mmol) 5.1 (1.3-39.1) 5.7 (1.9-20.2) 0.988 4.7 (1.3-39.1) 6.4 (1.9-39.5) *0.007 
eGFR (ml/min/1.73m2) 88.2±14.8 90.7±11.8 0.524 90.6±14.9 86.5±13.9 0.090 
CKD273 score -0.337±0.302 0.396±0.175 *<0.001 -0.549±0.216 0.038±0.235 *<0.001 
Risk category (H/L) NA NA NA 0/72 16/56 *<0.001 
 
 
Table 6-2.  Clinical characteristics according to proteomic risk classification (left hand columns) and mean CKD273 score (right hand 
columns). 
Data are mean±SD and median (range) depending on distribution.  eGFR calculated using CKD-EPI formula.  Of note, normoalbuminuria was defined 
as 2 of 3 consecutive spot ACR being <30mg/g.  Therefore two participants had median ACR technically within the microalbuminuric range but were still 
included in the study.  Comparisons are by 2-sample t-test, using transformed data where appropriate.  * denotes statistical significance.  RAAS, renin 
angiotensin aldosterone system; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; 
ACR, albumin: creatinine ratio; eGFR, estimated glomerular filtration rate. 
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STNFR 1, cystatin C and ultrasound measures of renal morphology were also 
measured in this cohort.  Table 6-3 displays these values according to participant 
risk categories.  When analysed according to CKD273 risk status, there was no 
significant difference in markers of renal morphology, cystatin C or STNFR1 
levels between groups.  However, when the analysis was performed according to 
mean CKD273 score in more evenly sized groups, STNFR1 levels were 
significantly higher in participants with CKD273 above the mean.  There was no 
significant association between CKD273 and kidney size (r=0.042, p=0.491) or 
cortical thickness (r=0.044, p=0.673).  Nor was there an association with STNFR1 
or cystatin C levels in this cohort of patients with preserved renal function 
(r=0.079, p=0.435 for STNFR1; r=0.053, p=0.605 for Cystatin C).  Renal 
morphological parameters were both closely correlated with eGFR as shown in 
Figure 6-4.   
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Figure 6-3.  Association between CKD273 classifier and clinical indices of DN in 
normoalbuminuric patients with preserved eGFR. 
Correlations by Pearson’s method using raw data for eGFR and transformed data for 
ACR.  * denotes statistical significance.  Of note, the relationship between CKD273 and 
ACR was no longer significant on multivariate regression modelling.  ACR, 
albumin:creatinine ratio; eGFR, estimated glomerular filtration rate. 
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Low risk  
(n=128) 
High risk  
(n=16) 
P-value 
CKD273<mean 
(n=72) 
CKD273>mean 
(n=72) 
P-value 
ACR (mg/mmol) 5.1 (1.3-39.1) 5.7 (1.9-20.2) 0.988 4.7 (1.3-39.1) 6.4 (1.9-39.5) *0.007 
eGFR (ml/min/1.73m2) 88.2±14.8 90.7±11.8 0.524 90.6±14.9 86.5±13.9 0.090 
Cystatin C (mg/l) 0.72±0.21 0.74±0.15 0.828 0.71±0.2 0.74±0.21 0.381 
STNFR1 (pg/ml) 149.3 (75.3-294.7) 136.5 (107.1-184.9) 0.306 133.3(75.3-273.4) 155.3 (95.4-294.8) *0.032 
Kidney size (cm) 10.8±0.97 11.2±0.83 0.154 10.8±0.94 10.8±0.98 0.985 
Cortical thickness (cm) 1.73±0.21 1.77±0.22 0.443 1.73±0.22 1.74±0.21 0.780 
 
 
Table 6-3.  Renal parameters according to proteomic risk classification (left hand columns) and mean CKD273 score (right hand columns). 
Data are mean±SD and median (range) depending on distribution.  eGFR calculated using CKD-EPI formula.  Of note, normoalbuminuria was defined 
as 2 of 3 consecutive spot ACR being <30mg/g.  Therefore two participants had median ACR technically within the microalbuminuric range but were still 
included in the study.  Comparisons are by 2-sample t-test, using transformed data where appropriate.  * denotes statistical significance.  ACR, albumin: 
creatinine ratio; eGFR, estimated glomerular filtration rate; STNFR1, soluble tumour necrosis factor receptor type 1. 
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Figure 6-4.  Association between eGFR and renal morphology. 
Correlations by Pearson’s method using raw data * denotes statistical significance. eGFR, 
estimated glomerular filtration rate. 
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6.4.3 CKD273 and subclinical vascular damage 
Both clinical markers of vascular damage and circulating cardiovascular 
biomarkers were measured.  While 144 participants underwent clinical vascular 
phenotyping, biomarker studies were performed in a subset of 100 participants 
as a convenient sample size. 
 
6.4.3.1 Clinical vascular phenotypes 
Vascular phenotypes are shown in Table 6-4.  There was a spread of measures 
spanning the continuum from lower to higher levels of cardiovascular risk.   
Comparing subclinical organ damage between “high” and “low” risk groups; cf-
PWV was numerically higher and cIMT numerically lower among high risk 
patients, but neither of these findings reached statistical significance and their 
relevance in such disparately-sized groups is questionable.  When the cohort was 
split by mean CKD273 score there were no significant differences in markers of 
subclinical vascular damage between subgroups.  On univariate analysis there 
was no association between these markers and CKD273 score (r=0.134, p=0.131 
for cf-PWV; r=-0.051, p=0.558 for cIMT). 
Of course DN is generally thought of as a microvascular complication of diabetes 
and these vascular parameters focus more on larger vessels.  For this reason 
retinopathy status was selected as a crude surrogate for microvascular disease.  
As shown in Figure 6-5 the prevalence of retinopathy was no different in 
participants with CKD273 score above or below the mean. 
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 Low risk 
(n=128) 
High risk 
(n=16) 
P-value CKD273<mean 
(n=72) 
CKD273>mean 
(n=72) 
P-value 
cf-PWV (m/s) 9.2 (6.3-13.9) 9.7 (7.7-12.3) 0.053 9.4 (6.3-13.9) 9.3 (6.5-13.9) 0.600 
cIMT (mm) 0.858±0.170 0.766±0.145 0.051 0.860±0.18 0.836±0.16 0.417 
 
 
 
Table 6-4.  Vascular phenotypes in 144 normoalbuminuric T2DM patients with preserved eGFR. 
Data are mean±SD or median (range) depending on distribution.  cf-PWV, carotid-femoral pulse wave velocity; cIMT, carotid intima media thickness. 
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Figure 6-5.  Prevalence of retinopathy in participants with CKD273 score above and 
below the mean. 
Green colour indicates absence of retinopathy; orange indicates presence of retinopathy.  
Percentage of participants in each category as shown.  Comparison by Fisher’s exact test.  
P=1.000 
 
 
 
 
 
6.4.3.2 Circulating cardiovascular biomarkers 
Table 6-5 shows circulating cardiovascular biomarker measurements in a subset 
of 100 study participants.  When analysed by proteomic risk classification there 
were no differences in circulating levels of CRP, NT-proBNP or TnT between 
“high” and “low” risk groups, although again the difference in size of these 
groups was marked.  When analysed by mean CKD273 score, although 
numerically higher in participants with classifier score above the mean, these 
differences did not reach statistical significance.  On univariate analysis no 
associations were demonstrated between CKD273 score and TnT (r=0.054, 
p=0.595); NT-proBNP (r=0.157, p=0.123); or CRP (r=-0.057, p=0.510).   
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 Low risk 
(n=91) 
High risk 
(n=9) 
P-value CKD273<mean 
(n=49) 
CKD273>mean 
(n=51) 
P-value 
CRP (mg/L) 1.2 (0-18.5) 1.2 (0.4-3.7) 0.957 1.19 (0.1-18.5) 1.22 (0.03-9.87) 0.597 
NT-proBNP (pg/ml) 52.8 (8.7-812.8) 47.3 (23.9-88.9) 0.378 47.7 (8.7-207.1) 56.9 (8.8-812.8) 0.109 
TnT (pg/ml) 7.7±5.6 10.4±10.1 0.452 7.4 ± 5.5 8.5 ± 6.7 0.367 
 
 
 
Table 6-5.  Circulating cardiovascular biomarkers in 100 normoalbuminuric T2DM patients with preserved eGFR. 
The table shows vascular phenotypes according to proteomic risk category (left columns) and mean CKD273 classifier score (right columns).  Data are 
mean±SD or median (range) depending on distribution.  Comparisons by 2-sample t-test using raw or transformed data where appropriate.  cf-PWV, 
carotid-femoral pulse wave velocity; cIMT, carotid intima media thickness. 
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6.5 Discussion 
Small, retrospective analyses have suggested that the CKD273 urinary proteomic 
classifier could be a useful early biomarker of  DN, identifying “at risk” patients 
in advance of any clinically detectable albuminuria or decline in eGFR [268, 295, 
296].  Validation of this concept requires a prospective study including 
biomarker-guided clinical intervention, and the PRIORITY trial will in due course 
determine whether CKD273 can perform adequately as a novel early DN 
biomarker [380].  In chapter 4 of this thesis the relationship between CKD273 
and renal and vascular phenotypes was explored in a small cohort of T2DM 
patients, spanning the spectrum of DN from normoalbuminuria to 
macroalbuminuria or reduced eGFR.  This cohort was small and the presence of 
albuminuria and CKD in some patients made it impossible to draw inference from 
this in terms of the wider T2DM population, particularly those without clinically 
detectable kidney disease, as these are the individuals in whom the classifier is 
believed to show true predictive potential.  In order to explore the relationship 
between CKD273 classifier score and vascular and renal phenotypes without the 
confounding influence of albuminuria, the present study included a larger cohort 
of T2DM patients with no discernible evidence of DN where guideline-endorsed 
clinical indices were well within the traditionally accepted “normal” range. 
In this study which included 144 participants who underwent detailed renal 
phenotyping including measurement of traditional clinical indices of kidney 
disease; novel biomarkers with pathophysiological significance and radiological 
assessment of renal morphology there was no association between CKD273 
classifier and any of these parameters.  On univariate analysis a weak 
correlation with UACR was seen but this was not evident in multivariate analysis.  
The lack of association with eGFR or UACR is at odds with previously published 
studies [289, 290] and to a degree also with the pilot work presented in chapter 
4.  However these studies included patients with established CKD and thus saw a 
greater spread of data than the current study, in which renal parameters 
remained well within the expected normal range.  In addition, no association 
was seen with renal morphology or selected novel renal biomarkers.  The clear 
relationship between renal morphological parameters and eGFR suggests that 
these measures were made correctly, and in fact they were also associated with 
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STNFR1 and cystatin C.  There are no published data exploring relationship of 
CKD273 classifier to novel renal biomarkers or morphology, but it may be that 
this small, homogeneous cohort was underpowered to detect an association 
given the limited spread of data.   
Despite the lack of association between CKD273 classifier and renal parameters 
or discernible differences between “high” and “low” risk groups there was a 
marked spread of CKD273 scores, and according to proteomic risk status 16 
participants (11%) were determined to be at “high risk” of later development of 
DN.  Of course the PRIORITY trial is based on the hypothesis that such “at risk” 
patients who may benefit from early intensive intervention cannot be identified 
by traditional clinical parameters, and it is tempting to infer from the lack of 
association with renal phenotypes that CKD273 is providing additional 
information on risk that is not conveyed by these other markers.  Time will tell 
whether these 16 individuals truly are at increased risk of progression to DN.  
This is not to infer that the CKD273 classifier outperforms the other markers 
evaluated in this study, indeed such assumptions cannot be made from cross-
sectional data; and it may well be the case that simply establishing a lower 
threshold for definition of MA for example could also identify patients at higher 
risk of progressive renal disease.  It does show, however, that a higher CKD273 
classifier score does not simply translate into higher UACR; STNFR1; cystatin C; 
or abnormal renal morphology; and therefore use of these markers to guide 
therapeutic decision-making may not provide the same information about the 
preclinical stages of disease i.e. they are not necessarily “interchangeable” with 
proteomics. 
The link between renal disease and cardiovascular risk is well-established and in 
some ways the kidney can be considered a window to the vasculature, as even 
low levels of UAE or minimal reductions in eGFR translate into increased risk of 
events [145].  MA is established not only as a renal marker but also as an 
indicator of cardiovascular risk.  In fact its utility for the latter is probably 
greater; as it is now generally accepted that not all patients who progress to DN 
will necessarily develop MA in advance of decline in GFR and MA is not always a 
key step in the inevitable progression towards ESRD.  For a “preclinical” disease 
marker such as CKD273 which is thought to identify high risk individuals at a very 
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early stage in disease development, it is unlikely that much association with 
symptomatic cardiovascular disease will be seen for the simple fact that these 
patients are at such an early stage in the evolution of CKD that any clinically 
relevant changes in the vasculature have not yet developed.  Similarly it is 
unlikely that the marker would detect significant cardiovascular disease in this 
particular study cohort, as symptomatic individuals or those who have suffered 
recent events were excluded as detailed in chapter 2.  However, one concern 
that remains is the unknown mechanistic significance of the abundant collagen 
fragments included in the classifier. 
Collagen fragments represent a significant proportion of the peptides captured 
within the CKD273 classifier [268].  Altered collagen turnover is key to a number 
of disease processes including both renal and cardiovascular disease.  In a panel 
used for early identification of DN it is tempting to speculate that this has 
mechanistic significance and these fragments are the result of altered GBM 
composition.  However the majority of differentially regulated fragments are 
cleaved from collagen types 1 and 3, which tend to originate more from the 
vasculature while collagen type 4 is found more abundantly in the kidney [457, 
458].  In addition, other proteomic panels have been evaluated for prediction of 
cardiovascular events [283] and a significant number of overlapping peptides 
between these classifiers and CKD273 have been noted.  In order to evaluate this 
in more detail, markers of subclinical organ damage are of some benefit as hard 
clinical endpoints will take some time to develop in this relatively low-risk 
cohort.  There was no demonstrable association between CKD273 classifier score 
and vascular stiffness or subclinical atherosclerosis, as assessed by cf-PWV and 
cIMT; nor with cardiovascular biomarkers including CRP; TnT and NT-proBNP in 
this study cohort.  The clinical vascular phenotype did not differ significantly 
between “high” and “low” risk patient groups. The trend towards higher cIMT in 
the low risk patients is unexpected, and could be explained by Type 1 error due 
to low numbers of high risk patients overall. 
To summarise, the results of this study suggest that inter-subject variation in 
CKD273 classifier score cannot be fully explained by renal biomarkers or kidney 
morphology.  In addition the classifier does not seem to simply be an indicator of 
subclinical vascular disease.  However there are a number of limitations to 
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consider.  First, this is a relatively small cohort which may be underpowered to 
detect small differences in clinical vascular phenotypes.  Second, the cross-
sectional nature of this project in combination with a lack of correlations cannot 
be translated into any clinically meaningful predictive information, however this 
will be addressed by the PRIORITY trial which will collect data not only on renal 
outcomes but also on cardiovascular events in a much larger study population.  
Finally, DN is generally considered a microvascular complication of diabetes and 
the clinical phenotyping methods used in this study focus on larger vessels. 
Retinopathy status was selected as a crude measure of microvascular disease in 
this cohort and while no difference in the prevalence of retinopathy was seen 
between “high” and “low” risk groups it is feasible that studies focusing on the 
microvasculature may have yielded different results.   
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7. Utility of the CKD273 classifier for prediction of 
renal endpoints in a cohort of patients with 
microalbuminuria 
7.1 Introduction 
DN and associated comorbid conditions place a significant burden on global 
healthcare services.  As such, recent years have seen an exponential increase in 
published manuscripts reporting on novel biomarkers for earlier diagnosis of the 
condition in order to facilitate delivery of targeted preventative therapies 
towards those individuals who stand to benefit most.  It is now understood that 
DN is a more heterogeneous condition than previously thought, and use of multi-
marker proteomic panels could therefore offer increased sensitivity and 
specificity for early diagnosis by simultaneously capturing alterations in 
numerous disease pathways.  Despite the surge of publications describing novel 
proteomic biomarkers none have yet reached the stage of clinical 
implementation as rigorous evaluation procedures are required to justify such 
transitions.  These stages have been described in more detail in chapter 4.  
The majority of the work contained within this thesis focusses on the CKD273 
urinary proteomic biomarker, which has shown particular promise as a tool for 
predicting progression of both diabetic and non-diabetic CKD [422].  The panel 
has been validated in several independent cohorts [289-291, 296, 298] and 
retrospective work has suggested utility beyond the current guideline-endorsed 
parameters for early identification of normoalbuminuric patients at risk of 
progression to DN [296], a hypothesis which is currently being tested in the 
PRIORITY trial [380].  While enhanced sensitivity and specificity for early, pre-
clinical diagnosis and targeted intervention represents the ‘holy grail’ of 
personalised medicine, one key step in proteomic biomarker evaluation requires 
demonstration of either enhanced sole performance or additive value to current 
diagnostic standards [459].  The PRIORITY trial will indeed evaluate the 
performance of CKD273 as an early diagnostic tool for DN in a large cohort of 
normoalbuminuric patients, but data on the performance of the classifier for re-
stratifying microalbuminuric patients are lacking.  The importance of this 
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particular issue may be questioned in the face of the drive towards offering 
early therapy primarily to prevent development of MA, however 
microalbuminuric patients represent a particularly interesting subpopulation for 
biomarker studies for a number of reasons. 
Firstly, the original prospective studies published in the 1980s which reported 
progression rates to overt proteinuria and DN of 60-80% in diabetic patients with 
MA have been followed by contemporary publications describing progression 
rates closer to 30% [21, 22, 28, 30, 31, 460].  In addition regression to 
normoalbuminuria is a common finding among this subpopulation and a 
significant proportion remain microalbuminuric without ever progressing to overt 
proteinuria or experiencing a GFR decline [19].  Second, many patients with 
diabetes have been shown to develop a reduction in GFR without ever becoming 
clinically microalbumin-positive [41, 45].  Thirdly, although development of MA 
has traditionally been equated with later development of DN it is also an 
extremely sensitive cardiovascular risk marker both in diabetic and non-diabetic 
populations.  There is currently no available means by which to differentiate MA 
linked to cardiovascular disease from MA indicative of underlying renal disease 
and it could therefore be argued that any change in UAE within the 
microalbuminuric range may reflect alterations relating to a completely 
different disease process that does not necessarily have a causal relationship to 
diabetic kidney disease [461].  Taken together, the issues described above may 
indicate that MA is not a necessary, committed and irreversible step in the 
progression of DN.  Whilst undoubtedly an important indicator of both renal and 
cardiovascular risk, the presence of MA should perhaps be evaluated as one 
factor within a broader range of biomarkers and clinical characteristics to 
accurately predict an individual’s risk of progressive renal disease.  Current 
guidelines advocate use of RAAS-blocking agents and more stringent blood 
pressure targets in MA positive diabetic patients in order to delay disease 
progression.  However, these and other antihypertensive agents are of course 
associated with side-effects and strict blood pressure targets can be problematic 
in certain subpopulations.  For example, in elderly patients aggressive 
hypertension management can be associated with falls and symptomatic 
hypotension [462] which in turn may limit adherence to treatment.  However, in 
the Systolic Blood Pressure Intervention Trial (SPRINT) these patterns were not 
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seen even with the tight blood pressure targets [463] required and this subject 
therefore remains controversial.  For these reasons, use of additional 
complementary biomarkers for accurate identification of microalbuminuric 
patients who are more or less likely to progress to overt DN could also be an 
attractive clinical tool to guide personalised therapy. 
While proteomic biomarker panels represent an exciting avenue for early and 
accurate diagnosis of a variety of conditions, simultaneously evaluating a large 
number of differentially regulated peptides means that these approaches can 
also provide insight into the pathogenic mechanisms underlying these conditions, 
offering potential to discover alternative novel biomarkers or therapeutic 
targets.  Of course the abundance of a particular peptide fragment in the urine 
could result from increased excretion or reduced degradation; and whether 
these peptides originate in the kidneys or bladder, the vasculature or more 
distal sites is also far from clear.  In addition, given that the majority of the 
peptides comprising the CKD273 classifier are collagen and albumin fragments it 
seems intuitive to question whether the panel merely represents a more 
sensitive MA test.  For these reasons, more detailed exploration of the 
abundance of individual peptide fragments and their relationship to patient 
characteristics is an equally important area for further study.  In order to 
address the issues described above a cohort of T2DM patients with MA, preserved 
renal excretory function at baseline and several years of follow up data was 
required.  To date, no study has assessed the performance of the CKD273 
classifier in this specific patient population. 
In 2011, Reinhard et al published the results of a cross-sectional study designed 
to determine the relationship between albumin excretion and circulating and 
imaging biomarkers of subclinical vascular disease in a cohort of 200 Danish 
T2DM patients with varying degrees of albuminuria and preserved renal function 
[464].  The cohort was subsequently followed up over the next 4 years at the 
Steno Diabetes Centre in order to determine factors predictive of cardiovascular 
outcomes [465].  Although the outcome of interest in the context of this 
particular study was cardiovascular events, follow up data included monitoring 
of eGFR and UAE.  This group therefore seemed ideally suited to evaluate the 
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predictive performance of the CKD273 classifier for prediction of renal events in 
patients with a degree of pre-existing early renal disease.   
The work described within this chapter was conducted with the collaboration of 
colleagues at the Steno Diabetes Centre in Denmark, using the cohort described 
above.  Drs Bernt-Johan von Scholten and Morten Lindhart were involved in 
drafting the ethical approval application, selection and dispatch of urine 
samples and provided the clinical data corresponding to study subjects.  The 
author was responsible for co-ordinating the conduct of the study, collation of 
results and statistical analysis. 
 
7.2 Aims 
The aims of this study were: 
 to explore determinants of the CKD273 classifier in a cohort of Danish 
T2DM patients with micro- or macroalbuminuria but preserved renal 
function; 
 to determine whether baseline CKD273 score could identify patients with 
micro- or macroalbuminuria who were more or less likely to experience a 
decline in eGFR; 
 to explore the relationship between individual peptide components of the 
CKD273 classifier and renal parameters. 
 
7.3 Methods 
The work contained within the chapter was designed in collaboration with 
colleagues at the Steno Diabetes Research Centre, where participants were 
originally recruited and followed-up as part of the index trial.  The design and 
methodology of both the original cross-sectional and later follow-up studies have 
been described elsewhere [464, 465].  Where relevant within this section key 
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elements will be described in brief but the primary focus will be methodology 
pertaining to the urinary proteomic study.   
 
7.3.1 Ethical approval 
The work described by Reinhard [464] and von Scholten [465] was compliant with 
the Declaration of Helsinki and approved by the local ethics committee.  All 
participants gave written informed consent at the time of inclusion.  The work 
described within this chapter was presented to the local Danish ethics 
committee as an additional research proposal and received approval in July 
2015. 
 
7.3.2 Participant selection and recruitment 
Recruitment into the index study has been described elsewhere [464].  In brief, 
200 T2DM patients attending the Steno Diabetes Centre secondary care clinic 
were identified between January 2007 and February 2008.  All received intensive 
multifactorial management including measures to address glycaemic control; 
lipid profile and blood pressure; as well as antiplatelet agents and lifestyle 
advice in accordance with the Steno-2 study [303].  Included patients were 
between 20 and 70 years of age; had the capacity to give informed consent; 
were diagnosed with T2DM according to the World Health Organization criteria; 
and had confirmed MA at screening, defined as UAE exceeding 30mg/24 hrs in 2 
out of 3 consecutive urine samples.  The presence of pre-existing coronary 
artery disease or other cardiac pathologies based on history, examination and 
electrocardiographic findings; and eGFR less than 60ml/min/1.73m2 (as this 
would preclude contrast imaging of the coronary vasculature) were key exclusion 
criteria.   
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7.3.3 Study visits 
All study-related procedures were performed at the Steno Diabetes Research 
Centre in Gentofte, Denmark.  In brief, after obtaining informed consent 
investigators documented participant medical and drug history and measured 
height, weight, BMI and blood pressure.  Peripheral blood samples were then 
taken for measurement of HbA1c, cholesterol and creatinine, as well as for 
storage for later biomarker analysis.  In addition a spot urine sample was 
obtained for storage as above.  eGFR was calculated using the CKI-EPI formula.  
Additional clinical measurements included assessment of the carotid, coronary 
and peripheral arteries.  These procedures have been described in detail 
elsewhere [464] and the data are not relevant to the study described within this 
chapter.   
 
7.3.4 Follow-up 
All study participants were traced through the Danish National Death and Danish 
National Health registers from January 1st 2014.  Information on date and cause 
of death were obtained for any deceased participants, and details pertaining to 
any hospitalisations were extracted.  As all participants were attending the 
Steno Diabetes Centre secondary care clinic at the time of recruitment, and 
many continued to do so following the original study, information on eGFR and 
UAE was available for the majority.    
 
7.3.5 Urinary proteomic sample selection 
After obtaining approval from the local Danish ethics committee, stored baseline 
urine samples were selected for proteomic analysis.  Selection was primarily 
based on sample availability.  Frozen 1ml aliquots of urine were available for 
188 participants.  These were packaged on dry ice and shipped from the Steno 
Centre to the University of Glasgow for analysis in July 2015.    
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7.3.6 Urinary proteomic analysis  
The preparation and subsequent CE-MS processing of urine samples were 
performed at the University of Glasgow as described in Chapter 4.  Data analysis 
and determination of CKD273 classifier score was performed at Mosaiques 
Diagnostics in Hannover according to the steps described in chapter 2.  At the 
time of processing and analysis no demographic information was available to the 
Glasgow study team in order to ensure all were blinded to participant 
demographics, renal function and outcomes.   
 
7.3.7 Data handling  
Prior to sample shipment collaborators at the Steno Diabetes Centre and 
University of Glasgow prepared a predefined data analysis plan.  As described 
above, the Glasgow study team were blinded to participant information 
including basic demographics; renal parameters; and outcomes until the 
proteomic analysis was complete.  Once CKD273 classifier scoring was available 
for all analysable samples this information was sent to collaborators at the Steno 
Diabetes Research Centre who then released individual patient data for 
statistical analysis.  Participants were identifiable only by unique study ID, and 
the link document was not available to the Glasgow study team.   
 
7.3.8 Endpoints 
The primary endpoint was defined as a decline in eGFR of at least 30% at any 
time point during follow up.  Transition in albuminuria status from micro- to 
macroalbuminuria at any time point during the follow up period was the 
predefined secondary endpoint.  Cardiovascular events were defined as a 
combination of cardiovascular mortality; non-fatal myocardial infarction; stroke; 
and heart failure.   
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7.3.9 Statistical Analysis 
Statistical analysis was carried out using SPSS (SPSS, IBM Analytics, New York, 
USA) and Minitab16 (Pennsylvania, USA) software packages.  Normality of data 
distribution was assessed by manual inspection of histograms and the 
Kolmogorov-Smirnov test.  Normally distributed data were expressed as mean ± 
SD, while data that were not normally distributed were expressed as median and 
interquartile range. Correlations were determined by Pearson’s method on 
normally distributed or appropriately transformed data.  In the event that data 
were zero-inflated normalisation was deemed inappropriate and correlations 
were therefore determined by Spearman’s rank method.  Kaplan-Meier plots and 
Cox regression models were used to determine the ability of CKD273 to predict 
progressive renal disease and mortality. 
 
7.4 Results 
Of the 188 urine samples received 31 failed quality control assessment following 
CE-MS analysis, meaning that CKD273 scores were available for 157 individual 
participants.   
 
7.4.1 Baseline characteristics 
Baseline characteristics of the cohort are shown in Table 7-1.  Of the 157 study 
participants with proteomic scores available 120 (76%) were male and 37 (24%) 
were female.  Median age was 60 years and participants had been diagnosed 
with diabetes for 12 years.  Median BMI was within the obese range and 27% of 
patients were smokers, but other risk factors including blood pressure; HbA1c; 
and cholesterol were well-controlled.  60% of study participants were affected 
by diabetic retinopathy.  All participants were microalbumin-positive on 24 hour 
urine collection at screening, however due to the variability of albuminuria 
there was a degree of spread at baseline.  While median UAE was within the 
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microalbuminuric range only 99 (63%) participants were microalbuminuric at 
baseline, 30 (19%) were normoalbuminuric and 28 (18%) had macroalbuminuria.  
Despite this, renal function was preserved with mean eGFR of 
89.5ml/min/1.73m2 and all participants had eGFR greater than 60 
ml/min/1.73m2 at baseline.  Median CKD273 classifier score was 0.271 (-1.078-
1.231).  
 
 
 
Parameter Mean±SD/Median (range) 
Age (years) 60 (26-71) 
Gender (M/F) 120/37 
Diabetes duration (years) 12 (1-36) 
Retinopathy (Y/N) 93/65 
Smokers (Y/N) 42/115 
BMI (kg/m2) 31.4 (21.6-55.6) 
SBP (mmHg) 129.6±16.1 
DBP (mmHg) 74.8±11.2 
HbA1c (mmol/mol) 59 (39-123) 
Cholesterol (mmol/l) 3.8 (2-7.6) 
UAE (mg/24hrs) 103 (3-1372) 
eGFR (ml/min/1.73m2) 89.5±17.4 
CKD273 score 0.271 (-1.078 – 1.231) 
 
 
 
Table 7-1.  Baseline characteristics of cohort. 
Data are mean ± SD or median (range) depending on distribution.  eGFR calculated by 
CKD-EPI formula.  ‘Retinopathy’ encompasses presence of retinal changes on digital 
retinal photography and participants who have undergone laser therapy.  BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated 
haemoglobin; UAE, urine albumin excretion; eGFR, estimated glomerular filtration rate. 
 
  
236 
 
 
Previous publications have established a classifier threshold of 0.343 for 
diagnosis of DN [268].  Taking this threshold as the diagnostic cut-off for the 
study population, 71 (45%) participants fell within the “high risk” category.  A 
comparison of clinical characteristics between participants with classifier score 
above and below the diagnostic threshold is shown in Table 7-2.  There was a 
higher proportion of male participants in the “high risk” group and more were 
smokers.  Apart from these characteristics the only parameter differing between 
the categories was UAE (57mg/24hrs vs 141mg/24hrs).  Other clinical parameters 
including age; blood pressure; BMI; HbA1c; cholesterol; and eGFR were not 
significantly different in patients with CKD273 score above or below the 
diagnostic cut-off for DN.   
 
 
 
Parameter CKD273>0.343 
(n=71) 
CKD273<0.343 
(n=86) 
P-value 
Age (years) 61 (59-71) 61 (60-70) 0.573 
Gender (M/F) 61/10 59/27 *0.010 
Diabetes duration (years) 10 (1-35) 13 (1-36) 0.153 
Retinopathy (Y/N) 42/29 53/33 0.752 
Smokers (Y/N) 27/44 16/70 *0.007 
BMI (kg/m2) 31.3 (22.5-55.6) 31.7 (21.6-45.6) 0.662 
SBP (mmHg) 130.4±17.4 128.8±15.3 0.547 
DBP (mmHg) 75±11.2 73.8±11.3 0.543 
HbA1c (mmol/mol) 59 (41-86) 59 (39-123) 0.118 
Cholesterol (mmol/l) 3.9 (2-7) 3.8 (2.2-6.1) 0.549 
UAE (mg/24hrs) 141 ( 9-1372) 57 ( 3-980) *<0.001 
eGFR (ml/min/1.73m2) 87.6±18 89.6±16 0.452 
CKD273 score 0.527 ( -1.078 -1.231) 0.140 ( -1.004 - 0.780) *<0.001 
 
 
 
Table 7-2.  Baseline characteristics of cohort according to CKD273 risk score. 
Data are mean±SD or median (range) depending on distribution.  eGFR calculated by 
CKD-EPI formula.  ‘Retinopathy’ encompasses presence of retinal changes on digital 
retinal photography and participants who have undergone laser therapy.  Comparisons 
are by 2-sample t-test on transformed data where appropriate. BMI, body mass index; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated 
haemoglobin; UAE, urine albumin excretion; eGFR, estimated glomerular filtration rate. 
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7.4.2 Determinants of CKD273 classifier score 
Chapter 5 focused on a cohort of normoalbuminuric T2DM patients and in this 
population with no evidence of established kidney disease there was a significant 
association between CKD273 score and UAE while no correlation was found with 
eGFR.  Univariate analysis of classifier score determinants in the current 
population with varying degrees of albuminuria revealed statistically significant 
associations with both UAE (r=0.494, p=<0.001) and eGFR (r=-0.208, p=0.009) as 
shown in Figure 7-1.  The only other clinical parameter associated with CKD273 
score was age (r=0.182, p=0.023).   Other clinical characteristics including 
disease duration (r=0.086, p=0.285); BMI (r=-0.072, p=0.368); blood pressure 
(r=0.067, p=0.402 for systolic; r=-0.071, p=0.382 for diastolic); HbA1c (r=-0.039, 
p=0.625); and cholesterol (r=0.042, p=0.602) were not associated with classifier 
score in this population. 
Multivariate analysis shown in Tables 7-3 and 7-4 demonstrates that when all 
factors significantly associated with classifier score were included in a regression 
model the relationship between age and CKD273 lost significance while eGFR 
and UAE together explain 30% of the variability in CKD273 score.  When other 
variables that could potentially influence DN status were included in the model 
again only eGFR and UAE remained as significant determinants of classifier 
score, with R2 value of 30.92%.   
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Figure 7-1.  Association between CKD273 classifier and clinical indices of DN. 
Correlations by Pearson’s method using raw data for eGFR and transformed data for 
ACR.  * denotes statistical significance.  ACR, albumin: creatinine ratio; eGFR, estimated 
glomerular filtration rate. 
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Variable Coefficient SE Coefficient P-value 
Constant 1.194 0.417 *0.005 
Age (years) 0.078 0.077 0.313 
UAE (mg/24hrs) 0.541 0.071 *<0.001 
eGFR (ml/min/1.73m2) -0.013 0.005 *0.007 
 
 
Table 7-3.  Regression model 1 including all parameters associated with CKD273 on 
univariate analysis. 
Adjusted R² 30%.  SE, standard error; urine albumin excretion; eGFR, estimated 
glomerular filtration rate. 
 
 
 
 
Variable Coefficient SE Coefficient P-value 
Constant 1.676 0.647 *0.011 
UAE (mg/24hrs) 0.570 0.073 *<0.001 
eGFR (ml/min/1.73m2) -0.013 0.004 *0.003 
Disease duration (years) 0.010 0.077 0.895 
BMI (kg/m2) -0.112 0.065 0.088 
SBP (mmHg) 0.005 0.005 0.332 
HbA1c (mmol/mol) 0.014 0.075 0.855 
 
 
Table 7-4.  Regression model 2 including all parameters associated with CKD273 on 
univariate analysis as well as factors which could potentially contribute to DN 
status. 
Adjusted R² 30.92%.  SE, standard error; UAE, urine albumin excretion; eGFR, estimated 
glomerular filtration rate; BMI, body mass index; SBP, systolic blood pressure; HbA1c, 
glycated haemoglobin. 
 
 
7.4.3 Individual component peptides 
The CKD273 classifier includes 273 differentially expressed urinary peptides and 
these data are assimilated to calculate the overall classifier score using SVM 
modelling.  To determine the relationship between individual peptides and renal 
parameters the raw peptide expression data were obtained for each study 
participant.  Of all 273 peptides included in the classifier 54 correlated 
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significantly with UAE on univariate analysis as shown in Table 7-5 and 23 were 
found to be correlated with eGFR as shown in Table 7-6.   
 
Peptide ID 
Correlation 
coefficient 
 Peptide ID 
Correlation 
coefficient 
p2505 0.192*  p79136 0.184* 
p24117 0.165*  p80012 -0.164* 
p30174 0.280**  p80891 0.200* 
p32470 -0.216**  p81424 0.275** 
p38011 0.168*  p82325 -0.169* 
p38879 0.227**  p82509 -0.204* 
p39163 -0.169*  p84192 0.175* 
p40645 0.297**  p86798 0.260** 
p44969 -0.228**  p89325 0.250** 
p45347 0.189*  p90344 -0.235** 
p49295 -0.236**  p92257 0.405** 
p50172 -0.220**  p92698 0.297** 
p50840 -0.257**  p96370 0.269** 
p51120 0.294**  p97301 0.322** 
p55523 -0.225**  p102392 0.296** 
p55582 -0.174*  p105105 -0.158* 
p56457 0.243**  p107929 0.316** 
p60216 0.217**  p118597 -0.222** 
p62778 -0.167*  p119026 0.245** 
p67097 -0.172*  p122400 -0.159* 
p67386 -0.234**  p125402 -0.337** 
p67462 -0.159*  p126253 0.248** 
p67632 0.328**  p130108 -0.221** 
p70413 0.238**  p130243 -0.216** 
p70911 -0.164*  p130661 0.341** 
p72533 -0.235**  p131102 0.215** 
p73697 -0.311**  p136698 0.258** 
 
 
Table 7-5.  Correlation coefficients between UAE and the 54 individual peptides 
which are significantly associated with this parameter on univariate analysis. 
* denotes significance at the level of 0.05 (2-tailed).  ** denotes significance at the level of 
0.01 (2-tailed). 
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Peptide ID 
Correlation 
coefficient 
 Peptide ID 
Correlation 
coefficient 
p20756 0.211**  p66483 -0.162* 
p25053 0.185*  p70911 0.160* 
p3508 0.230**  p71312 -0.316** 
p35339 0.178*  p7408 0.169* 
p37715 0.169*  p76839 0.166* 
p39163 0.174*  p97506 -0.203* 
p41476 0.157*  p105105 0.199* 
p42594 0.215**  p107460 0.235** 
p48580 0.205**  p108724 0.210** 
p51875 0.184*  p124886 0.173* 
p51932 0.194*  p156878 -0.175* 
p62778 0.167*    
 
 
Table 7-6.  Correlation coefficients between eGFR and the 23 individual peptides 
which are significantly associated with this parameter on univariate analysis. 
* denotes significance at the level of 0.05 (2-tailed).  ** denotes significance at the level of 
0.01 (2-tailed). 
 
 
Representative examples illustrating these correlations is shown in Figure 7-2, 
highlighting the fact that some peptides are positively whilst others are 
negatively correlated with renal parameters.  There was virtually no overlap 
between these peptides as only 4 correlated with both UAE and eGFR (Table 7-
7).  These were all differentially regulated fragments of collagen α-1 chain and 
collagen α-2 chain. 
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Figure 7-2.  Relationships between individual peptides and renal parameters. 
eGFR, estimated glomerular filtration rate; ACR, albumin: creatinine ratio. 
 
 
 
 
Peptide ID 
Correlation 
coefficient 
UAE 
Correlation 
coefficient 
eGFR 
p39163  -0.169* 0.174* 
p62778  -0.167* 0.167* 
p70911 -0.164* 0.160* 
p105105 -0.158* 0.199* 
 
 
Table 7-7.  Correlation coefficients between the 4 peptides which are associated 
with both UAE and eGFR on univariate analysis. 
* denotes significance at the level of 0.05 (2-tailed).  UAE, urine albumin excretion; eGFR, 
estimated glomerular filtration rate.  All peptides IDs correspond to fragments of collagen 
α-1 and collagen α-2. 
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7.4.4 Renal endpoints 
After 4 years of follow up 18 patients (11%) had transitioned to 
macroalbuminuria while 29 (18%) had experienced a decline in eGFR of at least 
30%.  Twenty one (13%) participants died during the follow up period and 33 
(21%) had been hospitalised as a result of a cardiovascular event. 
The limitations of MA as an early renal biomarker have been discussed in detail 
in chapter 1.  A number of authors have shown that MA does not necessarily 
herald an inevitable decline in renal function and in fact a proportion of patients 
never progress beyond this stage.  In order to determine whether any clinical 
parameters can be used to differentiate those who are more likely to progress to 
macroalbuminuria over the 4 year follow up period only the subpopulation of 
participants who were microalbuminuric at baseline (n=99) were selected for 
further analysis.  A comparison of baseline characteristics between those who 
remained microalbuminuric (n=81) and those who progressed to 
macroalbuminuria (n=18, defined as 24hr UAE greater than 300mg) is shown in 
Table 7-8.  In summary, there was no difference in age; gender; disease 
duration; smoking status; BMI; blood pressure; HbA1c; cholesterol or baseline 
UAE between progressors and non-progressors.  As expected, a greater 
proportion of progressors had retinopathy at baseline and eGFR was lower in this 
group, although still well within what is clinically considered to be the “normal” 
range.  CKD273 classifier score at baseline did not differentiate progressors from 
non-progressors in this sub-population.   
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Parameter 
Non-progressors 
(n=81) 
Progressors 
(n=18) 
P-value 
Age (years) 61 (32-70) 62 (41-70) 0.217 
Gender (M/F) 60/21 14/4 0.458 
Diabetes duration (years) 10 ( 1-35) 15 ( 4-36) 0.183 
Retinopathy (Y/N) 45/36 14/4 *0.032 
Smokers (Y/N) 17/64 6/12 0.222 
BMI (kg/m2) 31.2 (24.3-55.6) 31.1 ( 21.6-45.4) 0.464 
SBP (mmHg) 129±16 128±14 0.844 
DBP (mmHg) 74±11 71±10 0.120 
HbA1c (mmol/mol) 61 (39-110) 71 (44-112) 0.077 
Cholesterol (mmol/l) 3.8 (2-6.1) 3.8 (2.7-4.8) 0.705 
UAE (mg/24hrs) 79 (31-290) 103 (30-276) 0.141 
eGFR (ml/min/1.73m2) 92±17 82±11 *0.005 
CKD273 score 0.275 (-1.00 -1.231) 0.436 (-0.044-0.668) 0.108 
 
 
 
Table 7-8.  Clinical features progressors vs non-progressors (UAE). 
Data are median (range) or mean ± SD depending on distribution.  eGFR calculated by 
CKD-EPI formula. Comparisons are by 2-sample t-test on transformed data where 
appropriate. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; HbA1c, glycated haemoglobin; UAE, urine albumin excretion; eGFR, estimated 
glomerular filtration rate. 
 
 
 
Of course progression to macroalbuminuria does not necessarily imply decline in 
eGFR.  In order to explore the role of clinical parameters in predicting eGFR 
decline the whole cohort (n=157) was split into progressors (n=29), defined as a 
decline in eGFR of more than 30% at any time during follow up in keeping with 
the pre-determined primary endpoint, and non-progressors (n=112) whose eGFR 
did not decline significantly.  This comparison is shown in Table 7-9.  Only 
differences in age and baseline eGFR were statistically significant between these 
subgroups, although once again baseline eGFR remained well within what is 
clinically considered the “normal” range.  Baseline CKD273 classifier score was 
not significantly different between those who experienced a decline in eGFR and 
those who did not.  
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Parameter 
Non-progressors 
(n=112) 
Progressors 
(n=29) 
P-value 
Age (years) 61 (29-71) 62 (43-71) *0.021 
Gender (M/F) 86/26 23/6 0.771 
Diabetes duration (years) 12 (1-36) 13 (3-22) 0.970 
Retinopathy (Y/N) 65/47 19/10 0.461 
Smokers (Y/N) 31/81 6/23 0.437 
BMI (kg/m2) 32 (23-56) 31 (22-45) 0.582 
SBP (mmHg) 129±16 132±14 0.355 
DBP (mmHg) 75±11 74±12 0.871 
HbA1c (mmol/mol) 59 (39-123) 58 (42-112) 0.848 
Cholesterol (mmol/l) 3.9 (2-6.6) 3.8 (2.9-6) 0.466 
UAE (mg/24hrs) 80 (3-1073) 96 (7-1372) 0.358 
eGFR (ml/min/1.73m2) 91±17 82±14 *0.009 
CKD273 score 0.283 (-1.078-1.231) 0.261 (-0.972-0.774) 0.992 
 
 
Table 7-9.  Clinical features progressors vs non-progressors (eGFR). 
Data are median (range) or mean ± SD depending on distribution.  eGFR calculated by 
CKD-EPI formula. Comparisons are by 2-sample t-test on transformed data where 
appropriate. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; HbA1c, glycated haemoglobin; UAE, urine albumin excretion; eGFR, estimated 
glomerular filtration rate. 
 
 
 
 
7.4.5 Survival analysis 
Of course cross-sectional analysis cannot be used to infer any predictive value of 
clinical or laboratory parameters.  In order to determine whether baseline 
CKD273 classifier score is predictive of later decline in renal function Kaplan-
Meier analysis was performed. 
The pre-defined primary endpoint for this analysis was occurrence of a decline in 
eGFR of at least 30% at any time point during the follow-up period.  When the 
cohort were divided into subgroups with CKD273 scores above and below the 
published threshold for diagnosis of DN (0.343) there was no significant 
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difference in incidence of the primary endpoint (Log Rank (Mantel Cox) 
p=0.598).  This is illustrated by the Kaplan-Meier plot in Figure 7-3. 
 
 
 
 
 
 
Figure 7.3.  Kaplan Meier plot illustrating renal survival in patients with CKD273 
score above and below threshold for diagnosis of DN. 
Green line represents CKD273 score above 0.343; blue line represents CKD273 score 
less than 0.343.  Vertical marks on each curve represent censored data. There was no 
significant difference in incidence of the primary renal endpoint in patients with CK273 
above threshold for diagnosis of DN.  Log Rank (Mantel Cox) p=0.598. 
 
 
 
 
In order to adjust renal survival as categorised by CKD273 score for other 
determinants of renal function baseline UAE and eGFR were included in a Cox 
regression model.  When these 3 predictors of renal function decline were 
considered, only UAE and eGFR at baseline were significant predictors of a later 
decline in eGFR as shown in Figure 7-4 and Table 7-9.  When CKD273 classifier 
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score was considered as a continuous rather than categorical variable in this 
model the significance level for the variable "CKD273" was improved (p=0.096 vs 
p=0.168) as shown in Table 7-10.  For this reason the cohort was also divided 
into tertiles of CKD273 score for survival analysis.  However, CKD273 classifier 
score was not a significant predictor of renal survival when the cohort was 
considered in 3 distinct groups according to CKD273 tertile (Log Rank (Mantel 
Cox) p=0.864), nor when tertile 1 was compared with tertiles 2 and 3 in 
combination (Log Rank (Mantel Cox) p=0.862) as shown in Figures 7-5 and 7-6. 
 
 
 
 
 
Figure 7-4.  Survival plot illustrating renal survival in patients with CKD273 score 
above and below threshold for diagnosis of DN, adjusted for baseline UAE and 
eGFR. 
Green line represents CKD273 score above 0.343; blue line represents CKD273 score 
less than 0.343.  Cox regression analysis confirms that there is no significant difference in 
renal survival between the two groups (p=0.168). The covariables UAE and eGFR at 
baseline contribute significantly to incidence of the primary renal endpoint (p=0.016 for 
UAE; p=0.007 for eGFR). 
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 B SE Wald df Sig. Exp (B) 
CKD273 Category .563 .408 1.903 1 .168 1.756 
Baseline UAE 
(mg/24hrs) 
.002 .001 5.826 1 .016 1.002 
Baseline eGFR 
(ml/min/1.73m2) 
-.031 .011 7.294 1 .007 .970 
 
 
Table 7-9.  Cox regression model for renal event including CKD273 risk category 
and baseline renal parameters UAE and eGFR. 
CKD273 threshold for diagnosis of DN is 0.343.  B, regression coefficient; SE, standard 
error of regression coefficient; Wald, wald statistic (b/SE)2; df, degree of freedom; Sig, 
significance level; Exp (B), odds ratio; UAE, urine albumin excretion; eGFR, estimated 
glomerular filtration rate. 
 
 
 
 
 
 
 B SE Wald df Sig. Exp (B) 
CKD273 score -.942 .566 2.769 1 .096 .390 
Baseline UAE 
(mg/24hrs) 
.002 .001 6.590 1 .010 1.002 
Baseline eGFR 
(ml/min/1.73m2) 
-.035 .012 8.609 1 .003 .966 
 
 
Table 7-10.  Cox regression model for renal event including CKD273 score as a 
continuous variable and baseline renal parameters UAE and eGFR.  
B, regression coefficient; SE, standard error of regression coefficient; Wald, wald statistic 
(b/SE)2; df, degree of freedom; Sig, significance level; Exp (B), odds ratio; UAE, urine 
albumin excretion; eGFR, estimated glomerular filtration rate. 
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Figure 7-5.  Kaplan Meier plot illustrating renal survival according to CKD273 tertile. 
Blue line represents tertile 1 (53 patients; CKD273 score -1.078 to 0.143; median -0.165); 
green represents tertile 2 (52 patients; CKD273 score 0.150 to 0.472; median 0.267); red 
represents tertile 3 (52 patients; CKD273 score 0.480 to 1.231; median 0.594). Vertical 
marks on each curve represent censored data.  There was no significant difference in 
incidence of the primary renal endpoint based on CKD273 tertile at baseline.  Log Rank 
(Mantel Cox) p=0.864. 
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Figure 7-6.  Kaplan Meier plot illustrating renal survival according to CKD273 tertile. 
Blue line represents tertile 1; green represents tertiles 2 and 3. Vertical marks on each 
curve represent censored data.  There was no significant difference in incidence of the 
primary renal endpoint based on CKD273 tertile at baseline.  Log Rank (Mantel Cox) 
p=0.862. 
 
 
 
 
 
As the majority of the study cohort had some degree of albuminuria at baseline, 
many individuals had high cardiovascular risk and may have died from this cause 
before reaching a renal endpoint.  There was no significant difference in 
cardiovascular events between patients with CKD273 score above and below the 
pre-defined diagnostic threshold (Log Rank (Mantel Cox) p=0.598) as shown in 
Figure 7-7.  However, analysis of all-cause mortality revealed that CKD273 score 
above 0.343 was a significant predictor of death in this cohort (Log Rank (Mantel 
Cox) p=0.004) as shown in Figure 7-8.  
251 
 
 
 
 
 
 
Figure 7-7.  Kaplan Meier plot illustrating cardiovascular events in patients with 
CKD273 score above and below threshold for diagnosis of DN. 
Green line represents CKD273 score above 0.343; blue line represents CKD273 score 
less than 0.343.  Vertical marks on each curve represent censored data. There was no 
significant difference in incidence of cardiovascular events in patients with CK273 above 
threshold for diagnosis of DN.  Log Rank (Mantel Cox) p=0.598. 
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Figure 7-8.  Kaplan Meier plot illustrating all-cause mortality in patients with 
CKD273 score above and below threshold for diagnosis of DN. 
Green line represents CKD273 score above 0.343; blue line represents CKD273 score 
less than 0.343.  Vertical marks on each curve represent censored data. CKD273 
classifier score above the threshold for diagnosis of DN was a significant predictor of 
mortality.  Log Rank (Mantel Cox) p=0.004. 
 
 
 
 
Table 7-11 shows a comparison of baseline characteristics between participants 
who died during follow up (n=21) and those who survived (n=136).  In summary, 
participants who died during follow up were significantly older and there was a 
higher proportion of smokers in this subpopulation.  All other clinical parameters 
including gender; diabetes duration; blood pressure; BMI; HbA1c; cholesterol; 
retinopathy status; and UAE were not found to be significantly different.  Median 
CKD273 classifier score at baseline was higher in participants who died during 
follow up and this difference did reach statistical significance.   Inclusion of age, 
253 
 
 
gender and CKD273 category in a Cox regression model revealed that both age 
and CKD273 were significant predictors of mortality as shown in Table 7-12 and 
Figure 7-9.  These characteristics remained the only significant predictors of 
mortality in a more comprehensive model including additional covariates as 
shown in Table 7-13 and also when adjusted for smoking (data not shown). 
 
Parameter 
Survivors 
(n=136) 
Death during 
follow-up 
(n=21) 
P-value 
Age (years) 60 (29-71) 66 (50-70) *0.003 
Gender (M/F) 101/35 19/2 0.077 
Diabetes duration (years) 12 (1-35) 14 (4-36) 0.135 
Retinopathy (Y/N) 79/57 16/5 0.104 
Smokers (Y/N) 32/104 11/10 *0.009 
BMI (kg/m2) 29 (22-56) 27 (24-44) 0.608 
SBP (mmHg) 129±16 132±19 0.571 
DBP (mmHg) 75±11 70±11 0.087 
HbA1c (mmol/mol) 52 (39-123) 51 (43-91) 0.211 
Cholesterol (mmol/l) 3.8 (2-6.6) 4 (2.4-7) 0.682 
UAE (mg/24hrs) 78 (3-1372) 196 (9-864) 0.116 
eGFR (ml/min/1.73m2) 89±17 87±16 0.581 
CKD273 score 0.249 (-1.078-1.133) 0.502 (-0.229-1.231) *0.013 
 
 
 
Table 7-11.  Baseline characteristics of cohort according to mortality during follow 
up.  Data are mean±SD or median (range) depending on distribution. 
eGFR calculated by CKD-EPI formula.  ‘Retinopathy’ encompasses presence of retinal 
changes on digital retinal photography and participants who have undergone laser 
therapy.  Comparisons are by 2-sample t-test on transformed data where appropriate and 
* denotes statistical significance. BMI, body mass index; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; UAE, urine albumin 
excretion; eGFR, estimated glomerular filtration rate. 
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 B SE Wald df Sig. Exp (B) 
Sex -.567 .751 .569 1 .451 .567 
Age at baseline .125 .047 7.196 1 .007 1.133 
CKD273 category -1.189 .520 5.221 1 .022 .304 
 
 
Table 7-12.  Cox regression model for mortality including CKD273 risk category, 
age and gender. 
CKD273 threshold for diagnosis of DN is 0.343.  B, regression coefficient; SE, standard 
error of regression coefficient; Wald, wald statistic (b/SE)2; df, degree of freedom; Sig, 
significance level; Exp (B), odds ratio. 
 
 
 
 
 
 
 
 
Figure 7-9.  Survival plot illustrating all-cause mortality in patients with CKD273 
score above and below threshold for diagnosis of DN adjusted for age and gender. 
Green line represents CKD273 score above 0.343; blue line represents CKD273 score 
less than 0.343. CKD273 classifier score above the threshold for diagnosis of DN 
(p=0.022) and age (p=0.007) were significant predictors of mortality.   
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 B SE Wald df Sig. Exp (B) 
Sex -.718 .774 .861 1 .353 .488 
Age at baseline (yrs) .162 .056 8.373 1 .004 1.176 
CKD273 category -1.311 .535 6.002 1 .014 .269 
HbA1c at baseline 
(mmol/mol) 
-.110 .230 .227 1 .634 .896 
BMI at baseline 
(kg/m²) 
.079 .050 2.507 1 .113 1.082 
SBP at baseline 
(mmHg) 
-.001 .015 .005 1 .943 .999 
Retinopathy status 
at baseline 
.651 .551 1.396 1 .237 1.917 
Cholesterol at 
baseline (mmol/L) 
.238 .282 .709 1 .400 1.268 
UAE at baseline 
(mg/24hrs) 
-.001 .001 .921 1 .337 .999 
eGFR at baseline 
(ml/min/1.73m²) 
.018 .018 1.008 1 .315 1.018 
 
 
Table 7-13.  Cox regression model for mortality including CKD273 category and 
additional baseline covariates. 
CKD273 threshold for diagnosis of DN is 0.343.  HbA1c, glycated haemoglobin; BMI, body 
mass index; SBP, systolic blood pressure; UAE, urine albumin excretion; eGFR, 
estimated glomerular filtration rate.  B, regression coefficient; SE, standard error of 
regression coefficient; Wald, wald statistic (b/SE)2; df, degree of freedom; Sig, 
significance level; Exp (B), odds ratio. 
 
 
 
From this analysis it appears therefore that the CKD273 classifier is not a 
predictor of decline in renal function or cardiovascular events in T2DM patients 
with established early stage kidney disease as indicated by the presence of 
micro- or macroalbuminuria and preserved eGFR.  The classifier does, however, 
appear to predict mortality in this population which could therefore compete 
with risk of progressive CKD.   
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7.5 Discussion 
The CKD273 urinary proteomic biomarker is currently being evaluated as a tool 
for early detection of DN in advance of MA reaching levels in the urine which are 
deemed significant by current clinical thresholds.  Validation studies in a number 
of different cohorts have been promising [289-292, 295, 296] and the 
prospective PRIORITY trial will ultimately determine whether CKD273 is a useful 
guide to early preventative therapy [380].  Trials such as ROADMAP and 
BENEDICT [373, 376] have provided evidence that such early intervention can 
potentially delay or prevent the onset of MA, and targeting therapy towards 
individuals at highest risk could minimise the unwanted side-effects and adverse 
events associated with these agents if prescribed in an unselected, low-risk 
population. 
Current clinical guidelines advocate prescription of RAAS blocking agents to 
patients who are persistently microalbuminuric.  While the evidence for this 
intervention is certainly compelling [314, 315] such individuals are not 
necessarily all at equally high risk of progression to ESRD.  As discussed in 
chapter 1, it is now accepted that MA does not herald an inevitable progression 
towards decline in eGFR in all patients.  In fact, a significant proportion of 
patients will regress to normoalbuminuria over time [31, 33] and a number will 
remain within the MA stage without ever progressing further [30].  It could be 
argued therefore that strategies to identify individuals with persistent MA who 
are less likely to progress to ESRD may also be associated with some benefits, for 
example in patients who are intolerant of RAAS blocking agents, or who 
experience symptomatic hypotension while clinicians strive to achieve strict 
blood pressure targets.  
Previous publications have established a classifier threshold of 0.343 for 
diagnosis of DN [268].  The cohort included in this work had varying levels of 
albuminuria (median 103mg/24hrs) and by current clinical standards can 
therefore be assumed to have a degree of established underlying kidney disease 
despite preserved eGFR.  It is well known however that not all MA-positive 
patients will progress towards a decline in eGFR, and indeed 54% of the cohort 
described above had CKD273 score below the diagnostic cut-off for DN.   
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Prognostic potential cannot be inferred from cross-sectional analysis.  Previously 
published work where the classifier has been retrospectively applied to baseline 
samples from longitudinal studies has suggested that CKD273 could be a useful 
tool for prediction of later decline in eGFR; transition in albuminuria status; and 
even hard clinical outcomes such as progression to ESRD and mortality [289-292, 
296, 422].  The majority of these studies were relatively small, and included 
populations with notable diversity in terms of range of renal excretory function; 
UAE and aetiology of underlying CKD.  Moreover the findings have not been 
consistent and in healthier cohorts only small numbers of events were seen 
[291]. 
Work described in this chapter showed that the CKD273 classifier did not predict 
the primary endpoint of 30% reduction in eGFR in a cohort composed entirely of 
T2DM patients with median UAE in the microalbuminuric range but preserved 
renal function at baseline.  This finding was consistent when CKD273 was 
considered both as a categorical and continuous variable.  Traditional renal risk 
markers UAE and eGFR at baseline were, however, significantly associated with 
renal outcomes during follow up.  This finding is at odds with previously 
published work by Schanstra et al, who found that the classifier significantly 
improved prediction of CKD progression in a larger cohort of patients with 
similar UAE and eGFR at baseline [290].  However, this large cohort included 
patients with CKD of mixed aetiology and the investigators selected 5% decline in 
eGFR per year as the primary endpoint so it is not unexpected that more events 
were seen.  Furthermore this study reported receiver operating curve statistics 
and net reclassification indices but no formal survival analysis was carried out.  
More recently Pontillo et al reported data from 2672 patients with CKD held in 
Human Urinary Proteome database in order to assess the utility of the classifier 
for identification of rapid progressors (defined as decline in eGFR of greater than 
5ml/min/1.73m2 per year) at different disease stages.  This cohort also had UAE 
within the microalbuminuric range but preserved eGFR and were therefore 
clinically similar to the group described in this chapter.  Their analysis showed 
that the classifier outperformed UAE for identification of rapid progressors in the 
subpopulation with eGFR greater than 70ml/min/1.73m2; but its utility declined 
as disease stages advanced [292].  Once again, this was not a clinically 
homogeneous group as the underlying aetiology of CKD was varied and in 
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addition the results were based on receiver operating curve statistics rather than 
formal survival analysis.   
Although published work at a general population level has assessed the 
predictive performance of the classifier using Cox regression modelling [291] the 
study described within this chapter is the first to formally evaluate the 
predictive ability of CKD273 in a homogeneous cohort of T2DM patients using this 
statistical methodology.  The finding that UAE and eGFR at baseline were 
stronger predictors of renal survival is perhaps not surprising given that these 
patients had a degree of pre-existing renal disease and the power of the 
classifier appears to lie more with prediction of DN in lower-risk patients.  
However, in view of the fact that the majority of the subjects included in this 
work had micro- or macroalbuminuria the competing effects of cardiovascular 
events and mortality must also be considered, as it is often the case that 
individuals with DN die from cardiovascular events before ever progressing to 
ESRD [285, 385].  The work described within this chapter showed that CKD273 is 
not a predictor of a composite endpoint of cardiovascular events in T2DM 
patients with elevated UAE but preserved eGFR, however the classifier did 
specifically predict all-cause mortality.  The explanation for this finding is 
unclear but for a number of subjects the cause of death was unknown and it is 
therefore plausible that these could be cardiovascular deaths, particularly in 
view of the association between cardiovascular mortality and CKD, even in its 
very early stages [145].  Published data concerning the relationship between 
CKD273 and mortality are conflicting.  The results described in this chapter are 
in agreement with the work published by Argiles et al, who described an 
association between baseline CKD273 score and later mortality in a small cohort 
of patients with more advanced CKD of varied aetiology [289].  Conversely, a 
large general population level study found that CKD273 did not predict all-cause 
mortality [291].  However, participants included were younger and 
normoalbuminuric therefore the mean follow up period of 6 years may not have 
been adequate to address this question in a lower-risk cohort.    
Work described in chapter 5 of this thesis showed that in a cohort of 
normoalbuminuric T2DM patients CKD273 classifier score correlated with age, 
BMI and ACR but not with other traditional clinical parameters and together 
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these factors explained only 7.72% of the variability in classifier score.  Previous 
work in patients with more advanced established kidney disease has shown a 
strong negative association between eGFR and CKD273 [289, 422], a finding that 
was confirmed in the work described above.  Patients included in the current 
study had evidence of early stage established kidney disease but preserved renal 
excretory function.  In this population, CKD273 score was associated with eGFR, 
UAE and age.  However, these parameters explained only 30% of the variability 
in classifier score.  Taken together these data support the hypothesis that the 
CKD273 classifier may be providing prognostic information beyond traditional 
clinical parameters. 
Another aim of the study described in this chapter was to explore the 
relationships between individual peptides and renal parameters.  This question is 
particularly relevant in the context of the association between UAE and CKD273 
described both in this chapter and in published studies [289, 290] as this 
association has led many to speculate that CKD273 is simply a more sensitive 
albuminuria test.  Certainly the fact that a number of peptides captured by the 
classifier are albumin fragments would seem to support this argument.  Work 
described in this chapter has shown that only 77 of the 273 peptides captured by 
the classifier are associated with either eGFR or UAE, whilst the remaining 196 
are not.  Given that the studies contained within this thesis have shown 
repeatedly that only 10-30% of the variability in classifier score can be explained 
by traditional parameters, it seems intuitive that the 196 peptides not 
associated with renal function may indeed be conveying additional information 
beyond these conventional markers.  Furthermore, the patterns of association 
between individual peptides, UAE and eGFR are varied.  If the classifier were 
simply a more sensitive measure of albuminuria then surely it would be expected 
that scatterplots for all 54 peptides associated with UAE would show positive 
relationships.  Finally, although 54 individual peptides are associated with UAE 
and 23 with eGFR, only 4 peptides were found to be associated with both 
parameters.  The fact that there is virtually no overlap between these 
associations suggests that many individual peptides convey specific information 
about other pathophysiological mechanisms underlying the development of DN.     
For example, in the study by Schanstra and colleagues the peptide fragments 
displaying the strongest correlation with baseline eGFR were fragments of α1-
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antitrypsin; β2M; and collagen α1 (I) chain, whilst only α1-antitrypsin and serum 
albumin fragments were strongly associated with eGFR slope [290]. 
Strengths of this work include: recruitment of a more clinically homogeneous 
cohort of patients than many previously published studies; availability of 
longitudinal follow-up data; selection of a clinically relevant primary endpoint 
rather than surrogate markers; and determination of the predictive potential of 
the CKD273 classifier using formal survival analysis.  The study described within 
this chapter also has a number of limitations.  First, the original sample size was 
small and was further limited by sample availability at the time of selection.  
Second, although included participants were found to be microalbuminuric at 
screening there was a wide range of UAE at baseline, highlighting the variability 
of this parameter and meaning that a number of participants (at least 18%) could 
be considered to have established DN at inclusion as evidenced by UAE within 
the macroalbuminuric range.  Third, the small sample size translated into a low 
number of events, limiting the applicability of the survival analysis. 
In conclusion, the CKD273 urinary proteomic classifier was not a predictor of 
renal survival in this cohort of T2DM patients with elevated UAE.  However, 
CKD273 did predict mortality in this population and this competing effect may 
have resulted in a lower number of renal events.   
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8. Discussion 
8.1 The clinical context 
The prevalence of diabetes continues to rise at an alarming rate in both 
developed and developing countries.  This, in turn, has impacted on the 
development of DN which remains both one of the most frequent complications 
of the disease as well as ranking among the leading causes of ESRD worldwide.  
The economic impact of DN is staggering; both in terms of provision of RRT and 
the significant burden of cardiovascular morbidity and mortality associated with 
CKD and diabetes.  Despite devastating effects of DN on patients and their 
families as well as healthcare budgets and services our understanding of the 
pathogenesis and progression of the condition remains relatively limited, and 
standard clinical strategies for both treatment and prevention are largely 
unchanged since the landmark trials of the early 1990s highlighted the benefits 
of RAAS blocking agents in patients with MA or overt albuminuria. 
Even with widespread use of these agents a significant proportion of patients 
continue to progress to ESRD, leading some to speculate that earlier intervention 
in the pre-clinical stages of disease may offer additional benefits.  Clinical trials 
aiming to answer this question have generally shown that untargeted use of 
RAAS blocking agents in low-risk populations can delay the onset of MA, but with 
an associated cost in terms of side effects and adverse events meaning that this 
strategy is not endorsed by current clinical guidelines.  However, this then begs 
the question of whether early identification of “at risk” individuals and 
subsequently targeting preventative therapy in a personalised medicine 
approach may redress this balance?  Current clinical practice is centred on the 
detection of MA as an early clinical index of DN [144], however accumulating 
evidence in recent years has challenged the paradigm of basing practice solely 
on this single marker.  Although there is irrefutable evidence connecting 
absolute levels of UAE and its rate of change over time with development of DN 
[155, 165, 300] the specificity and sensitivity of MA as a single biomarker for 
early detection are limited.  The drive away from focussing on the traditional 
“albuminuric” pathway towards identification of novel disease pathways and 
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alternative risk markers has stimulated a surge of publications describing novel 
biomarkers for preclinical detection of DN, although none have yet made the 
transition into routine practice.  Accurate determination of risk is integral to 
clinical decision-making in order to facilitate formulation of the most 
appropriate management plan for each individual patient and it is therefore 
essential to critically evaluate all novel biomarkers according to predetermined 
standards if these are intended for use in the clinical setting [379, 459].  The 
work contained within this thesis therefore focussed on applying these 
predetermined evaluation standards to CKD273, a novel urinary proteomic 
biomarker which has shown potential as an early diagnostic indicator of DN. 
 
8.2 Unmet clinical need and potential novel 
therapeutic strategy 
The preliminary step in appraising a novel biomarker requires demonstration of 
an unmet clinical need and the availability of a suitable intervention.  The 
underpinning supporting evidence is outlined in the introduction to this thesis.  
As described in chapter 1, MA is often the first clinical marker to indicate early 
DN.  Despite being the current gold standard tool for monitoring response to 
treatment and determining prognosis, its sensitivity and specificity for early 
disease detection are limited.  Novel biomarkers are therefore required in order 
to facilitate identification of diabetic patients in the preliminary stages of DN 
development and thereby target preventative intervention towards those who 
stand to benefit most.  The search for clinically useful early markers of DN is 
hampered to a degree by the heterogeneity of the condition and its complex 
pathogenesis, likely involving simultaneous alterations in multiple mechanisms.  
As such, single biomarkers may be inadequate for precise recognition of at risk 
patients and exploration of multimarker strategies such as proteomics may prove 
more effective.   
Another key factor for consideration in biomarker development is the availability 
of effective therapeutic interventions to prevent or delay progression of the 
condition in question.  In the case of DN agents which act on the RAAS are the 
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current guideline-endorsed strategy for patients with clinically detectable MA 
[144] but despite their widespread use a proportion of patients continue to 
progress towards ESRD.  Recent years have seen a renewed interest in the role of 
the non-genomic effects of aldosterone in the initiation and progression of 
cardiovascular and renal disease through a variety of mechanisms including 
endothelial dysfunction; oxidative stress; fibrosis; and inflammation, with some 
suggesting that MRAs should be prescribed to all CKD patients akin to the 
prescribing of aspirin in ischaemic heart disease [466].  There remains a 
reluctance among clinicians to use these drugs in CKD patients in combination 
with ACE-I or ARB because of perceived risks of hyperkalaemia and decline in 
GFR [392, 393] and the combination is not currently endorsed by clinical 
guidelines.  The meta-analysis presented in chapter 3 served to determine 
whether these agents are a safe and effective therapeutic option for patients 
with CKD, in particular to more precisely determine effects on urinary protein or 
albumin excretion and to quantify the risk of clinically significant 
hyperkalaemia.  Using both published data and unpublished summary data 
obtained from authors of 19 trials the work described in chapter 3 is the largest 
and most comprehensive meta-analysis on this matter to date.  This work 
confirms that combining MRA with other RAAS blocking agents can offer 
substantial reductions of up to 31% in any measure of urinary protein or albumin 
excretion at the cost of small reduction in GFR and a three-fold increased risk of 
development of hyperkalaemia.  Although this seems clinically intolerable at 
first glance, the definition of hyperkalaemia in the majority of included studies 
was 5.5mmol/L, a value which would not trigger therapeutic intervention in 
routine clinical practice.  The incidence of clinically significant hyperkalaemia 
necessitating treatment was far lower.  When interpreted in the context of 
recent meta-analysis evidence that a 30% reduction in urinary protein or albumin 
excretion has the potential to confer a 23.7% reduction in risk of ESRD [156] this 
quantifiable risk of hyperkalaemia could be acceptable in certain circumstances.  
Furthermore, the recently published Mineralocorticoid Receptor Antagonist 
Tolerability Study in Diabetic Nephropathy (ARTS-DN) confirmed that use of the 
nonsteroidal MRA Finerenone offers significant reductions in albuminuria with a 
lower incidence of hyperkalaemia [415].  In addition, the relationship between 
proteinuria and cardiovascular outcomes must be considered.  While there is 
little published evidence that reductions in urinary protein or albumin excretion 
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translate into improved cardiovascular outcomes in patients with CKD and 
longterm studies focussing on hard clinical endpoints are lacking; a number of 
small studies, mainly in dialysis dependent patients, have shown beneficial 
effects on surrogate cardiovascular markers including cIMT [401], left ventricular 
mass [335, 399] and arterial stiffness [335, 340].  When considered in the 
context of the multitude of adverse effects of aldosterone on the cardiovascular 
system; the importance of minimising proteinuria to delay or prevent progression 
to ESRD; the potential clinical impact of novel agents such as Finerenone and 
aldosterone synthase inhibitors [467] ; and the direct relationship between 
proteinuria and cardiovascular risk; the evidence presented in chapter 3 
certainly justifies further evaluation of the longer term risks and benefits of MRA 
treatment in CKD patients.  Chapters 1 and 3 of this thesis therefore illustrate 
the preliminary stages of biomarker evaluation; demonstration of unmet clinical 
need and availability of a suitable intervention. 
 
8.3 Proof of concept and validation 
The second phase in biomarker evaluation requires demonstration that the 
biomarker in question can accurately identify the condition under study [379] 
and the pilot work described in chapter 4 of this thesis was designed in order to 
meet this criterion.  The study confirmed that the CKD273 urinary proteomic 
biomarker was indeed able to reliably distinguish normoalbuminuric T2DM 
patients from those with MA and overt DN.  Application of the predefined 
classifier threshold of 0.343 to the local test cohort resulted in identification of 
DN with sensitivity of 80% and specificity of 77%.  This work served to solidify the 
biological foundation for the CKD273 test as a DN risk marker and confirmed the 
critical diagnostic threshold, factors which underpin the conduct of the large 
scale multicentre prospective study described in chapter 5.  Moreover, such 
local level validation is essential to ensure that there has been no “overfitting” 
of the initial training set [268] and reproducibility of results is a key requirement 
for successful biomarker implementation.  The majority of statistical approaches 
used in biomarker discovery assume that findings can be generalised and that 
the biomarker is only associated with the condition under investigation.  As 
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these assumptions are not generally reflected in a “real world” setting, 
validation in independent cohorts is essential and the work presented in chapter 
4 served to ascertain the general clinical applicability of CKD273.   
The findings illustrated in chapter 4 are consistent with early published 
discovery data.  The first paper to describe the CKD273 biomarker highlighted its 
utility for diagnosis of CKD with sensitivity of 85.5% and specificity of 100% [268], 
a degree of accuracy that could not be fully replicated in the local validation 
study.  However, the work was based on samples from a heterogeneous group of 
patients with CKD of varying aetiology rather than pure diabetes-related disease 
and it is therefore not unexpected that diagnostic accuracy will vary in a more 
homogeneous cohort.  One key argument emerging from this discrepancy is of 
course that CKD273 may therefore not be the optimal biomarker for diagnosis of 
DN specifically.  This is undoubtedly true and the PRIORITY study [380] will serve 
to answer this question in due course.  It should be borne in mind, however, that 
DN itself is a heterogeneous condition and many patients with diabetes and CKD 
may have mixed aetiological factors including diabetes, hypertension and 
vascular disease contributing to renal dysfunction.  In addition, the multiple 
interacting pathophysiological mechanisms underpinning development of DN may 
limit the applicability of a single biomarker for diagnosis of such a complex 
condition.  As such, the concept of a multimarker “omics”-based strategy is 
appealing [468]. 
While CKD273 may indeed not be the ideal DN biomarker, the work outlined in 
chapter 4 is consistent with a 2014 multicentre validation study where 
application of the pre-determined classifier threshold of 0.343 accurately 
distinguished DN from diabetic controls with AUC varying between 0.9 and 1.0 
across 9 different centres [298] irrespective of patient age, gender or race.  
These results further support the stability of the classifier for identification of 
DN.  Of course both this study and the local validation work outlined in chapter 4 
identified a number of “false” positives.  Given what is known about the 
predictive potential of the classifier it could be argued that these false positives 
may in fact be true positives but simply at a very early, preclinical stage of 
disease detectable only by more sensitive means.  Such judgements cannot be 
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inferred from cross sectional work alone and biomarker evaluation also requires 
proof of incremental value beyond the current gold standard [379]. 
 
8.4 Incremental value beyond established risk markers 
The third phase in biomarker evaluation involves establishing whether additive 
information is conveyed by the biomarker in question over and above that 
obtained using the current guideline-endorsed parameters [379].  This point was 
addressed by the results set out in chapter 7, where the effectiveness of CKD273 
for prediction of hard clinical endpoints was determined in an independent 
cohort with a degree of established kidney disease as evidenced by albuminuria 
levels above the currently accepted “normal” range.  Although there is a small 
body of evidence which suggests that CKD273 may have predictive potential 
beyond traditional parameters such as UAE and eGFR the majority of these 
studies have been carried out in heterogeneous cohorts including CKD of varying 
aetiology as well as with a broad range of baseline renal function.  The study 
described in chapter 7 was the first to assess the predictive power of CKD273 in 
a cleaner cohort of patients with T2DM and elevated UAE.  This choice of cohort 
seemed a particularly relevant progression as it is well-established that not all 
individuals with MA progress to develop a decline in eGFR or reach ESRD, 
therefore if a novel biomarker could be used to identify individuals who are 
more or less likely to progress this information would have a great deal of 
clinical relevance in terms of directing preventative therapy.  Although survival 
analysis did not support the use of CKD273 to predict 30% reduction in eGFR over 
a 4 year follow up period the biomarker does appear to predict all-cause 
mortality in this sub-population.  The mechanisms underpinning this relationship 
are unclear but this finding is in keeping with other published studies in patients 
with more advanced kidney disease [289]. 
The results laid out in chapter 7 suggest that in T2DM patients with established 
kidney disease the CKD273 proteomic classifier does not perform well as a 
predictor of decline in eGFR.  The published literature evaluating the potential 
of CKD273 in that regard is limited; at the time the study described in chapter 7 
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was carried out only 2 small studies had evaluated the predictive capabilities of 
CKD273 in a purely diabetic population[295, 296].  Both these studies were small 
and focussed on surrogate endpoints rather than hard clinical outcomes.  
Moreover, neither used formal survival analysis to determine the predictive 
capabilities of the classifier.  Several additional studies have assessed the value 
of CKD273 in more heterogeneous populations with CKD of varying aetiology.  A 
small study in 76 patients with more advanced CKD found that classifier score 
above 0.55 predicted progression to dialysis and death over a 3 year follow up 
period [289].  In a larger cohort of 522 patients with CKD 1-3 and MA the 
classifier was shown to perform better than UAE for identification of patients 
whose kidney disease progressed more rapidly during follow up [290].  These 
findings were echoed in a recent large study including samples from 2672 
patients [292] although in general the predictive power was best in early stage 
CKD and declined from CKD 3 onwards.  Placing the results detailed in chapter 7 
in the context of the available literature it seems that if the classifier has value 
as a DN biomarker, this may be more evident in the earliest stages of disease, 
rather than in patients with established kidney disease.   
A further aspect to consider when evaluating the additive information provided 
by the CKD273 classifier is its relationship to clinical renal parameters in the 
regression models presented in chapter 5.  In this cohort of normoalbuminuric 
patients with T2DM there was a relatively large spread of classifier scores and 
CKD273 was associated with ACR on both univariate and multivariate analysis, 
yet this factor only explained a small proportion of the variability in CKD273 
score.  Furthermore, comparative data shown in chapter 6 did not demonstrate 
any major clinically relevant differences in baseline clinical parameters between 
“high” and “low” risk patients based on CKD273 classifier score.  If the 
hypothesis that CKD273 is indeed an early indicator of kidney disease proves to 
be correct, then the data shown in chapters 5 and 6 would seem to suggest that 
many other as yet unexplained factors contribute significantly to variability in 
classifier score and in this case it could indeed be argued that CKD273 provides 
some additional information beyond traditional parameters.  The PRIORITY trial 
[380] will determine in due course whether this hypothesis is indeed correct.   
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8.5 Clinical utility 
In order to make the transition from bench to bedside the clinical utility of a 
novel biomarker must also be rigorously assessed [379].  MA is the current 
guideline endorsed tool for determination of DN risk.  As well as being a marker 
of renal risk there is a large body of literature confirming its predictive value for 
cardiovascular morbidity and mortality across a number of different populations 
[469].  This could also be viewed as a limitation in terms of specificity, as it is 
difficult to determine whether an individual with MA will progress to DN, 
cardiovascular disease or both.  In order to be a clinically useful early indicator 
of DN, the ideal biomarker would have a high degree of specificity for the 
condition in question.  The work described in chapter 6 of this thesis was 
designed with this particular aspect of biomarker evaluation in mind as this 
question had not been addressed in previously published studies appraising 
CKD273.  The lack of association with clinical markers of vascular stiffness and 
subclinical atherosclerosis implies that CKD273 could indeed be a more specific 
early biomarker of renal disease, although of course it is impossible to 
disentangle this relationship completely in view of the cardiovascular risk 
associated with CKD as well as the fact that this was a cross-sectional study and 
prospective data confirming this conjecture are lacking.   
 
8.6 Clinical outcomes 
Definitive judgement of the clinical relevance of a novel biomarker hinges on 
whether use in clinical decision-making improves patient outcomes.  The 
ultimate test is a prospective, biomarker-guided randomised clinical trial where 
therapeutic strategy is determined by the biomarker under investigation.  The 
work contained within chapters 2 and 5 of this thesis illustrates the design, 
rationale and baseline characteristics of patients included in the PRIORITY trial 
[380].  This innovative prospective, proteomic biomarker-guided clinical trial 
was designed to determine whether CKD273 truly can outperform MA as an early 
biomarker for DN, and in addition will determine the impact of early 
intervention with MRAs on disease progression.  Whilst this doubtless represents 
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a significant step forward in clinical translation of proteomic biomarkers and will 
provide important data irrespective of the eventual outcome, it remains to be 
seen whether the relatively short follow up period will allow accumulation of 
clinically meaningful numbers of endpoints.  Furthermore, using development of 
MA as the primary endpoint requires reliance on surrogate biomarkers rather 
than hard clinical endpoints.  This raises the concept of whether use of surrogate 
markers is acceptable in prospective studies of conditions such as DN which can 
take many years to evolve, and would consequently require prolonged follow up 
in order to achieve the holy grail of a biomarker guided trial based on hard 
clinical outcomes.  Irrespective of its flaws as an early biomarker MA is the 
current guideline endorsed earliest clinical index of DN and remains the pivotal 
moment in an individual’s clinical course which results in the prescription of 
renoprotective therapy.  To that end, detection of MA is a clinically relevant 
surrogate endpoint which impacts on patient treatment in routine clinical 
practice.  It could be argued that the clinical need for early biomarkers is of 
more pressing importance that achieving flawless study design in the context of 
conditions such as DN with far-reaching clinical, social and economic 
implications.  Moreover, if the CKD273 panel does prove to be an effective early 
biomarker for DN this could itself have implications for the conduct of future 
clinical trials through identification of a higher-risk population for inclusion in 
studies, meaning smaller sample sizes and shorter durations of follow up would 
be required in order to accumulate endpoints.    
 
8.7 Unanswered questions 
Whilst CKD273 is undoubtedly the proteomic biomarker which so far has 
progressed furthest in the pathway to clinical implementation, a number of 
unanswered questions remain.  For instance, the cost effectiveness of routine 
population-level proteomic testing has yet to be determined.  At the time of 
writing proteomics is an expensive technique using specialised equipment which 
is not widely available and limited personnel are trained in is operation.  
Whether these costs are acceptable as a trade off with the financial burden 
associated with renal replacement therapy or hospitalisations for cardiovascular 
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disease in DN patients has yet to be formally evaluated.  Proteomics has 
potential not only as a diagnostic tool, but also as a means to improve our 
understanding of the pathophysiology of complex disease.  However, at present 
the significance of the appearance of individual peptides in the urine is not 
known; i.e. does the source protein itself play a pivotal role in the progression of 
DN, or is the particular peptide fragment and the means by which it is cleaved 
from the source protein by specific proteases of greater relevance?  Surely 
proteomic technologies cannot transition into routine clinical practice until the 
wealth of data generated by these techniques can be appropriately interpreted 
for maximum clinical exploitation.  Similarly, if the CKD273 biomarker is 
ultimately shown to identify patients who are at high risk of progression to DN, 
this begs the question of which phenotypic features differentiate these high risk 
individuals from the rest of the normoalbuminuric T2DM population.  From the 
work contained within this thesis neither traditional clinical parameters nor 
intermediate vascular phenotypes appear to be strikingly different between high 
and low risk groups according to proteomic classification.  Further work is 
therefore required in order to address this issue. 
 
8.8 Future perspectives 
A number of the findings described within this thesis merit further dissection.  
Firstly, the genetics of DN remain largely unexplored.  It is well known that 
diabetic complications cluster in families and shared phenotypes have been 
demonstrated in both twin and offspring studies, as such the importance of 
family history cannot be underplayed.  At present, details of family history are 
not collected as part of the PRIORITY study baseline visit however collecting 
these data retrospectively at subsequent visits would add a further interesting 
dimension to the trial.  Second, the majority of peptides captured in the CKD273 
classifier are differentially regulated collagen fragments; mainly collagens type I 
and III.  Although in the case of CKD273 the classifier was developed purely as a 
biomarker rather than a tool to delve into disease mechanisms, it is attractive to 
speculate that these data highlight the key role of collagen metabolism in the 
early genesis of DN.  It is well known of course that thickening of the GBM is one 
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of the earliest histological signs of DN, however the GBM is largely comprised of 
collagen type IV, with types I and III found in higher quantities in the 
vasculature.  Identifying the source of these fragments of collagens type I and III 
could therefore offer novel mechanistic insights into DN development, as well 
the link between renal disease and the vasculature.  The wealth of peptide data 
obtained from a CE-MS run can also be exploited to explore protease activity in 
greater details and quantifying changes in MMP activity in early disease could 
translate into identification of novel therapeutic targets for DN prevention.  
Thirdly, although few statistically significant differences were identified 
between “high” and “low risk” subjects in the analysis presented in chapter 6, a 
number of numerical differences would be considered clinically significant.  For 
example BMI, systolic and diastolic BP and cholesterol were numerically higher in 
patients with CKD273 score above the threshold for identification of DN 
suggesting a possible link between DN risk and features of the metabolic 
syndrome.  This finding merits longitudinal examination when data are available 
upon completion of the trial.  Finally, as detailed in chapter 7, CKD273 was not 
found to be predictive of a 30% GFR decline in T2DM patients with elevated UAE.  
This was perhaps not unexpected in view of the small number of events and 
short follow up duration, and is in support of the use of CKD273 as biomarker in 
early, preclinical DN.  However, exploration of the relationship between CKD273 
and alternative renal endpoints such as change in GFR may be of interest.  
Furthermore, including intermediate vascular phenotypes in the analysis may 
help to tease out the interesting mortality finding further. 
 
8.9 Conclusion 
Translation of any novel biomarker or panel of biomarkers from discovery in the 
laboratory into routine clinical practice is a prolonged process requiring a 
number of necessary validation and evaluation steps.  Not only should the 
biomarker’s clinical worth be rigorously tested, it is imperative that appropriate 
treatment strategies can be offered to those patients deemed “at risk”, 
otherwise the ethics of pre-clinical diagnosis could be questioned if no specific 
intervention is available.  The work contained within this thesis takes the 
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CKD273 biomarker from discovery, through validation steps which ultimately 
informed the implementation of a large-scale biomarker guided prospective 
clinical trial.  The studies described herein have confirmed the availability of a 
treatment which could be effective in reducing risk of progression to overt DN if 
used in selected patients, and demonstrated that the CKD273 biomarker may 
indeed have potential to identify these patients at an early stage.  Moreover 
these are the first studies to evaluate the relationship between CKD273 and 
intermediate vascular phenotypes, an intuitive question given that much of the 
panel is composed of differentially regulated collagens, the origins of which are 
not yet clear.  Time, and the PRIORITY trial, will tell whether CKD273 truly is a 
clinically useful early DN biomarker which could be a game-changer in clinical 
management of normoalbuminuric T2DM patients who are traditionally 
considered to be at low risk of progressive renal disease and not routinely 
offered preventative therapies.  Regardless of the eventual outcome of the trial, 
PRIORITY represents a unique and innovative concept for evaluation of a 
proteomic biomarker and highlights the far-reaching future potential of “omics” 
technologies in offering truly personalised medicine.   
  
273 
 
 
9. References 
1 International Diabetes Federation (2015) IDF Atlas, 7th Edition. Brussels, 
Belgium 
2 Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. 
L. and Zelmanovitz, T. (2005) Diabetic nephropathy: diagnosis, prevention, 
and treatment. Diabetes Care. 28, 164-176 
3 Ritz, E., Rychlik, I., Locatelli, F. and Halimi, S. (1999) End-stage renal 
failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. 
Am J Kidney Dis. 34, 795-808 
4 Collins, A. J., Foley, R. N., Chavers, B., et al. (2012) United States Renal 
Data System 2011 Annual Data Report: Atlas of chronic kidney disease & 
end-stage renal disease in the United States. Am J Kidney Dis. 59, A7, e1-
420 
5 Reutens, A. T. and Atkins, R. C. (2011) Epidemiology of diabetic 
nephropathy. Contrib Nephrol. 170, 1-7 
6 Groop, P. H., Thomas, M. C., Moran, J. L., et al. (2009) The presence and 
severity of chronic kidney disease predicts all-cause mortality in type 1 
diabetes. Diabetes. 58, 1651-1658 
7 Adler, A. I., Stevens, R. J., Manley, S. E., et al. (2003) Development and 
progression of nephropathy in type 2 diabetes: the United Kingdom 
Prospective Diabetes Study (UKPDS 64). Kidney Int. 63, 225-232 
8 Mogensen, C. E., Christensen, C. K. and Vittinghus, E. (1983) The stages in 
diabetic renal disease. With emphasis on the stage of incipient diabetic 
nephropathy. Diabetes. 32 Suppl 2, 64-78 
9 Jerums, G., Premaratne, E., Panagiotopoulos, S. and MacIsaac, R. J. (2010) 
The clinical significance of hyperfiltration in diabetes. Diabetologia. 53, 
2093-2104 
10 Amin, R., Turner, C., van Aken, S., et al. (2005) The relationship between 
microalbuminuria and glomerular filtration rate in young type 1 diabetic 
subjects: The Oxford Regional Prospective Study. Kidney Int. 68, 1740-1749 
11 Chaiken, R. L., Eckert-Norton, M., Bard, M., et al. (1998) Hyperfiltration in 
African-American patients with type 2 diabetes. Cross-sectional and 
longitudinal data. Diabetes Care. 21, 2129-2134 
12 Brenner, B. M., Lawler, E. V. and Mackenzie, H. S. (1996) The 
hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 49, 1774-
1777 
13 Vallon, V., Richter, K., Blantz, R. C., Thomson, S. and Osswald, H. (1999) 
Glomerular hyperfiltration in experimental diabetes mellitus: potential role 
of tubular reabsorption. J Am Soc Nephrol. 10, 2569-2576 
14 Mogensen, C. E., Steffes, M. W., Deckert, T. and Christiansen, J. S. (1981) 
Functional and morphological renal manifestations in diabetes mellitus. 
Diabetologia. 21, 89-93 
274 
 
 
15 Wiseman, M. J., Saunders, A. J., Keen, H. and Viberti, G. (1985) Effect of 
blood glucose control on increased glomerular filtration rate and kidney 
size in insulin-dependent diabetes. N Engl J Med. 312, 617-621 
16 Magee, G. M., Bilous, R. W., Cardwell, C. R., Hunter, S. J., Kee, F. and 
Fogarty, D. G. (2009) Is hyperfiltration associated with the future risk of 
developing diabetic nephropathy? A meta-analysis. Diabetologia. 52, 691-
697 
17 Tervaert, T. W., Mooyaart, A. L., Amann, K., et al. (2010) Pathologic 
classification of diabetic nephropathy. J Am Soc Nephrol. 21, 556-563 
18 Mauer, S. M., Steffes, M. W., Ellis, E. N., Sutherland, D. E., Brown, D. M. 
and Goetz, F. C. (1984) Structural-functional relationships in diabetic 
nephropathy. J Clin Invest. 74, 1143-1155 
19 Steinke, J. M., Sinaiko, A. R., Kramer, M. S., et al. (2005) The early natural 
history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary 
albumin excretion rate patterns in initially normoalbuminuric patients. 
Diabetes. 54, 2164-2171 
20 Vart, P., Scheven, L., Lambers Heerspink, H. J., et al. (2016) Urine 
albumin-creatinine ratio versus albumin excretion for albuminuria staging: 
a prospective longitudinal cohort study. Am J Kidney Dis. 67, 70-78 
21 Mogensen, C. E. (1984) Microalbuminuria predicts clinical proteinuria and 
early mortality in maturity-onset diabetes. N Engl J Med. 310, 356-360 
22 Parving, H. H., Oxenboll, B., Svendsen, P. A., Christiansen, J. S. and 
Andersen, A. R. (1982) Early detection of patients at risk of developing 
diabetic nephropathy. A longitudinal study of urinary albumin excretion. 
Acta Endocrinol (Copenh). 100, 550-555 
23 Schwartz, M. M., Lewis, E. J., Leonard-Martin, T., Lewis, J. B. and Batlle, 
D. (1998) Renal pathology patterns in type II diabetes mellitus: relationship 
with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant. 
13, 2547-2552 
24 Najafian, B., Kim, Y., Crosson, J. T. and Mauer, M. (2003) Atubular 
glomeruli and glomerulotubular junction abnormalities in diabetic 
nephropathy. J Am Soc Nephrol. 14, 908-917 
25 White, K. E., Marshall, S. M. and Bilous, R. W. (2008) Prevalence of 
atubular glomeruli in type 2 diabetic patients with nephropathy. Nephrol 
Dial Transplant. 23, 3539-3545 
26 White, K. E., Marshall, S. M. and Bilous, R. W. (2007) Are glomerular 
volume differences between type 1 and type 2 diabetic patients 
pathologically significant? Diabetologia. 50, 906-912 
27 An, Y., Xu, F., Le, W., et al. (2015) Renal histologic changes and the 
outcome in patients with diabetic nephropathy. Nephrol Dial Transplant. 
30, 257-266 
28 Viberti, G. C., Jarrett, R. J. and Keen, H. (1982) Microalbuminuria as 
prediction of nephropathy in diabetics. Lancet. 2, 611 
29 Mogensen, C. E. and Christensen, C. K. (1984) Predicting diabetic 
nephropathy in insulin-dependent patients. N Engl J Med. 311, 89-93 
275 
 
 
30 Rossing, P., Hougaard, P. and Parving, H. H. (2005) Progression of 
microalbuminuria in type 1 diabetes: ten-year prospective observational 
study. Kidney Int. 68, 1446-1450 
31 Perkins, B. A., Ficociello, L. H., Silva, K. H., Finkelstein, D. M., Warram, J. 
H. and Krolewski, A. S. (2003) Regression of microalbuminuria in type 1 
diabetes. N Engl J Med. 348, 2285-2293 
32 Giorgino, F., Laviola, L., Cavallo Perin, P., Solnica, B., Fuller, J. and 
Chaturvedi, N. (2004) Factors associated with progression to 
macroalbuminuria in microalbuminuric Type 1 diabetic patients: the 
EURODIAB Prospective Complications Study. Diabetologia. 47, 1020-1028 
33 Gaede, P., Tarnow, L., Vedel, P., Parving, H. H. and Pedersen, O. (2004) 
Remission to normoalbuminuria during multifactorial treatment preserves 
kidney function in patients with type 2 diabetes and microalbuminuria. 
Nephrol Dial Transplant. 19, 2784-2788 
34 Yamada, T., Komatsu, M., Komiya, I., et al. (2005) Development, 
progression, and regression of microalbuminuria in Japanese patients with 
type 2 diabetes under tight glycemic and blood pressure control: the 
Kashiwa study. Diabetes Care. 28, 2733-2738 
35 Araki, S., Haneda, M., Sugimoto, T., et al. (2005) Factors associated with 
frequent remission of microalbuminuria in patients with type 2 diabetes. 
Diabetes. 54, 2983-2987 
36 Costacou, T., Ellis, D., Fried, L. and Orchard, T. J. (2007) Sequence of 
progression of albuminuria and decreased GFR in persons with type 1 
diabetes: a cohort study. Am J Kidney Dis. 50, 721-732 
37 Perkins, B. A., Ficociello, L. H., Ostrander, B. E., et al. (2007) 
Microalbuminuria and the risk for early progressive renal function decline in 
type 1 diabetes. J Am Soc Nephrol. 18, 1353-1361 
38 Perkins, B. A., Ficociello, L. H., Roshan, B., Warram, J. H. and Krolewski, 
A. S. (2010) In patients with type 1 diabetes and new-onset 
microalbuminuria the development of advanced chronic kidney disease may 
not require progression to proteinuria. Kidney Int. 77, 57-64 
39 Skupien, J., Warram, J. H., Smiles, A. M., et al. (2012) The early decline in 
renal function in patients with type 1 diabetes and proteinuria predicts the 
risk of end-stage renal disease. Kidney Int. 82, 589-597 
40 Pavkov, M. E., Knowler, W. C., Lemley, K. V., Mason, C. C., Myers, B. D. 
and Nelson, R. G. (2012) Early renal function decline in type 2 diabetes. 
Clin J Am Soc Nephrol. 7, 78-84 
41 Krolewski, A. S., Niewczas, M. A., Skupien, J., et al. (2014) Early 
progressive renal decline precedes the onset of microalbuminuria and its 
progression to macroalbuminuria. Diabetes Care. 37, 226-234 
42 Pugliese, G. (2014) Updating the natural history of diabetic nephropathy. 
Acta Diabetol. 51, 905-915 
43 Dwyer, J. P., Parving, H. H., Hunsicker, L. G., Ravid, M., Remuzzi, G. and 
Lewis, J. B. (2012) Renal Dysfunction in the Presence of Normoalbuminuria 
in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal Med. 2, 1-
10 
276 
 
 
44 Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., Holman, R. R. and 
Group, U. S. (2006) Risk factors for renal dysfunction in type 2 diabetes: 
U.K. Prospective Diabetes Study 74. Diabetes. 55, 1832-1839 
45 Thomas, M. C., Macisaac, R. J., Jerums, G., et al. (2009) Nonalbuminuric 
renal impairment in type 2 diabetic patients and in the general population 
(national evaluation of the frequency of renal impairment cO-existing with 
NIDDM [NEFRON] 11). Diabetes Care. 32, 1497-1502 
46 Penno, G., Solini, A., Bonora, E., et al. (2011) Clinical significance of 
nonalbuminuric renal impairment in type 2 diabetes. J Hypertens. 29, 1802-
1809 
47 Molitch, M. E., Steffes, M., Sun, W., et al. (2010) Development and 
progression of renal insufficiency with and without albuminuria in adults 
with type 1 diabetes in the diabetes control and complications trial and the 
epidemiology of diabetes interventions and complications study. Diabetes 
Care. 33, 1536-1543 
48 Yokoyama, H., Sone, H., Oishi, M., et al. (2009) Prevalence of albuminuria 
and renal insufficiency and associated clinical factors in type 2 diabetes: 
the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial 
Transplant. 24, 1212-1219 
49 Penno, G., Solini, A., Zoppini, G., et al. (2012) Rate and determinants of 
association between advanced retinopathy and chronic kidney disease in 
patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular 
Events (RIACE) Italian multicenter study. Diabetes Care. 35, 2317-2323 
50 Macisaac, R. J. and Jerums, G. (2011) Diabetic kidney disease with and 
without albuminuria. Curr Opin Nephrol Hypertens. 20, 246-257 
51 Ekinci, E. I., Jerums, G., Skene, A., et al. (2013) Renal structure in 
normoalbuminuric and albuminuric patients with type 2 diabetes and 
impaired renal function. Diabetes Care. 36, 3620-3626 
52 James, M. T., Grams, M. E., Woodward, M., et al. (2015) A Meta-analysis of 
the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and 
Hypertension With Acute Kidney Injury. Am J Kidney Dis. 66, 602-612 
53 Pavenstadt, H., Kriz, W. and Kretzler, M. (2003) Cell biology of the 
glomerular podocyte. Physiol Rev. 83, 253-307 
54 Obeidat, M., Obeidat, M. and Ballermann, B. J. (2012) Glomerular 
endothelium: a porous sieve and formidable barrier. Exp Cell Res. 318, 964-
972 
55 Weinbaum, S., Tarbell, J. M. and Damiano, E. R. (2007) The structure and 
function of the endothelial glycocalyx layer. Annu Rev Biomed Eng. 9, 121-
167 
56 Miner, J. H. (2012) The glomerular basement membrane. Exp Cell Res. 318, 
973-978 
57 Mora-Fernandez, C., Dominguez-Pimentel, V., de Fuentes, M. M., Gorriz, J. 
L., Martinez-Castelao, A. and Navarro-Gonzalez, J. F. (2014) Diabetic 
kidney disease: from physiology to therapeutics. J Physiol. 592, 3997-4012 
58 The Diabetes Control and Complications Trial Research Group (1993) The 
effect of intensive treatment of diabetes on the development and 
277 
 
 
progression of long-term complications in insulin-dependent diabetes 
mellitus. N Engl J Med. 329, 977-986 
59 UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-
glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 
33). Lancet. 352, 837-853 
60 Mauer, S. M., Steffes, M. W., Connett, J., Najarian, J. S., Sutherland, D. E. 
and Barbosa, J. (1983) The development of lesions in the glomerular 
basement membrane and mesangium after transplantation of normal 
kidneys to diabetic patients. Diabetes. 32, 948-952 
61 Kaiser, N., Sasson, S., Feener, E. P., et al. (1993) Differential regulation of 
glucose transport and transporters by glucose in vascular endothelial and 
smooth muscle cells. Diabetes. 42, 80-89 
62 Brownlee, M. (2005) The pathobiology of diabetic complications: a unifying 
mechanism. Diabetes. 54, 1615-1625 
63 Geraldes, P. and King, G. L. (2010) Activation of protein kinase C isoforms 
and its impact on diabetic complications. Circ Res. 106, 1319-1331 
64 Ahmed, N. (2005) Advanced glycation endproducts--role in pathology of 
diabetic complications. Diabetes Res Clin Pract. 67, 3-21 
65 Steffes, M. W., Osterby, R., Chavers, B. and Mauer, S. M. (1989) Mesangial 
expansion as a central mechanism for loss of kidney function in diabetic 
patients. Diabetes. 38, 1077-1081 
66 Ruiz-Ortega, M. and Egido, J. (1997) Angiotensin II modulates cell growth-
related events and synthesis of matrix proteins in renal interstitial 
fibroblasts. Kidney Int. 52, 1497-1510 
67 Han, D. C., Isono, M., Hoffman, B. B. and Ziyadeh, F. N. (1999) High 
glucose stimulates proliferation and collagen type I synthesis in renal 
cortical fibroblasts: mediation by autocrine activation of TGF-beta. J Am 
Soc Nephrol. 10, 1891-1899 
68 van Det, N. F., Verhagen, N. A., Tamsma, J. T., et al. (1997) Regulation of 
glomerular epithelial cell production of fibronectin and transforming 
growth factor-beta by high glucose, not by angiotensin II. Diabetes. 46, 
834-840 
69 Thrailkill, K. M., Clay Bunn, R. and Fowlkes, J. L. (2009) Matrix 
metalloproteinases: their potential role in the pathogenesis of diabetic 
nephropathy. Endocrine. 35, 1-10 
70 Nee, L., Tuite, N., Ryan, M. P. and McMorrow, T. (2007) TNF-alpha and IL-1 
beta-mediated regulation of MMP-9 and TIMP-1 in human glomerular 
mesangial cells. Nephron Exp Nephrol. 107, e73-86 
71 McLennan, S. V., Kelly, D. J., Schache, M., et al. (2007) Advanced glycation 
end products decrease mesangial cell MMP-7: a role in matrix accumulation 
in diabetic nephropathy? Kidney Int. 72, 481-488 
72 Qing-Hua, G., Ju-Ming, L., Chang-Yu, P., Zhao-Hui, L., Xiao-Man, Z. and Yi-
Ming, M. (2008) The kidney expression of matrix metalloproteinase-9 in the 
diabetic nephropathy of Kkay mice. J Diabetes Complications. 22, 408-412 
278 
 
 
73 Tashiro, K., Koyanagi, I., Ohara, I., et al. (2004) Levels of urinary matrix 
metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 
diabetic nephropathy. J Clin Lab Anal. 18, 206-210 
74 Nakamura, T., Ushiyama, C., Suzuki, S., et al. (2000) Urinary excretion of 
podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 
15, 1379-1383 
75 Cheng, S., Pollock, A. S., Mahimkar, R., Olson, J. L. and Lovett, D. H. 
(2006) Matrix metalloproteinase 2 and basement membrane integrity: a 
unifying mechanism for progressive renal injury. FASEB J. 20, 1898-1900 
76 Takamiya, Y., Fukami, K., Yamagishi, S., et al. (2013) Experimental 
diabetic nephropathy is accelerated in matrix metalloproteinase-2 
knockout mice. Nephrol Dial Transplant. 28, 55-62 
77 McLennan, S. V., Wang, X. Y., Moreno, V., Yue, D. K. and Twigg, S. M. 
(2004) Connective tissue growth factor mediates high glucose effects on 
matrix degradation through tissue inhibitor of matrix metalloproteinase 
type 1: implications for diabetic nephropathy. Endocrinology. 145, 5646-
5655 
78 Rysz, J., Banach, M., Stolarek, R. A., et al. (2007) Serum matrix 
metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue 
inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol. 20, 444-
452 
79 Peeters, S. A., Engelen, L., Buijs, J., et al. (2015) Plasma levels of matrix 
metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 
are associated with vascular complications in patients with type 1 diabetes: 
the EURODIAB Prospective Complications Study. Cardiovasc Diabetol. 14, 31 
80 Cai, G., Zhang, X., Hong, Q., et al. (2008) Tissue inhibitor of 
metalloproteinase-1 exacerbated renal interstitial fibrosis through 
enhancing inflammation. Nephrol Dial Transplant. 23, 1861-1875 
81 Ries, C. (2014) Cytokine functions of TIMP-1. Cell Mol Life Sci. 71, 659-672 
82 Lopez, B., Gonzalez, A. and Diez, J. (2010) Circulating biomarkers of 
collagen metabolism in cardiac diseases. Circulation. 121, 1645-1654 
83 Fishman, A. P. (1982) Endothelium: a distributed organ of diverse 
capabilities. Ann N Y Acad Sci. 401, 1-8 
84 Quyyumi, A. A. (1998) Endothelial function in health and disease: new 
insights into the genesis of cardiovascular disease. Am J Med. 105, 32S-39S 
85 Goldberg, R. B. (2009) Cytokine and cytokine-like inflammation markers, 
endothelial dysfunction, and imbalanced coagulation in development of 
diabetes and its complications. J Clin Endocrinol Metab. 94, 3171-3182 
86 De Caterina, R., Libby, P., Peng, H. B., et al. (1995) Nitric oxide decreases 
cytokine-induced endothelial activation. Nitric oxide selectively reduces 
endothelial expression of adhesion molecules and proinflammatory 
cytokines. J Clin Invest. 96, 60-68 
87 Garg, U. C. and Hassid, A. (1989) Nitric oxide-generating vasodilators and 
8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and 
proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83, 
1774-1777 
279 
 
 
88 Speed, J. S. and Pollock, D. M. (2013) Endothelin, kidney disease, and 
hypertension. Hypertension. 61, 1142-1145 
89 Cines, D. B., Pollak, E. S., Buck, C. A., et al. (1998) Endothelial cells in 
physiology and in the pathophysiology of vascular disorders. Blood. 91, 
3527-3561 
90 Flammer, A. J., Anderson, T., Celermajer, D. S., et al. (2012) The 
assessment of endothelial function: from research into clinical practice. 
Circulation. 126, 753-767 
91 Giugliano, D., Marfella, R., Coppola, L., et al. (1997) Vascular effects of 
acute hyperglycemia in humans are reversed by L-arginine. Evidence for 
reduced availability of nitric oxide during hyperglycemia. Circulation. 95, 
1783-1790 
92 Bucala, R., Tracey, K. J. and Cerami, A. (1991) Advanced glycosylation 
products quench nitric oxide and mediate defective endothelium-
dependent vasodilatation in experimental diabetes. J Clin Invest. 87, 432-
438 
93 Takahashi, K., Ghatei, M. A., Lam, H. C., O'Halloran, D. J. and Bloom, S. R. 
(1990) Elevated plasma endothelin in patients with diabetes mellitus. 
Diabetologia. 33, 306-310 
94 Caballero, S., Sengupta, N., Afzal, A., et al. (2007) Ischemic vascular 
damage can be repaired by healthy, but not diabetic, endothelial 
progenitor cells. Diabetes. 56, 960-967 
95 Huvers, F. C., De Leeuw, P. W., Houben, A. J., et al. (1999) Endothelium-
dependent vasodilatation, plasma markers of endothelial function, and 
adrenergic vasoconstrictor responses in type 1 diabetes under near-
normoglycemic conditions. Diabetes. 48, 1300-1307 
96 Jager, A., van Hinsbergh, V. W., Kostense, P. J., et al. (1999) von 
Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and 
nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol. 19, 
3071-3078 
97 Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, T. and 
Kofoed-Enevoldsen, A. (1989) Albuminuria reflects widespread vascular 
damage. The Steno hypothesis. Diabetologia. 32, 219-226 
98 Targher, G., Bertolini, L., Zoppini, G., Zenari, L. and Falezza, G. (2005) 
Increased plasma markers of inflammation and endothelial dysfunction and 
their association with microvascular complications in Type 1 diabetic 
patients without clinically manifest macroangiopathy. Diabet Med. 22, 999-
1004 
99 Matsumoto, K., Sera, Y., Ueki, Y., Inukai, G., Niiro, E. and Miyake, S. 
(2002) Comparison of serum concentrations of soluble adhesion molecules 
in diabetic microangiopathy and macroangiopathy. Diabet Med. 19, 822-826 
100 Yilmaz, M. I., Saglam, M., Qureshi, A. R., et al. (2008) Endothelial 
dysfunction in type-2 diabetics with early diabetic nephropathy is 
associated with low circulating adiponectin. Nephrol Dial Transplant. 23, 
1621-1627 
280 
 
 
101 Astrup, A. S., Tarnow, L., Pietraszek, L., et al. (2008) Markers of 
endothelial dysfunction and inflammation in type 1 diabetic patients with 
or without diabetic nephropathy followed for 10 years: association with 
mortality and decline of glomerular filtration rate. Diabetes Care. 31, 1170-
1176 
102 Persson, F., Rossing, P., Hovind, P., et al. (2008) Endothelial dysfunction 
and inflammation predict development of diabetic nephropathy in the 
Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) 
study. Scand J Clin Lab Invest. 68, 731-738 
103 Stehouwer, C. D., Gall, M. A., Twisk, J. W., Knudsen, E., Emeis, J. J. and 
Parving, H. H. (2002) Increased urinary albumin excretion, endothelial 
dysfunction, and chronic low-grade inflammation in type 2 diabetes: 
progressive, interrelated, and independently associated with risk of death. 
Diabetes. 51, 1157-1165 
104 Makino, H., Doi, K., Hiuge, A., et al. (2008) Impaired flow-mediated 
vasodilatation and insulin resistance in type 2 diabetic patients with 
albuminuria. Diabetes Res Clin Pract. 79, 177-182 
105 Stehouwer, C. D., Henry, R. M., Dekker, J. M., Nijpels, G., Heine, R. J. and 
Bouter, L. M. (2004) Microalbuminuria is associated with impaired brachial 
artery, flow-mediated vasodilation in elderly individuals without and with 
diabetes: further evidence for a link between microalbuminuria and 
endothelial dysfunction--the Hoorn Study. Kidney Int Suppl, S42-44 
106 Stehouwer, C. D., Yudkin, J. S., Fioretto, P. and Nosadini, R. (1998) How 
heterogeneous is microalbuminuria in diabetes mellitus? The case for 
'benign' and 'malignant' microalbuminuria. Nephrol Dial Transplant. 13, 
2751-2754 
107 Sibal, L., Aldibbiat, A., Agarwal, S. C., et al. (2009) Circulating endothelial 
progenitor cells, endothelial function, carotid intima-media thickness and 
circulating markers of endothelial dysfunction in people with type 1 
diabetes without macrovascular disease or microalbuminuria. Diabetologia. 
52, 1464-1473 
108 Lopes-Virella, M. F., Baker, N. L., Hunt, K. J., et al. (2013) Baseline 
markers of inflammation are associated with progression to 
macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 36, 2317-2323 
109 Stehouwer, C. D. (2004) Endothelial dysfunction in diabetic nephropathy: 
state of the art and potential significance for non-diabetic renal disease. 
Nephrol Dial Transplant. 19, 778-781 
110 Morgan, T. (2003) Renin, angiotensin, sodium and organ damage. Hypertens 
Res. 26, 349-354 
111 Widdop, R. E., Matrougui, K., Levy, B. I. and Henrion, D. (2002) AT2 
receptor-mediated relaxation is preserved after long-term AT1 receptor 
blockade. Hypertension. 40, 516-520 
112 Rocha, R., Stier, C. T., Jr., Kifor, I., et al. (2000) Aldosterone: a mediator 
of myocardial necrosis and renal arteriopathy. Endocrinology. 141, 3871-
3878 
281 
 
 
113 Romagni, P., Rossi, F., Guerrini, L., Quirini, C. and Santiemma, V. (2003) 
Aldosterone induces contraction of the resistance arteries in man. 
Atherosclerosis. 166, 345-349 
114 Navar, L. G., Inscho, E. W., Majid, S. A., Imig, J. D., Harrison-Bernard, L. 
M. and Mitchell, K. D. (1996) Paracrine regulation of the renal 
microcirculation. Physiol Rev. 76, 425-536 
115 Quan, A. and Baum, M. (1996) Endogenous production of angiotensin II 
modulates rat proximal tubule transport. J Clin Invest. 97, 2878-2882 
116 Singh, R., Alavi, N., Singh, A. K. and Leehey, D. J. (1999) Role of 
angiotensin II in glucose-induced inhibition of mesangial matrix 
degradation. Diabetes. 48, 2066-2073 
117 Zimpelmann, J., Kumar, D., Levine, D. Z., et al. (2000) Early diabetes 
mellitus stimulates proximal tubule renin mRNA expression in the rat. 
Kidney Int. 58, 2320-2330 
118 Wehbi, G. J., Zimpelmann, J., Carey, R. M., Levine, D. Z. and Burns, K. D. 
(2001) Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 
receptors. Am J Physiol Renal Physiol. 280, F254-265 
119 Awad, A. S., Webb, R. L., Carey, R. M. and Siragy, H. M. (2004) Renal nitric 
oxide production is decreased in diabetic rats and improved by AT1 
receptor blockade. J Hypertens. 22, 1571-1577 
120 Sharma, K., Eltayeb, B. O., McGowan, T. A., et al. (1999) Captopril-induced 
reduction of serum levels of transforming growth factor-beta1 correlates 
with long-term renoprotection in insulin-dependent diabetic patients. Am J 
Kidney Dis. 34, 818-823 
121 Uhrenholt, T. R., Schjerning, J., Hansen, P. B., et al. (2003) Rapid 
inhibition of vasoconstriction in renal afferent arterioles by aldosterone. 
Circ Res. 93, 1258-1266 
122 Kimura, G., Saito, F., Kojima, S., et al. (1987) Renal function curve in 
patients with secondary forms of hypertension. Hypertension. 10, 11-15 
123 Hollenberg, N. K. (2004) Aldosterone in the development and progression of 
renal injury. Kidney Int. 66, 1-9 
124 Sun, Y., Zhang, J., Zhang, J. Q. and Ramires, F. J. (2000) Local angiotensin 
II and transforming growth factor-beta1 in renal fibrosis of rats. 
Hypertension. 35, 1078-1084 
125 Lee, S. H., Yoo, T. H., Nam, B. Y., et al. (2009) Activation of local 
aldosterone system within podocytes is involved in apoptosis under diabetic 
conditions. Am J Physiol Renal Physiol. 297, F1381-1390 
126 Brown, N. J., Agirbasli, M. A., Williams, G. H., Litchfield, W. R. and 
Vaughan, D. E. (1998) Effect of activation and inhibition of the renin-
angiotensin system on plasma PAI-1. Hypertension. 32, 965-971 
127 Siragy, H. M. and Xue, C. (2008) Local renal aldosterone production induces 
inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol. 
93, 817-824 
128 Lu, Y., Ku, E. and Campese, V. M. (2010) Aldosterone in the pathogenesis 
of chronic kidney disease and proteinuria. Curr Hypertens Rep. 12, 303-306 
282 
 
 
129 Halimi, J. M. and Mimran, A. (1995) Albuminuria in untreated patients with 
primary aldosteronism or essential hypertension. J Hypertens. 13, 1801-
1802 
130 Ribstein, J., Du Cailar, G., Fesler, P. and Mimran, A. (2005) Relative 
glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 16, 
1320-1325 
131 Bomback, A. S. and Klemmer, P. J. (2007) The incidence and implications 
of aldosterone breakthrough. Nat.Clin.Pract.Nephrol. 3, 486-492 
132 Yoneda, T., Takeda, Y., Usukura, M., et al. (2007) Aldosterone 
breakthrough during angiotensin II receptor blockade in hypertensive 
patients with diabetes mellitus. Am J Hypertens. 20, 1329-1333 
133 Schjoedt, K. J., Andersen, S., Rossing, P., Tarnow, L. and Parving, H. H. 
(2004) Aldosterone escape during blockade of the renin-angiotensin-
aldosterone system in diabetic nephropathy is associated with enhanced 
decline in glomerular filtration rate. Diabetologia. 47, 1936-1939 
134 Moranne, O., Bakris, G., Fafin, C., Favre, G., Pradier, C. and Esnault, V. L. 
(2013) Determinants and changes associated with aldosterone breakthrough 
after angiotensin II receptor blockade in patients with type 2 diabetes with 
overt nephropathy. Clin.J.Am.Soc.Nephrol. 8, 1694-1701 
135 Schmidt, B. M., Sammer, U., Fleischmann, I., Schlaich, M., Delles, C. and 
Schmieder, R. E. (2006) Rapid nongenomic effects of aldosterone on the 
renal vasculature in humans. Hypertension. 47, 650-655 
136 Ziyadeh, F. N. and Wolf, G. (2008) Pathogenesis of the podocytopathy and 
proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 4, 39-45 
137 Zatz, R., Dunn, B. R., Meyer, T. W., Anderson, S., Rennke, H. G. and 
Brenner, B. M. (1986) Prevention of diabetic glomerulopathy by 
pharmacological amelioration of glomerular capillary hypertension. J Clin 
Invest. 77, 1925-1930 
138 Gnudi, L., Thomas, S. M. and Viberti, G. (2007) Mechanical forces in 
diabetic kidney disease: a trigger for impaired glucose metabolism. J Am 
Soc Nephrol. 18, 2226-2232 
139 Ikee, R., Kobayashi, S., Hemmi, N., et al. (2005) Correlation between the 
resistive index by Doppler ultrasound and kidney function and histology. Am 
J Kidney Dis. 46, 603-609 
140 Heine, G. H., Reichart, B., Ulrich, C., Kohler, H. and Girndt, M. (2007) Do 
ultrasound renal resistance indices reflect systemic rather than renal 
vascular damage in chronic kidney disease? Nephrol Dial Transplant. 22, 
163-170 
141 Nosadini, R., Velussi, M., Brocco, E., et al. (2006) Increased renal arterial 
resistance predicts the course of renal function in type 2 diabetes with 
microalbuminuria. Diabetes. 55, 234-239 
142 Bruno, R. M., Daghini, E., Landini, L., et al. (2011) Dynamic evaluation of 
renal resistive index in normoalbuminuric patients with newly diagnosed 
hypertension or type 2 diabetes. Diabetologia. 54, 2430-2439 
283 
 
 
143 Leon, C. A. and Raij, L. (2005) Interaction of haemodynamic and metabolic 
pathways in the genesis of diabetic nephropathy. J Hypertens. 23, 1931-
1937 
144 KDIGO. (2013) KDIGO 2012 Clinical Practice Guideline for Evaluation and 
Management of Chronic Kidney Disease. Kidney International Supplements. 
3, 73-90 
145 Ninomiya, T., Perkovic, V., de Galan, B. E., et al. (2009) Albuminuria and 
kidney function independently predict cardiovascular and renal outcomes in 
diabetes. J Am Soc Nephrol. 20, 1813-1821 
146 Stevens, L. A. and Levey, A. S. (2009) Measured GFR as a confirmatory test 
for estimated GFR. J Am Soc Nephrol. 20, 2305-2313 
147 Stevens, L. A., Coresh, J., Feldman, H. I., et al. (2007) Evaluation of the 
modification of diet in renal disease study equation in a large diverse 
population. J Am Soc Nephrol. 18, 2749-2757 
148 Michels, W. M., Grootendorst, D. C., Verduijn, M., Elliott, E. G., Dekker, F. 
W. and Krediet, R. T. (2010) Performance of the Cockcroft-Gault, MDRD, 
and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am 
Soc Nephrol. 5, 1003-1009 
149 Levey, A. S., Stevens, L. A., Schmid, C. H., et al. (2009) A new equation to 
estimate glomerular filtration rate. Ann Intern Med. 150, 604-612 
150 Ishani, A., Grandits, G. A., Grimm, R. H., et al. (2006) Association of single 
measurements of dipstick proteinuria, estimated glomerular filtration rate, 
and hematocrit with 25-year incidence of end-stage renal disease in the 
multiple risk factor intervention trial. J Am Soc Nephrol. 17, 1444-1452 
151 Tuttle, K. R., Bakris, G. L., Bilous, R. W., et al. (2014) Diabetic Kidney 
Disease: A Report From an ADA Consensus Conference. Diabetes Care. 37, 
2864-2883 
152 Camargo, E. G., Soares, A. A., Detanico, A. B., et al. (2011) The Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is less 
accurate in patients with Type 2 diabetes when compared with healthy 
individuals. Diabet Med. 28, 90-95 
153 Guidone, C., Gniuli, D., Castagneto-Gissey, L., et al. (2012) 
Underestimation of urinary albumin to creatinine ratio in morbidly obese 
subjects due to high urinary creatinine excretion. Clin Nutr. 31, 212-216 
154 Gansevoort, R. T., Matsushita, K., van der Velde, M., et al. (2011) Lower 
estimated GFR and higher albuminuria are associated with adverse kidney 
outcomes. A collaborative meta-analysis of general and high-risk population 
cohorts. Kidney Int. 80, 93-104 
155 Astor, B. C., Matsushita, K., Gansevoort, R. T., et al. (2011) Lower 
estimated glomerular filtration rate and higher albuminuria are associated 
with mortality and end-stage renal disease. A collaborative meta-analysis 
of kidney disease population cohorts. Kidney Int. 79, 1331-1340 
156 Lambers Heerspink, H. J., Kropelin, T. F., Hoekman, J. and de Zeeuw, D. 
(2015) Drug-Induced Reduction in Albuminuria Is Associated with 
Subsequent Renoprotection: A Meta-Analysis. J Am Soc Nephrol. 26, 2055-
2064 
284 
 
 
157 de Zeeuw, D., Remuzzi, G., Parving, H. H., et al. (2004) Albuminuria, a 
therapeutic target for cardiovascular protection in type 2 diabetic patients 
with nephropathy. Circulation. 110, 921-927 
158 Yokoyama, H., Araki, S., Haneda, M., et al. (2012) Chronic kidney disease 
categories and renal-cardiovascular outcomes in type 2 diabetes without 
prevalent cardiovascular disease: a prospective cohort study (JDDM25). 
Diabetologia. 55, 1911-1918 
159 Bruno, G., Merletti, F., Bargero, G., et al. (2007) Estimated glomerular 
filtration rate, albuminuria and mortality in type 2 diabetes: the Casale 
Monferrato study. Diabetologia. 50, 941-948 
160 Hillege, H. L., Fidler, V., Diercks, G. F., et al. (2002) Urinary albumin 
excretion predicts cardiovascular and noncardiovascular mortality in 
general population. Circulation. 106, 1777-1782 
161 Rossing, P., Hougaard, P., Borch-Johnsen, K. and Parving, H. H. (1996) 
Predictors of mortality in insulin dependent diabetes: 10 year observational 
follow up study. BMJ. 313, 779-784 
162 Stadler, M., Auinger, M., Anderwald, C., et al. (2006) Long-term mortality 
and incidence of renal dialysis and transplantation in type 1 diabetes 
mellitus. J Clin Endocrinol Metab. 91, 3814-3820 
163 de Boer, I. H., Rue, T. C., Cleary, P. A., et al. (2011) Long-term renal 
outcomes of patients with type 1 diabetes mellitus and microalbuminuria: 
an analysis of the Diabetes Control and Complications Trial/Epidemiology of 
Diabetes Interventions and Complications cohort. Arch Intern Med. 171, 
412-420 
164 Fioretto, P., Steffes, M. W. and Mauer, M. (1994) Glomerular structure in 
nonproteinuric IDDM patients with various levels of albuminuria. Diabetes. 
43, 1358-1364 
165 Babazono, T., Nyumura, I., Toya, K., et al. (2009) Higher levels of urinary 
albumin excretion within the normal range predict faster decline in 
glomerular filtration rate in diabetic patients. Diabetes Care. 32, 1518-1520 
166 Klausen, K., Borch-Johnsen, K., Feldt-Rasmussen, B., et al. (2004) Very low 
levels of microalbuminuria are associated with increased risk of coronary 
heart disease and death independently of renal function, hypertension, and 
diabetes. Circulation. 110, 32-35 
167 Ogawa, Y., Goto, T., Tamasawa, N., et al. (2008) Serum cystatin C in 
diabetic patients. Not only an indicator for renal dysfunction in patients 
with overt nephropathy but also a predictor for cardiovascular events in 
patients without nephropathy. Diabetes Res Clin Pract. 79, 357-361 
168 Laterza, O. F., Price, C. P. and Scott, M. G. (2002) Cystatin C: an improved 
estimator of glomerular filtration rate? Clin Chem. 48, 699-707 
169 Stevens, L. A., Coresh, J., Schmid, C. H., et al. (2008) Estimating GFR using 
serum cystatin C alone and in combination with serum creatinine: a pooled 
analysis of 3,418 individuals with CKD. Am J Kidney Dis. 51, 395-406 
170 Shastri, S., Katz, R., Shlipak, M. G., et al. (2011) Cystatin C and 
albuminuria as risk factors for development of CKD stage 3: the Multi-
Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 57, 832-840 
285 
 
 
171 McNamara, N. V., Chen, R., Janu, M. R., Bwititi, P., Car, G. and Seibel, M. 
(2009) Early renal failure detection by cystatin C in Type 2 diabetes 
mellitus: varying patterns of renal analyte expression. Pathology. 41, 269-
275 
172 Kazumi, T., Hozumi, T., Ishida, Y., et al. (1999) Increased urinary 
transferrin excretion predicts microalbuminuria in patients with type 2 
diabetes. Diabetes Care. 22, 1176-1180 
173 Jerums, G., Allen, T. J. and Cooper, M. E. (1989) Triphasic changes in 
selectivity with increasing proteinuria in type 1 and type 2 diabetes. Diabet 
Med. 6, 772-779 
174 Jerums, G., Cooper, M. E., Seeman, E., Murray, R. M. and McNeil, J. J. 
(1987) Spectrum of proteinuria in type I and type II diabetes. Diabetes 
Care. 10, 419-427 
175 Narita, T., Hosoba, M., Kakei, M. and Ito, S. (2006) Increased urinary 
excretions of immunoglobulin g, ceruloplasmin, and transferrin predict 
development of microalbuminuria in patients with type 2 diabetes. 
Diabetes Care. 29, 142-144 
176 Kanauchi, M., Akai, Y. and Hashimoto, T. (2002) Transferrinuria in type 2 
diabetic patients with early nephropathy and tubulointerstitial injury. Eur J 
Intern Med. 13, 190-193 
177 Yaqoob, M., McClelland, P., Patrick, A. W., Stevenson, A., Mason, H. and 
Bell, G. M. (1995) Tubular damage in microalbuminuric patients with 
primary glomerulonephritis and diabetic nephropathy. Ren Fail. 17, 43-49 
178 Katavetin, P., Katavetin, P., Susantitaphong, P., et al. (2010) Urinary type 
IV collagen excretion predicts subsequent declining renal function in type 2 
diabetic patients with proteinuria. Diabetes Res Clin Pract. 89, e33-35 
179 Araki, S., Haneda, M., Koya, D., et al. (2010) Association between urinary 
type IV collagen level and deterioration of renal function in type 2 diabetic 
patients without overt proteinuria. Diabetes Care. 33, 1805-1810 
180 Kado, S., Aoki, A., Wada, S., et al. (1996) Urinary type IV collagen as a 
marker for early diabetic nephropathy. Diabetes Res Clin Pract. 31, 103-108 
181 Yamazaki, M., Ito, S., Usami, A., et al. (1995) Urinary excretion rate of 
ceruloplasmin in non-insulin-dependent diabetic patients with different 
stages of nephropathy. Eur J Endocrinol. 132, 681-687 
182 Meyer, T. W., Bennett, P. H. and Nelson, R. G. (1999) Podocyte number 
predicts long-term urinary albumin excretion in Pima Indians with Type II 
diabetes and microalbuminuria. Diabetologia. 42, 1341-1344 
183 White, K. E., Bilous, R. W. and Diabiopsies Study, G. (2004) Structural 
alterations to the podocyte are related to proteinuria in type 2 diabetic 
patients. Nephrol Dial Transplant. 19, 1437-1440 
184 Dalla Vestra, M., Masiero, A., Roiter, A. M., Saller, A., Crepaldi, G. and 
Fioretto, P. (2003) Is podocyte injury relevant in diabetic nephropathy? 
Studies in patients with type 2 diabetes. Diabetes. 52, 1031-1035 
185 Kandasamy, Y., Smith, R., Lumbers, E. R. and Rudd, D. (2014) Nephrin - a 
biomarker of early glomerular injury. Biomark Res. 2, 21 
286 
 
 
186 Patari, A., Forsblom, C., Havana, M., Taipale, H., Groop, P. H. and 
Holthofer, H. (2003) Nephrinuria in diabetic nephropathy of type 1 
diabetes. Diabetes. 52, 2969-2974 
187 Ng, D. P., Tai, B. C., Tan, E., et al. (2011) Nephrinuria associates with 
multiple renal traits in type 2 diabetes. Nephrol Dial Transplant. 26, 2508-
2514 
188 Petrica, L., Vlad, A., Gluhovschi, G., et al. (2014) Proximal tubule 
dysfunction is associated with podocyte damage biomarkers nephrin and 
vascular endothelial growth factor in type 2 diabetes mellitus patients: a 
cross-sectional study. PLoS One. 9, e112538 
189 Hara, M., Yamagata, K., Tomino, Y., et al. (2012) Urinary podocalyxin is an 
early marker for podocyte injury in patients with diabetes: establishment 
of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia. 55, 
2913-2919 
190 Bolignano, D., Donato, V., Coppolino, G., et al. (2008) Neutrophil 
gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J 
Kidney Dis. 52, 595-605 
191 Yang, Y. H., He, X. J., Chen, S. R., Wang, L., Li, E. M. and Xu, L. Y. (2009) 
Changes of serum and urine neutrophil gelatinase-associated lipocalin in 
type-2 diabetic patients with nephropathy: one year observational follow-
up study. Endocrine. 36, 45-51 
192 Bolignano, D., Lacquaniti, A., Coppolino, G., et al. (2009) Neutrophil 
gelatinase-associated lipocalin as an early biomarker of nephropathy in 
diabetic patients. Kidney Blood Press Res. 32, 91-98 
193 Fu, W. J., Li, B. L., Wang, S. B., et al. (2012) Changes of the tubular 
markers in type 2 diabetes mellitus with glomerular hyperfiltration. 
Diabetes Res Clin Pract. 95, 105-109 
194 Nielsen, S. E., Reinhard, H., Zdunek, D., et al. (2012) Tubular markers are 
associated with decline in kidney function in proteinuric type 2 diabetic 
patients. Diabetes Res Clin Pract. 97, 71-76 
195 Nielsen, S. E., Andersen, S., Zdunek, D., Hess, G., Parving, H. H. and 
Rossing, P. (2011) Tubular markers do not predict the decline in glomerular 
filtration rate in type 1 diabetic patients with overt nephropathy. Kidney 
Int. 79, 1113-1118 
196 Conway, B. R., Manoharan, D., Manoharan, D., et al. (2012) Measuring 
urinary tubular biomarkers in type 2 diabetes does not add prognostic value 
beyond established risk factors. Kidney Int. 82, 812-818 
197 Vaidya, V. S., Niewczas, M. A., Ficociello, L. H., et al. (2011) Regression of 
microalbuminuria in type 1 diabetes is associated with lower levels of 
urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-
beta-D-glucosaminidase. Kidney Int. 79, 464-470 
198 Looker, H. C., Colombo, M., Hess, S., et al. (2015) Biomarkers of rapid 
chronic kidney disease progression in type 2 diabetes. Kidney Int. 88, 888-
896 
287 
 
 
199 Panduru, N. M., Sandholm, N., Forsblom, C., et al. (2015) Kidney injury 
molecule-1 and the loss of kidney function in diabetic nephropathy: a likely 
causal link in patients with type 1 diabetes. Diabetes Care. 38, 1130-1137 
200 Kern, E. F., Erhard, P., Sun, W., Genuth, S. and Weiss, M. F. (2010) Early 
urinary markers of diabetic kidney disease: a nested case-control study 
from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis. 
55, 824-834 
201 Weitgasser, R., Schnoell, F., Gappmayer, B. and Kartnig, I. (1999) 
Prospective evaluation of urinary N-acetyl-beta-D-glucosaminidase with 
respect to macrovascular disease in elderly type 2 diabetic patients. 
Diabetes Care. 22, 1882-1886 
202 Martin, P., Hampton, K. K., Walton, C., Tindall, H. and Davies, J. A. (1990) 
Microproteinuria in type 2 diabetes mellitus from diagnosis. Diabet Med. 7, 
315-318 
203 Hong, C. Y., Hughes, K., Chia, K. S., Ng, V. and Ling, S. L. (2003) Urinary 
alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian 
subjects in Singapore. Diabetes Care. 26, 338-342 
204 Koh, K. T., Chia, K. S. and Tan, C. (1993) Proteinuria and enzymuria in non-
insulin-dependent diabetics. Diabetes Res Clin Pract. 20, 215-221 
205 Hong, C. Y., Chia, K. S. and Ling, S. L. (2000) Urinary protein excretion in 
Type 2 diabetes with complications. J Diabetes Complications. 14, 259-265 
206 Kalansooriya, A., Holbrook, I., Jennings, P. and Whiting, P. H. (2007) Serum 
cystatin C, enzymuria, tubular proteinuria and early renal insult in type 2 
diabetes. Br J Biomed Sci. 64, 121-123 
207 Mahfouz, M. H., Assiri, A. M. and Mukhtar, M. H. (2016) Assessment of 
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Retinol-Binding 
Protein 4 (RBP4) in Type 2 Diabetic Patients with Nephropathy. Biomark 
Insights. 11, 31-40 
208 Ikenaga, H., Suzuki, H., Ishii, N., Itoh, H. and Saruta, T. (1993) Enzymuria 
in non-insulin-dependent diabetic patients: signs of tubular cell 
dysfunction. Clin Sci (Lond). 84, 469-475 
209 De Carvalho, J. A., Bochi, G. V., Sangoi, M. B. and Moresco, R. N. (2012) 
Assessment of urinary gamma-glutamyltransferase in type 2 diabetic 
patients with glomerular hyperfiltration. Clin Chim Acta. 413, 817-818 
210 Kamijo, A., Sugaya, T., Hikawa, A., et al. (2004) Urinary excretion of fatty 
acid-binding protein reflects stress overload on the proximal tubules. Am J 
Pathol. 165, 1243-1255 
211 Nielsen, S. E., Sugaya, T., Tarnow, L., et al. (2009) Tubular and glomerular 
injury in diabetes and the impact of ACE inhibition. Diabetes Care. 32, 
1684-1688 
212 Chou, K. M., Lee, C. C., Chen, C. H. and Sun, C. Y. (2013) Clinical value of 
NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes 
mellitus patients. PLoS One. 8, e54863 
213 Kottgen, A., Glazer, N. L., Dehghan, A., et al. (2009) Multiple loci 
associated with indices of renal function and chronic kidney disease. Nat 
Genet. 41, 712-717 
288 
 
 
214 Below, A. A., Chakraborty, J., Khuder, S. H. and Haselhuhn, G. D. (1999) 
Evaluation of urinary Tamm-Horsfall protein in post-menopausal diabetic 
women. J Diabetes Complications. 13, 204-210 
215 Torffvit, O. and Agardh, C. D. (1993) Tubular secretion of Tamm-Horsfall 
protein is decreased in type 1 (insulin-dependent) diabetic patients with 
diabetic nephropathy. Nephron. 65, 227-231 
216 Torffvit, O., Agardh, C. D. and Thulin, T. (1999) A study of Tamm-Horsfall 
protein excretion in hypertensive patients and type 1 diabetic patients. 
Scand J Urol Nephrol. 33, 187-191 
217 Schlatzer, D., Maahs, D. M., Chance, M. R., et al. (2012) Novel urinary 
protein biomarkers predicting the development of microalbuminuria and 
renal function decline in type 1 diabetes. Diabetes Care. 35, 549-555 
218 Pfleiderer, S., Zimmerhackl, L. B., Kinne, R., Manz, F., Schuler, G. and 
Brandis, M. (1993) Renal proximal and distal tubular function is attenuated 
in diabetes mellitus type 1 as determined by the renal excretion of alpha 1-
microglobulin and Tamm-Horsfall protein. Clin Investig. 71, 972-977 
219 Navarro, J. F. and Mora-Fernandez, C. (2006) The role of TNF-alpha in 
diabetic nephropathy: pathogenic and therapeutic implications. Cytokine 
Growth Factor Rev. 17, 441-450 
220 Radeke, H. H., Meier, B., Topley, N., Floge, J., Habermehl, G. G. and 
Resch, K. (1990) Interleukin 1-alpha and tumor necrosis factor-alpha induce 
oxygen radical production in mesangial cells. Kidney Int. 37, 767-775 
221 Navarro, J. F., Mora, C., Gomez, M., Muros, M., Lopez-Aguilar, C. and 
Garcia, J. (2008) Influence of renal involvement on peripheral blood 
mononuclear cell expression behaviour of tumour necrosis factor-alpha and 
interleukin-6 in type 2 diabetic patients. Nephrol Dial Transplant. 23, 919-
926 
222 Navarro, J. F., Mora, C., Maca, M. and Garca, J. (2003) Inflammatory 
parameters are independently associated with urinary albumin in type 2 
diabetes mellitus. Am J Kidney Dis. 42, 53-61 
223 Niewczas, M. A., Ficociello, L. H., Johnson, A. C., et al. (2009) Serum 
concentrations of markers of TNFalpha and Fas-mediated pathways and 
renal function in nonproteinuric patients with type 1 diabetes. Clin J Am 
Soc Nephrol. 4, 62-70 
224 Gohda, T., Niewczas, M. A., Ficociello, L. H., et al. (2012) Circulating TNF 
receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 
23, 516-524 
225 Niewczas, M. A., Gohda, T., Skupien, J., et al. (2012) Circulating TNF 
receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol. 23, 
507-515 
226 Pavkov, M. E., Weil, E. J., Fufaa, G. D., et al. (2016) Tumor necrosis factor 
receptors 1 and 2 are associated with early glomerular lesions in type 2 
diabetes. Kidney Int. 89, 226-234 
227 Ridker, P. M., Rifai, N., Stampfer, M. J. and Hennekens, C. H. (2000) 
Plasma concentration of interleukin-6 and the risk of future myocardial 
infarction among apparently healthy men. Circulation. 101, 1767-1772 
289 
 
 
228 Shankar, A., Sun, L., Klein, B. E., et al. (2011) Markers of inflammation 
predict the long-term risk of developing chronic kidney disease: a 
population-based cohort study. Kidney Int. 80, 1231-1238 
229 Dalla Vestra, M., Mussap, M., Gallina, P., et al. (2005) Acute-phase markers 
of inflammation and glomerular structure in patients with type 2 diabetes. 
J Am Soc Nephrol. 16 Suppl 1, S78-82 
230 Giunti, S., Tesch, G. H., Pinach, S., et al. (2008) Monocyte 
chemoattractant protein-1 has prosclerotic effects both in a mouse model 
of experimental diabetes and in vitro in human mesangial cells. 
Diabetologia. 51, 198-207 
231 Wada, T., Furuichi, K., Sakai, N., et al. (2000) Up-regulation of monocyte 
chemoattractant protein-1 in tubulointerstitial lesions of human diabetic 
nephropathy. Kidney Int. 58, 1492-1499 
232 Tashiro, K., Koyanagi, I., Saitoh, A., et al. (2002) Urinary levels of 
monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and 
renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 
16, 1-4 
233 Morii, T., Fujita, H., Narita, T., et al. (2003) Association of monocyte 
chemoattractant protein-1 with renal tubular damage in diabetic 
nephropathy. J Diabetes Complications. 17, 11-15 
234 Pickup, J. C., Mattock, M. B., Chusney, G. D. and Burt, D. (1997) NIDDM as 
a disease of the innate immune system: association of acute-phase 
reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 40, 
1286-1292 
235 Gomes, M. B. and Nogueira, V. G. (2004) Acute-phase proteins and 
microalbuminuria among patients with type 2 diabetes. Diabetes Res Clin 
Pract. 66, 31-39 
236 Jiang, H., Guan, G., Zhang, R., et al. (2009) Increased urinary excretion of 
orosomucoid is a risk predictor of diabetic nephropathy. Nephrology 
(Carlton). 14, 332-337 
237 Wu, L. L., Chiou, C. C., Chang, P. Y. and Wu, J. T. (2004) Urinary 8-OHdG: 
a marker of oxidative stress to DNA and a risk factor for cancer, 
atherosclerosis and diabetics. Clin Chim Acta. 339, 1-9 
238 Hinokio, Y., Suzuki, S., Hirai, M., Chiba, M., Hirai, A. and Toyota, T. (1999) 
Oxidative DNA damage in diabetes mellitus: its association with diabetic 
complications. Diabetologia. 42, 995-998 
239 Hinokio, Y., Suzuki, S., Hirai, M., Suzuki, C., Suzuki, M. and Toyota, T. 
(2002) Urinary excretion of 8-oxo-7, 8-dihydro-2'-deoxyguanosine as a 
predictor of the development of diabetic nephropathy. Diabetologia. 45, 
877-882 
240 Ogawa, S., Mori, T., Nako, K., Kato, T., Takeuchi, K. and Ito, S. (2006) 
Angiotensin II type 1 receptor blockers reduce urinary oxidative stress 
markers in hypertensive diabetic nephropathy. Hypertension. 47, 699-705 
241 Daimon, M., Ono, Y., Saito, T., et al. (1999) Increased serum levels of 
pentosidine, but not carboxymethyl lysine, in type 2 diabetes without 
obvious diabetic nephropathy. Diabetes Care. 22, 877-878 
290 
 
 
242 Daimon, M., Sugiyama, K., Kameda, W., et al. (2003) Increased urinary 
levels of pentosidine, pyrraline and acrolein adduct in type 2 diabetes. 
Endocr J. 50, 61-67 
243 Calabrese, V., Mancuso, C., Sapienza, M., et al. (2007) Oxidative stress and 
cellular stress response in diabetic nephropathy. Cell Stress Chaperones. 
12, 299-306 
244 Piarulli, F., Sartore, G., Ceriello, A., et al. (2009) Relationship between 
glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic 
patients. Diabetologia. 52, 1419-1425 
245 Tanji, N., Markowitz, G. S., Fu, C., et al. (2000) Expression of advanced 
glycation end products and their cellular receptor RAGE in diabetic 
nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 11, 1656-
1666 
246 Seaquist, E. R., Goetz, F. C., Rich, S. and Barbosa, J. (1989) Familial 
clustering of diabetic kidney disease. Evidence for genetic susceptibility to 
diabetic nephropathy. N Engl J Med. 320, 1161-1165 
247 Canani, L. H., Gerchman, F. and Gross, J. L. (1999) Familial clustering of 
diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes. 48, 
909-913 
248 Family Investigation of Nephropathy and Diabetes Research Group., N. and 
Diabetes Research, G. (2003) Genetic determinants of diabetic 
nephropathy: the family investigation of nephropathy and diabetes (FIND). 
J Am Soc Nephrol. 14, S202-204 
249 Igo, R. P., Jr., Iyengar, S. K., Nicholas, S. B., et al. (2011) Genomewide 
linkage scan for diabetic renal failure and albuminuria: the FIND study. Am 
J Nephrol. 33, 381-389 
250 Mueller, P. W., Rogus, J. J., Cleary, P. A., et al. (2006) Genetics of Kidneys 
in Diabetes (GoKinD) study: a genetics collection available for identifying 
genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J 
Am Soc Nephrol. 17, 1782-1790 
251 Pezzolesi, M. G., Poznik, G. D., Mychaleckyj, J. C., et al. (2009) Genome-
wide association scan for diabetic nephropathy susceptibility genes in type 
1 diabetes. Diabetes. 58, 1403-1410 
252 Germain, M., Pezzolesi, M. G., Sandholm, N., et al. (2015) SORBS1 gene, a 
new candidate for diabetic nephropathy: results from a multi-stage 
genome-wide association study in patients with type 1 diabetes. 
Diabetologia. 58, 543-548 
253 Mooyaart, A. L., Valk, E. J., van Es, L. A., et al. (2011) Genetic associations 
in diabetic nephropathy: a meta-analysis. Diabetologia. 54, 544-553 
254 Zhao, Y. Y. (2013) Metabolomics in chronic kidney disease. Clin Chim Acta. 
422, 59-69 
255 Shah, V. O., Townsend, R. R., Feldman, H. I., Pappan, K. L., Kensicki, E. 
and Vander Jagt, D. L. (2013) Plasma metabolomic profiles in different 
stages of CKD. Clin J Am Soc Nephrol. 8, 363-370 
291 
 
 
256 Hirayama, A., Nakashima, E., Sugimoto, M., et al. (2012) Metabolic 
profiling reveals new serum biomarkers for differentiating diabetic 
nephropathy. Anal Bioanal Chem. 404, 3101-3109 
257 Zhang, J., Yan, L., Chen, W., et al. (2009) Metabonomics research of 
diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-
MS system. Anal Chim Acta. 650, 16-22 
258 Pena, M. J., Lambers Heerspink, H. J., Hellemons, M. E., et al. (2014) 
Urine and plasma metabolites predict the development of diabetic 
nephropathy in individuals with Type 2 diabetes mellitus. Diabet Med. 31, 
1138-1147 
259 Kenyon, G. L., DeMarini, D. M., Fuchs, E., et al. (2002) Defining the 
mandate of proteomics in the post-genomics era: workshop report. Mol Cell 
Proteomics. 1, 763-780 
260 Kim, M. S., Pinto, S. M., Getnet, D., et al. (2014) A draft map of the human 
proteome. Nature. 509, 575-581 
261 Paik, Y. K., Jeong, S. K., Omenn, G. S., et al. (2012) The Chromosome-
Centric Human Proteome Project for cataloging proteins encoded in the 
genome. Nat Biotechnol. 30, 221-223 
262 Kolch, W., Neususs, C., Pelzing, M. and Mischak, H. (2005) Capillary 
electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis 
and biomarker discovery. Mass Spectrom Rev. 24, 959-977 
263 Fliser, D., Novak, J., Thongboonkerd, V., et al. (2007) Advances in urinary 
proteome analysis and biomarker discovery. J Am Soc Nephrol. 18, 1057-
1071 
264 Dakna, M., He, Z., Yu, W. C., Mischak, H. and Kolch, W. (2009) Technical, 
bioinformatical and statistical aspects of liquid chromatography-mass 
spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-
MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt 
Technol Biomed Life Sci. 877, 1250-1258 
265 Wright, E. P., Prasad, K. A., Padula, M. P. and Coorssen, J. R. (2014) Deep 
imaging: how much of the proteome does current top-down technology 
already resolve? PLoS One. 9, e86058 
266 Purohit, S., Podolsky, R., Schatz, D., et al. (2006) Assessing the utility of 
SELDI-TOF and model averaging for serum proteomic biomarker discovery. 
Proteomics. 6, 6405-6415 
267 Pontillo, C., Filip, S., Borras, D. M., Mullen, W., Vlahou, A. and Mischak, H. 
(2015) CE-MS-based proteomics in biomarker discovery and clinical 
application. Proteomics Clin Appl. 9, 322-334 
268 Good, D. M., Zurbig, P., Argiles, A., et al. (2010) Naturally occurring human 
urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell 
Proteomics. 9, 2424-2437 
269 Lepedda, A. J., Cigliano, A., Cherchi, G. M., et al. (2009) A proteomic 
approach to differentiate histologically classified stable and unstable 
plaques from human carotid arteries. Atherosclerosis. 203, 112-118 
292 
 
 
270 de Kleijn, D. P., Moll, F. L., Hellings, W. E., et al. (2010) Local 
atherosclerotic plaques are a source of prognostic biomarkers for adverse 
cardiovascular events. Arterioscler Thromb Vasc Biol. 30, 612-619 
271 Jin, X., Xia, L., Wang, L. S., et al. (2006) Differential protein expression in 
hypertrophic heart with and without hypertension in spontaneously 
hypertensive rats. Proteomics. 6, 1948-1956 
272 Lindsey, M. L., Goshorn, D. K., Comte-Walters, S., et al. (2006) A 
multidimensional proteomic approach to identify hypertrophy-associated 
proteins. Proteomics. 6, 2225-2235 
273 Gallego-Delgado, J., Lazaro, A., Osende, J. I., et al. (2006) Proteomic 
analysis of early left ventricular hypertrophy secondary to hypertension: 
modulation by antihypertensive therapies. J Am Soc Nephrol. 17, S159-164 
274 Dawson, J., Walters, M., Delles, C., Mischak, H. and Mullen, W. (2012) 
Urinary proteomics to support diagnosis of stroke. PLoS One. 7, e35879 
275 Wei, Y. J., Huang, Y. X., Shen, Y., et al. (2009) Proteomic analysis reveals 
significant elevation of heat shock protein 70 in patients with chronic heart 
failure due to arrhythmogenic right ventricular cardiomyopathy. Mol Cell 
Biochem. 332, 103-111 
276 Pinet, F., Beseme, O., Cieniewski-Bernard, C., et al. (2008) Predicting left 
ventricular remodeling after a first myocardial infarction by plasma 
proteome analysis. Proteomics. 8, 1798-1808 
277 Fertin, M., Beseme, O., Duban, S., Amouyel, P., Bauters, C. and Pinet, F. 
(2010) Deep plasma proteomic analysis of patients with left ventricular 
remodeling after a first myocardial infarction. Proteomics Clin Appl. 4, 654-
673 
278 Kuznetsova, T., Mischak, H., Mullen, W. and Staessen, J. A. (2012) Urinary 
proteome analysis in hypertensive patients with left ventricular diastolic 
dysfunction. Eur Heart J. 33, 2342-2350 
279 Laine, P., Pentikainen, M. O., Wurzner, R., et al. (2002) Evidence for 
complement activation in ruptured coronary plaques in acute myocardial 
infarction. Am J Cardiol. 90, 404-408 
280 Sukhova, G. K., Shi, G. P., Simon, D. I., Chapman, H. A. and Libby, P. 
(1998) Expression of the elastolytic cathepsins S and K in human atheroma 
and regulation of their production in smooth muscle cells. J Clin Invest. 
102, 576-583 
281 Darde, V. M., de la Cuesta, F., Dones, F. G., Alvarez-Llamas, G., Barderas, 
M. G. and Vivanco, F. (2010) Analysis of the plasma proteome associated 
with acute coronary syndrome: does a permanent protein signature exist in 
the plasma of ACS patients? J Proteome Res. 9, 4420-4432 
282 Delles, C., Schiffer, E., von Zur Muhlen, C., et al. (2010) Urinary proteomic 
diagnosis of coronary artery disease: identification and clinical validation in 
623 individuals. J Hypertens. 28, 2316-2322 
283 Brown, C. E., McCarthy, N. S., Hughes, A. D., et al. (2015) Urinary 
proteomic biomarkers to predict cardiovascular events. Proteomics Clin 
Appl. 9, 610-617 
293 
 
 
284 Neisius, U., Koeck, T., Mischak, H., et al. (2016) Urine proteomics in the 
diagnosis of stable angina. BMC Cardiovasc Disord. 16, 70 
285 Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. and Hsu, C. Y. (2004) 
Chronic kidney disease and the risks of death, cardiovascular events, and 
hospitalization. N.Engl.J.Med. 351, 1296-1305 
286 Hemmelgarn, B. R., Manns, B. J., Lloyd, A., et al. (2010) Relation between 
kidney function, proteinuria, and adverse outcomes. JAMA. 303, 423-429 
287 Di Angelantonio, E., Chowdhury, R., Sarwar, N., Aspelund, T., Danesh, J. 
and Gudnason, V. (2010) Chronic kidney disease and risk of major 
cardiovascular disease and non-vascular mortality: prospective population 
based cohort study. BMJ. 341, c4986 
288 Glorieux, G., Mullen, W., Duranton, F., et al. (2015) New insights in 
molecular mechanisms involved in chronic kidney disease using high-
resolution plasma proteome analysis. Nephrol Dial Transplant. 30, 1842-
1852 
289 Argiles, A., Siwy, J., Duranton, F., et al. (2013) CKD273, a new proteomics 
classifier assessing CKD and its prognosis. PLoS One. 8, e62837 
290 Schanstra, J. P., Zurbig, P., Alkhalaf, A., et al. (2015) Diagnosis and 
Prediction of CKD Progression by Assessment of Urinary Peptides. J Am Soc 
Nephrol. 26, 1999-2010 
291 Gu, Y. M., Thijs, L., Liu, Y. P., et al. (2014) The urinary proteome as 
correlate and predictor of renal function in a population study. Nephrol 
Dial Transplant. 29, 2260-2268 
292 Pontillo, C., Jacobs, L., Staessen, J. A., et al. (2016) A urinary proteome-
based classifier for the early detection of decline in glomerular filtration. 
Nephrol Dial Transplant 
293 Rossing, K., Mischak, H., Dakna, M., et al. (2008) Urinary proteomics in 
diabetes and CKD. J Am Soc Nephrol. 19, 1283-1290 
294 Alkhalaf, A., Zurbig, P., Bakker, S. J., et al. (2010) Multicentric validation 
of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS 
One. 5, e13421 
295 Zurbig, P., Jerums, G., Hovind, P., et al. (2012) Urinary proteomics for 
early diagnosis in diabetic nephropathy. Diabetes. 61, 3304-3313 
296 Roscioni, S. S., de Zeeuw, D., Hellemons, M. E., et al. (2013) A urinary 
peptide biomarker set predicts worsening of albuminuria in type 2 diabetes 
mellitus. Diabetologia. 56, 259-267 
297 Lindhardt, M., Persson, F., Zurbig, P., et al. (2016) Urinary proteomics 
predict onset of microalbuminuria in normoalbuminuric type 2 diabetic 
patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial 
Transplant; in press. 
298 Siwy, J., Schanstra, J. P., Argiles, A., et al. (2014) Multicentre prospective 
validation of a urinary peptidome-based classifier for the diagnosis of type 
2 diabetic nephropathy. Nephrol Dial Transplant. 29, 1563-1570 
294 
 
 
299 Andersen, S., Mischak, H., Zurbig, P., Parving, H. H. and Rossing, P. (2010) 
Urinary proteome analysis enables assessment of renoprotective treatment 
in type 2 diabetic patients with microalbuminuria. BMC Nephrol. 11, 29 
300 Fox, C. S., Matsushita, K., Woodward, M., et al. (2012) Associations of 
kidney disease measures with mortality and end-stage renal disease in 
individuals with and without diabetes: a meta-analysis. Lancet. 380, 1662-
1673 
301 Tonelli, M., Muntner, P., Lloyd, A., et al. (2012) Risk of coronary events in 
people with chronic kidney disease compared with those with diabetes: a 
population-level cohort study. Lancet. 380, 807-814 
302 National Institute for Health and Care Excellence (2014) Chronic kidney 
disease in adults:  assessment and management. NICE guideline (CG182) 
303 Gaede, P., Lund-Andersen, H., Parving, H. H. and Pedersen, O. (2008) 
Effect of a multifactorial intervention on mortality in type 2 diabetes. N 
Engl J Med. 358, 580-591 
304 Group, A. S., Cushman, W. C., Evans, G. W., et al. (2010) Effects of 
intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 
362, 1575-1585 
305 Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V. and Patel, A. 
(2015) Blood pressure lowering in type 2 diabetes: a systematic review and 
meta-analysis. JAMA. 313, 603-615 
306 Grassi, G., Mancia, G. and Nilsson, P. M. (2016) Specific Blood Pressure 
Targets for Patients With Diabetic Nephropathy? Diabetes Care. 39 Suppl 2, 
S228-233 
307 Bakris, G. L., Weir, M. R., Shanifar, S., et al. (2003) Effects of blood 
pressure level on progression of diabetic nephropathy: results from the 
RENAAL study. Arch Intern Med. 163, 1555-1565 
308 Pohl, M. A., Blumenthal, S., Cordonnier, D. J., et al. (2005) Independent 
and additive impact of blood pressure control and angiotensin II receptor 
blockade on renal outcomes in the irbesartan diabetic nephropathy trial: 
clinical implications and limitations. J Am Soc Nephrol. 16, 3027-3037 
309 American Diabetes Association (2016) Standards of Medical Care in 
Diabetes-2016: Summary of Revisions. Diabetes Care. 39 Suppl 1, S4-5 
310 Weber, M. A., Schiffrin, E. L., White, W. B., et al. (2014) Clinical practice 
guidelines for the management of hypertension in the community a 
statement by the American Society of Hypertension and the International 
Society of Hypertension. J Hypertens. 32, 3-15 
311 James, P. A., Oparil, S., Carter, B. L., et al. (2014) 2014 evidence-based 
guideline for the management of high blood pressure in adults: report from 
the panel members appointed to the Eighth Joint National Committee (JNC 
8). JAMA. 311, 507-520 
312 Lewis, E. J., Hunsicker, L. G., Bain, R. P. and Rohde, R. D. (1993) The 
effect of angiotensin-converting-enzyme inhibition on diabetic 
nephropathy. The Collaborative Study Group. N Engl J Med. 329, 1456-1462 
313 Viberti, G., Mogensen, C. E., Groop, L. C. and Pauls, J. F. (1994) Effect of 
captopril on progression to clinical proteinuria in patients with insulin-
295 
 
 
dependent diabetes mellitus and microalbuminuria. European 
Microalbuminuria Captopril Study Group. JAMA. 271, 275-279 
314 Lewis, E. J., Hunsicker, L. G., Clarke, W. R., et al. (2001) Renoprotective 
effect of the angiotensin-receptor antagonist irbesartan in patients with 
nephropathy due to type 2 diabetes. N Engl J Med. 345, 851-860 
315 Brenner, B. M., Cooper, M. E., de, Z. D., et al. (2001) Effects of losartan on 
renal and cardiovascular outcomes in patients with type 2 diabetes and 
nephropathy. N.Engl.J.Med. 345, 861-869 
316 Patel, A., Group, A. C., MacMahon, S., et al. (2007) Effects of a fixed 
combination of perindopril and indapamide on macrovascular and 
microvascular outcomes in patients with type 2 diabetes mellitus (the 
ADVANCE trial): a randomised controlled trial. Lancet. 370, 829-840 
317 Mann, J. F., Schmieder, R. E., McQueen, M., et al. (2008) Renal outcomes 
with telmisartan, ramipril, or both, in people at high vascular risk (the 
ONTARGET study): a multicentre, randomised, double-blind, controlled 
trial. Lancet. 372, 547-553 
318 Tobe, S. W., Clase, C. M., Gao, P., et al. (2011) Cardiovascular and renal 
outcomes with telmisartan, ramipril, or both in people at high renal risk: 
results from the ONTARGET and TRANSCEND studies. Circulation. 123, 1098-
1107 
319 Imai, E., Chan, J. C., Ito, S., et al. (2011) Effects of olmesartan on renal 
and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a 
multicentre, randomised, placebo-controlled study. Diabetologia. 54, 2978-
2986 
320 Fried, L. F., Emanuele, N., Zhang, J. H., et al. (2013) Combined 
angiotensin inhibition for the treatment of diabetic nephropathy. 
N.Engl.J.Med. 369, 1892-1903 
321 Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J., Hollenberg, N. K. and 
Investigators, A. S. (2008) Aliskiren combined with losartan in type 2 
diabetes and nephropathy. N Engl J Med. 358, 2433-2446 
322 Parving, H. H., Brenner, B. M., McMurray, J. J., et al. (2012) Cardiorenal 
end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 367, 
2204-2213 
323 Epstein, M., Williams, G. H., Weinberger, M., et al. (2006) Selective 
aldosterone blockade with eplerenone reduces albuminuria in patients with 
type 2 diabetes. Clin J Am Soc Nephrol. 1, 940-951 
324 Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F. and Parving, H. H. 
(2005) Beneficial effects of adding spironolactone to recommended 
antihypertensive treatment in diabetic nephropathy: a randomized, double-
masked, cross-over study. Diabetes Care. 28, 2106-2112 
325 Schjoedt, K. J., Rossing, K., Juhl, T. R., et al. (2005) Beneficial impact of 
spironolactone in diabetic nephropathy. Kidney Int. 68, 2829-2836 
326 Van Den Meiracker, A. H., Baggen, R. G., Pauli, S., et al. (2006) 
Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, 
blood pressure and renal function. J Hypertens. 24, 2285-2292 
296 
 
 
327 Saklayen, M. G., Gyebi, L. K., Tasosa, J. and Yap, J. (2008) Effects of 
additive therapy with spironolactone on proteinuria in diabetic patients 
already on ACE inhibitor or ARB therapy: results of a randomized, placebo-
controlled, double-blind, crossover trial. J Investig Med 56, 714-719 
328 Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. and Toto, R. D. 
(2009) Addition of angiotensin receptor blockade or mineralocorticoid 
antagonism to maximal angiotensin-converting enzyme inhibition in 
diabetic nephropathy. J Am Soc Nephrol. 20, 2641-2650 
329 Nielsen, S., Perrson, F., Frandsen, E., et al. (2012) Spironolactone 
diminishes urinary albumin excretion in patients with type 1 diabetes and 
microalbuminuria: a randomized placebo-controlled crossover study. 
Diabetic Medicine. 29, e184-e190 
330 Ziaee, A., Abbas, V. A., Oveisi, S., Javadi, A., Hashemipour, S. and 
Kazemifar, A. M. (2013) Effects of additive therapy with spironolactone on 
albuminuria in diabetes mellitus: A pilot randomized clinical trial. Caspian 
J Intern Med. 4, 648-653 
331 Bianchi, S., Bigazzi, R. and Campese, V. M. (2006) Long-term effects of 
spironolactone on proteinuria and kidney function in patients with chronic 
kidney disease. Kidney Int. 70, 2116-2123 
332 Chrysostomou, A., Pedagogos, E., MacGregor, L. and Becker, G. J. (2006) 
Double-blind, placebo-controlled study on the effect of the aldosterone 
receptor antagonist spironolactone in patients who have persistent 
proteinuria and are on long-term angiotensin-converting enzyme inhibitor 
therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc 
Nephrol. 1, 256-262 
333 Tylicki, L., Lizakowski, S., Rutkowski, P., et al. (2012) The enhanced renin-
angiotensin-aldosteron system pharmacological blockade--which is the 
best? Kidney Blood Press Res. 36, 335-343 
334 Tylicki, L., Rutkowski, P., Renke, M., et al. (2008) Triple pharmacological 
blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: 
an open-label crossover randomized controlled trial. Am J Kidney Dis. 52, 
486-493 
335 Edwards, N. C., Steeds, R. P., Stewart, P. M., Ferro, C. J. and Townend, J. 
N. (2009) Effect of spironolactone on left ventricular mass and aortic 
stiffness in early-stage chronic kidney disease: a randomized controlled 
trial. J Am Coll Cardiol. 54, 505-512 
336 Abolghasmi, R. and Taziki, O. (2011) Efficacy of low dose spironolactone in 
chronic kidney disease with resistant hypertension. Saudi J Kidney Dis 
Transpl. 22, 75-78 
337 Guney, I., Selcuk, N. Y., Altintepe, L., Atalay, H., Basarali, M. K. and 
Buyukbas, S. (2009) Antifibrotic effects of aldosterone receptor blocker 
(spironolactone) in patients with chronic kidney disease. Ren Fail. 31, 779-
784 
338 Ando, K., Ohtsu, H., Uchida, S., Kaname, S., Arakawa, Y. and Fujita, T. 
(2014) Anti-albuminuric effect of the aldosterone blocker eplerenone in 
non-diabetic hypertensive patients with albuminuria: a double-blind, 
297 
 
 
randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2, 944-
953 
339 Boesby, L., Elung-Jensen, T., Klausen, T. W., Strandgaard, S. and Kamper, 
A. L. (2011) Moderate antiproteinuric effect of add-on aldosterone 
blockade with eplerenone in non-diabetic chronic kidney disease. A 
randomized cross-over study. PLoS One. 6, e26904 
340 Boesby, L., Elung-Jensen, T., Strandgaard, S. and Kamper, A. L. (2013) 
Eplerenone attenuates pulse wave reflection in chronic kidney disease 
stage 3-4--a randomized controlled study. PLoS One. 8, e64549 
341 Wang, W., Li, L., Zhou, Z., Gao, J. and Sun, Y. (2013) Effect of 
spironolactone combined with angiotensin converting enzyme inhibitors 
and/or angiotensin II receptor blockers on chronic glomerular disease. Exp 
Ther Med. 6, 1527-1531 
342 ACCORD Study Group, Buse, J. B., Bigger, J. T., et al. (2007) Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and 
methods. Am J Cardiol. 99, 21i-33i 
343 Zinman, B., Wanner, C., Lachin, J. M., et al. (2015) Empagliflozin, 
Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 
373, 2117-2128 
344 Skrtic, M., Yang, G. K., Perkins, B. A., et al. (2014) Characterisation of 
glomerular haemodynamic responses to SGLT2 inhibition in patients with 
type 1 diabetes and renal hyperfiltration. Diabetologia. 57, 2599-2602 
345 Cherney, D. Z., Perkins, B. A., Soleymanlou, N., et al. (2014) Renal 
hemodynamic effect of sodium-glucose cotransporter 2 inhibition in 
patients with type 1 diabetes mellitus. Circulation. 129, 587-597 
346 Wanner, C., Inzucchi, S. E., Lachin, J. M., et al. (2016) Empagliflozin and 
progression of kidney disease in type 2 diabetes. N Engl J Med. 375, 323-
334 
347 Heerspink, H. J., Perkins, B. A., Fitchett, D. H., Husain, M. and Cherney, D. 
Z. (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of 
diabetes mellitus: cardiovascular and kidney effects, potential 
mechanisms, and clinical applications. Circulation. 134, 752-772 
348 Tanaka, T., Higashijima, Y., Wada, T. and Nangaku, M. (2014) The 
potential for renoprotection with incretin-based drugs. Kidney Int. 86, 701-
711 
349 Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016) Liraglutide 
and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375, 311-
322 
350 Muskiet, M. H., Tonneijck, L., Smits, M. M., Kramer, M. H., Heerspink, H. J. 
and van Raalte, D. H. (2015) Pleiotropic effects of type 2 diabetes 
management strategies on renal risk factors. Lancet Diabetes Endocrinol. 3, 
367-381 
351 Palmer, S. C., Craig, J. C., Navaneethan, S. D., Tonelli, M., Pellegrini, F. 
and Strippoli, G. F. (2012) Benefits and harms of statin therapy for persons 
with chronic kidney disease: a systematic review and meta-analysis. Ann 
Intern Med. 157, 263-275 
298 
 
 
352 Wanner, C., Tonelli, M. and Kidney Disease: Improving Global Outcomes 
Lipid Guideline Development Work Group, M. (2014) KDIGO Clinical Practice 
Guideline for Lipid Management in CKD: summary of recommendation 
statements and clinical approach to the patient. Kidney Int. 85, 1303-1309 
353 Molitch, M. E., Adler, A. I., Flyvbjerg, A., et al. (2015) Diabetic kidney 
disease: a clinical update from Kidney Disease: Improving Global Outcomes. 
Kidney Int. 87, 20-30 
354 Ekinci, E. I., Clarke, S., Thomas, M. C., et al. (2011) Dietary salt intake and 
mortality in patients with type 2 diabetes. Diabetes Care. 34, 703-709 
355 Lambers Heerspink, H. J., Holtkamp, F. A., Parving, H. H., et al. (2012) 
Moderation of dietary sodium potentiates the renal and cardiovascular 
protective effects of angiotensin receptor blockers. Kidney Int. 82, 330-337 
356 Hansen, H. P., Tauber-Lassen, E., Jensen, B. R. and Parving, H. H. (2002) 
Effect of dietary protein restriction on prognosis in patients with diabetic 
nephropathy. Kidney Int. 62, 220-228 
357 Pan, Y., Guo, L. L. and Jin, H. M. (2008) Low-protein diet for diabetic 
nephropathy: a meta-analysis of randomized controlled trials. Am J Clin 
Nutr. 88, 660-666 
358 Dieterle, W., Mann, J. and Kutz, K. (2005) Multiple-dose pharmacokinetics, 
pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor 
antagonist SPP301 in man. Int J Clin Pharmacol Ther. 43, 178-186 
359 Mann, J. F., Green, D., Jamerson, K., et al. (2010) Avosentan for overt 
diabetic nephropathy. J Am Soc Nephrol. 21, 527-535 
360 de Zeeuw, D., Coll, B., Andress, D., et al. (2014) The endothelin antagonist 
atrasentan lowers residual albuminuria in patients with type 2 diabetic 
nephropathy. J Am Soc Nephrol. 25, 1083-1093 
361 de Zeeuw, D., Akizawa, T., Audhya, P., et al. (2013) Bardoxolone methyl in 
type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 369, 
2492-2503 
362 Parvanova, A., van der Meer, I. M., Iliev, I., et al. (2013) Effect on blood 
pressure of combined inhibition of endothelin-converting enzyme and 
neutral endopeptidase with daglutril in patients with type 2 diabetes who 
have albuminuria: a randomised, crossover, double-blind, placebo-
controlled trial. Lancet Diabetes Endocrinol. 1, 19-27 
363 UK HARP-III Collaborative Group (2016) Randomized multicentre pilot study 
of sacubitril/valsartan versus irbesartan in patients with chronic kidney 
disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, 
trial design and baseline data. Nephrol Dial Transplant; in press 
364 McCormick, B. B., Sydor, A., Akbari, A., Fergusson, D., Doucette, S. and 
Knoll, G. (2008) The effect of pentoxifylline on proteinuria in diabetic 
kidney disease: a meta-analysis. Am J Kidney Dis. 52, 454-463 
365 Navarro-Gonzalez, J. F., Mora-Fernandez, C., Muros de Fuentes, M., et al. 
(2015) Effect of pentoxifylline on renal function and urinary albumin 
excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am 
Soc Nephrol. 26, 220-229 
299 
 
 
366 Jalal, D. I., Rivard, C. J., Johnson, R. J., et al. (2010) Serum uric acid 
levels predict the development of albuminuria over 6 years in patients with 
type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 
Diabetes study. Nephrol Dial Transplant. 25, 1865-1869 
367 Ficociello, L. H., Rosolowsky, E. T., Niewczas, M. A., et al. (2010) High-
normal serum uric acid increases risk of early progressive renal function 
loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 33, 
1337-1343 
368 Siu, Y. P., Leung, K. T., Tong, M. K. and Kwan, T. H. (2006) Use of 
allopurinol in slowing the progression of renal disease through its ability to 
lower serum uric acid level. Am J Kidney Dis. 47, 51-59 
369 Goicoechea, M., de Vinuesa, S. G., Verdalles, U., et al. (2010) Effect of 
allopurinol in chronic kidney disease progression and cardiovascular risk. 
Clin J Am Soc Nephrol. 5, 1388-1393 
370 Maahs, D. M., Caramori, L., Cherney, D. Z., et al. (2013) Uric acid lowering 
to prevent kidney function loss in diabetes: the preventing early renal 
function loss (PERL) allopurinol study. Curr Diab Rep. 13, 550-559 
371 The EUCLID Study Group (1997) Randomised placebo-controlled trial of 
lisinopril in normotensive patients with insulin-dependent diabetes and 
normoalbuminuria or microalbuminuria. Lancet. 349, 1787-1792 
372 Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of 
ramipril on cardiovascular and microvascular outcomes in people with 
diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. 
Lancet. 355, 253-259 
373 Ruggenenti, P., Fassi, A., Ilieva, A. P., et al. (2004) Preventing 
microalbuminuria in type 2 diabetes. N Engl J Med. 351, 1941-1951 
374 Ruggenenti, P., Perna, A., Ganeva, M., Ene-Iordache, B., Remuzzi, G. and 
Group, B. S. (2006) Impact of blood pressure control and angiotensin-
converting enzyme inhibitor therapy on new-onset microalbuminuria in 
type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc 
Nephrol. 17, 3472-3481 
375 Bilous, R., Chaturvedi, N., Sjolie, A. K., et al. (2009) Effect of candesartan 
on microalbuminuria and albumin excretion rate in diabetes: three 
randomized trials. Ann Intern Med. 151, 11-20, W13-14 
376 Haller, H., Ito, S., Izzo, J. L., Jr., et al. (2011) Olmesartan for the delay or 
prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 364, 907-
917 
377 Vejakama, P., Thakkinstian, A., Lertrattananon, D., Ingsathit, A., 
Ngarmukos, C. and Attia, J. (2012) Reno-protective effects of renin-
angiotensin system blockade in type 2 diabetic patients: a systematic 
review and network meta-analysis. Diabetologia. 55, 566-578 
378 Persson, F., Lindhardt, M., Rossing, P. and Parving, H. H. (2016) Prevention 
of microalbuminuria using early intervention with renin-angiotensin system 
inhibitors in patients with type 2 diabetes: A systematic review. J Renin 
Angiotensin Aldosterone Syst. 17 
300 
 
 
379 Hlatky, M. A., Greenland, P., Arnett, D. K., et al. (2009) Criteria for 
evaluation of novel markers of cardiovascular risk: a scientific statement 
from the American Heart Association. Circulation. 119, 2408-2416 
380 Lindhardt, M., Persson, F., Currie, G., et al. (2016) Proteomic prediction 
and Renin angiotensin aldosterone system Inhibition prevention Of early 
diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria 
(PRIORITY): essential study design and rationale of a randomised clinical 
multicentre trial. BMJ Open. 6, e010310 
381 Mischak, H., Vlahou, A. and Ioannidis, J. P. (2013) Technical aspects and 
inter-laboratory variability in native peptide profiling: the CE-MS 
experience. Clin Biochem. 46, 432-443 
382 Dueck, A. C., Mendoza, T. R., Mitchell, S. A., et al. (2015) Validity and 
Reliability of the US National Cancer Institute's Patient-Reported Outcomes 
Version of the Common Terminology Criteria for Adverse Events (PRO-
CTCAE). JAMA Oncol. 1, 1051-1059 
383 Jantos-Siwy, J., Schiffer, E., Brand, K., et al. (2009) Quantitative urinary 
proteome analysis for biomarker evaluation in chronic kidney disease. J 
Proteome Res. 8, 268-281 
384 Jha, V., Garcia-Garcia, G., Iseki, K., et al. (2013) Chronic kidney disease: 
global dimension and perspectives. Lancet. 382, 260-272 
385 Tonelli, M., Wiebe, N., Culleton, B., et al. (2006) Chronic kidney disease 
and mortality risk: a systematic review. J.Am.Soc.Nephrol. 17, 2034-2047 
386 Mathiesen, E. R., Hommel, E., Hansen, H. P., Smidt, U. M. and Parving, H. 
H. (1999) Randomised controlled trial of long term efficacy of captopril on 
preservation of kidney function in normotensive patients with insulin 
dependent diabetes and microalbuminuria. BMJ. 319, 24-25 
387 Jafar, T. H., Schmid, C. H., Landa, M., et al. (2001) Angiotensin-converting 
enzyme inhibitors and progression of nondiabetic renal disease. A meta-
analysis of patient-level data. Ann.Intern.Med. 135, 73-87 
388 The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) 
(1997) Randomised placebo-controlled trial of effect of ramipril on decline 
in glomerular filtration rate and risk of terminal renal failure in proteinuric, 
non-diabetic nephropathy. Lancet. 349, 1857-1863 
389 Strippoli, G. F., Bonifati, C., Craig, M., Navaneethan, S. D. and Craig, J. C. 
(2014) Angiotensin converting ensyme inhibitors and angiotensin II receptor 
antagonists for preventing the progression of diabetic kidney disease. In 
Cochrane Database of Systematic Reviews Issue 4 
390 ONTARGET Investigators (2008) Telmisartan, ramipril or both in aptients at 
high risk for vascular events. N Engl J Med. 358, 1547-1559 
391 Kunz, R., Friedrich, C., Wolbers, M. and Mann, J. F. (2008) Meta-analysis: 
effect of monotherapy and combination therapy with inhibitors of the renin 
angiotensin system on proteinuria in renal disease. Ann Intern Med. 148, 
30-48 
392 Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R. and Strippoli, G. F. 
(2009) Aldosterone antagonists for preventing the progression of chronic 
301 
 
 
kidney disease: a systematic review and meta-analysis. Clin J Am Soc 
Nephrol. 4, 542-551 
393 Bolignano, D., Palmer, S. C., Navaneethan, S. D. and Strippoli, G. F. (2014) 
Aldosterone antagonists for preventing the progression of chronic kidney 
disease. Cochrane Database Syst Rev. 4, CD007004 
394 Blasi, E. R., Rocha, R., Rudolph, A. E., Blomme, E. A., Polly, M. L. and 
McMahon, E. G. (2003) Aldosterone/salt induces renal inflammation and 
fibrosis in hypertensive rats. Kidney Int. 63, 1791-1800 
395 Rocha, R., Chander, P. N., Zuckerman, A. and Stier, C. T., Jr. (1999) Role 
of aldosterone in renal vascular injury in stroke-prone hypertensive rats. 
Hypertension. 33, 232-237 
396 Cicoira, M., Zanolla, L., Franceschini, L., et al. (2002) Relation of 
aldosterone "escape" despite angiotensin-converting enzyme inhibitor 
administration to impaired exercise capacity in chronic congestive heart 
failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J 
Cardiol. 89, 403-407 
397 Sato, A., Hayashi, K., Naruse, M. and Saruta, T. (2003) Effectiveness of 
aldosterone blockade in patients with diabetic nephropathy. Hypertension. 
41, 64-68 
398 Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F. and Parving, H. H. 
(2005) Beneficial effects of adding spironolactone to recommended 
antihypertensive treatment in diabetic nephropathy: a randomized, double-
masked, cross-over study. Diabetes Care. 28, 2106-2112 
399 Taheri, S., Mortazavi, M., Shahidi, S., et al. (2009) Spironolactone in 
chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis 
Transpl. 20, 392-397 
400 Taheri, S., Mortazavi, M., Pourmoghadas, A., Seyrafian, S., Alipour, Z. and 
Karimi, S. (2012) A prospective double-blind randomized placebo-controlled 
clinical trial to evaluate the safety and efficacy of spironolactone in 
patients with advanced congestive heart failure on continuous ambulatory 
peritoneal dialysis. Saudi J Kidney Dis Transpl. 23, 507-512 
401 Vukusich, A., Kunstmann, S., Varela, C., et al. (2010) A randomized, 
double-blind, placebo-controlled trial of spironolactone on carotid intima-
media thickness in nondiabetic hemodialysis patients. Clin J Am Soc 
Nephrol. 5, 1380-1387 
402 Ito, Y., Mizuno, M., Suzuki, Y., et al. (2014) Long-term effects of 
spironolactone in peritoneal dialysis patients. J Am Soc Nephrol. 25, 1094-
1102 
403 Sica, D. A. (2009) Hyperkalemia risk in chronic kidney disease: deterrent to 
the use of aldosterone receptor antagonism or not. Hypertension. 53, 749-
750 
404 Epstein, M. (2009) Hyperkalemia as a constraint to therapy with 
combination Renin-Angiotensin system blockade: the elephant in the room. 
J Clin Hypertens (Greenwich.). 11, 55-60 
302 
 
 
405 Higgins, J. P., Altman, D. G., Gotzsche, P. C., et al. (2011) The Cochrane 
Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 343, 
d5928 
406 Walsh, M., Manns, B., Garg, A. X., et al. (2015) The Safety of Eplerenone in 
Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. Clin J 
Am Soc Nephrol. 10, 1602-1608 
407 Matsumoto, Y., Mori, Y., Kageyama, S., et al. (2014) Spironolactone 
reduces cardiovascular and cerebrovascular morbidity and mortality in 
hemodialysis patients. J Am Coll Cardiol. 63, 528-536 
408 Coresh, J., Selvin, E., Stevens, L. A., et al. (2007) Prevalence of chronic 
kidney disease in the United States. JAMA. 298, 2038-2047 
409 de Zeeuw, D., Remuzzi, G., Parving, H. H., et al. (2004) Albuminuria, a 
therapeutic target for cardiovascular protection in type 2 diabetic patients 
with nephropathy. Circulation. 110, 921-927 
410 Ferrario, C. M. and Schiffrin, E. L. (2015) Role of mineralocorticoid 
receptor antagonists in cardiovascular disease. Circ Res. 116, 206-213 
411 Jafar, T. H., Stark, P. C., Schmid, C. H., et al. (2003) Progression of 
chronic kidney disease: the role of blood pressure control, proteinuria, and 
angiotensin-converting enzyme inhibition: a patient-level meta-analysis. 
Ann Intern Med. 139, 244-252 
412 Ruggenenti, P., Perna, A., Loriga, G., et al. (2005) Blood-pressure control 
for renoprotection in patients with non-diabetic chronic renal disease 
(REIN-2): multicentre, randomised controlled trial. Lancet. 365, 939-946 
413 Juurlink, D. N., Mamdani, M. M., Lee, D. S., et al. (2004) Rates of 
hyperkalemia after publication of the Randomized Aldactone Evaluation 
Study. N Engl J Med. 351, 543-551 
414 Preston, R. A., Afshartous, D., Garg, D., Medrano, S., Alonso, A. B. and 
Rodriguez, R. (2009) Mechanisms of impaired potassium handling with dual 
renin-angiotensin-aldosterone blockade in chronic kidney disease. 
Hypertension. 53, 754-760 
415 Bakris, G. L., Agarwal, R., Chan, J. C., et al. (2015) Effect of finerenone on 
albuminuria in patients with diabetic nephropathy: a randomized clinical 
trial. JAMA. 314, 884-894 
416 Bakris, G. L., Pitt, B., Weir, M. R., et al. (2015) Effect of patiromer on 
serum potassium level in patients with hyperkalemia and diabetic kidney 
disease: the AMETHYST-DN randomized clinical trial. JAMA. 314, 151-161 
417 Morales, E., Millet, V. G., Rojas-Rivera, J., et al. (2013) Renoprotective 
effects of mineralocorticoid receptor blockers in patients with proteinuric 
kidney diseases. Nephrol Dial Transplant. 28, 405-412 
418 Matsushita, K., van, d., V, Astor, B. C., et al. (2010) Association of 
estimated glomerular filtration rate and albuminuria with all-cause and 
cardiovascular mortality in general population cohorts: a collaborative 
meta-analysis. Lancet. 375, 2073-2081 
419 Hill, N. R., Lasserson, D., Thompson, B., et al. (2014) Benefits of 
Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) 
trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-
303 
 
 
month study of 2,616 patients within primary care with stage 3b chronic 
kidney disease to compare the efficacy of spironolactone 25 mg once daily 
in addition to routine care on mortality and cardiovascular outcomes versus 
routine care alone: study protocol for a randomized controlled trial. Trials. 
15, 160 
420 Jun, M., Turin, T. C., Woodward, M., et al. (2015) Assessing the Validity of 
Surrogate Outcomes for ESRD: A Meta-Analysis. J.Am.Soc.Nephrol. 
421 Biomarkers Definitions Working Group (2001) Biomarkers and surrogate 
endpoints: preferred definitions and conceptual framework. Clin Pharmacol 
Ther. 69, 89-95 
422 Critselis, E. and Lambers Heerspink, H. (2016) Utility of the CKD273 peptide 
classifier in predicting chronic kidney disease progression. Nephrol Dial 
Transplant. 31, 249-254 
423 Dinneen, S. F. and Gerstein, H. C. (1997) The association of 
microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. 
A systematic overview of the literature. Arch Intern Med. 157, 1413-1418 
424 Jensen, J. S., Feldt-Rasmussen, B., Strandgaard, S., Schroll, M. and Borch-
Johnsen, K. (2000) Arterial hypertension, microalbuminuria, and risk of 
ischemic heart disease. Hypertension. 35, 898-903 
425 Romundstad, S., Holmen, J., Kvenild, K., Hallan, H. and Ellekjaer, H. 
(2003) Microalbuminuria and all-cause mortality in 2,089 apparently healthy 
individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study 
(HUNT), Norway. Am J Kidney Dis. 42, 466-473 
426 Kannel, W. B., Stampfer, M. J., Castelli, W. P. and Verter, J. (1984) The 
prognostic significance of proteinuria: the Framingham study. Am Heart J. 
108, 1347-1352 
427 de Zeeuw, D., Remuzzi, G., Parving, H. H., et al. (2004) Proteinuria, a 
target for renoprotection in patients with type 2 diabetic nephropathy: 
lessons from RENAAL. Kidney Int. 65, 2309-2320 
428 Henry, R. M., Ferreira, I., Kostense, P. J., et al. (2004) Type 2 diabetes is 
associated with impaired endothelium-dependent, flow-mediated dilation, 
but impaired glucose metabolism is not; The Hoorn Study. Atherosclerosis. 
174, 49-56 
429 von Scholten, B. J., Reinhard, H., Hansen, T. W., et al. (2016) Markers of 
inflammation and endothelial dysfunction are associated with incident 
cardiovascular disease, all-cause mortality, and progression of coronary 
calcification in type 2 diabetic patients with microalbuminuria. J Diabetes 
Complications. 30, 248-255 
430 Schram, M. T., Chaturvedi, N., Schalkwijk, C. G., Fuller, J. H., Stehouwer, 
C. D. and Group, E. P. C. S. (2005) Markers of inflammation are cross-
sectionally associated with microvascular complications and cardiovascular 
disease in type 1 diabetes--the EURODIAB Prospective Complications Study. 
Diabetologia. 48, 370-378 
431 Mancia, G., Fagard, R., Narkiewicz, K., et al. (2013) 2013 ESH/ESC 
guidelines for the management of arterial hypertension: the Task Force for 
the Management of Arterial Hypertension of the European Society of 
304 
 
 
Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur 
Heart J. 34, 2159-2219 
432 Avolio, A. P., Van Bortel, L. M., Boutouyrie, P., et al. (2009) Role of pulse 
pressure amplification in arterial hypertension: experts' opinion and review 
of the data. Hypertension. 54, 375-383 
433 Namasivayam, M., McDonnell, B. J., McEniery, C. M., O'Rourke, M. F. and 
Anglo-Cardiff Collaborative Trial Study, I. (2009) Does wave reflection 
dominate age-related change in aortic blood pressure across the human life 
span? Hypertension. 53, 979-985 
434 Nichols, W. W., ORourke, M. F. and Vlachopoulos, C. (2011) McDonald's 
Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles, 
6th Edition. Mcdonald's Blood Flow in Arteries: Theoretical, Experimental 
and Clinical Principles, 6th Edition, 1-741 
435 Vlachopoulos, C., Aznaouridis, K., O'Rourke, M. F., Safar, M. E., Baou, K. 
and Stefanadis, C. (2010) Prediction of cardiovascular events and all-cause 
mortality with central haemodynamics: a systematic review and meta-
analysis. Eur Heart J. 31, 1865-1871 
436 Williams, B., Lacy, P. S., Thom, S. M., et al. (2006) Differential impact of 
blood pressure-lowering drugs on central aortic pressure and clinical 
outcomes: principal results of the Conduit Artery Function Evaluation 
(CAFE) study. Circulation. 113, 1213-1225 
437 Vlachopoulos, C., Xaplanteris, P., Aboyans, V., et al. (2015) The role of 
vascular biomarkers for primary and secondary prevention. A position paper 
from the European Society of Cardiology Working Group on peripheral 
circulation: Endorsed by the Association for Research into Arterial Structure 
and Physiology (ARTERY) Society. Atherosclerosis. 241, 507-532 
438 Touboul, P. J., Hennerici, M. G., Meairs, S., et al. (2012) Mannheim carotid 
intima-media thickness and plaque consensus (2004-2006-2011). An update 
on behalf of the advisory board of the 3rd, 4th and 5th watching the risk 
symposia, at the 13th, 15th and 20th European Stroke Conferences, 
Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, 
Germany, 2011. Cerebrovasc Dis. 34, 290-296 
439 Perk, J., De Backer, G., Gohlke, H., et al. (2012) European Guidelines on 
cardiovascular disease prevention in clinical practice (version 2012). The 
Fifth Joint Task Force of the European Society of Cardiology and Other 
Societies on Cardiovascular Disease Prevention in Clinical Practice 
(constituted by representatives of nine societies and by invited experts). 
Eur Heart J. 33, 1635-1701 
440 Lorenz, M. W., Polak, J. F., Kavousi, M., et al. (2012) Carotid intima-media 
thickness progression to predict cardiovascular events in the general 
population (the PROG-IMT collaborative project): a meta-analysis of 
individual participant data. Lancet. 379, 2053-2062 
441 Den Ruijter, H. M., Peters, S. A., Anderson, T. J., et al. (2012) Common 
carotid intima-media thickness measurements in cardiovascular risk 
prediction: a meta-analysis. JAMA. 308, 796-803 
305 
 
 
442 Wang, T. J., Larson, M. G., Levy, D., et al. (2004) Plasma natriuretic 
peptide levels and the risk of cardiovascular events and death. N Engl J 
Med. 350, 655-663 
443 Di Angelantonio, E., Chowdhury, R., Sarwar, N., et al. (2009) B-type 
natriuretic peptides and cardiovascular risk: systematic review and meta-
analysis of 40 prospective studies. Circulation. 120, 2177-2187 
444 de Lemos, J. A., Drazner, M. H., Omland, T., et al. (2010) Association of 
troponin T detected with a highly sensitive assay and cardiac structure and 
mortality risk in the general population. JAMA. 304, 2503-2512 
445 deFilippi, C. R., de Lemos, J. A., Christenson, R. H., et al. (2010) 
Association of serial measures of cardiac troponin T using a sensitive assay 
with incident heart failure and cardiovascular mortality in older adults. 
JAMA. 304, 2494-2502 
446 Everett, B. M., Cook, N. R., Magnone, M. C., et al. (2011) Sensitive cardiac 
troponin T assay and the risk of incident cardiovascular disease in women 
with and without diabetes mellitus: the Women's Health Study. Circulation. 
123, 2811-2818 
447 McNulty, M., Mahmud, A., Spiers, P. and Feely, J. (2006) Collagen type-I 
degradation is related to arterial stiffness in hypertensive and 
normotensive subjects. J Hum Hypertens. 20, 867-873 
448 Intengan, H. D. and Schiffrin, E. L. (2001) Vascular remodeling in 
hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 
38, 581-587 
449 Scheven, L., de Jong, P. E., Hillege, H. L., et al. (2012) High-sensitive 
troponin T and N-terminal pro-B type natriuretic peptide are associated 
with cardiovascular events despite the cross-sectional association with 
albuminuria and glomerular filtration rate. Eur Heart J. 33, 2272-2281 
450 Laurent, S., Cockcroft, J., Van Bortel, L., et al. (2006) Expert consensus 
document on arterial stiffness: methodological issues and clinical 
applications. Eur Heart J. 27, 2588-2605 
451 de Jong, P. E., Hillege, H. L., Pinto-Sietsma, S. J. and de Zeeuw, D. (2003) 
Screening for microalbuminuria in the general population: a tool to detect 
subjects at risk for progressive renal failure in an early phase? Nephrol Dial 
Transplant. 18, 10-13 
452 Ben-Shlomo, Y., Spears, M., Boustred, C., et al. (2014) Aortic pulse wave 
velocity improves cardiovascular event prediction: an individual participant 
meta-analysis of prospective observational data from 17,635 subjects. J Am 
Coll Cardiol. 63, 636-646 
453 Karras, A., Haymann, J. P., Bozec, E., et al. (2012) Large artery stiffening 
and remodeling are independently associated with all-cause mortality and 
cardiovascular events in chronic kidney disease. Hypertension. 60, 1451-
1457 
454 Drummond, K., Mauer, M., International Diabetic Nephropathy Study Group 
(2002) The early natural history of nephropathy in type 1 diabetes: II. Early 
renal structural changes in type 1 diabetes. Diabetes. 51, 1580-1587 
306 
 
 
455 Inoue, T., Kato, T., Uchida, T., et al. (2005) Local release of C-reactive 
protein from vulnerable plaque or coronary arterial wall injured by 
stenting. J Am Coll Cardiol. 46, 239-245 
456 Emerging Risk Factors Collaborators, Kaptoge, S., Di Angelantonio, E., et 
al. (2010) C-reactive protein concentration and risk of coronary heart 
disease, stroke, and mortality: an individual participant meta-analysis. 
Lancet. 375, 132-140 
457 Phillips, A. O., Steadman, R., Morrisey, K., Martin, J., Eynstone, L. and 
Williams, J. D. (1997) Exposure of human renal proximal tubular cells to 
glucose leads to accumulation of type IV collagen and fibronectin by 
decreased degradation. Kidney Int. 52, 973-984 
458 Portik-Dobos, V., Anstadt, M. P., Hutchinson, J., Bannan, M. and Ergul, A. 
(2002) Evidence for a matrix metalloproteinase induction/activation system 
in arterial vasculature and decreased synthesis and activity in diabetes. 
Diabetes. 51, 3063-3068 
459 Mischak, H., Vlahou, A., Righetti, P. G. and Calvete, J. J. (2014) Putting 
value in biomarker research and reporting. J Proteomics. 96, A1-3 
460 Rossing, P. (2005) The changing epidemiology of diabetic microangiopathy 
in type 1 diabetes. Diabetologia. 48, 1439-1444 
461 MacIsaac, R. J., Ekinci, E. I. and Jerums, G. (2014) Progressive diabetic 
nephropathy. How useful is microalbuminuria?: contra. Kidney Int. 86, 50-
57 
462 Scuteri, A., Modestino, A., Frattari, A., Di Daniele, N. and Tesauro, M. 
(2012) Occurrence of hypotension in older participants. Which 24-hour 
ABPM parameter better correlate with? J Gerontol A Biol Sci Med Sci. 67, 
804-810 
463 SPRINT Research Group, Wright, J. T., Jr., Williamson, J. D., et al. (2015) A 
Randomized Trial of Intensive versus Standard Blood-Pressure Control. N 
Engl J Med. 373, 2103-2116 
464 Reinhard, H., Wiinberg, N., Hansen, P. R., et al. (2011) NT-proBNP levels, 
atherosclerosis and vascular function in asymptomatic type 2 diabetic 
patients with microalbuminuria: peripheral reactive hyperaemia index but 
not NT-proBNP is an independent predictor of coronary atherosclerosis. 
Cardiovasc Diabetol. 10, 71 
465 von Scholten, B. J., Reinhard, H., Hansen, T. W., et al. (2015) Additive 
prognostic value of plasma N-terminal pro-brain natriuretic peptide and 
coronary artery calcification for cardiovascular events and mortality in 
asymptomatic patients with type 2 diabetes. Cardiovasc Diabetol. 14, 59 
466 Bomback, A. S., Kshirsagar, A. V. and Klemmer, P. J. (2009) Renal aspirin: 
will all patients with chronic kidney disease one day take spironolactone? 
Nat Clin Pract Nephrol. 5, 74-75 
467 Namsolleck, P. and Unger, T. (2014) Aldosterone synthase inhibitors in 
cardiovascular and renal diseases. Nephrol Dial Transplant. 29 Suppl 1, i62-
i68 
468 Schutte, E., Gansevoort, R. T., Benner, J., Lutgers, H. L. and Lambers 
Heerspink, H. J. (2015) Will the future lie in multitude? A critical appraisal 
307 
 
 
of biomarker panel studies on prediction of diabetic kidney disease 
progression. Nephrol Dial Transplant. 30 Suppl 4, iv96-104 
469 Currie, G. and Delles, C. (2013) Proteinuria and its relation to 
cardiovascular disease. Int J Nephrol Renovasc Dis. 7, 13-24 
 
  
308 
 
 
 
  
309 
 
 
 
 
 
 
 
 
 
Appendix 1 
 
PRIORITY Study: Invitation Letter 
 
  
310 
 
 
  
311 
 
 
 
312 
 
 
  
313 
 
 
 
314 
 
 
  
315 
 
 
 
316 
 
 
  
317 
 
 
 
318 
 
 
  
319 
 
 
 
320 
 
 
  
321 
 
 
 
 
 
 
 
 
 
Appendix 2 
 
PRIORITY Study: Participant Information Sheet 
 
  
322 
 
 
  
323 
 
 
 
324 
 
 
  
325 
 
 
 
326 
 
 
  
327 
 
 
 
328 
 
 
  
329 
 
 
 
330 
 
 
  
331 
 
 
 
332 
 
 
  
333 
 
 
 
334 
 
 
  
335 
 
 
 
 
 
 
 
 
 
Appendix 3 
 
PRIORITY Study: Consent Form 
 
  
336 
 
 
 
337 
 
 
 
338 
 
 
  
339 
 
 
 
 
 
 
 
 
 
Appendix 4 
 
PRIORITY Study: Alert Card 
 
  
340 
 
 
  
341 
 
 
 
 
 
 
 
 
 
Appendix 5 
 
PRIORITY Study: Information Letter 
 
  
342 
 
 
  
343 
 
 
 
 
 
 
 
 
 
Appendix 6 
 
Meta-analysis: Search Strategy 
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We searched the following databases for relevant clinical studies: 
 
A) EMBASE (1947 – December 2014) 
 
1) Aldo antagonist*.mp      
2) Mineralocorticoid receptor blocker*.mp   
3) Mineralocorticoid receptor antagonist*.mp  
4) Mineralocorticoid antagonist*.mp    
5) Spironolactone*.mp      
6) Potassium Canrenoate*.mp    
7) Canrenone*.mp      
8) Aldadiene Potassium*.mp     
9) Aldadiene*.mp       
10) SC-9376*.mp       
11) SC-9420*.mp       
12) SC-14266*.mp     
13) Eplerenone*.mp      
14) Aldactone*.mp       
15) Novospiroton*.mp      
16) Spiractin*.mp       
17) Soldactone*.mp      
18) Soludactone*.mp      
19) Practon*.mp       
20) Phanurane*.mp      
21) Luvion*.mp       
22) Contaren*.mp       
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23) Eplecard*.mp       
24) Epleran*.mp       
25) Eptus*.mp       
26) Planep*.mp       
 
1) Chronic renal disease*.mp     
2) Chronic renal failure*.mp     
3) Chronic kidney insufficiency*.mp    
4) Chronic renal insufficiency*.mp    
5) Chronic kidney disease*.mp     
6) Chronic kidney failure*.mp     
7) Proteinuria*.mp      
8) Albuminuria*.mp      
9) Renal replacement therapy*.mp  
10) Dialysis*.mp       
11) Haemodialysis*.mp      
12) Peritoneal dialysis*.mp     
13) Kidney transplant*.mp      
14) Renal transplant*.mp      
15) Kidney transplantation*.mp     
16) Renal transplantation*.mp     
 
SEARCH 1 AND SEARCH 2 = 116 
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B) PubMed (1966 – December 2014) 
 
1) MeSH Aldosterone antagonist    
2) Canrenoate Potassium (tw)     
3) Canrenone$(tw)      
4) Aldadiene potassium (tw)     
5) Aldadiene(tw)       
6) Spironolactone(tw)      
7) Eplerenone(tw)      
8) Aldactone(tw)       
9) Aldosterone antagonist(tw)     
10) Practon(tw)       
11) Phamurane(tw)      
12) Soldactone(tw)      
13) Soludactone(tw)      
14) Spiractin(tw)       
15) Novospiroton(tw)      
16) SC-9376(tw)       
17) SC-9420(tw)       
18) SC-14266(tw)       
19) Luvion(tw)       
20) Contaren(tw)       
21) Eplecard(tw)       
22) Epleran(tw)       
23) Planep(tw)       
24) Mineralocorticoid Receptor Antagonist(tw)  
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25) Mineralocorticoid Receptor Blocker(tw)   
 
1) Chronic kidney disease(tw)     
2) Chronic renal disease(tw)     
3) Chronic kidney failure(tw)     
4) Chronic renal failure(tw)     
5) Chronic kidney insufficiency(tw)    
6) Chronic renal insufficiency(tw)    
7) MeSH chronic renal failure     
8) MeSH chronic kidney failure     
9) MeSH chronic kidney insufficiency    
10) MeSH chronic renal insufficiency    
11) MeSH renal replacement therapy    
12) MeSH dialysis peritoneal     
13) MeSH dialysis renal      
14) MeSH proteinuria      
15) MeSH albuminuria      
16) MeSH renal transplant 
17) MeSH kidney transplant     
18) Proteinuria$(tw)      
19) albuminuria$(tw)      
20) renal replacement therapy$(tw)    
21) haemodialysis$(tw)      
22) dialysis$(tw)       
23) peritoneal dialysis$(tw)     
24) renal transplantation$(tw)     
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25) kidney transplant$(tw)      
 
SEARCH 1 AND SEARCH 2 = 57 
 
C) Cochrane (1947 – December 2014) 
 
1) MeSH Aldosterone antagonist    
2) Canrenoate Potassium (tw)     
3) Canrenone$(tw)      
4) Aldadiene potassium (tw)     
5) Aldadiene(tw)       
6) Spironolactone(tw)      
7) Eplerenone(tw)      
8) Aldactone(tw)       
9) Aldosterone antagonist(tw)     
10) Practon(tw)       
11) Phamurane(tw)      
12) Soldactone(tw)      
13) Soludactone(tw)      
14) Spiractin(tw)       
15) Novospiroton(tw)      
16) SC-9376(tw)       
17) SC-9420(tw)       
18) SC-14266(tw)       
19) Luvion(tw)       
20) Contaren(tw)       
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21) Eplecard(tw)       
22) Epleran(tw)       
23) Planep(tw)       
24) Mineralocorticoid Receptor Antagonist(tw)  
25) Mineralocorticoid Receptor Blocker(tw)   
 
1) Chronic kidney disease(tw)     
2) Chronic renal disease(tw)     
3) Chronic kidney failure(tw)     
4) Chronic renal failure(tw)     
5) Chronic kidney insufficiency(tw)    
6) Chronic renal insufficiency(tw)    
7) MeSH chronic renal failure     
8) MeSH chronic kidney failure     
9) MeSH chronic kidney insufficiency    
10) MeSH chronic renal insufficiency    
11) MeSH renal replacement therapy    
12) MeSH dialysis peritoneal     
13) MeSH dialysis renal      
14) MeSH proteinuria      
15) MeSH albuminuria      
16) MeSH renal transplant 
17) MeSH kidney transplant     
18) Proteinuria$(tw)      
19) albuminuria$(tw)      
20) renal replacement therapy$(tw)    
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21) haemodialysis$(tw)      
22) dialysis$(tw)       
23) peritoneal dialysis$(tw)     
24) renal transplantation$(tw)     
25) kidney transplant$(tw)   
 
SEARCH 1 AND SEARCH 2 = 126 
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Meta-analysis: Data Extraction Form 
 
  
352 
 
 
Dear colleague, thank you for considering our proposal to join the above meta-analysis. The 
following is a list of data required to enable us to incorporate data from your trial in to the meta-
analysis. 
 
1. Blood Pressure (office measurement) 
a. Mean systolic BP (±SD) at baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
b. Mean diastolic BP (±SD) at baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
c. Mean systolic BP (±SD) at end of study 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
d. Mean diastolic BP (±SD) at end of study 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
e. Mean change (±SD) in systolic BP from baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
f. Mean change (±SD) in diastolic BP from baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
 
2. Renal Function 
a. Mean serum creatinine (±SD) at baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
b. Mean serum creatinine (±SD) at end of study 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
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c. Mean change (±SD) in serum creatinine from baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
d. Mean GFR (±SD) at baseline (actual or estimated GFR accepted) 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
e. Mean GFR (±SD) at end of study (actual or estimated GFR accepted) 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
f. Mean change (±SD) in GFR from baseline (actual or estimated GFR accepted) 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
 
3. Renal protein/albumin excretion 
Please specify whether proteinuria or albuminuria has been measured (PCR or ACR). 
a. Mean protein/albumin creatinine ratio (±SD) at baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
b. Mean protein/albumin creatinine ratio (±SD) at end of study 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
c. Mean change in protein/albumin creatinine ratio (±SD) from baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
d. Mean 24 hour protein/albumin excretion (±SD) at baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
e. Mean 24 hour protein/albumin excretion (±SD) at end of study 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
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f. Mean change in 24 hour protein/albumin excretion (±SD) from baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
 
4. Serum potassium 
a. Mean serum potassium (±SD) at baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
b. Mean serum potassium (±SD) at end of study 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
c. Mean change in serum potassium (±SD) from baseline 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
d. Number of patients who developed Hyperkalaemia (K+>5.5) after baseline visit 
i. Treatment group (±SD)  …………………………………………. 
ii. Control group (±SD)  …………………………………………. 
  
355 
 
 
 
 
 
 
 
 
 
Appendix 8 
 
Pilot Study: Patient Information Sheet 
 
  
356 
 
 
  
357 
 
 
  
358 
 
 
  
359 
 
 
  
360 
 
 
  
361 
 
 
 
 
 
 
 
 
 
Appendix 9 
 
Pilot Study: Consent Form 
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Vascular Substudy: Patient Information Sheet 
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Vascular Substudy: Consent Form 
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